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Anticoagulants are the basis for treatment and prevention of thrombotic diseases. The 
currently available medicines are associated with a wide range of adverse reactions that 
mandates developing new anticoagulants. Several lines of evidence support the superiority of 
factor Xa (FXa) as a promising target to develop novel anticoagulants. This work focuses on the 
design of direct and indirect FXa inhibitors using an interdisciplinary approach. As indirect FXa 
inhibitors, a focused library of tetrasulfated N–arylacyl tetrahydroisoquinoline (THIQ) non–
saccharide allosteric antithrombin activators was designed, synthesized, and biochemically 
evaluated to establish their structure–activity relationship (SAR). An N–arylacyl THIQ analog 
having carboxylate at position–3, two sulfate groups at positions–5 and –8 of THIQ moiety, 
butanoyl linker, and two sulfate groups at positions–2 and –5 of the phenolic monocyclic moiety  
  
xvi 
was identified as the most promising nonsaccharide antithrombin activator with KD of 1322 ± 
237 µM and acceleration potential of 80–fold. Its biochemical profile indicates a strong 
possibility that it activates antithrombin by the pre–equilibrium pathway rather than the induced– 
fit mechanism utilized by heparin analogs. A similar interdisciplinary approach was exploited to 
design direct FXa inhibitors that possess high selectivity and are potentially orally bioavailable. 
Structurally, the designed direct FXa inhibitors are neutral THIQ dicarboxamides. THIQ 
dicarboxamide is a privileged structure with a semi–rigid character, a structural feature that 
potentially offers high selectivity for targeting FXa over other coagulation and digestive 
proteases. It can also be thought of as an amino acid–like structure, which affords accessibility to 
a large number of compounds using well established peptide chemistry. Mechanistically, the 
designed inhibitors were expected to bind to FXa in the active site and function as orthosteric 
inhibitors. These direct FXa active site inhibitors are also likely to inhibit clot–bound enzyme. 
Nearly 60 THIQ dicarboxamides were synthesized and biochemically evaluated. Through 
detailed SAR analysis, the most potent analog was designed and found to exhibit an IC50 of 270 
nM (Ki = 135 nM), an improvement of more than 207–fold over the first inhibitor synthesized in 
the study. The most potent inhibitor displayed at least 1887–fold selectivity for FXa over other 
coagulation enzymes and a selectivity index of at least 279–fold over the digestive serine 
proteases. This analog doubled plasma clotting times at 17–20 µM, which are comparable to 
those of agents being currently studied in clinical trials.  Overall, allosteric and orthosteric 
approaches led to the design of indirect and direct small molecule inhibitors of FXa based on the 
THIQ scaffold. This work introduces two promising molecules, a tetrasulfated N–arylacyl THIQ 
analog as a heparin mimetic and a neutral THIQ dicarboxamide as a potent, selective, and 
potentially bioavailable peptidomimetic, for further advanced medicinal chemistry studies.  
1 
 
CHAPTER 1: INTRODUCTION 
 
Blood coagulation is the hallmark of hemostasis. Hemostasis is described as physiologic 
clotting which prevents excessive blood loss from injured blood vessels. The coagulation 
cascade maintains a balance between blood flow and blood clotting under physiologic 
conditions, the dysfunction of which results in hemorrhage or thrombosis.  
1.1. The Coagulation Cascade Model—The coagulation process comprises a series of 
proteolytic reactions working in a cascade fashion. This process can be triggered either by the 
intrinsic pathway1,2 or by the extrinsic pathway, both of which converge at factor Xa (FXa) 
(Figure 1).3-5  
 1.1.1. The Intrinsic Pathway— In this pathway, all clotting factors are present in the 
blood and are activated when blood comes in contact with activated platelets. Factor XII in 
plasma is activated to factor XIIa (FXIIa) upon interaction with collagen or other negatively 
charged surfaces (as in vascular endothelium damage, lipoproteins in hyperlipidemia, or bacteria 
in infections) with the aid of high molecular–weight kininogen (HMWK). The resulting FXIIa 
activates factor XI to factor XIa (FXIa) which eventually activates factor IX to factor IXa 
(FIXa). FIXa combines later with factor VIIIa (FVIIIa) to form the tenase complex in the 
presence of calcium and phospholipids. This complex subsequently activates factor X to FXa.3,6,7  
1.1.2. The Extrinsic Pathway— The extrinsic pathway is activated in an injury without 
direct contact with nonphysiological surfaces, by endothelium damage, or by hypoxia resulting 
from reduced blood flow.7 This pathway is triggered when tissue factor (TF) of the extravascular 
system comes in contact with factor VII in the plasma after injuries to blood vessels. TF activates 
factor VII to factor VIIa (FVIIa) forming a TF–FVIIa complex which subsequently activates 
factor X to FXa.3,6,7 
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1.1.3. The Common Pathway— Both intrinsic and extrinsic pathways converge at FXa, 
the first serine protease in the common pathway leading to clot formation. The resulting FXa, 
from either pathway, complexes with factor Va (FVa), calcium, and phospholipid to form 
prothrombinase. Prothrombinase subsequently activates factor II (prothrombin) to factor IIa 
(FIIa, thrombin) which converts factor I (fibrinogen) to factor Ia (FIa, fibrin) monomers. Factor 
XIIIa (FXIIIa) which is also activated by thrombin, converts the soluble fibrin to cross-linked 
fibrin on the surface of the activated platelets and forms an impermeable hemostatic plug. 
Thrombin also provides positive feedback to the cascade by activating factor XI, factor VIII in 
the intrinsic pathway, and factor V in the common pathway. This ensures the efficient generation 
of a burst of thrombin and hence fibrin.3,6,7 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The coagulation cascade: procoagulant proteins and regulatory natural anticoagulants. 
APC— Activated Protein C, AT— Antithrombin, HMWK— High molecular weight kininogen, 
PL— Phospholipids, TF— Tissue factor, TFPI— Tissue Factor Pathway Inhibitor.  
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1.2. Physiologic Regulators of Coagulation— Excessive clotting is certainly 
detrimental and should be physiologically avoided. At least three anticoagulant proteins exist 
naturally in our body to regulate the procoagulant activity of coagulation proteins. These proteins 
include antithrombin (AT),8 activated protein C (APC),9 and tissue factor pathway inhibitor 
(TFPI).10 The former two anticoagulants target the process of amplification and propagation, 
while the latter anticoagulant inhibits the initiation steps of coagulation (Figure 1). AT belongs to 
the serpin (serine protease inhibitor) family. AT is considered to be the major inhibitor of 
thrombin, FXa, and FIXa.8, 11 AT also seems to inhibit FVIIa12 and FXIa.13 However, AT is an 
intrinsically poor anticoagulant and needs heparin, a highly sulfated glycosaminoglycan (GAG), 
to enhance its inhibitory activity toward the serine proteases of the coagulation about 300–4,000-
fold.14APC inhibits both FVa and FVIIIa.9 APC physiologically forms upon activation of protein 
C by the thrombin–thrombomodulin complex. Lastly, TFPI inhibits only FXa.10 
1.3. Thrombotic Diseases and Current Therapeutic Options—  
1.3.1. Thrombotic Diseases— Dysfunction of the coagulation process may lead either to 
hemorrhage (haemophilia) or clotting disorders (thrombosis). Thrombosis is the underlying cause 
of several cardiovascular diseases. Thrombi could form in blood arteries leading to acute 
myocardial infarction or ischemic stroke. Formation of thrombi in the venous circulation may 
result in deep vein thrombosis which can lead to life–threatening pulmonary embolism. The 
morbidity and mortality rates associated with thrombotic diseases are vast. For example, venous 
thromboembolism afflicts annually up to 600,000 individuals in the US and is implicated in at 
least 100,000 deaths.15 The blood clotting disorders are the second most frequent cause of death 
in cancer patients with a mortality rate of about 15–20% of hospitalized cancer patients.16 
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1.3.2. Current Therapeutic Options— Given the overwhelming impact of thrombotic 
diseases, developing therapies that prevent and treat these diseases has received a great deal of 
attention and is still in high demand. Therapies which are used to prevent and/or treat thrombotic 
diseases belong primarily to three different mechanistic classes including fibrinolytic agents, 
antiplatelet agents, and more importantly anticoagulants.17  
1.3.3. Anticoagulants— Anticoagulants are the mainstay for prevention and treatment of 
all thrombotic diseases. They stop pathological clot formation by inhibiting directly or indirectly 
one or more procoagulant enzymes. Practically, only thrombin and FXa, the two serine proteases 
of the common pathway, have been successfully targeted by inhibition for anticoagulant 
activity.6,7,17  
Structurally, clinically approved anticoagulants comprise a wide variety of compounds 
that are either small molecules or macromolecules. They include saccharides such as heparin, 
low molecular weight heparins (LMWHs), and fondaparinux. Heparin and LMWHs are 
particularly highly heterogeneous and polydisperse preparations of a mixture of chemical entities 
while fondaparinux is homogenous synthetic pentasaccharide.7,14,17 Clinically available 
anticoagulants also include coumarins such as warfarin, peptides such as bivalirudin, and 
peptiomimetics such as argatroban, dabigatran etexilate and rivaroxaban.17 All of these 
anticoagulants are highly homogenous preparations of a single chemical entity (Figure 2).  
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Figure  2. Representative examples of clinically available anticoagulants. 
 
Mechanistically, the intended inhibition could be achieved by direct or indirect inhibition 
of the targeted enzyme. Direct enzyme inhibitors may compete with the endogenous substrate; 
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therefore they can be competitive active site inhibitors. They may also disrupt the catalytic triad 
of the procoagulant proteases by inducing nonproductive conformational change through binding 
to an allosteric site; therefore they can be un– or non– competitive inhibitors.  Hirudin, 
argatroban, and dabigataran etexilate are examples of direct thrombin inhibitors, whereas 
rivaroxaban is the only approved direct FXa inhibitor.6,7,17 The catalytic activity of the 
procoagulant serine proteases can be also indirectly abolished by activating natural anticoagulant 
proteins such as AT. The activated natural anticoagulant will act as inhibitory substrate for the 
coagulation procoagulant enzymes. Unfractionated heparin, LMWHs, and fondaparinux 
pentasaccharide are the most common AT activators in the clinic, where they are prescribed to 
promote the indirect inhibition of FXa and/or thrombin.  Indirect anticoagulants also include 
those molecules that adversely affect the biosynthesis of coagulation factors. Warfarin, the 
prototypic vitamin K antagonist, inhibits the post–translational process necessary for the 
biosynthesis of fully functional coagulation enzymes.7 
The core of this work is to design direct and indirect FXa inhibitors as anticoagulants. 
Accordingly, the following sections will focus on relevant observations that assess the 
superiority of FXa as promising drug target for anticoagulant activity, structural and mechanistic 
details about AT and AT–based indirect anticoagulants, structural and mechanistic studies 
related to FXa, and the current status of direct inhibitors.  
1.4. Factor Xa or Thrombin: Which is Better as an Anticoagulant Target— It is 
generally understood that the more downstream a procoagulant protease in the coagulation 
cascade is being inhibited, the better anticoagulant efficacy the inhibitor can achieve.  In 
contrast, the more upstream a procoagulant is being inhibited, the less likelihood of bleeding risk 
the inhibitor causes. Therefore, FXa inhibitors are likely to possess more anticoagulant efficacy 
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than inhibitors of FVIIa, FIXa, FXIa, and FXIIa and leads to less bleeding complications relative 
to thrombin inhibitors. Several lines of evidence support the superiority of FXa as more effective 
and safer drug target as follows:  
1) FXa is more thrombogenic than thrombin18 and activation of one molecule of FX results in 
the generation of 1000 molecules of thrombin due to the amplification nature of the coagulation 
cascade.19 This implies that a lower dose of FXa inhibitor is needed to effect anticoagulation 
relative to the needed dose of thrombin inhibitor to effect the same response. 
2) Fondaparinux, indirect FXa inhibitor, has a significant antithrombotic potential and safety 
compared with enoxaparin, a LMWH that has both anti-thrombin and anti-FXa activity. In 
extensive orthopedic trials of venous thromboembolism prophylaxis, fondaparinux showed a 
55% reduction in venous thromboembolism compared with enoxaparin.20,21 In patients with 
cardiac disease, fondaparinux and enoxaparin showed equivalent efficacy in myocardial 
infarction and refractory ischemia, but fondaparinux showed a significant reduction in major 
bleeding compared with the LMWH. Therefore, fondaparinux has provided strong clinical proof 
supporting the concept that specific FXa inhibition provides more effective and safer therapy.20,21  
3) Compared with thrombin, FXa is known to have limited number of functions besides 
activating prothrombin to thrombin via the action of the prothrombinase complex. Thrombin has 
a range of important activities within and outside the coagulation process, the inhibition of which 
might influence the efficacy and safety of specific thrombin inhibitors.22,23   
4) FXa inhibitors are generally associated with less rebound hypercoagulation, which is more 
common with unfractionated heparin24,25 and direct thrombin inhibitors.25 
1.5. Validating Factor Xa as Drug Target — The viability of FXa inhibition was first 
tested in 1987. The first FXa inhibitor, the naturally occurring compound antistasin, was isolated 
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from the salivary glands of the Mexican leech Haementeria officinalis.26,27 Antistasin is a 119 
amino–acid polypeptide.  Enzyme kinetic studies revealed that it is a slow, tight–binding, potent 
FXa inhibitor with an average Ki of 0.45 nM.28 Another naturally occurring FXa inhibitor is a 
single–chain, 60 amino–acid peptide known as the tick anticoagulant peptide (TAP). TAP was 
isolated in 1990 from extracts of the soft tick Ornithodoros moubata. Similar to antistasin, TAP 
is a slow, tight–binding inhibitor of FXa with Ki of ~0.6 nM.29 
These two natural FXa inhibitors which have >50000–fold selectivity for FXa over other 
related clotting serine proteases were exploited to guide the efforts to understand the physiologic 
role of FXa in hemostasis and thrombosis, and to validate FXa as a viable drug target for new 
effective anticoagulants.30-34 The antithrombotic effects of these compounds were compared with 
those of direct thrombin inhibitors (hirudins) and of indirect thrombin and FXa inhibitors 
(unfractionated heparin and LMWHs) in animal models of thrombosis. The studies concluded 
that direct FXa inhibitors could be a more effective approach to anticoagulation, and might also 
offer a wider therapeutic window.30-34 In fact, FXa is now being targeted by two clinically 
approved anticoagulants: fondaparinux (saccharide indirect FXa inhibitor) and rivaroxaban 
(peptiomimetic direct FXa inhibitor). 
1.6. Antithrombin and Antithrombin–Based Anticoagulants —Clinically used 
anticoagulants are generally direct or indirect inhibitors of coagulation–related enzymes. The 
widely used anticoagulants, heparins, are primarily indirect inhibitors of thrombin and FXa. 
Unfractionated heparin and LMWHs are AT activators for the accelerated inhibition of thrombin 
and FXa, whereas the pentasaccharide fondaparinux is an allosteric activator of the inhibitory 
activity of AT only toward FXa. Non-saccharide AT allosteric activators were also designed as 
anticoagulants by Desai and co–workers for the accelerated inhibition of FXa. 
9 
 
1.6.1. Antithrombin and the Kinetics of Proteases Inhibition— AT is a plasma 
glycoprotein belonging to the serpin superfamily.35 It is a major regulator of blood clotting which 
inactivates a number of serine proteases in the coagulation cascade, especially thrombin and 
FXa.36 Although the rates of AT inhibition of these enzymes are slow under physiological 
conditions, AT interaction with cell–surface polysaccharide species, such as heparan sulfate, 
accelerates the inactivation of the procoagulant proteases several fold.37  
Several crystal structures of AT are available in which the serpin is present in three 
different forms, namely, intact (uncleaved, native), active, or cleaved inactive forms. The 
structures of intact, uncleaved free AT reveals 9 α–helices surrounding 3 β-sheets.38-40 In this 
form, several structural features are important:14,35  
1) A dominant five–stranded β-sheet A, approximately in the center of the serpin. 
2) A reactive center loop (RCL) of 15 residues containing the reactive bond R393–S394 (P1–
P1′) at the top of the serpin. 
3) The partial insertion of the two residues G379–S380 at the N-terminal end of the RCL as a 
short β-strand between strands 3 and 4 of β–sheet A in AT. This partially inserted RCL 
undergoes major changes during the process of protease inhibition.  
The structure of AT cleaved at the reactive bond is very similar to intact AT except for 
the complete insertion of RCL as a new strand in β–sheet A. This structural change results in the 
movement of the P1 residue in the RCL from the original side to the opposite side of AT. This 
dramatic conformational change following cleavage of the P1-P1′ bond in the RCL by the target 
enzyme is critical for the disruption of the catalytic triad of the protease, thereby resulting in the 
inactivation of the enzyme.41-44 
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The mechanism of AT–mediated inhibition of thrombin and FXa is known as the serpin 
‘mousetrap’ mechanism in which AT acts as bait to trap the target enzyme (E) in an equimolar, 
covalent, inactive complex (E*–AT*). The RCL initially interacts with the active site of the 
protease as in a normal substrate reaction to form the Michaelis–Menten complex (E:AT). This is 
rapidly followed by cleavage of the scissile bond P1-P1′ in the RCL to form an acyl–enzyme 
intermediate (E-AT) that undergoes a massive rearrangement to disrupt the enzyme’s catalytic 
triad resulting in the protease inhibition (E*-AT*). The efficacy of the inhibition is occasionally 
diminished by the substrate pathway; however, the contribution of this pathway is negligible 
under normal experimental conditions (Figure 3).14,42-45 
 
 
Figure  3. Antithrombin–mediated mousetrap inhibition of coagulation proteins. AT—
Antithrombin, E:AT—Micahelis–Menten Complex, E–AT— Acyl–Enzyme Intermediate, E*–
AT*—Antithrombin–Enzyme Complex, ATC— Cleaved Antithrombin, RCL—Reactive Center 
Loop. The figure is adapted from reference 7. 
Enzyme kinetic studies revealed that the AT–mediated inhibition rates of thrombin and 
FXa are significantly lower than those of most serpins that inhibit their target serine proteases 
with a second–order rate constant limited only by diffusion.14 At pH 7.4 and 25 °C, uncatalyzed 
in vitro thrombin inhibition rates are in the range of 7–11 × 103 M-1s-1,46-48 while those for FXa 
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are in the range of 2–3 × 103 M-1s-1.14 The slow rates of thrombin and FXa inhibition are 
dramatically increased in the presence of heparins. The second–order rate constant for thrombin 
inhibition by AT–heparin complex is in the range of 1–4 ×107 M-1s-1 representing an acceleration 
of more than 2,000–fold. Likewise, the second–order rate constant for FXa inhibition by AT–
heparin complex reaches 1.5 ×106 M-1s-1 giving rise to an increase of some 600–fold.49-52 
Physiologically, the acceleration in FXa inhibition may reach 2,400–fold due to calcium ions.53 
This enhancement in inhibition of thrombin and FXa explains the clinical use of heparin as an 
anticoagulant.  
No more than 33% of heparin chains bind AT with high affinity. These high affinity 
chains contain a specific sequence of five residues that contribute nearly 95% of AT binding 
energy. The five–residue sequence is called heparin pentasaccharide DEFGH. This variant 
selectively inactivates FXa as it accelerates AT inhibition of FXa about 300–fold, while it 
accelerates AT inhibition of thrombin only about 1.7–fold.52   
1.6.2. Mechanism of Heparin Activation of Antithrombin — There are two different 
mechanisms for heparin–activated AT inhibition of FXa and thrombin. In the case of FXa, the 
mechanism is known as the two–step, induced fit mechanism or the conformation activation 
mechanism. In this mechanism, high–affinity heparin, or pentasaccharide DEFGH, binds to the 
HBS on AT resulting in a conformational change that travels to the RCL. The resulting 
conformational change expels the partially inserted RCL residues and thus exposes a new exosite 
in AT. The exposed RCL in heparin-AT complex is better recognized by FXa resulting in ~300–
600–fold accelerated cleavage of the amide scissile bond and rapid formation of the covalently 
inhibited complex (E*-AT*) (Figures 3 and 4).45,51, 52, 54,55 
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In contrast, the mechanism and the heparin structural requirements for the AT–mediated 
inhibition of thrombin are different. The predominant effect of heparin in accelerating thrombin 
inhibition arises from a bridging mechanism. Tight binding of AT to the DEFGH sequence in 
full length heparin is followed by the binding of thrombin to the same chain to form an AT–
heparin–thrombin ternary complex. Thrombin then diffuses along the polyanionic chain to 
encounter the inhibitor resulting in at least 2,000-fold acceleration in inhibition under 
physiological conditions.7 A saccharide length of about 18 residues is needed to simultaneously 
hold thrombin and AT for the accelerated inhibition.56,57 Recent investigations suggest that such 
a template mechanism may also play an important role in vivo for AT inhibition of FXa. In the 
presence of physiological concentrations of calcium ion, full-length heparin was found to 
accelerate the inhibition of FXa about 40-fold suggesting that longer chains bind to an exosite on 
the FXa enzyme that is only exposed in presence of calcium ion (Figure 4).53  
It is important to note that the HBS on AT is located approximately 20 Å away from the 
RCL and is primarily two binding domains. The two domains are pentasaccharide–binding site 
(PBS) and the extended heparin binding site (EHBS) (Figure 5). The former domain is formed by 
charged residues of helices A and D, and the polypeptide N-terminus. The crystal structure and 
the mutagenesis studies of AT–pentasaccharide complex show that residues R47, K114, K125, 
and R129 in this region interact with DEFGH.58-63 In addition to interacting with PBS, full-length 
heparin binds to EHBS, an extended region formed by residues R132, K133, and R136 at the C–
terminal end of helix D.64 The interaction of DEFGH (or full-length heparin) with PBS results in 
transmission of binding energy for conformational change in the RCL, suggesting that heparin 
activation of AT is an allosteric phenomenon.58,65  
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Figure  4. Antithrombin–mediated heparin indirect inhibition of coagulation proteases. AT—
Antithrombin, HBS— Heparin Binding Site, RCL— Reactive Center Loop, H— Heparin. This 
figure is adapted from reference 7. 
 
 
 
 
 
 
 
 
 
 
Figure  5.  Structure of antithrombin–pentasaccharide DEFGH complex. A) Heparin binding site 
and RCL. B) Close-up view of the interacting amino acids of PBS with DEFGH and the non–
interacting amino acids of EHBS. This figure is adapted from reference 7. 
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1.6.3. Classes of Antithrombin–Based Anticoagulants— 
1.6.3.1. Heparin and Low Molecular Weight Heparins— Heparin, glycosaminoglycan 
(GAG), is a heterogenous and polydisperse mixture of highly negatively charged linear 
polysaccharide chains with an average weight of ~14,000. Heparin is a (1—>4) linked 
copolymer of glucosamine and uronic acid residues that are variously sulfated and acetylated.14 
Heparin could be of high affinity or low affinity to its physiological target, AT. The high–affinity 
heparin is rich in the pentasaccharide DEFGH sequence and binds to plasma AT with sub–
nanomolar affinity at physiological pH resulting in the anticoagulant activity. Such binding is 
promoted by ionic (40%) and nonionic (60%) interactions between the sulfate and carboxylate 
groups of DEFGH and positively charged lysines and arginines in the PBS.52 Low–affinity 
heparin has less repetition of  the DEFGH sequence and binds AT with nearly 1,000-fold lower 
affinity resulting in much less AT–assisted inhibition acceleration.66  
The mid–1990s witnessed the discovery of LMWHs which were developed to address the 
many complications accompanying heparin therapy.67-69 LMWHs are 1/3rd in length as compared 
to full length heparin and are commercially produced from heparin through chemical14 or 
enzymatic depolymerization.70-72 Although chemically and mechanistically similar to heparin, the 
binding affinity of LMWHs for AT significantly varies. Their anti-FXa activity and thrombin 
inhibition depends on the fraction of DEFGH sequences present in each preparation and the 
proportion of high–affinity chains that have length greater than 18 saccharides, respectively.73,74  
Established advantages of LMWHs over heparin are the greater bioavailability, better 
pharmacokinetics, reduced thrombocytopenia, and more predictable dose response, which allows 
for fixed doses to be administered without laboratory monitoring.75,76 Nevertheless, LMWHs are 
still associated with a high risk of bleeding.76-79 
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1.6.3.2. Heparin Pentasaccharide DEFGH — The heparin pentasaccharide sequence 
DEFGH can be chemically dissected into two chemical domains; a trisaccharide DEF and a 
disaccharide GH domain. The GH sequence consists of α–L–iduronic acid unit sulfated at the 2–
position and β–D–glucosamine unit sulfated at the 2– and 6–positions. The D unit in the 
trisaccharide DEF is identical to the H unit whereas the E residue is the unsulfated β–D–
glucouronic acid. A structural feature that characterizes the DEFGH sequence is the central β–D–
glucosamine residue F consisting of three sulfates at the 2–, 3–, and 6–positions (Figure 2). 14 
Mechanistically, the heparin pentasaccharide DEFGH is a selective anti-FXa molecule. 
Accelerated inhibition of FXa by DEFGH is an indirect mechanism and is achieved by activating 
AT through the two–step, induced–fit, allosteric mechanism depicted in figure 4.7 The two 
domains in DEFGH differently contribute to the conformational activation of AT. 52,80,81 
Biochemical studies with the truncated variants, trisaccharide DEF and tetrasaccharide 
EFGH′′ (1–OCH3 and 3–OSO3- as opposed to 1–OH and 3–OH in DEFGH) indicate that the 
DEF sequence is critical for both the initial recognition of the heparin–binding site and 
conformational activation processes in AT.82,83 In addition, the efficient conformational 
activation of AT to achieve ~300-fold FXa inhibition acceleration can be achieved with 
trisaccharide DEF except that the affinity of DEF for AT is much weaker (KD ~66 µM) under 
physiological conditions.83 Therefore, it seems that the disaccharide unit GH of the 
pentasaccharide only enhances the affinity of the pentasaccharide for the conformationally 
activated inhibitor.81  
Clinically, heparin pentasaccharide DEFGH is more effective than a LMWH in 
preventing venous thromboembolism and was equally safe.84,85 Structurally, DEFGH is relatively 
decorated with limited number of negative charges, thus it shows reduced non–specific 
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interactions and improved bioavailability in comparison to the polymeric heparins.86-89 
Synthetically, the heparin pentasaccharide was initially assembled in about 40 steps, yet the 
reported synthetic protocol helped in establishing the structure–activity relationship (SAR).90,91 
Furthermore, crystal structure of the pentasaccharide–AT complex as well as as enzyme kinetics 
using the plasma as well as the mutated AT shows that each of the sulfate and carboxylate 
groups interacts with either one or more lysine or arginine residues in the PBS (Figure 6).81 
Following are the important conclusions of these studies (Figure 7): 14, 91-96 
1) N–acetylation of the non–reducing end glucosamine residue D results in formation of 
D′EFGH which has about 50% anti–FXa activity of the N–sulfated pentasaccharide DEFGH.91 
2) Four sulfate groups, at the 6–position of residue D, 3– and 2–positions of residue F, and 2–
position of residue H, are extremely critical for high–affinity binding to AT. For example, 
removing 3-OSO3- of residue F resulted in an approximately 3 × 106–fold loss in affinity.91,92 
3) The carboxylate groups of uronic acid residues are also important as demonstrated by 
pentasaccharides DE′FGH and DEFG′H that exhibit less than 5% of the activity of the reference 
DEFGH.14 
4) Replacement of NHSO3- group in all three glucosamine residues with OSO3- and 
introduction of methyl ethers at the free hydroxyl groups increased FXa inhibitory activity 
~200%. The new pentasaccharide (DEFGH–NGA) contains glucose residues instead of 
glucosamines, which made the total synthesis much easier. This pentasaccharide retains the same 
negatively charged groups of the natural pentasaccharide and hence is likely to retain the 
conformational preference and flexibility of the parent molecule.93 
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Figure  6.  The antithrombin– pentasaccharide interactions. Highlighted amino acids are of 
PBS. Functional groups in red are essential for interaction with AT while functional groups in 
blue are needed as optimal structural features. 
5) Replacing the sulfate group on the D residue of DEFGH–NAG with a methoxy group led 
to the discovery of idraparinux, which exhibits about 269% of the activity of the reference 
DEFGH.  Idraparinux can be synthesized from glucose in only 25 steps. It binds to AT with 
approximately 50–fold higher affinity and has at least a 10–fold longer half life than 
fondaparinux. Although an injection of idraparinux once–a–week is enough to achieve and 
maintain the required clinical blood level in patients, idraparinux has a substantial higher rate of 
major bleeding. Clinical trials had to be stopped because the heparin antidote was not effective 
with bleeding caused by idraparinux. This led to the development of biotinylated idraparinux that 
was as effective as idraparinux in animal models of thrombosis, and avidin injection resulted in 
complete neutralization of its anticoagulant activity.94,95 
6) A C-pentasaccharide consisting of a carbon (CH2)–based interglycosidic bond between 
residues D and E shows FXa inhibitory activity approximately 34% better than DEFGH.96 
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Figure 7. Pentasaccharide derivatives synthesized to establish structure–activity relationship. 
Anti-factor Xa activity is reported as U/mg. 
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1.6.3.3. Nonsaccharide, Aromatic, and Allsoteric Activators of Antithrombin—  
Unfractionated heparin and LMWHs indirectly inhibit FXa by the induced fit allosteric 
mechanism that results in an acceleration level of ~600–fold for the AT–mediated inhibition. 
Heparins occupy the entire heparin-binding site that consists of PBS as well as EHBS. In 
contrast, the specific sequence pentasaccharide DEFGH binds only to the PBS and activates AT 
for the ~300–fold accelerated inhibition of FXa by the same mechanism. Detailed SAR studies 
show that several anionic groups of DEFGH are critical for its high–affinity interaction with AT. 
Nevertheless, studies with truncated variants indicate that DEF is the minimum structure that 
retains the functional role of heparin represented by the allosteric activation, although with 
significant loss of affinity under physiological conditions. 
To design novel anticoagulants based on the allosteric activation of AT, various attempts 
have been made. Yet, all of these attempts have recruited a saccharide scaffold as a mimic of 
heparin.97-105 Comparative studies with a number of scaffolds such as fucoidan,97,98 curdlan 
sulfate,99 chitosan,100 galactomannan,101 and others suggest that the heparin scaffold is uniquely 
tuned to activate AT. In fact, all newer molecules designed to potently bind AT have been 
derivatives of DEFGH.104,105 Implied in such designs is the assumption that a saccharide scaffold 
was essential to induce AT activation. The assumption was made because of the remarkable loss 
in accelerated inhibition following a saccharide ring disruption in the pentasaccharide 
framework.  However, a major concern with the saccharide–based approach is the difficulty of 
synthesis. Accordingly, the Desai group challenged this assumption by designing non–saccharide 
allosteric activators of AT for the accelerated inhibition of FXa.106-110 The non–saccharide, 
aromatic mimetics of heparin are likely to provide several advantages over the saccharide 
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skeleton including greater non–ionic binding energy in AT recognition, enhanced hydrophobicity 
for possible oral delivery, improved synthetic accessibility, and higher specificity of action in 
comparison to heparin’s several activities.106,110,111  
Based on the interaction of DEF with the PBS of AT, two generations of non-saccharide, 
aromatic allosteric activators of AT were designed. The molecules of both generations were 
assessed biochemically under similar physiologic conditions to determine their affinity (KD) by 
fluorescence spectroscopy and their AT acceleration potential by UV-Vis spectroscopy.106-110 
The first generation utilized protein–based approach in which HINT–assisted molecular 
modeling studies guided the design of sulfated flavonoid–based scaffolds.106 In this  generation, 
(–)-epicatechin sulfate (ECS) was initially designed and was found to interact with AT with an 
affinity comparable to DEF.106,107, 109 ECS accelerated the inhibition of FXa ~10–fold. Other 
molecules were designed in a similar fashion, however their acceleration potentials did not 
increase beyond ~20–fold in comparison to the ~300–fold known for DEF (Figure 8).106-109  
 
  
 
 
 
 
 
 
 
Figure 8. The affinity and the acceleration potential of flavonoid–based allosteric antithrombin 
activators.  
21 
 
To improve the design concept of non–saccharide allosteric AT activators, a 
pharmacophore–based approach was later exploited to design the second generation of AT 
activators based on the tetrahydroisoquinoline (THIQ) architecture.110 Structure–activity 
relationship studies of DEF show that the sulfate groups at the 6–position on residue D, the 3–
position and the 2–position on residue F as well as the 6–carboxylate group of residue E are 
critical for conformational activation of AT. Therefore, the pharmacophore was extracted and the 
four critical groups were connected in three–dimensional space leading to a blueprint of a 
potential AT activator. The blueprint was transformed into a potential organic activator by 
introducing rigidity and simplifying the structure for rapid synthesis. Several scaffolds were 
modeled and their three–dimensional similarities with the extracted pharmacophore were 
assessed resulting in THIQ being as the best scaffold candidate to be decorated with the essential 
sulfate and carboxylate groups. Accordingly, four THIQ–based potential AT activators were 
synthesized and biochemically evaluated (Figure 9).110  
 
 
 
 
 
 
 
 
 
Figure  9. The affinity and the acceleration potential of THIQ–based allosteric antithrombin 
activators.  
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The best molecule identified in this generation was IAS5 which exhibited a KD of 320 
µM. More importantly, the acceleration in AT inhibition of FXa induced by IAS5 was found to 
be ~30–fold. Overall, results listed in figure 9 suggest that possibly all sulfate and carboxylate 
groups of IAS5 are important for the accelerated FXa inhibition by the activated AT as even a 
unit change in functional group modification appears to be not tolerated well.110 In comparison to 
the first generation flavonoid–based activators, IAS5 was found to be ~1.5– to 3–fold better at 
AT acceleration, suggesting reasonable improvement in design. Detailed competitive binding 
and molecular modeling studies have indicated that both designed small molecules, flavonoid–
based and THIQ–based molecules, prefer to bind in EHBS rather than the PBS to which DEFGH 
bind which explains their weaker acceleration potential.106-110 
Far from the above novel approaches for designing non–saccharide, aromatic, and 
allosteric AT activators for the accelerated inhibition of FXa, their syntheses are challenging 
because of sulfation which typically leads to or is associated with the following consequences:112 
1) nearly all sulfated molecules are water soluble, which makes them difficult to isolate in highly 
pure form; 2) the presence of inorganic salts, the proportion of which is usually higher at small 
synthetic scales; 3) aromatic sulfates are relatively unstable under acidic conditions and high 
temperatures; 4) the lack of maneuverability following introduction of sulfate group as only few 
functional group transformations can be successfully performed in the presence of a sulfate 
group. This essentially forces the design of the synthetic scheme to include sulfation as the final 
step; 5) the above complications increase geometrically for a poly–sulfated aromatic scaffold; 6) 
although a synthetic approach for a mono–sulfated scaffold should be easy to extend to a poly–
sulfated scaffold, polysulfation is practically challenging. The major challenge is driving the 
reaction to completion to sulfate all available reactive functional groups. As the number of these 
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groups increases on a small scaffold, sulfation becomes progressively more difficult because of 
high anionic crowding, resulting in numerous partially sulfated side–products; and 7) lack of 
sulfation regioselectivity is a dominant issue with polyfunctional substrates. 
Various synthetic protocols are available to effect sulfation. The flavonoids–based AT 
activators were mainly synthesized by a protection/deprotection strategy using trichloroethyl 
chlorosulfate as sulfate group donor.112 For THIQ–based AT activators, a high yielding 
microwave–assisted sulfation protocol was developed. The latter protocol has certainly helped in 
addressing many of the difficulties associated with sulfation reaction.113  
1.7. Factor Xa and Factor Xa Active Site Inhibitors as Anticoagulants —  
1.7.1. Factor Xa: Function— Biologically, FXa plays a critical role in the common 
pathway of the coagulation cascade. Together with FVa, calcium ions, and phospholipid surface, 
FXa forms the prothrombinase complex that is responsible for the conversion of prothrombin to 
thrombin. This eventually leads to clot formation and wound closure.114-115Deficiency of FXa 
may disturb hemostasis resulting in severe bleeding tendencies.116 Yet, this severe bleeding risk 
is only possible when FXa activity drops to less than 1% of its normal activity. Therefore, it 
seems that FXa activity can be suppressed without significantly affecting the hemostasis and thus 
with relatively minimal risk of bleeding, a highly desirable property for an ideal anticoagulant.116 
1.7.2. Factor Xa: Structure— FXa structurally belongs to the family of trypsin–like 
serine proteases, which are involved in many physiological functions. Considering the desired 
safety profile for any medicine, a designed FXa inhibitor should be selective against all other 
serine proteases particularly thrombin and trypsin. Inhibiting thrombin activity along with that of 
FXa may cause life–threatening bleeding. Trypsin is a digestive enzyme and although its 
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inhibition consequences have not been thoroughly studied, orally active FXa inhibitor should be 
selective against trypsin. 
The FXa structure was first determined by X–ray crystallography in 1993.117 FXa consists 
of a 254 amino acids–containing heavy chain and a 142 amino acids–containing light chain. The 
heavy chain contains the trypsin–like serine protease domain, whereas the light chain is built up 
of a glutamate-rich domain and two epidermal growth factor–like domains. FXa is formed from 
the precursor protein FX following cleavage of a 52 amino acid activation peptide by FIXa or 
FVIIa.6,7,17,118 
The catalytic domain of FXa consists of two similar antiparallel β-barrel folds that 
together form the catalytic triad of H57, D102, and S195 and substrate binding site. The FXa 
binding site is defined by the S1 and S4 subsites and surrounding residues. S1 is a deep, largely 
hydrophobic cleft at the bottom of which lies the D189 and Y228 side chains. S4 is a strongly 
hydrophobic pocket defined by the side chains of Y99, F174, and W215. The most potent ligands 
reported in the literature engage both sites (Figure 10).6,7,17,118 
Despite the fact that FXa shares high sequence and spatial similarity with other serine 
proteases particularly trypsin and thrombin, structural differences do exist among them and thus 
provide the fundamental structural basis to design selective FXa inhibitors. Substrate specificities 
of both FXa and thrombin are trypsin–like, yet they are more restricted than trypsin. The active 
site of FXa is more open (groove–like) compared to the narrow and deep active site of thrombin 
(canyon–like). Both the proteases prefer arginine–like residues at P1 of the substrate or inhibitors 
in order to interact by ionic and hydrogen bonds with D189 at the base of S1 pocket. Table 1 
shows the structural comparison for the four subsites of active sites in FXa and thrombin, which 
have been exploited to design selective FXa inhibitors.6,7,17,118 
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Figure 10. A) A top view of Connolly surface of the factor Xa binding site (PDB ID: 2P16). 
Carbon is in green, oxygen is in red, nitrogen is in blue, hydrogen is in white, and sulfur is in 
yellow. B) A close up view of the factor Xa binding site. The S4/aromatic box is in green, the 
cationic hole is highlighted in pink, the blue color is for the catalytic triad, the S1 pocket is in 
magenta, the disulfide box is in orange, and the S3 is indicated by yellow. This figure is adapted 
from reference 17. 
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Table 1. Structural comparison between the subsites of factor Xa and thrombin. 
Subsite Factor Xa Thrombin 
S1 
D189 at the base preferring 
arginine–like P1 
(I227 and Q192) 
D189 at the base preferring  
arginine–like P1  
(F227 and E192) 
S2 
Obstructed by Y99 side chain  
Binds to small residues such as 
glycine in P2 
Created by W60D, Y60A, H57, 
W215, L99 
Binds to large lipophilic residues 
such valine and proline in P2 
S3 Flat surface having S172 shielded by 
the larger F174 Flat surface having exposed T172 
S4 
Aromatic hydrophobic pocket of 
Y99, W215, F174 
Cation carbonyls of L96, E97, T98 
(More open pocket) 
Aliphatic hydrophobic pocket of N98, 
L99, I174,W215 
(Less open pocket) 
 
1.7.3. Active Site Factor Xa Inhibitors: Chemical Classes— Several chemical 
scaffolds were considered to develop reversible, synthetic, potent and selective active site FXa 
inhibitors. Considering the chemical anatomy of all FXa inhibitors developed thus far, their 
structures can be dissected into three chemical domains: a bifunctional core structure, which is 
decorated by two chemical arms that fit into subsites S1 and S4. All promising FXa inhibitors 
adopt L– or V–shaped conformations. Active site FXa inhibitor discovery and development has 
undergone three primary phases as follows (Figure 11): 
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Figure 11.  Evolution of reversible active site factor Xa inhibitors. Functional groups in blue are      
highly basic, functional groups in red are mildly basic, whereas those in green are  nonbasic, 
lipophilic functional groups. 
1) Highly basic scaffolds—The early discovery efforts were concentrated on symmetric bis–
benzamidines which resulted from programs launched earlier to develop potent and selective 
thrombin inhibitors. The resulting FXa inhibitors were generally moderately potent and were not 
selective against other serine proteases in the coagulation cascade and digestive system. It was 
later discovered that desymmetrization of the scaffold improved potency and selectivity against 
other serine proteases. However, all FXa inhibitors developed in this stage suffered from poor 
oral bioavailability. 6,7,17,118 
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2) Mildly basic scaffolds— In this phase, one of the highly basic benzamidine/amidine 
moieties on the scaffold (P1 or P4) was replaced with a mildly basic to nonbasic functional group 
such as pyridine–containing or sulfonamide–substituted aromatic scaffolds in order to improve 
the oral bioavailability. This led to improved bioavailability and selectivity and resulted in 
relatively diminished FXa inhibition in some cases. 6,7,17,118 
3) Nonbasic lipophilic scaffolds— The remaining basic benzamidine/amidine on the 
scaffold was replaced by another mildly basic to nonbasic functional group. This led to the 
discovery of several highly potent, highly selective, and orally bioavailable direct FXa inhibitors. 
6,7,17,118 Optimization of pharmacokinetic measures of molecules belonging to this class has been 
accomplished resulting in promising drug candidates, which have been advanced into clinical 
development such as apixaban,119 betrixaban,120 eribaxaban,121 edoxaban,122 LY517717,118 
darexaban,123 and TAK-442.124 Of these, rivaroxaban was approved in 2011 in US.125 The 
anatomy of this class of FXa inhibitors is depicted in figure 12. 
Figure 12.  Chemical anatomy of the most promising orally bioavailble active site factor Xa 
inihibitors having three chemical domains. Describtion of the optimal features of the chemical 
arms is included. The chemical space of the bifunctional core structure involves either flexible or 
rigid scaffolds. 
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1.7.4. Oral Active Site Factor Xa Inhibitors — In this section, oral direct FXa 
inhibitors which have demonstrated high potency, remarkable selectivity, and good 
pharmacokinetic profile will be detailed. The P1 and P4 moities are highlighted. All of the 
following FXa inhibitors are at different stages of clinical trials, except for rivaroxaban, which 
was approved by FDA in 2011 as the first oral direct FXa inhibitor to be used to reduce the risk 
of stroke and systemic embolism and in the prophylaxis of deep vein thrombosis.114 
A) Rivaroxaban — Rivaroxaban is the 
first potent, selective, orally bioavailble direct 
FXa inhibitor. It has oxazolidinone as the 
bifunctional core structure, chlorothienyl unit 
as P1 group, and morpholinone moiety as P4 
residue. X–ray crystallography studies revealed that rivaroxaban forms two hydrogen bonds to 
G219: a strong hydrogen bond from the carbonyl oxygen of the oxazolidinone core and a weaker 
one from the amino group of the chlorothiophenecarboxamide. The two hydrogen bonds and the 
(S)–oxazolidinone core guarantee the L-shape needed for FXa binding. The oxazolidinone core 
and the aryl ring are coplanar.125 
In the S1 pocket, the key interaction of rivaroxaban with FXa involves the 
chlorothiophene moiety as its chlorine substituent interacts with the aromatic ring of Y228 
located at the bottom of the S1 pocket. In the S4 pocket, the nonpolar aryl ring extends across the 
face of W215, and the morpholinone moiety is sandwiched between Y99 and F174. The carbonyl 
group of the morpholinone does not interact directly with FXa, however it is essential to bring 
the morpholinone ring into a perpendicular arrangement to the aryl ring, and thus increasing the 
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aromatic ring stacking and edge–to–face interaction. This interaction also displaces a molecule 
of water providing a further entropic binding contribution.125 
Rivaroxaban has a Ki of 0.4 nM. Concentrations of 0.23 µM and 0.69 µM are needed to 
double the clotting times PT and aPTT, respectively. It exhibits >10,000–fold greater selectivity 
for FXa over other serine proteases. Due to the lack of the arginine–like moieties and the 
presence of chlorothiophene group, rivaroxaban demonstrates high oral bioavailability of 57–
66% (rat) and 60–80% (dog).118,126 
B) Apixaban — Apixaban is another 
nonbasic FXa inhibitor having 7-oxo-4,5,6,7-
tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-
carboxamide as the bifunctional core structure, p–
methoxyphenyl unit as P1 group, and piperidinone moiety as P4 residue.  
The X–ray structure analysis of this inhibitor shows that in the S1 pocket the p-methoxy 
group displaces an unfavorably bound water molecule. The pyrazole N2 nitrogen atom interacts 
with the backbone of N192 and the carbonyl oxygen atom of the carboxamide interacts with the 
NH unit of G216. The orientation of the lactam phenyl residue in the S4 pocket indicates an 
edge-to-face interaction with W215.119 
Apixaban has a Ki of 0.08 nM and 3.8 µM and 5.1 µM concentrations are needed to 
double the clotting times PT and aPTT, respectively. It is selective for FXa and inhibits thrombin 
and trypsin, with Ki values of about 3 µM and >15 µM, respectively. Apixaban exhibits high oral 
bioavailability of 51% (chimpanzee), 88% (dog), and 34% (rat) due to the lack of the arginine–
like moieties.118,126 
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C)  Betrixaban — Betrixaban is oral bioavailable, 
potent and selective competitive FXa inhibitor. It exhibits 
>86,000–fold greater selectivity for FXa over other related 
proteases. Betrixaban adopts the same binding modes of 
rivaroxaban and apixaban. Particularly, the core structure 
of m–methoxy anthanilamide holds p–chloropyridine–
amine to fit into the S1 pocket while N,N–dimethylamidine to interact with the S4 pocket. The 
chlorine of the former group interacts with Y228 and the amide NH hydrogen bonds with G218. 
The dimethylamidine group forms cation– interaction in the lipophilic S4 pocket. Suprisingly, 
betrixaban has good oral bioavailability although the amidine group is protonated under 
physiological conditions. Biologically, betrixaban has a Ki of 0.12 nM. It doubles the clotting 
times of PT at plasma concentration of 0.4 µM. Betrixaban has oral bioavailability of 23.8 % 
(rat), 51.6% (dog), and 58.7% (monkey).118,120,126 
D)  Darexaban — Darexaban was developed 
using anthranilamide as core structure. Darexaban has 
high affinity for human FXa with a Ki of 31 nM and 
relatively low affinity for other serine proteases such as 
thrombin, trypsin, kallikrein and plasmin with Ki’s of at least 10 µM. PT clotting time is doubled 
by 1.2 µM of darexaban.118,126 
 The structure of darexaban was only disclosed recently after studying its metabolic 
profile. It was concluded that this molecule undergoes Phase II metabolic glucuronidation at the 
phenolic group resulting in more potent metabolite.123 
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Molecular modeling studies indicated that p-methoxyphenyl moiety deeply occupies the 
S1 pocket, while the 1,4-diazepane moiety fits into the S4 pocket. It was further suggested that 
the backbone carbonyl group of G216 and the backbone NH group of G218 hydrogen bond to 
the NH group of the amide bond linked to the methoxyphenyl moiety and the carbonyl group of 
the amide bond connected to the 4-(1,4-diazepane) benzene, respectively. This binding mode 
guarantees the preferred L–conformation, with the hydroxy group of the central benzene facing 
out toward the solvent. Therefore, glucuronidation of darexaban takes place without colliding 
with any residual portions of FXa, and the glucuronic acid moiety is exposed to the solvent, 
thereby stabilizing the moiety by hydration. Furthermore, the binding mode indicated that the 
carboxyl group of the glucuronic acid moiety interacts with R143 and K147.123  
E) TAK–442 — TAK-442 is in clinical 
development for the treatment of thromboembolic 
diseases. The X–ray structure of the complex with 
human FXa confirmed that the 6–chloronaphthyl 
group occupies the S1 substrate binding pocket in which the chlorine atom has a hydrophobic 
interaction with Y228. The sulfonyl oxygen atom is involved in a hydrogen bond with N192. In 
addition, hydrogen bonds between the oxygen atoms of the amide carbonyl group and the 
hydroxy group and the backbone NH units of G219 and G216, respectively, were observed. The 
cyclic urea interacts with the aromatic amino acids of the S4 pocket whereas the carbonyl group 
forms a water–mediated contact with the amide oxygen atom of K96.124 Lastly TAK–442 is 
potent FXa inhibitor as it inhibits FXa with a Ki of 1.8 nM and doubles the clotting time aPTT at 
0.59 µM.118,126 
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CHAPTER 2: DRAWBACKS OF THE CURRENT ANTICOAGULANTS AND 
SPECIFIC AIMS OF THE CURRENT WORK 
 
2.1. Drawbacks of Indirect Anticoagulants: Heparins and Coumarins—Heparins and 
coumarins are essentially irreversible indirect inhibitiors of the coagulation enzymes. The 
drawbacks of heparins stem from their enormous structural heterogeneity and polydispersity in 
addition to the redundant number of sulfate groups. Drawbacks associated with warfarin relate to 
its essentially non–specific mechanism as it eventually inhibits several clotting factors. Heparins 
and warfarin cause several adverse effects and fatal outcomes as follows: 
1) Significant bleeding is the major risk imposed not only by heparins and warfarin but also 
by all current anticoagulants. The anticoagulant class was ranked first in two consecutive years 
of 2003 and 2004 with respect to the total deaths from drugs causing adverse effects in 
therapeutic use.7 From 1990 through 2000, warfarin was ranked in the top 10 for most number of 
serious and adverse event reports received by the FDA.127 Unfractionated heparin, LMWHs, and 
fondaparinux also exhibit bleeding complications, although the last two variants were developed 
to address the bleeding risk of the unfractionated form.128-133 Although the action of the 
polymeric heparins can be terminated by protamine, yet fondaparinux does not have an effective 
antidote to reverse excessive bleeding. 134,135 
2) Because warfarin targets the liver which is the main physiologic machinery for the 
metabolic and detoxification processes of most drugs and food ingredients, warfarin suffers from 
several drug–drug or drug–food interactions which result in excessive or inadequate 
anticoagulation and sometimes excessive bleeding.136-141Another implication of warfarin 
mechanism is the well–reported narrow therapeutic window.7 
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3) Heparins and warfarin also suffer from significant intra– and inter–patient response 
variability which requires frequent laboratory monitoring. The inconsistent response with 
heparin is due to differences in the bioavailability and from heparin binding to proteins in the 
plasma and on cells, which are elevated in very ill patients. In addition, heparins do not inhibit 
clot–bound thrombin.142-144 The variations in patient response to warfarin are likely to be because 
of genetic polymorphism.145,146 
4) Heparin–induced thrombocytopenia is a lethal complication affecting 2.6% of patients 
taking heparin or LMWHs.147,148 It refers to a significant drop in platelet count between 4 and 14 
days after the initiation of therapy as a result of heparin–induced platelet activation.149 
5) The high risk for heparin to be contaminated with other glycosaminoglycans is very 
serious drawback. Several severe allergic reactions following the use of unfractionated heparin 
were reported in 2007 in the US. The reactions resulted in at least 8 deaths. Investigations 
determined that heparin was contaminated up to 30% by oversulfated chondroitin sulfate. 150,151   
6) Other limitations of heparins include the development of osteoporosis in patients receiving 
high dose therapy for more than six months152 and the poor oral bioavailability.7 
2.2. Drawbacks of Direct Anticoagulants — Direct inhibition of coagulation enzymes 
has been suggested to offer several advantages over the indirect inhibitors. Available direct 
inhibitors are thrombin inhibitors, FXa inihibtors, or dual thrombin and FXa inhibitors. Direct 
inhibitors are generally reversible inhibitors that are capable of inhibiting both the free forms of 
clotting enzymes and the clot–bound enzymes. Several direct inhibitors are neutral molecules, 
thus they offer the advantage of having better oral bioavailbility. Furthermore, direct 
anticoagulants possess more selectivity toward their corresponding targets, and therefore they 
have relatively limited off–target events. For example, none of the direct anticoagulants is 
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associated with the life–threatening thrombocytopenia or osteoporosis. Finally, patients receiving 
such anticoagulants are expected to show consistent clinical profiles over the time course of 
therapy. Accordingly, administration of direct inhibitors of clotting enzymes as anticoagulants 
does not demand laborious and expensive laboratory monitoring. Despite all of these advantages, 
direct anticoagulants are still associated with some deleterious events as follows:  
1) All direct thrombin inhibitors such as hirudin, bivalirudin and argatroban are associated 
with significant bleeding episodes.7 Particularly, hirudin and its recombinant variants lack an 
effective antidote, thus limiting their use to patients refractory to heparins or patients with high 
susceptibility to thrombocytopenia.153,154  
2) Because hirudins are foreign peptides, they are potentially immunogenic and may cause 
life-threatening complications.155  
3) Hirudins are extremely potent. The thrombin Ki values are 20, 60 and 200 fM for hirudin, 
lepirudin and desirudin, respectively,156,157 which makes these peptides essentially irreversible 
and likely to possess narrow therapeutic windows. Bivalirudin was later rationally designed to 
address some of the hirudins complications. It binds thrombin with a Ki of 1–2 nM, has more 
predictable anticoagulant response, and lower immunogenicity, yet it has short duration of action 
(plasma half life 25 min).7 
4) Other inhibitor–specific drawbacks include the hepatotoxicity of ximelagatran,158 mast cell 
degranulation and histamine-release159,160 as well as poor bioavailability of cationic and peptidic 
direct inhibitors, and lastly the short duration of action of argatroban, which is approved for use 
in patients at high risk for thrombocytopenia (plasma half life 24 min).7 
2.3. Ideal Characteristics of Anticoagulants — According to several reports in literature, 
the hypothetical “ideal” anticoagulants should:6,7,17,114,118 1) be administered orally; 2) have rapid 
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onset of action and several hours of duration of action; 3) have wide therapeutic window; 4) have 
little or no inter–individual variability; 5) have little or no interaction with food and other drugs; 
and 6) have predictable pharmacokinetic and pharmacodynamic characteristics.  
Other characteristics include no requirement of dose adjustment or coagulation 
monitoring, high efficacy with respect to reduced thromboembolic incidents, availability of 
antidote, and good safety profile especially with regard to the bleeding risk. 
2.4. Specific Aims of the Current Work — Despite the significant improvements 
offered by the recently approved oral anticoagulants such as dabigatran etexilate (oral thrombin 
inhibitor that was first approved in October 2010 in US), and rivaroxaban (oral FXa inhibitor that 
was first approved in July 2011 in US), contrasting the profile of ideal anticoagulants with that of 
the clinically approved ones reveals an unmet need for new anticoagulants. 
For example, on December 2011, the FDA initiated an investigation into serious bleeding 
events associated with dabigatran etexilate stating that the "FDA is working to determine 
whether the reports of bleeding in patients taking Pradaxa (dabigatran etexilate) are occurring 
more commonly than would be expected, based on observations in the large clinical trial that 
supported the approval of Pradaxa [RE-LY trial]."161 In November 2011, Boehringer Ingelheim 
confirmed 260 fatal bleeding events worldwide between March 2008 and October 2011 because 
of Pradaxa.215 
Furthermore, the efficacy and safety of the new anticoagulants is yet to be established in 
high risk populations such as cancer patients, pregnant and lactating women, and patients with 
hepatic diseases. The cerebrovascular bleeding is fast becoming a real concern, especially with 
the oral anticoagulants where mortality rate rises to 67%.162 
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Therefore, with such high demand for new anticoagulants, the current work deals with 
two specific aims (Figure 13): 
1) Design, synthesis, and biochemical evaluation of sulfated, nonsaccharide, allosteric 
activators of antithrombin based on the 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
(THIQ3CA) scaffold. These activators are expected to serve as indirect FXa inhibitors. This aim 
will be discussed in Chapters 3, 4, and 6. 
2) Design, synthesis and biochemical characterization of direct FXa inhibitors based on 
the 1,2,3,4-tetrahydroisoquinoline (THIQ) dicarboxamides. This aim will be discussed in 
Chapters 5 and 6. 
The first goal is of particular interest as it tends to establish a synthetic library of sulfated 
small molecules. Although the library is supposed to serve the stated objective, however 
establishing such a library demands optimizing or developing techniques to deal with sulfated 
compounds at several levels including synthesis, isolation, identification, and characterization. 
Furthermore, as the synthesized compounds carry the unique structural characteristic of being 
sulfated, they are elected to be potential heparin functional mimetics. In fact, the executed 
compounds of the chemical library will be added to a larger library of sulfated compounds for 
screening against other proteins interacting with heparin. This should help in addressing 
questions at a fundamental level regarding heparin–protein interactions. Finally, in lieu of 
appropriate computational tools to model such interactions, the biological profile of the 
synthesized compounds should help to validate, optimize, or develop new computational tools in 
order to eventually help in designing potent and selective heparin functional mimetics with high 
level of confidence and for the vast biological activities of heparin. 
  
 
 
 
 
 
 
 
 
 
Figure 13. Outline of the specific
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 aims of the current work. 
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CHAPTER 3: SYNTHESIS OF ELECTRONICALLY RICH N-SUBSTITUTED, 1,2,3,4–
TETRAHYDROISOQUINOLINE-3–CARBOXYLIC ACID ESTERS: PRECURSORS OF 
ANTITHROMBIN ACTIVATORS 
 
3.1. Introduction— Nitrogen heterocycles are key building blocks for a large number of 
medicinally–relevant molecules and serve as fundamental scaffolds for discovering drugs. The 
1,2,3,4–tetrahydroisoquinoline (THIQ) scaffold is an especially useful nitrogen heterocycle due 
to  its ability to quickly enhance structural diversity of a potential library. An interesting variant 
of the THIQ scaffold is the 1,2,3,4–tetrahydroisoquinoline–3–carboxylic acid (THIQ3CA) 
structure, which has been utilized in the design of several pharmacologically relevant 
molecules.163-166Desai and co–workers have exploited the THIQ3CA scaffold in the rational 
design of non–saccharide activators of AT.110  
Several methods are available for synthesis of the THIQ3CA analogs.167-175 The Pictet-
Spengler167 and Bischler–Napieralski168 reactions, which rely on cyclization of β-arylethylamine 
derivatives in presence of a protic or Lewis acid,176-187 are among most common protocols for 
this purpose. Several other methods have also been developed including cycloaddition and enyne 
metathesis reactions for the synthesis of 1,2–dihydroisoquinoline–3–carboxylic acids169 and 5,6–, 
6,7–, or 7,8–functionalized THIQ3CA esters.170,171 
An interesting method to synthesize THIQ3CA analogs has been to utilize α,α’–dibromo-
O-xylenes as dielectrophiles in reaction with a glycine equivalent. The glycine equivalents 
studied to date include (2S)–2–isopropyl–3,6–dimethoxy–5–methyl–2,5–dihydropyrazine (a),188 
(R)–di–tert–butyl 2–tert–butyl–4–oxoimidazolidine–1,3–dicarboxylate (b),189 diethyl 
acetamidomalonate (c),190 ethyl acetamidocyano–acetate (d),191 ethyl 2–(benzylidene 
amino)acetate (e),192 (6R)–6–isopropyl–3–methyl–5–phenyl–3,6–dihydro–2H–1,4–oxazin–2–one 
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(f),193 and 1,4–diacetyl piperazine-2,5-dione (g) (Figure 14).194 An alternative to using dibromo-
O-xylenes as electrophiles in the reaction with glycine donors is α-methyl benzyl bromide, which 
when reacted with (2S,5S)–1–benzoyl–2-tert–butyl-3,5-dimethyl–imidazolidin–4–one (h) 
(Figure 14) afforded α,β–dimethyl THIQ3CA after Pictet-Spengler cyclization.195 At a 
fundamental level, the glycine equivalents in these reactions undergo base-mediated, 
simultaneous or sequential C– and N– alkylation to afford racemic or enantiomerically pure 
products. If alkylation is sequential, then N–alkylation can be achieved by acid–mediated 
hydrolytic cyclization.188,193 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Glycine equivalents reported in literature for the synthesis of THIQ. 
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We have been interested in developing a THIQ3CA–based library to gain insight into the 
mechanism of AT activation by non-saccharide mimetics of heparin.106-110 The unique highly 
sulfated nature of the parent biomolecule, heparin, dictates that the THIQ3CA scaffold contain 
multiple hydroxyls for sulfation in the last step.112 Unfortunately, appropriate polyphenolic 
THIQ3CA precursors are either not available commercially or their purported synthesis based on 
literature reports fails to yield product in high yields and purity. More specifically, the starting 
materials (dimethoxy–β–arylethylamines) for the synthesis of 5,6–dimethoxy–, 5,8–dimethoxy–, 
and 6,7–dimethoxy–THIQ3CA esters using Pictet-Spengler and Bischler–Napieralski reactions 
are not available. The glycine equivalents approach is also not feasible for our targeted 
THIQ3CA derivatives because of the lack of availability of appropriate α,α’–dibromo-O–
xylenes. In fact, a survey of literature shows that each THIQ3CA derivative synthesized to date 
through the glycine equivalent approach has not carried any functionalization on the aromatic 
ring of THIQ3CA.188,189,193,195 An added problem has been that these reactions require extended 
reflux in strong bases191,192,195 and/or concentrated mineral acids.188,189,191,193,195 Such strong 
conditions severely limit the nature of protecting groups that can be used in the synthesis of 
polyphenolic THIQ3CAs. Finally although useful, the cyclo–addition approaches have been 
developed primarily for unsubstituted or minimally substituted THIQ3CA esters and are long 
winding.169-171 Thus, we realized that developing a facile, concise, high yielding synthesis to 
THIQ3CA analogs containing phenolic groups placed at varying positions was necessary for 
exploring a library of such molecules as anticoagulants. 
3.2. Results and Discussion— 
3.2.1. Glycine Donor based Approach to Synthesize Electronically Rich THIQ3CA 
Esters— A quick retro-synthetic analysis of the THIQ3CA core suggested that the structure 
42 
 
could be built using three building blocks – a benzaldehyde, formaldehyde, and a glycine 
equivalent moiety (1–3) (Figure 15). While the benzaldehyde block is available with many 
different electronically rich substituents, which provides a facile entry to the desired THIQ3CA 
esters, the glycine block has stringent requirements. One of the requirements is that the glycine 
unit should possess a more nucleophilic α–carbon than its amine and carboxylic acid groups. 
This is satisfied by imidazolidine-2,4-dione 1, commonly refered to as hydantoin (Scheme 1). To 
test its applicability, we utilized 2,3–dimethoxy and 2,5–dimethoxy benzaldehydes (4 and 5) that 
should yield 5,6–dimethoxy– and 5,8–dimethoxy–THIQ3CA derivatives, which are not readily 
accessible through other competing approaches and form key scaffold of our novel 
anticoagulants.110 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  15. Retrosysnthetic analysis for THIQ3CA scaffold based on new glycine equivalents. 
This figure is adapted from reference 268.
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Scheme 1.   Synthesis of 5,6– and 5,8– dimethoxy THIQ3CA esters using 1 and 2 as glycine equivalent. Adapted from reference 268.
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Reaction of benzaldehyde 4 with 1 at 170 ᴼC gave intermediate 6, which was 
hydrogenated to imidazolidine-2,4-dione 8 (Scheme 1). The hydantoin moiety of 8 was 
hydrolyzed and the resulting crude acid was esterified through sequential treatments with SOCl2 
and ethanol to afford 2,3-dimethoxy phenylalanine ethyl ester 10. Pictet–Spengler cyclization of 
10 under acidic conditions with aqueous formaldehyde resulted in 5,6-dimethoxy-THIQ3CA 
ethyl ester 12. 5,8-Dimethoxy derivative 13 was also synthesized using the same protocol. 
Although useful, the above protocol was not as high yielding and efficient as desired. 
Two other glycine equivalents, namely (±)-Boc-α-phosphonoglycine trimethyl ester 2 (Scheme 
1) and (±)-Z-α-phosphonoglycine trimethyl ester 3 (Scheme 2), were studied to improve yield 
and enhance feasibility. It is known that the α-proton of trimethylphosphonate is considerably 
acidic and formation of a strong O-P bond in the by-product dimethyl phosphate drives the 
addition–elimination reaction.196 Thus, we reasoned that glycine donors 2 and 3 may allow the 
use of milder conditions to effect similar transformations than those used for hydantion 1. A 
further advantage is likely to arise from the use of 2 and 3 was the easier purification of products 
because the by–product was known to be water soluble. In contrast, the hydantoin adduct 
required hot methanol for solubilization. The reaction was also expected to yield a predominantly 
Z-product197 and thus, these glycine donors offered an excellent opportunity for the synthesis of 
THIQ3CA esters.198 
Trimethyl phosphonate 2 was first treated with 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) at 0 ᴼC in THF and then with either benzalaldehyde 4 or 5 in a dropwise manner to yield 
the corresponding benzylidene 14 or 15, respectively, in yields of 77–85%. Catalytic 
hydrogenation and acidification with equi-volume mixture of TFA and CH2Cl2 gave the α-
amino-β-aryl methyl acrylate 18 or 19 in 80–86% yield. Lastly, Pictet–Spengler cyclization using 
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the condition of 37% HCHO/TFA in CH2Cl2 at RT afforded the corresponding THIQ3CA methyl 
esters 20 and 21 within 5 h and high yields of 70–80%. 
3.2.2. Further Improvement in the Glycine Donor Approach— Analysis of the 
approach described in Scheme 1 led to the realization that a significant improvement in the 
overall efficiency of the process would be realized if alkene reduction and deprotection steps can 
be achieved in one step. Thus, benzyloxycarbonyl (Cbz) derivatized α–phosphonoglycine 
trimethyl ester 3 was treated with either benzaldehyde 4, 5, or 22 to yield benzylidenes 23–25 in 
77-85% yield (Scheme 2). The planned simultaneous reduction and deprotection strategy was 
employed on benzylidene 23 using catalytic hydrogenation (50 psi H2 (g) and 10% Pd(OH)2 on 
charcoal in equivolume mixture of CH3OH and t-butanol) to give the desired α-amino-β-aryl 
amino methyl esters 18, 19, and 26 in good yields (73-76%, Scheme 2). Pictet–Spengler 
cyclization with formaldehyde under acidic conditions afforded the corresponding THIQ3CA 
methyl esters 20, 21, and 27 in high yields. 
Overall, using hydantoin 1 as glycine donor led to two THIQ3CA ethyl esters 12 and 13 
in six steps, while using phosphonoglycine trimethyl ester 2 as a glycine donor gave two di–
activated THIQ3CA methyl esters 20 and 21 in four steps. An alternative strategy involved the 
glycine donor 3, which utilized three mild and efficient steps for the synthesis of THIQ3CA 
methyl esters 20, 21, and 27. The hydantoin-based approach afforded THIQ3CA ethyl esters in 
21–30% overall yields, while the phosphonoglycine trimethyl esters 2 and 3 led to yields of 43–
58% and 40–52%, respectively. Finally, the Horner–Wadsworth–Emmons/Pictet–Spengler 
approach for synthesis of activated THIQ3CA esters is mild, concise, and high yielding. 
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Scheme 2.  Synthesis of 5,6– , 5,8–, and 6,7– dimethoxy THIQ3CA esters using (±)-Z-α-
Phosphonoglycine trimethyl ester 3, as glycine equivalent. Adapted from reference 268. 
3.2.3. Synthesis of Advanced N-Arylacyl, N-Arylalkyl, and Bis-THIQ3CA Analogs— 
The synthetic protocol developed above (Scheme 2) appeared very attractive for preparing a 
library of electronically rich THIQ3CA derivatives. In particular, (±)-Z-α-phosphonoglycine 
trimethyl ester 3 was especially useful as several novel THIQ3CA–based compounds could be 
synthesized in near quantitative yields. These include the N-arylacyl THIQ3CA esters 30-35 and 
38-42; the N-arylalkyl THIQ3CA ester 43 and the bis-THIQ3CA esters 44 and 45 (Scheme 3). 
The N–benzoyl and N–acetyl THIQ3CA esters 30-35 were synthesized by direct N-
acylation using benzoyl or phenyl acetyl chloride in the presence of triethylamine. The N–
propanoyl and N–butanoyl THIQ3CA esters 38-42 were prepared using EDCI–mediated 
coupling reactions with appropriate propioinc or butanoic acids in presence of DMAP at RT.  
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The synthesis of N-alkylated derivatives was somewhat more challenging than that 
described above for N-acylated derivatives. Several bases (K2CO3, Cs2CO3, Et3N, and DIPEA), 
solvent systems (CH3CN, DMF and their mixtures), and heating methods (conventional refluxing 
and microwave) were screened to identify high yielding conditions for N-p-methoxybenzyl 
THIQ3CA methyl ester 43. A 92% yield of 43 was obtained following microwave-assisted 
heating of 1 equivalent of THIQ3CA methyl ester 27, 2.5 equivalents of DIPEA, 1.1 equivalents 
of p-methoxy benzyl chloride in CH3CN at 150 ºC for 30 min. Combining these optimized 
conditions with search for best xylene-based electrophile (α,α’–dichloro or dibromo– m– and p–
xylenes) led to a high yielding synthesis of bis-THIQ3CA derivatives 44 and 45. The best 
dimerization yield (62–66%) was obtained by refluxing two equivalents of THIQ3CA 28 with 
one equivalent of a xylene derivative in presence of 4 equivalents of Cs2CO3 in equivolume 
mixture of DMF and CH3CN. 
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Scheme 3.   Synthesis of N-substituted THIQ3CA-based library. The scheme is adapted from reference 268.
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Overall, a small library of 14 THIQ3CA esters was synthesized using a combination of 
Horner–Wadsworth–Emmons/Pictet–Spengler reactions (Schemes 2 and 3) in near quantitative 
yields. These derivatives vary at different structural levels including the substitution pattern of 
THIQ3CA (5,6–; 5,8–; or 6,7–disubstituted moiety); the type of ester at position–2 (methyl or 
ethyl ester); the length of the linker (benzyl, benzoyl, acetyl, propanoyl, or butanoyl); and the 
type of the linker (amide as in N-arylacyl THIQ3CA or amine as in N-arylalkyl THIQ3CA); and 
lastly the number and pattern of substituents on the aryl moiety (4–substituted; 2,5–disubstituted; 
or 3,4,5–trisubstituted moieties). The library of electronically rich THIQ3CA ester analogs, and 
their chemically modified forms including deprotected poly-phenolic or poly-sulfated 
derivatives, is likely to be useful in mapping protein binding site(s) so as to deduce optimal 
binding and/or selectivity properties. 
From the perspective of chemical synthesis, several points are noteworthy regarding 
synthesis using (±)–Z–α–phosphonoglycine trimethyl ester 3. First, this approach can be further 
exploited in synthesis of many unnatural α-amino acids and their corresponding cyclic rigid 
forms. Second, the Pictet–Spengler reaction is highly amenable to microwave conditions, which 
greatly expedites the construction of a library. Third, it is possible to control chirality at the 3- 
position to afford enantiomerically pure THIQ3CA using rhodium (I) or ruthenium (II)–
catalyzed asymmetric hydrogenation.199,200 These advantages are expected to further enhance the 
applicability of the THIQ3CA library for drug discovery purposes. 
3.2.4. NMR Studies on N-Arylacyl THIQ3CA esters— A 1H NMR spectrum is thought 
of as a classic reflection of the purity of a new compound. The N–arylacyl THIQ3CA esters 
synthesized in this work were highly pure entities as indicated by RP-HPLC and uPLC-MS 
analysis, however, each molecule demonstrated complex 1H NMR and 13C NMR spectra, which 
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could not be analyzed on the basis of a single conformational entity composition. We reasoned 
that the complexity of NMR spectra arises from the –N–C(O)– bond at position–2, which was 
likely to exhibit partial double-bond character with cis- and trans-isomers. It was likely that the 
energy barrier for rotation around the amide bond was large resulting in geometrically and 
magnetically nonequivalent N-substituents. This phenomenon of rotational isomerism has been 
observed earlier for non-carboxylated THIQ derivatives.201-206 Considering the medicinal 
importance of the carboxylated THIQ derivatives being studied, we decided to investigate this 
phenomenon in detail so as to aid development of appropriate computational protocols for the 
interaction of THIQ3CA with proteins. Derivatives 32 and 35 were chosen as representative 
THIQ3CA analogs. 
For molecule 35, two sets of nine 1H signals were observed at room temperature in 
CDCl3 (Figure 16, Table 2). The relative proportion of the two pairs of peaks was essentially 
identical across all seven signals and was approximately 75:25. Likewise, 32 displayed two sets 
of seven 1H signals (Table 3). In addition, the number of 13C signals for both 32 and 35 were 
double the number of carbons, although the frequencies for some atoms could not be measured 
accurately due to lower resolution. These observations suggested the possibility of two 
conformational isomers. 
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Table 2. 1H NMR-CDCl3 parameters for set of signals that reveal the rotational isomerism in 
derivative 35. 
 
 
 
 
 
Protons Chemical Shift (δ) Splitting Integration 
Ha, Position-3 5.51-5.49  & 4.94-4.92 dd & dd 1 
Hb, Position-1 4.91-4.60 dd 1 
Hb, Position-1 4.52-4.30 dd 1 
Hc, Methylene linker 3.76 broad s 2 
Hd, Methyl ester 3.67-3.3.66 d 3 
He, Position-4 3.14-3.00 dt 1 
He, Position-4 3.02-2.96 & 2.89-2.84 dd & dd 1 
Hf, Position-8 6.49-6.40 d 1 
Hg, Position-5 6.56-6.53 d 1 
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Figure 16. 1H NMR spectrum of THIQ3CA analog 35 in CDCl3 showing duplicity of signals at ambient temperature. Inset shows 
6.0-4.0 δ region, assignable to ‘a’ and ‘b’ protons, for better clarity.  The figure is adapted from reference 268.
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Table 3. 1H NMR-CDCl3 parameters for set of signals that reveal the rotational isomerism in 
derivative 32. 
 
 
 
 
 
Protons Chemical Shift (δ) Splitting Integration 
Ha, Position-3 5.64-5.62 & 4.96-4.94 dd & dd 1 
Hb, Position-1 5.02-4.78 dd 1 
Hb, Position-1 4.41-4.14 dd 1 
Hc, Methylene linker 3.79-3.73 d 2 
Hd, Methyl ester 3.54-3.43 d 3 
He, Position-4 3.42-3.37 m 1 
He, Position-4 2.78-2.72 & 2.55-2.49 dd & dd 1 
 
To understand whether polarity of solvent affects conformational preferences, the 1H 
NMR spectrum of 32 was studied in C6D6, CDCl3, CD3CN, and DMSO-d6 at ambient 
temperature. The effect was studied by monitoring Ha, Hd, and He signals (Figure 17). For proton 
He the splitting pattern changed dramatically as the solvent polarity increased. The two doublet 
of doublets in C6D6 and CDCl3 merged into an unresolved multiplet in CD3CN, and gave one 
doublet of doublet in DMSO-d6 (Figure 17A). Protons Ha and Hd belonging to carbon-3 and 
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methyl ester group, respectively, displayed a gradual loss of intensity as the signal spread due to 
increase in solvent polarity. Whereas the signal spread was 375.7 Hz for Ha in C6D6, it decreased 
to 62.0 Hz in DMSO-d6 (Figure 17C, see Table 4). Likewise, the spread decreased from 42.6 Hz 
(C6D6) to 9.7 Hz (DMSO-d6) for Hd (Figure 17B, Table 4). This likely indicates that the two 
conformers tend to coalesce with increasing solvent polarity which favorably stablizes the 
oppositely charged double bond charcter of position–3 amide bond.  
Table 4. The change in ∆δ for protons Ha and Hd of the two detected conformers of THIQ3CA 
derivative 32 in different solvents. 
Solvents Ha ∆δ (Hz) Hd ∆δ (Hz) 
C6D6 374.68 42.64 
CDCl3 
  269.22 46.76 
CD3CN 151.98 19.24 
DMSO-d6 61.98 9.68 
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 Figure 17. Solvent-dependent changes in the conformational isomerism of 32. A) 3.1-2.4 δ; B) 3.9-2.8 δ; and C) 6.2-3.8 δ.The 
figure is adapted from reference 268.
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The influence of temperature on the conformational distribution of THIQ3CA analog 32 
was studied by measuring spectral changes in DMSO-d6 over the range of 293 – 373 K. Figure 
18 shows that the signal spread (∆δ) between the signals of Ha (position-3 proton) and Hb 
(position-1 protons) gradually decreases as the temperature increases. Both signals retain distinct 
resonance positions until 353 K and then start to coalesce on the NMR time scale. Measurements 
at 373 K for both Ha and Hb show that the two conformers have lost their distinction and exhibit 
a rapidly equilibrating species. Likewise, two singlets at 3.54 and 3.49 δ corresponding to Hd 
merge as one singlet 3.57 δ and the two doublet of doublet at 2.78-2.72 δ and 2.55-2.49 δ 
corresponding to He also coalesce as one doublet at 2.82-2.78 δ (not shown). At ambient 
temperature, the ratio of the major to minor conformer was approximately 3 to 1, which 
equalized over the range of 353 – 373 K. 
The variable temperature results can be used to analyze the free energy of activation of 
the dynamic inter-conversion between the conformers. The Eyring equation based on detailed 
line-shape analysis is the most accurate method, although several other methods have been 
reported.206-208 Two approximations have been particularly useful including equations 1 and 2 
that afford reliable estimates of the free energy of interconversion (∆G++) in conjunction with the 
rate constant (kc) at the coalescence temperature (TC).207,208 In these equations, a is constant with 
a value of 0.004575 kcal/mol, T is the temperature in Kelvin (K), and ∆ν is the maximum peak 
separation in Hz. This approach has been shown to give reliable estimates for both coalescing 
singlets and doublets with different intensities as long as ∆ν > 4 Hz. 
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Figure 18. Temperature effect on the conformational isomerism of 32 in DMSO–d6. The 
entire 1H NMR spectrum of 32 was recorded but only the 5.6-3.8 δ range is shown for enhanced 
clarity. 1H NMR spectra at 293, 313, 333 and 353 K were recorded on a Varian 300 MHz 
instrument, while the spectrum at 373 K was recorded on a  Bruker 400 MHz. The figure is 
adapted from reference 268. 
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Using this approach, evaluation of the two singlets at 3.56 and 3.53 δ, belonging to the 
methyl ester proton Hd, resulted in values of 16.7 ± 1.0 kcal/mol and 15.5 ± 1.9 Hz for ∆G++ and 
kc at 353 K, respectively. This value is significantly higher than a value of 7.8 kcal/mol and 15 
kcal/mol for N-acetyl-1-benzyl and N-acetyl-1,3-dimethyl THIQ derivatives and comparable to 
the activation energy range of 17.7 – 20.1 measured for N-acetyl-1-alkylidene THIQ (Figure 
19).202-204 
Figure 19. THIQ derivatives display a wide range of energy barriers for conformational 
transitions. The N–arylacyl THIQ3CA esters studied in this work show a distinct high energy 
barrier of ~17 kca/mol. The figure is adapted from reference 268. 
Overall, our work reveals that the duplicity of NMR signals persists for all THIQ3CA 
derivatives irrespective of groups present on the scaffold as long as the position–2 linker is an 
amide. Conformational isomerism noted for N–arylacyl THIQ3CA analogs arises from rotational 
restrictions around the amide bond at position–2 with an estimated ∆G++ of ~17 kcal/mol. Lastly, 
we expect that the two corresponding rotational isomers to be equi-energetic with a calculated 
energy difference of 0.655 kcal/mol (∆G° = -2.3RTlogKe, in which ∆G° is the standard energy 
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difference; R is the gas constant; T is temperature in Kelvin and Ke is the equilibrium constant, 
which was found to be 0.33 based on the NMR study). 
3.3. Conclusion—In this work, we describe multiple strategies that yield THIQ3CAs 
containing multiple electron rich methoxy substituents. The work leads to a major conclusion 
that highly substituted, electron rich THIQ3CA analogs can be synthesized in three, mild, and 
high yielding steps based on Horner–Wadsworth–Emmons and Pictet–Spengler reactions. 
Interestingly, NMR studies indicate that the N–arylacyl–THIQ3CA derivatives display two equi-
energetic, conformational isomers that are separated by a high kinetic barrier of ~17 kcal/mol. 
This phenomenon is of major significance for structure-based drug design considering that such 
efforts typically utilize only one of the rotamers. 
3.4. Experimental Section— 
3.4.1. Chemicals and Reagents— Anhydrous CH2Cl2, THF, CH3CN, DMF, and toluene 
were purchased from Sigma-Aldrich (Milwaukee, WI) or Fisher Scientific (Pittsburgh, PA) and 
used as such. All other solvents were of reagent gradient and used as supplied. Other chemical 
reagents were purchased either from Sigma-Aldrich, Fisher Scientific, or Alfa-Aesar (Ward Hill, 
MA). Analytical TLC was performed using UNIPLATETM silica gel GHLF 250 µm pre-coated 
plates (ANALTECH, Newark, DE). TLC was visualized using light of 254 nm. Chemical 
reactions sensitive to air or moisture were carried out under nitrogen atmosphere in oven-dried 
glassware. All reagent solutions unless otherwise noted were handled under an inert nitrogen 
atmosphere using syringe techniques. Each chemical reaction was optimized to afford a yield of 
more than 65%. 
3.4.2. Purification of Reaction Products— Flash chromatography was performed using 
Combiflash RF from Teledyne Isco (Lincoln, NE) and disposable normal silica cartridges of 30–
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70 µ particle size, 230–400 mesh size and 60 Å pore size. The normal phase silica content of 
cartridges were 4–24 gms (for purification of 250–1000 mg crude samples). Mobile linear 
gradients utilized either EtOAc or CH3OH in hexanes or CH2Cl2, respectively. The flow rate of 
the mobile phase was in the range of 18 to 35 ml/min based on the size of the silica cartridge.   
3.4.3. NMR Studies— The 1H and 13C NMR spectra were recorded on Bruker 400 MHz 
spectrometer (unless otherwise noted) in CDCl3, DMSO-d6, CD3OD, C6D6 or CD3COCD3. 
Signals, in part per million (ppm), are either relative to the internal standard (tetramethyl silane, 
TMS) or to the residual peak of the solvent. The NMR data are being reported as: chemical shift 
(ppm), multiplicity of signal (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of 
doublet, m = multiplet, br = broad), coupling constants (Hz), and integration. 
1H and 13C NMR spectra of compounds were measured using 5 – 35 mg sample dissolved 
in 0.6 mL of solvent. For 1H NMR spectrum, 16 scans were recorded with a spectral width of 
8223.685 Hz, a FID resolution of 0.125 Hz, relaxation delay of 1 s, and acquisition time of 4 s, 
while the 13C spectra were recorded using 1024 – 10240 scans with a spectral width of 
24038.461 Hz, FID resolution of 0.367 Hz, acquisition time of 1.5 s, and a relaxation delay of 2 
s. Variable temperature NMR studies were performed on a Varian 300 MHz in the range of 293–
353 K and on a Bruker 400 MHz at temperatures up to 373 K. 
3.4.4. Mass Spectrometric Characterization— The ESI MS characterization of all 
THIQ3CA derivatives was performed using a Waters Acquity TDQ mass spectrometer in 
positive ion mode. Samples, dissolved in methanol, were infused at a rate of 20 µL/min and mass 
scans were collected in the range of 200 – 700 amu with a scan time of 1 s. The capillary and 
cone voltages were varied between 3 – 4 kV and 38 – 103 V, respectively. The extractor voltage 
was set to 3 V, the Rf lens voltage was 0.1 V, the source block temperature was 150 ºC, and 
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desolvation temperature was set to about 250 ºC. Ionization conditions were optimized for each 
compound to maximize ionization of the parent ion. 
3.4.5. General Synthetic Procedures and Spectral Characterization Data— 
General Procedure for Preparation of Benzylidene Imidazoline-2,4-dione 
Derivatives 6 and 7. Hydantoin 1 (5.0 gm, 50.0 mmol), anhydrous sodium acetate (8.2 gm, 
100.0 mmol) and aldehyde (4 or 5) (7.5 gm, 45.0 mmol) were successively added in a solution of 
glacial acetic acid (15 mL) and acetic anhydride (2 mL). The mixture was stirred at 170 °C under 
nitrogen atmosphere for 3 h. Upon cooling to 110 °C, water (100 mL) was added drop-wise and 
the mixture left for stirring overnight at RT. The orange precipitate of the desired compound was 
filtered off and then washed with water to remove acetic acid, the unreacted hydantoin, and 
sodium acetate. The orange solid was then purified by flash chromatography using mobile phase 
gradient of 40% to 100% (EtOAc: hexanes) to afford benzylidene imidazoline-2,4-dione 
derivative 6 or 7 as yellow to white solid in 65-72% yield. 
5-(2,3-dimethoxybenzylidene)imidazolidine-2,4-dione (6). 1H NMR (DMSO-d6, 400 
MHz): δ = 11.24 (br, 1H, NH), 10.39 (s, br, 1 H, NH), 7.25 (d, 1J = 6.9 Hz, 1 H, Ar), 7.08  (t, 1J 
= 8.0 Hz, 1H, Ar), 7.03 (d, 1J = 7.2, 1 H, Ar), 6.62 (s, 1 H, CH), 3.81 (s, 3 H, CH3), 3.74 (s, 3H, 
CH3). 13C NMR (DMSO-d6, 100 MHz): δ = 165.5, 155.5, 152.4, 147.1, 128.7, 126.7, 124.2, 
113.3, 102.3, 60.6, 55.7. MS (ESI) calculated for C12H12N2O4, [M+H]+, m/z 249.09, found for 
[M+Na]+, m/z 271.20. 
5-(2,5-dimethoxybenzylidene)imidazolidine-2,4-dione (7).  1H NMR (DMSO-d6, 400 
MHz): δ = 7.12 (d, 1J= 2.9 Hz, 1 H, Ar), 6.96 (d, 1J = 9.0 Hz, 1 H, Ar), 6.88-6.85 (dd, 1J= 3.0 
Hz, 2J = 9.0 Hz, 1 H, Ar), 6.55 (s, 1H, CH), 3.78 (s, 3H, CH3), 3.77 (s, 3H, CH3).  13C NMR 
(DMSO-d6, 100 MHz): δ =166.8, 157.1, 153.0, 151.4, 129.4, 122.6, 115.1, 114.1, 112.1, 101.8, 
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56.0, 55.5. MS (ESI) calculated for C12H12N2O4, [M+H]+, m/z 249.09, found for [M+Na]+, m/z 
271.23. 
General Procedure for Preparation of Benzyl Imidazoline-2,4-dione Derivatives 8 
and 9. Benzylidene imidazolidine-2,4-dione derivative (6 or 7) (7.3 gm, 29.5 mmol) was 
dissolved in hot ethanol (100 mL) followed by addition of 10% Pd/C (0.73 gm) after cooling. H2 
gas was then pumped into the reaction vessel to achieve 50 psi at RT. After stirring the mixture 
for 5 h, the catalyst was filtered on Celite, which was washed using a 1:1 mixture of EtOAc and 
CH3OH. The organic filtrate was concentrated in vacuo to afford the corresponding reduced 
product (8 or 9) in ~100% yield which was used without any further purification. 
5-(2,3-Dimethoxybenzyl)imidazolidine-2,4-dione (8). 1H NMR (DMSO-d6, 400 MHz): 
δ = 10.58 (s, 1 H, NH), 7.76 (s, 1 H, NH), 7.00-6.94 (dd, 1J = 8.0 Hz, 2J = 15.6, 1 H, Ar), 6.94-
6.91 (dd, 1J = 1.6 Hz, 2J = 8.2 Hz, 1 H, Ar), 6.81-6.79 (dd, 1J = 1.6 Hz, 2J = 7.4 Hz, 1 H, Ar), 
4.26 (t,  1J= 6.5 Hz, 1 H, CH), 3.79 (s, 3H, CH3), 3.73 (s, 3H, CH3), 3.09-3.04 (dd,  1J = 4.9 Hz, 
2J = 13.9 Hz, 1 H, CH), 2.81-2.76 (dd, 1J = 7.5 Hz, 2J = 13.9 Hz, 1 H, CH).  13C NMR (DMSO-
d6, 100 MHz): δ = 175.4, 157.3, 152.2, 147.1, 129.7, 122.4, 111.6, 60.0, 58.0, 55.5, 31.5. MS 
(ESI) calculated for C12H14N2O4, [M+H]+, m/z 251.10, found for [M+Na]+, m/z 273.24. 
5-(2,5-Dimethoxybenzyl)imidazolidine-2,4-dione (9). 1H NMR (DMSO-d6, 400 MHz): 
δ = 10.60 (s, 1 H, NH), 7.75 (s, 1 H, NH), 6.87 (d, 1J= 8.6 Hz, 1 H, Ar), 6.78 (d, 1J = 3.0 Hz, 1 H, 
Ar), 6.76-6.74 (m, 1 H, Ar), 4.26-4.22 (dd,  1J= 5.1 Hz, 2J = 7.2 Hz, 1 H, CH), 3.71 (s, 3H, CH3), 
3.68 (s, 3H, CH3), 3.08-3.03 (dd,  1J = 4.8 Hz, 2J = 13.8 Hz, 1 H, CH), 2.72-2.67 (dd, 1J = 7.6 
Hz, 2J = 13.8 Hz, 1 H, CH).  13C NMR (DMSO-d6, 100 MHz): δ =175.5, 157.4, 152.7, 151.5, 
125.4, 117.1, 112.2, 111.5, 57.4, 55.8, 55.2, 32.2.  MS (ESI) calculated for C12H14N2O4, [M+H]+, 
m/z 251.10, found for [M+Na]+, m/z 273.24. 
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General Procedure for Preparation of Dimethoxy Phenylalanine Ethyl Esters 10 and 
11. A mixture of the benzyl imidazolidine-2,4-dione (8 or 9) (7.0 gm, 28.0 mmol), barium 
hydroxide (14.4 gm, 84.0 mmol) and water (150 mL) was refluxed for 48 h, then filtered hot and 
the residue washed with hot water. Following cooling, the filtrate was acidified to pH 6.5 with 
50% H2SO4. The resulting BaSO4 precipitate was filtered and the pH of the aqueous filtrate 
adjusted to 9.0 using NH4OH. The aqueous filtrate was then concentrated, suspended in ethanol 
(100 mL), treated with thionyl chloride (20 mL of 2.0 M solution in CH2Cl2) at 0 ºC, and then 
mixture refluxed for 4 h. Following neutralization with saturated NaHCO3 solution, the reaction 
mixture was partitioned between EtOAc and water, and a crude product obtained from the 
EtOAc layer. Flash chromatography using 70% (EtOAc: hexanes) as the mobile phase was used 
to yield derivative 10 or 11 as white solid in 43-51% yield. 
Ethyl 2,3-dimethoxy phenylalanine (10). 1H NMR (CDCl3, 400 MHz): δ = 6.91 (t, 1J = 
7.9 Hz, 1 H, Ar),  6.75-6.73 (dd, 1J = 1.4 Hz, 2J = 8.2 Hz, 1 H, Ar), 6.70-6.68 (dd, 1J = 1.4 Hz, 2J 
= 7.6 Hz, 1 H, Ar) 4.10-4.04 (q, 1J = 7.2 Hz, 2 H, CH2), 3.78 (s, 3 H, CH3), 3.76 (s, 3 H, CH3), 
3.73-3.67 (m, 1 H, CH),  3.03-2.99 (dd, 1J = 5.6 Hz, 2J = 13.3 Hz, 1 H, CH), 2.83-2.78 (dd, 1J = 
8.3 Hz, 2J = 13.3 Hz, 1 H, CH), 1.15 (t, 1J= 7.1 Hz, 3 H, CH3). 13C NMR (CDCl3, 100 MHz): δ 
=175.1, 152.8, 147.7, 131.2, 123.8, 122.8, 111.3, 60.8, 60.5, 55.7, 55.1, 35.8, 14.1. MS (ESI) 
calculated for C13H19NO4, [M+H]+, m/z 254.14, found for [M+H]+, m/z 254.30. 
Ethyl 2,5-dimethoxy phenylalanine (11).  1H NMR (CDCl3, 400 MHz): 6.79-6.76 (m, 1 
H, Ar), 6.74 (d, 1J = 3.0 Hz, 1 H, Ar), 6.72 (d, 1J = 1.8 Hz, 1 H, Ar), 4.18-4.11 (q, 1J = 7.2 Hz, 
2H, CH2), 3.80-3.78 (m, 1H, CH),  3.77 (s, 3H, CH3), 3.74 (s, 3 H, CH3), 3.09-3.03 (dd, 1J = 6.0 
Hz, 2J = 12.2 Hz, 1 H, CH), 2.86-2.79 (dd, 1J = 9.0 Hz, 2J = 12.1 Hz, 1H, CH), 1.15 (t, 1J = 7.2 
Hz, 3 H, CH3). 13C NMR (CDCl3, 100 MHz): δ =173.1, 153.5, 151.9, 125.9, 117.4, 112.7, 111.5, 
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61.2, 56.0, 55.7, 53.8, 33.1, 14.1. MS (ESI) calculated for C13H19NO4, [M+H]+, m/z 254.14, 
found for [M+H]+, m/z 254.30. 
General Procedure for Pictet–Spengler Reaction to Synthesize 12, 13, 20, 21 and 27. 
A solution of substituted phenylalanine methyl (18, 19, or 26) (0.6 gm, 2.5 mmol) or ethyl ester 
(10 or 11) (0.5 gm, 2.0 mmol) in CH2Cl2 (10 mL) was treated with formaldehyde (37% aq. 
solution, 0.2-0.25  mL, 2.5-3.0 mmol) at RT. Trifluoro-acetic acid (TFA, 3.7-4.6 gm, 2.5-3.0 mL, 
10.0-12.5 mmol) was then slowly added over 15 min and the reaction mixture was stirred for 5 h 
following which it was diluted with CH2Cl2 (15 mL) and neutralized with saturated NaHCO3 
solution (20 mL). The organic extracts of the aqueous solution were combined, the solvent 
evaporated under reduced pressure, and the crude mixture was separated by flash 
chromatography using the mobile phase of 50% (EtOAc: hexanes) to give the desired THIQ3CA 
ethyl ester (12 or 13) or methyl ester (20, 21 or 27) as yellow oil in 70-82% yield. 
Ethyl 5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (12).  1H NMR 
(CDCl3, 400 MHz): δ = 6.73 (s, 2H, Ar), 4.10-3.80 (m, 5 H, CH, 2 × CH2), 3.80 (s, 3 H, CH3), 
3.79 (s, 3 H, CH3), 3.26 (d, 1J = 16.8 Hz, 1 H, CH), 3.04-2.94 (dd, 1J= 6.3 Hz, 2J = 17.1 Hz, 1 H, 
CH), 1.15 (t, 1J = 7.2 Hz, 3 H, CH3). 13C NMR (CDCl3, 100 MHz): δ = 173.2, 150.5, 146.5, 
127.5, 127.0, 121.7, 109.7, 61.1, 55.7, 55.5, 55.3, 42.8, 26.2, 14.1. MS (ESI) calculated for 
C14H19NO4, [M+H]+, m/z 266.14, found for [M+H]+, m/z 266.28. 
Ethyl 5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (13).  1H NMR 
(CDCl3, 400 MHz):  δ = 6.58 (d, 1J = 8.9 Hz, 1 H, Ar), 6.55 (d, 1J = 8.9 Hz, 1 H, Ar), 4.20-4.18 
(dd,  1J = 2.3 Hz, 2J = 7.2 Hz, 1 H, CH), 4.16-4.14 (dd, 1J = 2.2 Hz, 2J = 7.2 Hz, 1 H, CH), 4.13 
(d, 1J = 14.2 H, 1 H, CH), 3.80 (d, 1J = 17.0 Hz, 1 H, CH), 3.71 (s, 3 H, CH3), 3.69 (s, 3 H, CH3), 
3.59-3.55 (dd,  1J = 4.6 Hz, 2J = 10.4 Hz, 1 H, CH), 3.07-3.01 (ddd, 1J = 1.0 Hz, 2J = 4.5 Hz, 3J 
65 
 
=17.1 Hz, 1 H, CH), 2.64-2.57 (dd, 1J = 10.4 Hz, 2J = 17.1 Hz, 1 H, CH), 1.24 (t, 1J = 7.2 Hz, 3 
H, CH3). 13C NMR (CDCl3, 400 MHz): δ = 173.1, 151.2, 150.0, 124.9, 123.6, 107.4, 107.1, 61.1, 
55.7, 55.5, 55.3, 42.8, 26.2, 14.1. MS (ESI) calculated for C14H19NO4, [M+H]+, m/z 266.14, 
found for [M+H]+, m/z 266.28 . 
Methyl 5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (20). 1H NMR 
(CDCl3, 400 MHz): δ = 6.68 (s, 2H, Ar), 3.97-3.78 (m, 3H, CH, CH2), 3.75 (s, 3H, CH3), 3.73 (s, 
3H, CH3), 3.47, (s, 3 H, CH3), 3.22-312 (dd, 1J = 4.3 Hz, 2J = 17.4 Hz, 1H, CH), 2.97-2.91 (dd, 
1J = 9.2 Hz, 2J = 16.4 Hz, 1H, CH). 13C NMR (CDCl3, 100 MHz): δ = 173.2, 150.5, 146.5, 
127.5, 127.0, 121.7, 110.7, 60.1, 56.9, 55.8, 51.3, 49.3, 25.8. MS (ESI) calculated for 
C13H17NO4, [M+H]+, m/z 252.12, found for [M+H]+, m/z 252.26. 
Methyl 5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylat (21).  1H NMR 
(CDCl3, 400 MHz): δ = 6.53 (d, 1J = 3.1 Hz, 1 H, Ar), 6.52 (d, 1J = 2.9 Hz, 1 H, Ar), 3.94-3.87 
(m, 2H, CH2), 3.86-3.81 (dd, 1J = 7.8 Hz, 2J = 16.4 Hz, 1 H, CH), 3.69 (s, 3H, CH3), 3.67 (s, 3H, 
CH3), 3.46 (s, 3H, CH3), 3.12-3.13.06 (dd, 1J = 3.9 Hz, 2J = 17.2 Hz,1H, CH), 2.86-2.79 (dd, 1J = 
10.2 Hz, 2J = 17.4 Hz, 1H, CH). 13C NMR (CDCl3, 100 MHz): δ = 173.5, 151.2, 150.2, 124.7, 
123.2, 107.1, 106.8, 60.1, 56.4, 55.7, 51.2, 45.6, 25.0.  MS (ESI) calculated for C13H17NO4, 
[M+H]+, m/z 252.12, found for [M+H]+ m/z 252.14. 
Methyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (27). 1H NMR 
(CDCl3,400 MHz): δ = 6.52 (s, 1 H, Ar), 6.46 (s, 1 H, Ar), 4.08-3.98 (dd, 1J = 15.8 Hz, 2J= 25.6 
Hz, 2 H, CH2), 3.73-3.79 (m, 1 H, CH), 3.78 (s, 3 H, CH3), 3.77 (s, 3 H, CH3), 3.72 (s, 3 H, 
CH3), 3.00-2.95 (dd, 1J= 4.8 Hz, 2J = 16.1 Hz, 1 H, CH), 2.91-2.84 (dd,  1J = 9.7 Hz, 2J= 16.0 
Hz, 1 H, CH). 13C NMR (CDCl3, 100 MHz): δ = 172.7, 147.8, 125.5, 124.4, 111.7, 108.9, 55.9, 
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55.6, 52.3, 46.4, 30.6. MS (ESI) calculated for C13H17NO4, [M+H]+, m/z 252.12, found for 
[M+Na]+, m/z 274.19. 
General procedure for Horner–Wadsworth–Emmons Reaction for Synthesis of 14, 
15, 23, 24 and 25. To a solution of (±)-Boc-α-phosphono glycine trimethyl ester 2 (2.0 gm, 6.7 
mmol) or (±)-Z-α-phosphonoglycine trimethyl ester 3 (2.0 gm, 6.0 mmol) in dry THF (3 mL) 
was added DBU (0.91-1.0 gm, 6.0-6.7 mmol) and the mixture stirred for 30 min at 0 °C. A 
solution of either 2,3-dimethoxy benzaldehyde 4, 2,5-dimethoxy benzaldehyde 5, or 3,4-
dimethoxybenzaldehyde 22 (0.83-0.93 gm, 5.0-5.6 mmol) in dry THF (3 mL) was then added 
slowly. The reaction mixture was allowed to warm to RT, stirred for 5 h and the solvent 
evaporated under reduced pressure. The residue was taken up in EtOAc (50 mL) and following 
routine organic extraction and evaporation procedures a crude product was obtained. The crude 
product was then purified by flash chromatography using 30% (EtOAc: hexanes) as eluent to 
give 14, 15, or 23-25 as white to yellow solid in 77-85% yield. 
Methyl-2-(tert-butoxycarbonylamino)-3-(2,3-dimethoxyphenyl)acrylate (14). 1H 
NMR (CDCl3, 400 MHz): δ = 7.12 (s, 1 H, Ar), 7.06 (d, 1J = 4.3 Hz, 2 H, Ar), 6.91-6.89 (dd, 1J 
= 0.7 Hz, 2J = 4.8 Hz, 1H, CH), 3.88 (s, 3H, CH3), 3.86 (s, 3H, CH3), 3.80 (s, 3H, CH3), 1.40 (s, 
9H, 3 × CH3). 13C NMR (CDCl3, 100 MHz): δ = 166.2, 153.0, 152.9, 147.0, 128.3, 127.6, 124.2, 
121.9, 121.7, 112.7, 80.7, 61.4, 55.9, 52.5, 28.1. MS (ESI) calculated for C17H23NO6, [M+H]+, 
m/z 338.16, found for [M+H]+, m/z  338.32. 
Methyl-2-(tert-butoxycarbonylamino)-3-(2,5-dimethoxyphenyl)acrylate (15).  1H 
NMR (CDCl3, 400 MHz): δ = 7.21 (s, 1H, Ar), 7.01 (s, 1 H, Ar), 6.78 (t, 1J = 0.9 Hz, 1 H, CH), 
3.78 (s, 3H, CH3), 3.76 (s, 3H, CH3), 3.68 (s, 3H, CH3), 1.32 (s, 9 H, 3 × CH3). 13C NMR 
(CDCl3, 100 MHz): δ = 166.1, 153.4, 152.8, 151.5, 126.1, 123.8, 123.5, 116.1, 114.5, 112.6, 
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80.7, 56.5, 55.7, 52.4, 28.3. MS (ESI) calculated for C17H23NO6, [M+H]+, m/z 338.16, found for 
[M+Na]+, m/z 360.18. 
Methyl-2-(benzyloxycarbonylamino)-3-(2,3-dimethoxyphenyl)acrylate (23). 1H NMR 
(CDCl3, 400 MHz): δ = 7.32-7.28 (m, 5H, Ar), 7.18 (s, 1 H, Ar), 6.96-6.93 (m, 2 H, Ar), 6.83-
6.81 (m, 1 H, CH), 5.00 (s, 2 H, CH2), 3.79 (s, 3H, CH3), 3.73 (s, 3H, CH3) 3.69 (s, 3H, CH3). 
13C NMR (CDCl3, 100 MHz): δ = 165.7, 153.7, 153.0, 146.9, 136.0, 128.5, 128.3, 128.2, 128.0, 
127.0, 124.3, 123.7, 121.6, 112.9, 67.3, 61.5, 55.8, 52.6. MS (ESI) calculated for C20H21NO6, 
[M+H]+, m/z 372.14, found for [M+H]+, m/z 372.28. 
Methyl-2-(benzyloxycarbonylamino)-3-(2,5-dimethoxyphenyl)acrylate (24). 1H NMR 
(CDCl3, 400 MHz): δ = 7.34-7.30 (m, 5H, Ar), 6.99 (d, 1J= 2.0 Hz, 1 H, Ar), 6.84 (d, 1J = 2.4 
Hz, 2 H, Ar), 6.77-6.73 (m, 1H, CH), 5.08 (s, 2H, CH2), 3.73 (s, 6 H, 2 × CH3), 3.59 (s, 3H, 
CH3). 13C NMR (CDCl3, 100 MHz): δ =165.7, 153.5, 152.8, 151.4, 136.0, 128.6, 128.4, 128.2, 
125.8, 125.0, 123.4, 116.4, 114.4, 112.9, 67.3, 56.6, 55.6, 52.5. MS (ESI) calculated for 
C20H21NO6, [M+H]+, m/z 372.14, found for [M+H]+, m/z 372.32. 
Methyl-2-(benzyloxycarbonylamino)-3-(3,4-dimethoxyphenyl)acrylate (25).  1H 
NMR (400 MHz, CDCl3): δ = 7.36 (s, 1 H, Ar), 7.35-7.30 (m, 4 H, Ar), 7.13-7.11 (m, 2 H, Ar), 
6.90-6.85 (m, 1 H, Ar), 6.82 (d, 1J = 8.9 Hz, 1 H, CH), 6.26 (br, s, 1 H, NH), 5.13 (s, 2 H, CH2), 
3.90 (s, 3 H, CH3), 3.81 (s, 3 H, CH3), 3.71 (s, 1 H, CH3). 13C NMR (CDCl3, 100 MHz): δ = 
165.9, 150.4, 148.8, 136.0, 133.0, 130.0, 128.5, 128.3, 126.4, 124.2, 124.2, 122.1, 114.2, 112.2, 
110.9, 67.5, 55.9, 55.6, 52.6. MS (ESI) calculated for C20H21NO6, [M+H]+, m/z 372.14, found for 
[M+H]+, m/z  372.28. 
General Procedure for Catalytic Hydrogenation of N-Boc and N-Cbz Protected α-
Amino-β-aryl methyl acrylates. Method A: Methyl acrylate (14 or 15) (0.5 gm, 1.5 mmol) and 
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10% Pd/C (0.05 gm) were mixed in ethanol (15 mL) and H2 gas pumped into the reaction 
mixture at RT. After stirring the solution 5 h, the catalyst was filtered on Celite and the organic 
filtrate concentrated in vacuo to afford the reduced product (16 or 17) as white solid in ~100% 
yield. Method B: N-Cbz protected methyl acrylate 23, 24, or 25 (0.5 gm, 1.3 mmol) and 10% 
Pd(OH)2 (0.05 gm) on activated charcoal were mixed in CH3OH:t-butanol (1:1) mixture (10 mL) 
and H2 gas pumped into the mixture at RT. After stirring overnight, the catalyst was filtered on 
Celite, the organic filtrate concentrated in vacuo, and the residue purified by flash 
chromatography using 70% (EtOAc: hexanes) as mobile phase to afford the corresponding 
dimethoxy β-aryl-α-amino methyl ester 18 (oil), 19 (oil), or 26 as a yellow solid in 73-76% yield. 
Methyl 2-(tert-butoxycarbonylamino)-3-(2,3-dimethoxyphenyl)propanoate (16). 1H 
NMR (CDCl3, 400 MHz): δ = 7.00 (t, 1J = 1.5 Hz, 1H, Ar), 6.82 (d, 1J= 8.2 Hz, 1 H, Ar), 6.73 (d, 
1J= 7.6, 1 H, Ar), 5.32 (d, 1J= 7.0 Hz, 1 H, NH), 4.48-4.43 (dd, 1J= 6.8 Hz, 2J= 13.2 Hz, 1 H, 
CH), 3.86 (s, 3H, CH3), 3.84 (s, 3H, CH3), 3.71 (s,3H, CH3), 3.06-3.04 (m, 2 H, CH2), 1.39 (s, 
9H, 3 × CH3). 13C NMR (CDCl3, 100 MHz): δ = 172.8, 155.4, 152.7, 147.5, 130.1, 124.0, 122.7, 
111.6, 79.6, 60.6, 55.7, 54.7, 52.2, 32.4, 28.3. MS (ESI) calculated for C17H25NO6, [M+H]+, m/z 
340.18, found for [M+Na]+, m/z 361.82. 
Methyl 2-(tert-butoxycarbonylamino)-3-(2,5-dimethoxyphenyl)propanoate (17). 1H 
NMR (CDCl3, 400 MHz): δ = 6.70-6.68 (m, 2H, Ar), 6.61 (d, 1J= 2.8 Hz, 1 H, Ar), 5.19 (d, 1J= 
7.1 Hz, 1 H, NH), 4.45-4.39 (dd, 1J= 13.2 Hz,  2J= 7.0 Hz, 1 H, CH), 3.71 (s, 3H, CH3), 3.67 (s, 
3H, CH3), 3.64 (s, 3H, CH3), 2.96 (t, 1J= 4.8 Hz, 2H, CH2), 1.31 (s, 9H, 3 × CH3). 13C NMR 
(CDCl3, 100 MHz): δ = 172.7, 155.2, 153.5, 151.8, 125.7, 117.2, 112.7, 111.3, 79.5, 55.8, 55.6, 
54.1, 52.0, 32.9, 28.2. MS (ESI) calculated for C17H25NO6, [M+H]+, m/z 340.18, found for 
[M+Na]+, m/z 361.82. 
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Methyl 2,3-dimethoxy phenylalanine (18). 1H NMR (CDCl3, 400 MHz): δ = 8.47 (s, br, 
2H, NH2), 7.00 (t, 1J= 8.0 Hz, 1 H, Ar), 6.86-6.84 (dd,  1J= 1.2 Hz, 2J= 8.2 Hz, 1 H, Ar), 6.77-
6.75 (dd, 1J= 1.1 Hz, 2J= 7.6 Hz, 1 H, Ar), 4.34-4.31 (dd, 1J= 5.4 Hz, 2J= 7.0 Hz, 1 H, CH), 3.82 
(s, 3H, CH3), 3.81 (s, 3H, CH3), 3.69 (s, 3H, CH3), 3.36-3.31 (dd, 1J= 5.2 Hz, 1J= 14.2 Hz, 1 H, 
CH), 3.23-3.18 (dd, 1J= 5.2 Hz, 2J= 14.2 Hz, 1 H, CH). 13C NMR (CDCl3, 100 MHz): δ = 169.1, 
152.7, 147.1, 127.7, 124.7, 123.0, 112.5, 60.7, 55.6, 53.7, 53.0, 31.6. MS (ESI) calculated for 
C12H17NO4, [M+H]+, m/z 240.12, found for [M+H]+, m/z 240.24. 
Methyl 2,5-dimethoxy phenylalanine (19). 1H NMR (CDCl3, 400 MHz): δ = 6.71 (s, 
3H, Ar), 4.28-4.25 (dd, 1J= 8.0 Hz, 2J= 5.0 Hz, 1H, CH), 3.70 (s, 3H, CH3), 3.66 (s, 3H, CH3), 
3.63 (s, 3H, CH3), 3.33-3.28 (dd, 1J= 5.0 Hz, 2J= 14.1 Hz, 1 H, CH), 3.03-2.97 (dd, 1J= 8.0 Hz, 
2J= 14.1 Hz, 1H, CH). 13C NMR (CDCl3, 100 MHz): δ = 169.5, 153.4, 151.8, 123.0, 117.9, 
113.9, 111.7, 55.8, 53.0, 52.8, 32.0. MS (ESI) calculated for C12H17NO4, [M+H]+, m/z 240.12, 
found for [M+Na]+, m/z 262.15. 
Methyl 3,4-dimethoxy phenylalanine (26). 1H NMR (CDCl3, 400 MHz): δ = 6.73 (d, 
1J= 7.8 Hz,1 H, Ar), 6.66 (d, 1J = 7.4 Hz, 1 H, Ar), 6.65 (s, 1 H, Ar), 3.79-3.65 (m, 1 H, CH), 
3.79 (s, 3 H, CH3), 3.78 (s, 3H, CH3), 3.64 (s, 3H, CH3), 2.99-2.95 (dd, 1J= 4.8 Hz, 2J= 13.6 Hz, 
1H, CH),  2.79-2.74 (dd, 1J= 7.6 Hz, 2J= 13.6 Hz, 1H, CH), 1.86 (br, s, 2 H, NH2). 13C NMR 
(CDCl3, 100 MHz): δ = 175.2, 149.0, 148.0, 129.5, 121.4, 112.4, 111.3, 55.9, 55.8, 55.8, 52.0, 
40.4. MS (ESI) calculated for C12H17NO4, [M+H]+, m/z 240.12, found for [M+Na]+, m/z 262.22. 
General Procedure for N-Boc Deprotection to Synthesize 18 and 19. To a solution of 
N-Boc α–amino–β-aryl ester (16 or 17) (0.35 gm, 1.0 mmol) in CH2Cl2 (5 mL), trifluoro-acetic 
acid (TFA, 5 mL) was added drop-wise at 0 0C, and the mixture was warmed to RT. After 
stirring for 4 h, the reaction mixture was diluted with CH2Cl2 (25 mL) and neutralized by drop-
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wise addition of saturated aqueous NaHCO3 (20 mL). The organic layer was separated and 
following routine extraction, evaporation procedure gave a crude product, which was purified by 
flash chromatography using 70% (EtOAc: hexanes) to give the desired α–amino–β-aryl ester 18 
or 19 as yellow oil in 80-86% yield. The NMR spectra for the corresponding product are 
presented above. 
General Procedure for Step–wise Transesterification of THIQ3CA Methyl Esters to 
Ethyl Esters. To a stirred solution of dimethoxy THIQ3CA methyl ester (20, 21, or 27) (0.15 
gm, 0.6 mmol) in methanol (25 mL), lithium hydroxide (0.072 gm, 3.0 mmol) was added. The 
mixture was stirred at RT for 5 h and then concentrated in vacuo, and washed with ethanol (3 × 
10 mL). Ethanol (20 mL) was then added to the reaction solid residue followed by step-wise 
addition of thionyl chloride (SOCl2, 10 mL of 2 M in CH2Cl2) at 0 ºC. The resulting mixture was 
refluxed for 4 hours, then cooled to RT and neutralized with saturated NaHCO3 solution. The 
product was extracted with CH2Cl2 (3 × 50 mL) followed by routine extraction and concentration 
process to give a residue that was purified using 45% (EtOAc: hexanes) as eluent of flash 
chromatography to give corresponding ethyl ester 12, 13, or 28 as yellow oil in 55-72% yield. 
Ethyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (28). 1H NMR 
(CDCl3, 400 MHz): δ = 6.52 (s, 1 H, Ar), 6.45 (s, 1 H, Ar), 4.18-4.13 (q, 1J = 7.1 Hz, 2 H, CH2), 
3.96 (s, 2 H, CH2), 3.80 (s, 3 H, CH3), 3.79 (s, 3 H, CH3), 3.63-3.60 (dd, 1J = 4.7 Hz, 2J = 10.1 
Hz, 1 H, CH), 2.94-2.89 (dd, 1J = 4.6 Hz, 2J = 16.0 Hz, 1 H, CH), 2.83-2.77 (dd, 1J = 10.0 Hz, 2J 
= 15.8 Hz, 1 H, CH), 2.19 (br, s , 1 H, NH), 1.23 (t, 1J = 7.1 Hz, 3 H, CH3). 13C NMR (CDCl3, 
100 MHz): δ =173.1, 147.6, 126.7, 124.9, 111.8, 108.9, 61.0, 55.9, 55.9, 55.9, 47.0, 31.1, 14.2. 
MS (ESI) calculated for C14H19NO4, [M+H]+, m/z 266.14, found for [M+Na]+, m/z  288.21. 
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General Procedure for N-arylacylation of 1,2,3,4–tetrahydroisoquinoline–3–
carboxylic acid Methyl or Ethyl ester (THIQ3CA Ester) and 1,2,3,4–tetrahydroisoquinoline 
(THIQ). Method C: To a stirred solution of dimethoxy-1,2,3,4-tetrahydroisoquinoline (12, 13, 
20, 21 or 27-29) (0.2 gm, 0.8-1.0 mmol) and triethylamine (0.3 gm, 3.0 mmol) in anhydrous 
CH2Cl2 (10 mL) at 0 ºC was added 3,4,5-trimethoxy benzoyl chloride (0.24 gm, 1.05 mmol) or 
2,5-dimethoxylphenyl acetyl chloride (0.24  gm, 1.05 mmol). The reaction mixture was allowed 
to warm to RT, refluxed for 4 h and then diluted with CH2Cl2 (15 mL). After routine extraction 
and concentrations steps, the crude product was purified by flash chromatography utilizing 50% 
(EtOAc: hexanes) to give the desired N-arylacyl THIQ3CA ester (30-35) or N-arylacyl THIQ 
(36) as colorless or yellow oil in 85-92% yield. Method D: To a stirred solution of either 
propionic or butanoic acid (0.3 gm, 1.4 mmol) in anhydrous CH2Cl2 (5 mL) was added 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDCI, 0.3 gm, 1.55 mmol) and DMAP (0.17 gm, 1.4 
mmol) at RT under nitrogen atmosphere. Dimethoxy-1,2,3,4-tetrahydroisoquinoline (12, 21 or 
27) (0.4 gm, 1.5-1.6 mmol) in anhydrous CH2Cl2 (5 mL) was then added drop-wise. After 
stirring overnight, the reaction mixture was partitioned between 2 N HCl solution (20 mL) and 
CH2Cl2 (30 mL), and the organic layer washed with aqueous solution and concentrated to give a 
crude product. The crude product was purified using 50% (EtOAC: hexanes) as the mobile phase 
in flash chromatography to give the desired product (38-42) as colorless or yellow oil in 70–87 
% yield. 
Ethyl 5,6-dimethoxy-2-(3,4,5-trimethoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-
carboxylate (30). 1H NMR (CDCl3, 400 MHz): δ = 6.85-6.68 (m, 2 H, Ar), 6.64-6.60 (m, 2 H, 
Ar), 5.34-5.32 & 4.78-4.76 (m, 1 H, CH), 5.08-5.04 & 4.50-4.41 (m, 2 H, CH2), 4.13-3.98 (m, 2 
H, CH2), 3.80-3.74 (m, 15 H, 5 × CH3), 3.52-3.48 & 3.37-3.33 (d & dd, 1J = 16.3 Hz & 1J = 3.6 
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Hz, 2J = 16.3 Hz, 1 H, CH), 3.16-3.10 & 2.82-2.77 (dd & dd, 1J = 5.9 Hz, 2J = 16.2 Hz & 1J = 
4.8 Hz, 2J = 16.6 Hz, 1 H, CH), 1.18 & 1.07 (t & t, 1J = 6.7 Hz & 1J = 8.8 Hz, 3 H, CH3).  13C 
NMR (CDCl3, 100 MHz): δ = 171.5, 170.9, 170.5, 153.5, 153.4, 151.5, 151.0, 146.4, 139.4, 
131.1, 126.8, 126.0, 125.7, 125.0, 122.0, 121.1, 111.6, 111.0, 104.4, 103.8, 61.6, 61.4, 60.9, 60.6, 
60.4, 56.6, 56.3, 55.9, 52.0, 47.4, 42.9, 25.9, 24.7, 14.1. MS (ESI) calculated for C24H29NO8, 
[M+H]+, m/z 460.20, found for [M+H]+, m/z 460.40. 
Methyl-2-(2-(2,5-dimethoxy phenyl) acetyl)- 5,6-dimethoxy- 1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (31). 1H NMR (CDCl3, 400 MHz): δ = 6.77-6.62 (m, 5 H, Ar), 5.38-
5.35 & 4.96-4.94  (dd & dd,  1J = 4.0 Hz, 2J = 6.2 Hz & 1J = 2.5 Hz, 2J = 5.9 Hz, 1 H, CH),  
4.85-4.56 (dd, 1J = 17.0 Hz, 2J = 101.0 Hz, 1 H, CH), 4.49-4.34 (dd, 1J = 15.2 Hz, 2J = 43.2 Hz, 
1 H, CH), 3.75-3.63 (m, 14 H, CH2, 4 × CH3), 3.47 (d, 1J = 52.2 Hz, 3 H, CH3), 3.48-3.44 & 
3.39-3.34 (dd & dd, 1J = 2.5 Hz, 2J = 16.2 Hz & 1J = 4.0 Hz, 2J = 16.3 Hz, 1 H, CH), 2.92-2.86 
& 2.67-2.62 (dd & dd, 1J = 6.3 Hz, 2J = 16.3 Hz & 1J = 5.8 Hz, 2J = 16.2 Hz, 1 H, CH). 13C 
NMR (CDCl3, 100 MHz): δ = 171.4, 171.3, 171.0, 153.7, 151.4, 151.1, 150.9, 150.5, 146.3, 
146.0, 126.7, 125.6, 124.2, 123.8, 122.0, 121.4, 115.8, 113.2, 113.0, 111.5, 111.4, 111.0, 60.5, 
60.4, 56.0, 55.8, 55.7, 54.5, 52.3, 52.2, 51.5, 45.3, 43.0, 35.2, 35.0, 25.9, 24.9. MS (ESI) 
calculated for C23H27NO7, [M+H]+, m/z 430.19, found for [M+H]+, m/z 430.36. 
Methyl-2-(2-(2,5-dimethoxy phenyl) acetyl)- 5,8-dimethoxy- 1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (32). 1H NMR (CDCl3, 400 MHz): δ = 6.82-6.79 (dd, 1J = 2.9 Hz, 2J 
= 12.0 Hz, 1 H, Ar), 6.72 (d, 1J = 8.8 Hz, 1 H, Ar), 6.69-6.66 (dd, 1J = 2.8 Hz, 2J = 8.8 Hz, 1 H, 
Ar), 6.60-6.54 (m, 2 H, Ar), 5.64-5.62 & 4.96-4.94 (dd & dd, 1J = 2.4 Hz, 2J = 6.8 Hz & 1J = 1.6 
Hz, 2J = 6.4 Hz, 1 H, CH),  5.02-4.68 (dd, 1J = 18.8 Hz, 2J = 120.8 Hz, 1 H, CH), 4.41-4.14 (dd, 
1J = 17.1 Hz, 2J = 88.1 Hz, 1 H, CH),  3.76 (d, 1J = 23.8 Hz, 2 H, CH2), 3.71 (s, 3 H, CH3), 3.70 
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(s, 3 H, CH3), 3.67 (s, 3 H, CH3), 3.65 (s, 3 H, CH3),  3.48 (d, 1J = 46.7 Hz, 3 H, CH3), 3.42-3.36 
(m, 1 H, CH), 2.78-2.72 & 2.55-2.49 (dd & dd, 1J = 6.8 Hz, 2J = 17.0 Hz & 1J = 6.5 Hz, 2J = 
16.9 Hz, 1 H, CH). 13C NMR (100 MHz, CDCl3):  δ = 171.7, 171.7, 171.5, 171.0, 153.8, 153.6, 
151.3, 150.9, 150.6, 150.4, 150.1, 149.6, 124.4, 123.7, 122.3, 121.9, 121.1, 116.0, 115.6, 113.5, 
113.0, 111.6, 111.4, 108.1, 107.7, 107.5, 107.4, 56.1, 56.0, 55.8 (× 2), 55.7 (× 3), 55.4, 54.0, 
52.4, 52.2, 49.9, 41.2, 39.2, 35.1, 34.9, 25.2, 24.3. MS (ESI) calculated for C23H27NO7, [M+H]+, 
m/z 430.19, found for [M+Na]+, m/z 452.30. 
Ethyl- 2-(2-(2,5-dimethoxy phenyl) acetyl)- 5,8-dimethoxy- 1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (33). 1H NMR (CDCl3, 400 MHz): δ = 6.84-6.80 (dd, 1J = 2.8 Hz, 2J 
= 14.0 Hz, 1 H, Ar), 6.74-6.72 & 6.60-6.54  (m, 3 H, Ar), 6.69-6.66 (dd, 1J = 2.9 Hz, 2J = 8.9 Hz, 
1 H, Ar), 5.61-5.59 & 4.94-4.93 (dd & dd, 1J = 2.1 Hz, 2J = 6.6 Hz & 1J = 1.5 Hz, 2J = 6.4 Hz, 1 
H, CH), 5.00-4.68 (dd, 1J = 18.7 Hz, 2J = 110.4 Hz, 1 H, CH), 4.44-4.19 (dd, 1J = 17.1 Hz, 2J = 
81.3 Hz, 1 H, CH), 4.06-3.85 (m, 2 H, CH2), 3.80-3.58 (m, 12 H, 3 × CH3),  3.57-3.39 (m, 1 H, 
CH), 2.77-2.71 & 2.55-2.49 (dd & dd, 1J = 6.7 Hz, 2J =  17.0 Hz & 1J = 6.5 Hz, 2J = 17.2 Hz, 1 
H, CH), 1.06 & 0.98 (t  & t, 1J = 7.1 Hz & 1J = 7.1 Hz, 3 H, CH3). 13C NMR (CDCl3, 100 MHz): 
δ = 171.7, 170.9, 153.8, 153.6, 151.3, 151.0, 150.6, 150.4, 150.2, 149.9, 124.4, 123.7, 123.5, 
122.4, 122.0, 121.3,117.2, 116.0, 115.6, 113.5, 113.0, 111.7, 111.4, 108.2, 107.8, 107.6, 61.4, 
61.1, 56.2, 56.1, 56.0, 55.9, 55.8, 55.7, 55.7, 55.4, 54.2, 50.1,41.3, 39.3, 35.9, 35.0, 25.3, 24.3, 
14.0, 13.9. MS (ESI) calculated for C24H29NO7, [M+H]+, m/z 444.20, found for [M+H]+, m/z 
444.34. 
Ethyl 6,7-dimethoxy-2-(3,4,5-trimethoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-
carboxylate (34). 1H NMR (CDCl3, 400 MHz): δ = 6.85-6.60 (m, 4 H, Ar), 5.35-5.32 & 4.78-
4.75 (m, 1 H, CH), 5.10-5.04 & 4.50-4.40 (m, 2 H, CH2), 4.13-3.99 (m, 2 H, CH2), 3.81-3.73 (m, 
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15 H, 5 × CH3), 3.52-3.48 & 3.37-3.33 (d & dd, 1J = 16.3 Hz & 1J = 3.6 Hz, 2J = 16.3 Hz, 1 H, 
CH), 3.16-3.10 & 2.82-2.77 (dd & dd, 1J = 5.9 Hz, 2J = 16.2 Hz & 1J = 4.8 Hz, 2J = 16.7 Hz, 1 
H, CH), 1.17 & 1.06 (t & t, 1J = 6.7 Hz & 1J = 8.8 Hz, 3 H, CH3).  13C NMR (CDCl3, 400 MHz): 
δ = 171.5, 170.9, 170.5, 153.5, 153.4, 151.5, 151.0, 146.4, 139.4, 131.1, 126.8, 126.0, 125.7, 
125.0, 122.0, 121.1, 111.6, 111.0, 104.4, 103.8, 61.6, 61.4, 60.9, 60.6, 60.4, 56.6, 56.3, 55.9, 
52.0, 47.4, 42.9, 25.9, 24.7, 14.1. MS (ESI) calculated for C24H29NO8, [M+H]+, m/z 460.20, 
found for [M+H]+, m/z 460.34. 
Methyl- 2-(2-(2,5-dimethoxy phenyl) acetyl)- 6,7-dimethoxy- 1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (35). 1H NMR (CDCl3, 400 MHz): δ = 6.80 (d, 1J = 2.6 Hz, 1 H, 
Ar), 6.74 (d, 1J = 8.8 Hz, 1 H, Ar), 6.72-6.67 (m, 1 H, Ar), 6.54 (d, 1J = 14.1 Hz, 1 H, Ar), 6.45 
(d, 1J = 34.9 Hz, 1 H, Ar), 5.51-5.49 & 4.94-4.92 (dd & dd, 1J = 3.3 Hz, 2J = 6.0 Hz & 1J = 2.3 
Hz, 2J = 5.8 Hz, 1 H, CH), 4.91-4.60 (dd, 1J = 17.2 Hz, 2J = 108.8 Hz, 1 H, CH), 4.52-4.30 (dd, 
1J = 15.4 Hz, 2J = 71.5 Hz, 1 H, CH), 3.78-3.66 (m, 14 H, CH2, 4 × CH3), 3.50 (d, 1J = 51.5 Hz, 
3 H, CH3),  3.14-3.06 (dt, 1J = 3.4 Hz, 2J = 15.8 Hz, 1 H, CH),  3.02-2.97 & 2.89-2.85 (dd & dd, 
1J = 6.0 Hz, 2J = 18.8 Hz & 1J = 5.8 Hz, 2J = 15.8 Hz, 1 H, CH).  13C NMR (CDCl3, 100 MHz): 
δ =171.5, 171.4 (×2), 171.2, 153.8, 151.2, 150.6, 148.2, 148.1, 148.0, 147.7, 124.3, 124.2, 123.9, 
123.8, 122.8, 115.9, 115.8, 113.3, 112.9, 111.6, 111.4, 111.2, 111.0, 109.3, 109.0, 56.1 (×2), 56.0 
(×2), 55.9 (×2), 55.7, 55.0, 52.4, 52.3, 51.3, 45.5, 43.3, 35.3, 35.0, 31.2, 30.3. MS (ESI) 
calculated for C23H27NO7, [M+H]+, m/z 430.19, found for [M+Na]+, m/z 452.36. 
1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-(2,5-dimethoxyphenyl) 
ethanone (36). 1H NMR (CDCl3, 400 MHz): δ = 6.78-6.64 (m, 5H, Ar), 4.54 (d, 1J= 48.8 Hz, 
2H, CH2), 3.76 (s, 3H, CH3), 3.71(s, 3H, CH3), 3.69 (s, 3H, CH3), 3.67(s, 3H, CH3), 3.63-3.60 
(m, 3H, CH, CH2), 3.58-3.54 (m, 1H, CH), 2.78 (t, 1J = 6.0 Hz, 1 H, CH), 2.64 (t, 1J = 5.9 Hz, 1 
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H, CH). 13C NMR (CDCl3, 100 MHz): δ = 170.4, 170.2, 153.7, 151.2, 151.0, 150.9, 150.8, 
146.6, 146.2, 129.4, 128.5, 126.7, 126.2, 124.7, 122.0, 121.2, 117.1, 115.8, 112.9 (×2), 111.6 
(×2), 111.5, 110.9, 110.7, 60.3, 56.1 (×2), 56.0, 55.9, 55.7, 55.6, 47.2, 43.9, 43.2, 39.7, 35.9, 
35.1, 34.8, 23.6, 22.9. MS (ESI) calculated for C21H25NO5, [M+H]+, m/z 372.18, found for 
[M+Na]+, m/z 394.33. 
Ethyl- 2-(2-(2,5-dimethoxy phenyl) butanoyl)- 5,6-dimethoxy- 1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (38). 1H NMR (CDCl3, 400 MHz): δ = 6.79-5.59 (m, 5 H, Ar), 5.40-
5.37 & 4.67-4.65 (dd & dd, 1J = 3.6 Hz, 2J = 6.2 Hz & 1J = 2.8 Hz, 2J = 5.8 Hz, 1 H, CH), 4.79-
4.74 & 4.52-4.48 (dd, 1J = 16.8 Hz, 2J = 107.7 Hz, 1 H, CH),4.47-4.35 (dd, 1J = 15.1 Hz, 2J = 
29.7 Hz, 1 H, CH), 4.05-3.90 (m, 2 H, CH2), 3.80-3.60 (m, 12 H, 4 × CH3), 3.54-3.50 & 3.42-
3.37 (dd & dd, 1J = 2.6 Hz, 2J = 16.1 Hz & 1J = 3.6 Hz, 2J = 16.3 Hz, 1 H, CH), 2.86-2.80 (m, 1 
H, CH), 2.63-2.55 (m, 2 H, CH2), 2.43-2.26 (m, 2 H, CH2), 1.98-1.81 (m, 2 H, CH2), 1.08 & 1.00 
(t & t, 1J = 7.1 Hz, 1J = 7.1 Hz, 3 H, CH3). 13C NMR (CDCl3, 100 MHz): δ = 177.9, 173.1, 
171.1, 170.6, 153.5, 153.3, 151.9, 151.6, 151.4, 151.0, 146.4, 146.1, 131.3, 131.0, 129.8, 126.8, 
126.3, 126.0, 125.5, 122.0, 121.4, 116.4, 116.3, 111.5, 111.2, 111.0, 61.6, 61.1, 60.6, 60.5, 55.9, 
55.8, 55.7 (×2), 54.6, 51.1, 45.0, 42.9, 33.4, 33.1, 29.8, 29.8, 29.5, 26.1, 25.0, 24.9, 24.8, 14.1, 
14.0. MS (ESI) calculated for C26H33NO7, [M+H]+, m/z 472.23, found for [M+H]+, m/z 472.40. 
Methyl 2-(3-(2,5-dimethoxyphenyl)propanoyl)-5,8-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (39). 1H NMR (CDCl3, 400 MHz): δ = 6.73-6.67 (m, 2 H, Ar), 6.63-
6.54 (m, 3 H, Ar), 5.65-5.63 & 4.96-4.94 (dd & dd, 1J = 2.2 Hz, 2J = 6.8 Hz & 1J = 1.6 Hz, 2J = 
6.4 Hz, 1 H, CH), 5.03-4.98 & 4.61-4.56 (dd, 1J = 18.7 Hz, 2J = 168.5 Hz, 1 H, CH), 4.43-4.14 
(dd, 1J = 17.1 Hz, 2J = 98.6 Hz, 1 H, CH), 3.73 (s, 3 H, CH3), 3.70 (s, 3 H, CH3), 3.69 (s, 3 H, 
CH3), 3.67 (s, 3 H, CH3), 3.55 (s, 3 H, CH3), 3.52-3.47 & 3.43-3.38 (dd & dd, 1J = 1.4 Hz, 2J = 
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17.7 Hz & 1J = 2.0 Hz, 2J = 17.1 Hz, 1 H, CH), 2.94-2.85 (m, 2 H, CH2), 2.78-2.53 (m, 3 H, CH, 
CH2). 13C NMR (CDCl3, 100 MHz): δ = 173.2, 172.9,  171.6, 171.1, 153.6, 153.5, 151.8, 151.6, 
150.9, 150.6, 150.1, 149.6, 130.7, 130.3, 122.4, 122.3, 121.7, 121.1, 116.5, 116.4, 111.8, 111.5, 
111.2, 111.1, 108.1, 107.8, 107.6, 107.3, 55.8, 55.8, 55.7 (×2), 55.4, 55.3, 54.0, 52.6, 52.3, 49.6, 
41.0, 38.9, 34.2, 34.1, 27.2, 26.7, 25.3, 24.3. MS (ESI) calculated for C24H29NO7, [M+H]+, m/z 
444.20, found for [M+Na]+, m/z 465.97. 
Methyl 2-(4-(2,5-dimethoxyphenyl)butanoyl)-5,8-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (40). 1H NMR (CDCl3, 400 MHz): δ = 6.70-6.65 (m, 2 H, Ar), 6.63-
6.55 (m, 3 H, Ar), 5.63-5.60 & 4.72 (dd & d, 1J = 2.3 Hz, 2J = 6.8 Hz & 1J = 4.9 Hz, 1 H, CH), 
5.02-4.97 & 4.56-4.53 (dd, 1J = 18.7 Hz, 1J = 181.9 Hz, 1 H, CH), 4.44-4.09 (dd, 1J = 17.0 Hz, 2J 
= 117.8 Hz, 1 H, CH), 3.71 (s, 3 H, CH3), 3.70 (s, 3 H, CH3), 3.69 (s, 3  H, CH3), 3.67 (s, 3 H, 
CH3), 3.55 (s, 3 H, CH3), 3.40-3.37 (dd, 1J = 2.2 Hz, 2J = 17.1 Hz, 1 H, CH), 2.75-2.70 (dd, 1J = 
6.8 Hz, 2J = 17.0 Hz,1 H, CH), 2.66-2.53 (m, 2 H, CH2), 2.51-2.31 (m, 2 H, CH2), 1.97-1.89 (m, 
2 H, CH2). 13C NMR (CDCl3, 100 MHz): δ = 173.4, 173.0, 171.6, 171.0, 153.5, 151.9 (×2), 
150.6, 150.1, 149.6, 131.5, 131.2, 122.5, 122.4, 121.8, 121.1, 116.4, 116.3, 111.5, 111.3, 111.2, 
108.2, 107.8, 107.6, 107.4, 55.8, 55.7, 55.4, 53.9, 52.6, 52.3, 49.6, 40.9, 38.8, 33.3, 33.0, 29.9, 
29.8, 25.3, 25.1, 24.9, 24.3. MS (ESI) calculated for C25H31NO7, [M+H]+, m/z 458.22, found for 
[M+Na]+, m/z 480.40. 
Methyl 2-(3-(2,5-dimethoxyphenyl)propanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (41). 1H NMR (CDCl3, 400 MHz): δ = 6.72-6.69 (m, 2 H, Ar), 6.67-
6.63 (m, 1 H, Ar), 6.54 (d, 1J = 9.4 Hz, 1 H, Ar), 6.45 (s, 1 H, Ar), 5.52-5.50 & 4.87-4.85 (dd & 
dd, 1J = 3.0 Hz, 2J = 6.1 Hz & 1J = 2.4 Hz, 2J = 5.8 Hz, 1 H, CH), 4.88-4.54 (dd, 1J = 17.0 Hz, 2J 
= 120.7 Hz, 1 H, CH), 4.53-4.30 (dd, 1J = 17.2 Hz, 2J = 74.0 Hz, 1 H, CH), 3.78-3.67 (m, 12 H, 4 
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× CH3), 3.55 (d, 1J = 8.5 Hz, 3 H,CH3), 3.78-3.09 (m, 1 H, CH), 2.99-2.84 (m, 3 H, CH, CH2), 
2.70-2.67 (m, 2 H, CH2).13C NMR (CDCl3,100 MHz): δ = 172.8, 172.7, 171.6, 171.2, 153.6 
(×2), 151.8, 151.6, 148.3, 148.1 (×2), 147.8, 130.7, 130.3, 124.5, 124.1, 123.7, 122.9, 116.5 (×2), 
111.7, 111.5, 111.3 (×2), 111.2, 111.1, 111.0, 109.4, 108.9, 65.8, 55.9 (×2), 55.8, 55.7, 54.9, 
52.6, 52.3, 51.0, 46.9, 45.1, 43.1, 34.2, 30.3, 29.4, 27.1, 26.7, 26.5. MS (ESI) calculated for 
C24H29NO7, [M+H]+, m/z 444.20, found for [M+Na]+, m/z 466.04. 
Methyl 2-(4-(2,5-dimethoxyphenyl)butanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (42). 1H NMR (CDCl3, 400 MHz): δ = 6.71-6.62 (m, 3 H, Ar), 6.55 
(d, 1J = 6.16 Hz, 1 H, Ar), 6.46 (s, 1 H, Ar), 5.52-5.50 & 4.69-4.67 (dd & dd, 1J = 2.9 Hz, 2J =5.9 
Hz & 1J = 2.4 Hz, 2J = 5.6 Hz, 1 H, CH), 4.86-4.82 & 4.48-4.48 (dd, 1J = 17.0 Hz, 2J = 136.0 Hz, 
1 H, CH), 4.48-4.25 (dd, 1J = 16.0 Hz, 2J = 75.8 Hz, 1 H, CH), 3.78 (s, 3 H, CH3), 3.77 (s, 3 H, 
H3), 3.69 (s, 3 H, CH3), 3.68 (s, 3 H, CH3), 3.54 (d, 1J = 3.2 Hz, 3 H, CH3), 3.17-3.09 (m, 1 H, 
CH), 3.04-2.93 (m, 1 H, CH), 2.64-2.58 (m, 2 H, CH2), 2.44-2.40 (m, 2 H, CH2), 1.97-1.89 (m, 2 
H, CH2). 13C NMR (CDCl3, 100 MHz): δ =173.1, 173.0, 171.6, 171.1, 153.5, 151.9, 151.8, 
148.3, 148.1, 147.8, 131.3, 131.2, 124.5, 124.1, 123.6, 122.9, 116.5, 116.4, 111.5, 111.3 (×2), 
111.2 (×2), 111.0, 109.4, 109.0, 56.6, 56.0, 55.9 (×2), 55.7, 54.8, 52.6, 52.3, 50.9, 45.2, 43.1, 
33.1, 33.0, 31.6, 31.3, 30.9, 30.3, 29.8 (×2), 28.9, 25.0, 24.8. MS (ESI) calculated for 
C25H31NO7, [M+H]+, m/z 458.22, found for [M+Na]+, m/z 479.96. 
2-(2-(2,5-Dihydroxyphenyl)acetyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acid (37). To a stirred solution of THIQ3CA ester 35 (0.45 gm, 1.0 mmol) in 
anhydrous CH2Cl2 (5 mL), BBr3 (1 M solution in CH2Cl2, 0.4 gm, 9 mmol) was added dropwise 
at -78 0C under nitrogen atmosphere over 10 min. After 2 h, the reaction mixture was brought to 
RT and allowed to equilibrate overnight. A mixture of methanol/water (1:1 v/v, 2 mL) was then 
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added slowly at 0 0C and vigorously stirred for 10 min to quench the reaction. The reaction 
mixture was then concentrated and partitioned between EtOAc (25 mL) and saturated solution of 
NH4Cl (15 mL), and aqueous layer further washed with EtOAc (2 × 20 mL). The combined 
organic layer was concentrated in vacuo and the crude was purified by 0% to 25% 
(CH3OH:CH2Cl2) as mobile phase gradient in flash chromatography to yield 37 (75 %) as yellow 
solid. 1H NMR (acetone-d6, 400 MHz): δ = 6.65-6.58 (dd, 1J = 2.9 Hz, 2J = 25.1 Hz, 1 H, Ar), 
6.57-6.55 (dd, 1J = 3.2 Hz, 2J = 7.3 Hz, 1 H, Ar),  6.53 (d, 1J = 14.7 Hz, 2 H, Ar), 6.47-6.44 (dd, 
1J = 2.9 Hz, 1J = 8.6 Hz, 1 H, Ar), 5.20-5.18 & 5.15-5.13 (dd & dd, 1J = 3.6 Hz, 2J = 5.9 Hz & 1J 
= 2.6 Hz , 2J = 5.7 Hz, 1 H, CH), 4.79-3.43 (dd & dd, 2 H , CH2, and d & d &d, 2 H, CH2), 3.07-
3.02 & 3.01-2.96 (dd & dd, 1J = 2.5 Hz, 2J = 15.5 Hz & 1J = 3.6 Hz, 2J = 15.6 Hz, 1H, CH), 
2.88-2.84 (m, 1 H, CH). 13C NMR (acetone-d6, 100 MHz): δ = 173.3, 172.2, 151.3, 149.9, 149.5, 
145.0, 144.9, 124.7, 124.6, 124.5, 124.0, 123.3, 118.5, 118.0, 117.9, 117.8, 117.7, 115.7, 115.6, 
115.5, 115.2, 113.8, 113.7, 56.2, 52.6, 46.5, 43.9, 36.5, 36.1, 31.9, 30.9. MS (ESI) calculated for 
C18H17NO7, [M+H]+, m/z 360.11, found for [M+Na]+, m/z 382.24. 
Methyl 6,7-dimethoxy-2-(4-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline-3-
carboxylate (43). To a stirred solution of methyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-
3-carboxylate 27 (0.1 gm, 0.4 mmol) in CH3CN (2 mL), diisopropylethylamine (DIPEA) (0.15 
gm, 1.2 mmol) was slowly added. After 15 min, 4-methoxybenzyl chloride (0.078 gm, 0.5 
mmol) was dissolved in CH3CN (1 mL) and was then added slowly to the reaction mixture. The 
reaction mixture was heated up in the microwave (CEM Discover) for 20 min at 150 ºC.  The 
reaction mixture was cooled to RT, diluted with EtOAc (10 mL) and organic layer worked up as 
usual to give a crude product, which was purified using 30 % (EtOAc: hexanes) in flash 
chromatography to yield 43 (yellow oil, 92%). 1H NMR (CDCl3, 400 MHz): δ = 7.29 (d, 1J = 8.6 
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Hz, 2 H, Ar), 6.87 (d, 1J = 8.6 Hz, 2 H, Ar), 6.58 (s, 1 H, Ar), 6.47 (s, 1H, Ar), 3.95 (d, 1J = 15.2 
Hz, 1H, CH), 3.85 (d, 1J = 2.2 Hz, 2 H,CH2), 3.84 (s, 3 H, CH3), 3.80 (s, 3 H, CH3), 3.79 (s, 3 H, 
CH3), 3.77-3.75 (dd, 1J = 4.1 Hz, 2J = 6.0 Hz, 1 H, CH), 3.72 (d, 1J = 15.8 Hz, 1 H, CH), 3.68 (s, 
3 H, CH3), 3.14-3.09 (dd, 1J = 6.0 Hz, 2J = 16.1 Hz, 1 H, CH), 3.05-3.00 (dd, 1J = 3.8 Hz, 2J = 
16.0 Hz, 1 H, CH). 13C NMR (CDCl3, 100 MHz): δ = 173.2, 158.9, 147.5, 130.6, 130.1, 128.6, 
126.1, 124.0, 113.8, 111.3, 109.3, 58.9, 58.4, 55.9, 55.8, 55.3, 51.4, 50.6, 30.9. MS (ESI) 
calculated for C21H25NO5, [M+H]+, m/z 372.18, found for [M+H]+, m/z 372.32. 
General Procedure for Xylene-Based Dimerization of 6,7-Dimethoxy THIQ3CA 
Ethyl Ester. Ethyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 28 (0.75 gm, 2.8 
mmol) was dissolved in DMF:CH3CN (1:1 v/v, 8 mL) and stirred with Cs2CO3 (2.2 gm, 11.2 
mmol). After 15 min,  p- or m- α,α’-dibromo xylene (0.37 gm, 1.4 mmol) in CH3CN (2 mL) was 
slowly added to the reaction mixture and then refluxed for 12 h. The reaction mixture was 
cooled, partitioned between EtOAc (25 mL) and water (25 mL), and the organic layer processed 
in a routine manner to prepare a crude product, which was purified using 30% (EtOAc: hexanes) 
in flash chromatography to give the desired xylene-based dimer (44 or 45) as yellow oil in 62-
66% yield. 
Diethyl 2,2'-(1,3-phenylene bis(methylene)) bis(6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate) (44). 1H NMR (CDCl3, 400 MHz): δ = 7.41 (s, 1 H, Ar), 7.30 (s, 3 
H, Ar), 6.58 (s, 2 H, Ar), 6.46 (s, 2 H, Ar), 4.19-4.10 (m, 4 H, 2 × CH2), 33.99-3.93 (m, 6 H, 2 × 
CH, 2 × CH2), 3.84 (s, 6 H, 2 × CH3), 3.79 (s, 6 H, 2 × CH3), 3.76-3.72 (m, 4 H, 2 × CH2), 3.14-
3.09 (dd, 1J = 6.0 Hz, 2J = 16.1 Hz, 2 H, 2 × CH), 3.05-3.00 (dd, 1J = 4.0 Hz, 2J = 16.0 Hz, 2 H, 
2 × CH), 1.24 (t, 1J= 7.1 Hz, 6 H, 2 × CH3). 13C NMR (CDCl3, 100 MHz): δ = 172.7, 147.5, 
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138.9, 129.4, 128.3, 127.8, 126.1, 124.1, 111.3, 109.3, 60.3, 59.2, 59.0, 55.9, 55.8, 50.7, 31.1, 
14.4. MS (ESI) calculated for C36H44N2O8, [M+H]+, m/z 633.32, found for [M+H]+, m/z 633.16. 
Diethyl 2,2'-(1,4-phenylene bis(methylene)) bis(6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (45). 1H NMR (CDCl3, 400 MHz): δ = 7.28 (s, 4 H, Ar), 6.52 (s, 2 
H, Ar), 6.40 (s, 2 H, Ar), 4.12-4.05 (m, 4 H, 2 × CH2), 3.85-3.93 (m, 6 H, 2 × CH, 2 × CH2), 3.77 
(s, 6 H, 2 × CH3), 3.73 (s, 6 H, 2 × CH3), 3.60-3.70 (m, 4 H, 2 × CH2), 3.07-3.03 (dd, 1J = 3.5 
Hz, 2J = 14.9 Hz, 2 H, 2 × CH), 3.00-2.95 (dd, 1J = 4.1 Hz, 2J = 16.0 Hz, 2 H, 2 × CH), 1.18 (t, 
1J = 7.1 Hz, 6 H, 2 × CH3). 13C NMR (CDCl3, 100 MHz): δ = 172.7, 147.5, 138.8, 129.0, 126.0, 
124.1, 111.3, 109.2, 60.4, 59.2, 58.7, 55.9, 55.8, 50.7, 30.9, 14.4. MS (ESI) calculated for 
C36H44N2O8, [M+H]+, m/z 633.32, found for [M+H]+, m/z 633.23. 
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CHAPTER 4: DESIGNING NONSACCHARIDE, ALLOSTERIC ACTIVATORS OF 
ANTITHROMBIN FOR ACCELERATED INHIBITION OF FACTOR Xa 
 
4.1. Fundamental Hypothesis—Clinically used heparins are highly complex molecules 
known to be associated with multiple complications.209,210 Structurally, heparin–based 
anticoagulant therapy has remained essentially unchanged since its introduction in the 1930s. A 
synthetic version of DEFGH, called fondaparinux, is arguably the best anticoagulant with regard 
to such complications211,212 but its synthesis is complex and expensive, while it suffers, like 
heparins, from bleeding episodes.211-216 Accordingly, numerous attempts have been made to 
discover molecules that activate AT to overcome the drawbacks of heparins. A fundamental tenet 
of these efforts has been the assumed requirement of a saccharide scaffold.97-105  
To address the many drawbacks of the heparin–based AT activators, Desai hypothesized 
that replacing the saccharide skeleton with an aromatic scaffold to have eventually non–
saccharide, aromatic, allosteric AT activators acting as heparin functional mimetics for the 
accelerated inhibition of FXa should be possible. Such non–saccharide mimetics of heparin are 
likely to offer significant advantages, such as superior non-ionic binding energy in AT 
recognition,107 greater hydrophobicity for possible oral bioavailability,111,217,218 better synthetic 
accessibility, and narrower specificity of function in comparison to heparin’s multitude of 
activities.  
Two independent approaches had been used earlier by Desai and co–workers for 
designing AT activators that are radically different from the DEFGH–based saccharide 
molecules.106,110 These approaches led to the identification of IAS5, a molecule that displayed 
AT activation of nearly 30-fold.110  
82 
 
4.2. Updated Hypothesis: Design Goals and Design Elements for Non-Heparin 
Antithrombin Activators— The success with IAS5 indicated a strong possibility of uncovering 
potent, ease-to-synthesize, small, aromatic AT activators through a rational approach. Figure 20 
describes two possible mechanisms of AT activation. The induced fit mechanism is followed by 
nearly all heparins (including DEFGH and DEF),219 whereas the pre-equilibrium mechanism has 
been documented for oligosaccharides that lack the critical PBS recognition element (EFGH′′ 
and 3-O-Desulfonated DEFGH).83,92 The induced fit mechanism requires that the potential ligand 
recognize both the native (AT) as well as the activated state (AT*), while the pre-equilibrium 
mechanism primarily involves ligand recognition of AT*.  
Despite considerable effort, the exact mechanism of how the activating conformational 
change is brought about through the induced fit process remains unclear. In addition, no 
principles have been elucidated for designing highly sulfated nonsaccharide molecules that 
allosterically activate a protein such as AT. The major difficulty in designing such allosteric 
activators is that the binding site is shallow and highly surface exposed, which tends to not 
subscribe to a high affinity interaction. In addition, the two–step, induced fit allosteric AT 
activation requires that the binding energy is transmitted to the main body of the protein to 
induce activation.  
Thus design-wise, activators that utilize the pre-equilibrium pathway are expected to be 
easier to design as this pathway involves preferential recognition of only one AT form. Yet, an 
apparent limitation of the pre-equilibrium pathway could be inefficient activation because of the 
limiting rate of intrinsic conversion of AT to the AT* form. This implies that a key goal of the 
design strategy should be AT activation, which is reflected by acceleration in the AT inhibition 
of FXa brought about by the designed activator. A secondary goal of the design strategy could be 
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the affinity of the activator for AT. However, considering that the HBS of AT is a shallow, 
surface exposed region consisting primarily of amino acids involved in Coulomb-type 
interactions (Arg and Lys), high affinity as a ‘driver’ of design could take lesser importance at 
this early stage of non-heparin, organic activator design. 
IAS5 was found to bind in the EHBS and induce accelerated inhibition of FXa.110 This 
suggested that the non-saccharide AT activators most probably utilized the pre-equilibrium 
mechanism. The fact that the pharmacophore-based design, IAS5, could achieve about 30-fold 
acceleration in the inhibition of FXa suggested a strong potential of the pre-equilibrium 
mechanism. Thus, we have hypothesized that extending the linker between the bicyclic and 
monocyclic parts of IAS5 followed by number and position optimization for the sulfate groups 
should result in improved profile for IAS5 and should help in establishing the pre-equilibrium 
pathway as reliable mechanism to design clinically relevant non-saccharide AT allosteric 
activators. 
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Figure 20. A) Multistep mechanism of heparin activation of antithrombin . AT = native   
antithrombin; AT* = conformationally altered antithrombin; H = heparin; KD,IN and KD,PE refer to 
equilibrium dissociation constants of the first and last step of the induced-fit (IF) and pre-
equilibrium (PE) pathways, respectively. kf and kr refer to forward and reverse rate constants in 
the two pathways. See text for additional details. B) Structures of DEFGH (heparin 
pentasaccharide activator), which is known to activate AT through the induced-fit mechanism, 
EFGH′′ (tetrasacharide activator), and IAS5 (non-saccharide aromatic activator), which are 
thought to activate AT through the pre-equilibrium mechanism. Adapted from reference 231. 
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4.3. Results and Discussion— 
4.3.1. Design of Pre–Equilibrium Pathway Targeting Potential Antithrombin 
Activators— To improve upon the AT activation potential achieved with IAS5 by targeting the 
pre-equilibrium pathway of AT-mediated inhibition of FXa, a focused library of IAS5-related 
THIQ derivatives was generated in silico. Combinations of five major structural variations were 
considered in developing the library. These included the positions of two sulfate groups on the 
bicyclic THIQ moiety (3 possibilities: 6,7-; 5,8-; and 5,6-); the presence or absence of carboxylic 
group at 3-position (2 possibilities: –COO- and –H); the stereochemistry of carboxylate group at 
the 3-position (2 possibilities: R and S); the amide linker extension (2 possibilities:1-atom (-CO-) 
or 2-atom (-CH2-CO-)); and finally the positions of either two or three sulfate groups on the 
monocyclic part (5 possibilities: 2,3-; 2,4-; 2,5-; 2,3,4-; and 3,4,5- sulfates). 
The ninety designed, potential sulfated activators were docked onto the EHBS of AT* 
(activated AT) using GOLD and scored using GOLD as well as HINT, as described earlier in 
literature.106,107,220-222 This is the first study in which two scoring functions are simultaneously 
utilized to design nonsaccharide AT allosterc activators. GOLD better quantifies the polar 
interactions particularly the electrostatic as well as the hydrogen bonds of the activators’s 
sulfate/carboxylate interaction with AT’s lysine/arginine, thus GOLD allegedly better predicts 
the enthalpic component of the binding energy.  In contrast, HINT better quantifies the entropic 
component of the binding energy which is expected to play a significant role in the highly 
charged and hydrated interacting groups under physiologic conditions. 
In silico docking and scoring of highly sulfated molecules, e.g., those containing more 
than a couple of sulfate groups, onto proteins is still a growing area of algorithm design. There is 
no single algorithm that predicts binding site and geometry with high fidelity. Previously, the 
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Desai group designed a combinatorial virtual library screening strategy to improve the 
predictability of complex geometry, however this strategy is finely tuned for heparin-like 
saccharide sequences, which display reduced flexibility around typical inter-glycosidic 
torsions.220,223 Highly sulfated small organic molecules that exhibit significant backbone 
flexibility pose special challenges because of the phenomenally large conformational search 
space. The molecules tend to adopt multiple binding modes, which makes ranking less than 
straightforward. Hence, scoring with two functions, GOLD and HINT, was utilized. 
The GOLD and HINT scores of our reference activator IAS5 bound in the EHBS of AT* 
were 83.3 and 2200, respectively. The activator was found to interact with R129, R132, and 
K136 of EHBS, which corroborates competitive studies performed earlier.224 Analysis of the 
library docking results highlighted two molecules as potentially interesting, 67A225 and 58A225 
(Figures 21; chemical structures are in scheme 5. The S isomers of 67A225 and 58A225 
demonstrated GOLD scores of 83.9 and 93.0, and HINT scores of 2711 and 2772, respectively, 
while the R enantiomers had scores of 98.9 and 94.3 (GOLD) and 2200 and 2562 (HINT), 
respectively. This suggested that these designs may be potentially better at recognizing AT. The 
combinatorial library screen also indicated that 2,5–disulfated unicyclic ring was favored over 
four other possibilities and that both R and S enantiomers were likely to activate AT. 
Specifically, (R)–58A225 docking pose is reaching out to K125, which is a critical amino acid 
residue in the PBS. 
Molecules 67A225 and 58A225 were interesting from another angle too. These possess 
only four sulfate groups as opposed to five present in IAS5. This aided our ultimate goal of 
designing activators with the minimum number of sulfate groups (probably three) on a small 
scaffold so as to eliminate non-specific interactions arising from redundant negative charges. 
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Reduced polyanionic character coupled with greater hydrophobicity of the scaffold may enhance 
oral bioavailability, a feature that non-saccharide heparin mimetics are likely to possess. Thus, 
we decided to develop a small group of molecules around the 67A225 and 58A225 structures to 
identify optimal sulfate positions on the THIQ moiety and study the effect of 3-carboxylic acid 
and unicyclic – bicyclic linker length on AT activation.  
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Figure 21. Computational screening of a library of ninety potential sulfated activators docked 
onto the extended heparin binding site of the activated form of AT using GOLD. Starting with 
IAS5, our 2nd generation molecule showing 30-fold AT activation, a focused library considering 
structural variations on the positions of sulfate groups on the bicyclic and unicyclic rings, the 
presence or absence of carboxylic group at the 3-position, the stereochemistry at position 3, and 
the type of linker was built. Molecules showing high promise included 67A225 and 58A225 in 
both enantiomeric (R and S) forms. Shown here are three representative molecules. A) (S)-IAS5, 
B) (S)-67A225, and C) (R)-58A225. Adapted from reference 231. 
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4.3.2. Synthesis of Non-Saccharide, Sulfated N-Arylacyl THIQ Derivatives—The 
THIQ3CA scaffold was constructed from three components, formaldehyde, substituted 
benzaldehyde, and glycine moiety donor in four steps (Scheme 5). In our synthetic design, N-
Boc-α-phosphonoglycine trimethylester served as the glycine donor. Briefly, the Horner–
Wadsworth–Emmons reaction of the glycine donor and the desired dimethoxy benzaldehyde 9 or 
10 afforded the corresponding benzylidene in excellent yields. This was followed by catalytic 
hydrogenation using palladized charcoal, N-Boc de-protection using acidic conditions, and 
Pictet-Spengler cyclization with formaldehyde to give THIQ3CA methyl esters 13 and 14 in 
approximately 55% overall yield. Non-carboxylated THIQ derivative 2 was obtained through 
direct application of Pictet-Spengler reaction on the corresponding substituted phenethylamine 
while 6,7-dimethoxy THIQ, 1, is commercially available (Scheme 4). 
 
 
 
 
 
 
 
 
 
 
Scheme 4. (a) 2,5-dimethoxyphenyl acetic (n = 1) or butanoic acid (n = 3), EDCI, DMAP, 
rt/overnight, 70-95%, (b) BBr3/CH2Cl2, -78 0C/ 2 h, then rt/overnight, 65-85%, (c) SO3:NMe3/ 
(1:1) DMF:CH3CN, 80 0C/5 h, followed by Na+ exchange 45-75%. Adapted from reference 231. 
90 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5. (a) (±)-Boc-α-phosphonoglycine trimethylester, DBU/THF, rt/overnight, 77-85%, (b) H2/Pd/Ethanol, rt/5 h, 100%, (c) 
(1:1) TFA:CH2Cl2, rt/4 h, 85%, (d) 37% HCHO/TFA/ CH2Cl2, rt/ 5 h, 70-80%, (e) 2,5-dimethoxyphenyl acetic (n = 1), propionic (n = 
2), or butanoic acid (n = 3), EDCI, DMAP, rt/overnight, 70-95%, (f) BBr3/CH2Cl2, -78 0C/ 2 h, then rt/overnight, 65-85%, (g) 
SO3:NMe3/(1:1) DMF:CH3CN, 80 0C/5 h, followed by Na+ exchange 45-75%. Adapted from reference 231.
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The THIQ3CA esters were then elaborated to the bicyclic – unicyclic structures with 
variable linkers by coupling with appropriately substituted arylalkyl carboxylic acids. Thus, 
coupling with 2-(2,5-dimethoxy phenyl)acetic acid afforded the N-arylacylated THIQ3CA esters 
with a 2-atom linker (15a, 16a), whereas 3-atom (15b, 16b) and 4-atom linker structures (15c, 16c) 
were prepared using propionic and butanoic acid derivatives, respectively. The methoxyl 
protecting groups of the coupled N-arylacylated THIQ3CA esters were then removed using BBr3 
in CH2Cl2, which also led to the concomitant hydrolysis of the carboxylic ester, to yield the per-
phenolic N-arylacyl THIQ3CAs (17a-17c, 18a-18c). Likewise, the non-carboxylated THIQ 
derivatives, 3 and 4, as well as the corresponding per-phenolic THIQs, 5 and 6, were generated in a 
similar manner. Overall, the synthesis of the per-phenolic precursors of AT activators from the 
THIQ scaffold was achieved in 65-85% yield. To the best of our knowledge, these THIQ 
derivatives have not been reported in the literature and these high yields appear to be the best 
achieved so far for this class of molecules. 
The conversion of per-phenolic precursors, such as 17a-17c and 18a-18c, to their per-
sulfated derivatives is known to be a challenging.112 We have earlier developed a base-mediated, 
microwave-assisted per-sulfation protocol,113 however, this method resulted in partially sulfated 
compounds as well as degradation products as demonstrated by CE analysis. We inferred that the 
free carboxylic group of 17a-17c and 18a-18c interferes with base-mediated persulfation and 
hence explored neutral conditions without microwave heating. Refluxing the per-phenolic 
precursors in a 1:1 mixture of CH3CN: DMF with Me3N:SO3 complex for 5 hours gave 
significantly improved yields (41-75%) of the per-sulfated products (7, 8, 19a-19c, 20a-20c) 
(Schemes 4 and 5). It is worth mentioning here that per-sulfation of at least twelve per-phenolic 
THIQs was attempted, however, only eight compounds could be successfully isolated. Derivatives 
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with 5,6-di-sulfate and 3-carboxylate groups proved to be the most difficult perhaps because of 
limited access to the 5-position. 
4.3.3. Affinity of Sulfated N-Arylacyl THIQ Activators for Antithrombin— The 
binding affinity of heparins for plasma AT is typically measured through the 30 – 40% increase in 
intrinsic tryptophan fluorescence as a function of the concentration of the activator.52,83,219 
However, this technique did not work with the first generation non-saccharide activators because 
of insufficient signal.106,107 Later work with second generation molecules demonstrated a 
significantly different signal in comparison to the heparins. For IAS5–based activators, the intrinsic 
fluorescence decreased and reached a plateau at high ligand concentrations.110 We used this 
approach to measure the KD for AT interaction with the per-sulfated activators (7, 8, 19a-19c, 20a-
20c) in 20 mM sodium phosphate buffer at pH 6.0. Increasing concentrations of the synthesized 
per-sulfated derivatives gave a saturable decrease in intrinsic fluorescence of AT (Figure 22). The 
maximal change in fluorescence (∆FMAX) was found to be in the range of 25 – 100%, which 
provided excellent signal for KD measurement. For each per-sulfated derivative, the observed 
fluorescence decrease was fitted by the standard quadratic binding equation 5 to calculate the KD 
of AT – activator complex (Table 5). 
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Figure 22. Spectrofluorimetric measurement of the antithrombin affinity of sulfated N-arylacyl-
tetrahydroisoquinoline activators at pH 6.0, I 0.05, 25 °C. The binding of the activators (ο = 20b 
(58A325);  = 20a (58A225);  = 20c (58A425),  = 19c (67A425);  = 19b (67A325);  = 
19a (67A225)) to AT resulted in a saturable decrease in intrinsic tryptophan fluorescence at 340 
nm (λEX = 280 nm), which was fitted to the quadratic binding equation 5 to calculate the observed 
KD. Solid lines represent the non-linear regressional fit. The figure is adapted from reference 231. 
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Table 5. AT affinity of sulfated THIQActivators.a 
Activator KD (µM) ∆FMAX (%) 
58A225 394 ± 46 -40 ± 2 
58A325 420 ± 38 -127 ± 8 
58A425 1322 ± 237b -140 ± 14 
67A225 81 ± 14 -63 ± 5 
67A325 273 ± 49 -51 ± 4 
67A425 3883 ± 1325 -104 ± 26 
67225 753 ± 478 -38 ± 14 
56425 1123 ± 191 -24 ± 2 
IAS5c 320 ± 10 -130 ± 20 
ECSd 10.5 ± 1.2 nae 
 
 
 
 
 
 
 
aAffinity was measured using the decrease in intrinsic tryptophan fluorescence as a function of 
activator concentration in 20 mM sodium phosphate buffer, pH 6.0, containing 25 mM sodium 
chloride, 0.1 mM EDTA, and 0.1% PEG 8000 at 25 OC. See Experimental Procedures for 
additional details.bError represents ±1 S. E. cTaken from ref. 110. dTaken from ref. 106 and 
corresponds to results measured in 20 mM sodium phosphate buffer, pH 6.0, containing 0.1 mM 
EDTA and 0.1% PEG8000. enot applicable. 
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Overall, the AT affinity of the THIQ-based focused library was found to be mediocre to 
poor (80 – 3900 µM) in comparison to DEFGH (~0.001 µM).219 This is not too surprising 
considering that the DEFGH sequence has been optimized by nature through millions of years of 
evolution and heparin seems to have been designed specifically for recognizing AT. With regard to 
the first and second generation activators (2–300 µM), the measured affinity of activators studied 
in this work is less than expected.110,106 An important reason for this weaker affinity is that ECS 
and IAS5 (Figure 20) relied on a much smaller scaffold, which increases the sulfate charge density 
with a concomitant rise in the Coulombic forces of attraction.112 
Despite the relatively weak interaction with AT, the affinities demonstrate a strong 
structural dependence. For the 5,8–series containing the carboxylic acid group, the AT binding 
affinity ranged from 394 µM for 20a, named as 58A225 and containing a 2–atom linker, to 1322 
µM for 20c, named as 58A425 and containing a 4-atom linker (Table 5). Likewise, the AT affinity 
for the carboxylated 6,7–series ranged from 81 µM for 19a; 67A225, containing the 2–atom linker, 
to 3883 µM for 19c; 67A425, containing the 4-atom linker. Lastly, activators 7 and 8, named as 
67225 and 56425, and lacking 3–carboxylic acid group, demonstrated KD of 753 µM and 1123 
µM, respectively. The non-linear variation in affinity of these activators, more clearly 
demonstrated in the 6,7–series, probably suggests significant differences in binding mode despite 
their relatively similar structures. 
4.3.4. Antithrombin Activation by Sulfated N-Arylacyl THIQ Derivatives— A 
characteristic of AT activation is the acceleration in the rate of FXa inhibition by heparins and 
heparin mimetics. Accordingly, the second-order rate constant of AT inhibition of FXa in presence 
(kACT) and absence (kUNCAT) of sulfated N–arylacyl–THIQ derivatives was measured at pH 6.0, 25 
mM NaCl and 25 ºC, as described earlier in the previous work pertaining to the first and second 
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generations of AT activators.83,110,219 In this technique, the residual FXa activity is measured at 
various time intervals at a fixed concentration of the activator to determine the pseudo-first order 
observed rate constant (kOBS). Several kOBS measurements at various concentrations of the activator 
are performed to assess the phenomenon of AT activation. Figure 23 shows representative profiles 
for 19a (67A225) and 20b (58A325) in the concentration ranges of 0  9 µM and 0  28 µM, 
respectively. At a qualitative level, the profiles suggest that 67A225 (Figure 23A) accelerates AT 
inhibition of FXa at a rate faster than 58A325 (Figure 23B). 
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Figure 23. Kinetics of antithrombin inhibition of factor Xa in the presence of sulfated N-arylacyl-
tetrahydroisoquinoline activators 19a or 67A225 (A) and 20b or 58A325 (B) at pH 6.0, I 0.05, 25 
OC. The residual fXa activity was measured spectrophotometrically under pseudo-first order 
conditions through the initial rate of Spectrozyme FXa hydrolysis. The observed pseudo-first rate 
constant of fXa inhibition (kOBS) at each activator concentration was calculated from the 
exponential decrease. The figure is adapted from reference 231. 
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To evaluate AT activation on a quantitative level, the increase in kOBS as a function of the 
concentration of the each activator was analyzed using equation 6, as described earlier.110 The 
slope of this plot provides the second order rate constant of FXa inhibition by AT-activator 
complex (kACT), while the intercept yields the second order rate constant of FXa inhibition by AT 
alone (kUNCAT). The ratio of kACT to kUNCAT provides the acceleration in AT inhibition of FXa, a 
measure of AT activation induced by the activator. Figure 24 shows the profiles measured for each 
N-arylacyl-THIQ activator and Table 6 lists the acceleration calculated from the linear fits to the 
data. The data indicate significant differences in the acceleration potential of each sulfated 
activator.  
 
 
 
 
 
 
 
 
 
Figure 24. Acceleration in factor Xa inhibition by antithrombin - sulfated N-arylacyl-
tetrahydroisoquinoline activator complexes. The observed rate constant (kOBS) of fXa inhibition by 
AT in the presence of varying concentrations of the activator (ο = 20b (58A325);  = 20a 
(58A225);  = 20c (58A425),  = 19c (67A425);  = 19b (67A325);  = 19a (67A225)) was 
measured in a spectrophotometric assay at pH 6.0, I 0.05 and 25 OC. Solid lines represent linear 
regressional fits to the data using equation 6 to calculate the second-order rate constants, kACT and 
kUNCAT.  The figure is adapted from reference 231. 
k
O
B
S
/ 
[A
T
] 
(M
-1
s-
1
)
[Activator] / ([AT] + KD)
0.00
0.50
1.00
1.50
2.00
2.50
3.00
0 0.02 0.04 0.06 0.08 0.1
67A225
67A325
67A425
58A225
58A325
58A425
99 
 
Table 6. Acceleration in AT inhibition of FXa by sulfated THIQ activators.a 
Activator kUNCAT (M-1s-1) kACT (M-1s-1) Acceleration 
58A225 452 ± 17 32630 ± 1644 67.1 ± 5.9 
58A325 374 ± 10 11800 ± 789 29.3 ± 2.8 
58A425 543 ± 28b 46330 ± 2830 79.4 ± 8.9 
67A225 345 ± 38 19740 ± 1290 53.2 ± 9.3 
67A325 454 ± 21 8051 ± 751 16.5 ± 2.3 
67A425 378 ± 15 9640 ± 748 23.7 ± 2.8 
67225 386 ± 27 4582 ± 597 11.0 ± 2.2 
56425 375 ± 22 3337 ± 265 8.3 ± 1.1 
IAS5c ~2300 69780 ± 580 ~30.3 
ECSd ~120 909 ± 40 ~7.6 
 
 
 
 
 
 
aAntithrombin activation was measured using the discontinuous slow kinetics assay of monitoring 
residual fXa following incubation in the presence of the activator at a fixed concentration in 20 
mM sodium phosphate buffer, pH 6.0, containing 25 mM sodium chloride, 0.1 mM EDTA, and 
0.1% PEG 8000 at 25 OC.  bError represents ±1 S. E. cTaken from ref. 110 and corresponds to 
results measured in 20 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl, 0.1 mM 
EDTA and 0.1% PEG8000. dTaken from ref. 106 and corresponds to results measured in 20 mM 
sodium phosphate buffer, pH 6.0, containing 0.1 mM EDTA and 0.1% PEG8000. 
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The AT acceleration potential was found to be 79.4 for 58A425, 29.3 for 58A325, and 67.1 
for 58A225, while it was 23.7 for 67A425, 16.5 for 67A325, and 53.2 for 67A225 under identical 
conditions (pH 6.0, 25 mM NaCl, 25 °C). These results put forward three molecules studied here 
as significantly better than the best non-saccharide aromatic AT activator designed earlier.110 
Specifically, 58A425, 58A225 and 67A225 accelerate AT inhibition of FXa much better than 
IAS5. More importantly, the acceleration induced by 58A425, i.e., 80–fold, is only 3.8–fold lower 
than the 300-fold acceleration induced by DEFGH. In terms of advance in activator design, 
58A425 displays nearly 10-fold higher AT activation potential than the first designed non-
saccharide aromatic activator.106 
The results also indicate that the 5,8 series of activators is better than the 6,7 series of 
activators. Yet, the AT activation potential appears to follow a non-linear pattern with regard to the 
length of the linker in both series of molecules. For example, the 3-atom linker containing activator 
in both the series (5,8- and 6,7-series) displays weaker acceleration than the 2- and 4-atom 
counterparts. The reason for this behavior is not clear but may be due to different mode of binding 
of each activator. Finally, derivatives 56425 and 67225, which lack the 3-carboxylic acid group on 
the THIQ ring, exhibited AT acceleration of only 8.3 ± 1.1 and 11 ± 2.2, respectively. This implies 
that 3-carboxylic acid functionality of these activators is important for activation of AT.  
Finally, to assess the importance of sulfate groups in these activators, several per-phenolic 
parents of the sulfated activators were evaluated for interaction with AT and FXa. None of the 
tested per-phenolic parents displayed any measurable interaction. Further, each sulfated activator 
was assessed for its direct interaction with FXa in the absence of AT and found to lack any direct 
inhibition effect. These results support the conclusion that the designed bicyclic–unicyclic sulfated 
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N-arylacyl THIQ derivatives function as indirect inhibitors of FXa through allosteric activation of 
AT. 
4.4. Conclusion— Antithrombin is a key regulator of coagulation and prime target of 
heparins, clinically used anticoagulants. Heparins induce a two-step conformational activation of 
antithrombin, a process that has remained challenging to target with molecules devoid of the 
antithrombin binding pentasaccharide DEFGH. Computational screening of a focused library led 
to the design of two tetra-sulfated N-arylacyl tetrahydroisoquinoline variants as potential 
nonsaccharide activators of antithrombin. A high yielding synthetic scheme based on Horner–
Wadsworth–Emmons or Pictet–Spengler reactions was developed to facilitate the functionalization 
of the tetrahydoisoquinoline ring, which upon further amidation, deprotection, and sulfation gave 
the targeted nonsaccharide activators. Spectrofluorometric measurement of affinity displayed 
antithrombin binding affinities in the low to high micromolar range. Measurement of second-order 
rate constants of antithrombin inhibition of factor Xa in the presence and absence of the designed 
activators showed antithrombin activation in the range of 8–80-fold. This work puts forward 20c, a 
novel tetra-sulfated N-arylacyl tetrahydro–isoquinoline-based molecule that activates AT only 3.8-
fold less than that achieved with DEFGH, suggesting a strong possibility of rationally designing 
sulfated organic molecules as clinically relevant AT activators. 
4.5. Experimental Section— 
4.5.1. Chemicals— Anhydrous CH2Cl2, THF, CH3CN, and DMF were purchased from 
Sigma-Aldrich and used as such. All other solvents were of reagent gradient and used as 
purchased. Analytical TLC was performed using UNIPLATETM silica gel GHLF 250 µm pre-
coated plates (ANALTECH, Newark, DE). TLC was visualized by electromagnetic wave of 254 
nm and/or iodine. Column chromatography was performed using silica gel (200-400 mesh, 60 Å) 
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from Sigma Aldrich. Chemical reactions sensitive to air or moisture were carried out under 
nitrogen atmosphere in oven-dried glassware. All reagent solutions unless otherwise noted were 
handled under an inert nitrogen atmosphere using syringe techniques. 
4.5.2. Proteins— Human plasma AT and human FXa were purchased from Haematologic 
Technologies (Essex Junction, VT). Molar concentration of AT was calculated from absorbance 
measurements at 280 nm using a εmax of 37,700 M-1cm-1. AT was stored in 20 mM sodium 
phosphate buffer, pH 7.4, containing 100 mM NaCl, 0.1 mM  EDTA and 0.1% (w/v) PEG8000 at -
78 0C, while FXa was stored in 5 mM MES buffer, pH 6.0, containing 25 mM NaCl at -78 0C. 
Spectrozyme FXa was obtained from American Diagnostics (Greenwich, CT) and prepared in 20 
mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl, 0.1 mM EDTA and 0.1% (w/v) 
PEG8000. 
4.5.3. Modeling Antithrombin— Sybyl 8.1 (Tripos Associates, St. Louis, MO) was used 
for molecular modeling of AT – activator complexes. The structure of activated form of AT (ID: 
2GD4) was acquired from protein data bank (www.rcsb.org). Chain I of the crystal structure, 
which corresponds to the inhibitory monomer was used as a model of the activated antithrombin 
conformation. This form does not report the side chains of R46, K125, R132, K136, and K275, 
probably due to their significant flexibility. These side chains were introduced through appropriate 
modifications in Sybyl. Hydrogen atoms were added to the 2GD4 structure, while inorganic ions 
and water molecules were removed. Individual atoms were assigned Gasteiger-Hǚckel charges. To 
prepare this structure for docking and scoring protocols, energy minimization was performed using 
Tripos force field so as to reach a terminating gradient of 0.5 kcal/mol Å2 or a maximum of 
100,000 iterations. 
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4.5.4. Modeling the Virtual Library of Sulfated N-arylacyl THIQ Derivatives— Ninety 
IAS5-related potential AT activators were ‘synthesized’ in silico using LEGION combinatorial 
library design generator. For the sulfated activators, including IAS5, that have carboxylic group at 
3-position, both the enantiomers were modeled.  The atom type of sulfur and oxygen atoms in 
sulfate groups was modified to S.o2 and O.co2, respectively, and an ‘aromatic’ bond type was 
modeled between these atoms. The molecules were assigned Gasteiger-Hǚckel charges and were 
then energetically minimized using Tripos force field until a terminating gradient of 0.5 kcal/mol 
Å2 or a maximum of 100,000 iterations. 
4.5.5. Docking and Scoring— Docking of the potential sulfated AT activators onto the 
EHBS of the activated form of AT (AT*) was performed with GOLD 4.1 (Cambridge 
Crystallographic Data Center, UK). The EHBS comprised of electropositive residues, R129, R132, 
K133, K136 and K275, and other residues around them, as reported earlier.14,64 GOLD is a “soft 
docking” method that implicitly handles local protein flexibility by allowing a small degree of 
interpenetration, or van der Waals overlap, of ligand and protein atoms. GOLD also optimizes the 
positions of hydrogen-bond donating atoms on Ser, Thr, Tyr, and, most importantly, Lys and Arg 
residues as part of the docking process. Except for the automated number of iterations, the allowed 
amide bond flip, and the prohibited early termination, default parameters were employed during 
the GOLD docking runs. Docking was driven by the GOLD scoring function, while for ranking the 
docked solutions, a linear, modified form of the same scoring function (equation 3) was used, as 
reported earlier.220 
GOLDScore = HBEXT + 1.375 × VDWEXT  (3) 
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In this equation, HBEXT and VDWEXT are the “external” (non-bonded interactions taking 
place between the ligand and the target protein) hydrogen bonding and van der Waals terms, 
respectively. 
In addition to GOLD score, Hydropathic INTeractions (HINT) (EduSoft LC, Ashland, VA) 
scoring function was also used to score AT – activator complexes. HINT scores each atom-atom 
interaction in the ligand – biomolecule complex using a parameter set derived from experimental 
solvation partition coefficients.221 The interaction scores were calculated for each pose derived 
from docking using  equation 4, which describes the overall interaction as a double sum over the 
atoms within each component.106,107,220-222 In this equation, S is the solvent accessible surface area, 
a is the hydrophobic atom constant, T is a descriptor function, and R and r are functions of the 
distance between atoms i and j. From this equation, a binding score is calculated where bij 
describes specific interaction between atoms i and j and B describes the total interaction score 
between the two species. 
 = 	∑ ∑  =	∑∑(

 	+ )

	  (4) 
For HINT scoring of AT – activator complexes, energy minimization was first performed 
using Tripos force field until a terminating gradient of 0.005 kcal/mol Å2 was reached. AT and the 
activator were then partitioned as distinct molecules. AT was assigned HINT parameters from a 
dictionary of previously determined values. ‘Essential’ hydrogen atoms, i.e., only those attached to 
polar atoms, were explicitly considered in the models. Because HINT parameters for the sulfur 
atoms in higher oxidation states including sulfates are not well-established, sulfur interaction 
scores were removed from analysis.106,107,109 
4.5.6. Chemical Characterization of Compounds— 1H and 13C NMR were recorded on 
Bruker-400 MHz spectrometer in either CDCl3, CD3OD, acetone-d6, or D2O. Signals, in part per 
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million (ppm), are either relative to the internal standard (tetramethyl silane, TMS) or to the 
residual peak of the solvent. The NMR data are reported as chemical shift (ppm), multiplicity of 
signal (s= singlet, d= doublet, t= triplet, q= quartet, dd= doublet of doublet, m= multiplet), 
coupling constants (Hz), and integration. ESI MS of unsulfated molecules were recorded using 
Waters Acquity TQD MS spectrometer in positive ion mode. Samples were dissolved in methanol 
and infused at a rate of 20 µL/min. Mass scans were obtained in the range of 200-700 amu with a 
scan time of 1s and a scan rate of 500 amu/s. The capillary voltage was varied between 3 and 4 kV, 
while the cone voltage ranged from 38 to103 V. For sulfated molecules, ESI MS were recorded in 
negative ion mode. Samples were dissolved in 0.5% (v/v) formic acid in water and infused at a rate 
of 20 µL/min. Mass scans were obtained in the range of 200-1000 amu with a scan time of 1s and a 
scan rate of 800 amu/s. The capillary voltage was varied between 2.2 and 3.9 kV, while the cone 
voltage ranged from 60 to 74 V. Ionization conditions were optimized for each compound to 
maximize the ionization of the parent ion. Generally, the extractor voltage was set to 3 V, the Rf 
lens voltage was 0.1 V, the source block temperature was set to 150 ºC, and the desolvation 
temperature was about 250 ºC. 
4.5.7. Purification and Analytical Identification of Sulfated Compounds— Sulfated, 
non-saccharide, activators were purified using Sephadex G10 size exclusion chromatography. The 
quarternary ammonium counterion of sulfate groups present in the activators were exchanged for 
sodium ions using SP Sephadex-Na cation exchange chromatography. Sephadex G10 and SP 
Sephadex-Na chromatographies were performed using Flex columns (KIMBLE/KONTES, 
Vineland, NJ) of dimensions 170 × 1.5 cm and 75 × 1.5 cm, respectively. For regeneration of the 
cation exchange column, 1 L of 2 M NaCl solution was used. Water was used as eluent in both 
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chromatographies. Five mL fractions were collected and analyzed by reverse phase-HPLC (RP-
HPLC) and/or capillary electrophoresis (CE). 
Purity of compounds was assessed using RP-HPLC as well as CE. RP-HPLC analysis was 
carried out on a Shimadzu chromatography system using Waters Atlantis dC18 column (5 µm, 4.6 
× 250 mm). The mobile phase consisted of a 100 mM NaCl aqueous solution-CH3CN mixture (7:3 
v/v) run at a constant flow rate of 0.5 mL/min. Compounds were detected at either 254 and/or 215 
nm. The purity of each sulfated compound, as determined by RP-HPLC, was greater than 95%. CE 
experiments were performed using a Beckman P/ACE MDQ system (Fullerton, CA). 
Electrophoresis was performed at 25 ᴼC and a constant voltage of 8 kV or a constant current of 75 
µA using an uncoated fused silica capillary (ID 75 µm) with the total and effective lengths of 31.2 
cm and 21 cm, respectively. A sequential wash of 1 M HCl (10 min), water (3 min), 1 M NaOH 
(10 min), and water (3 min) at 20 psi was used to activate the capillary. Before each run, the 
capillary was rinsed with the run buffer; 50 mM sodium phosphate buffer of pH=3, for 3 min at 20 
psi. Sulfated compounds injected at the cathode (0.5 psi for 4 s) and detected at the anode (214 
nm). 
4.5.8. General Synthetic Procedures and Spectral Characterization Data— 
General procedure for Horner-Wadsworth-Emmons reaction. To a solution of (±)-
Boc-α-phosphono glycine trimethyl ester (1.2 equivalents) in dry THF (3 mL) was added DBU 
(1.2 equivalents), and the mixture was stirred for 30 min at 0 °C. A solution of 3,4-dimethoxy 
benzaldehyde 9 or 2,5-dimethoxy benzaldehyde 10 (1.0 equivalent) in dry THF (3 mL) was then 
added slowly, and the reaction mixture was warmed to RT and kept running overnight. After the 
solvent was removed under reduced pressure, the residue was dissolved in EtOAc (50 mL), 
quickly washed with saturated aqueous solutions of NaHCO3 (2 × 20 mL), brine (20 mL), and then 
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dried over anhydrous Na2SO4. The solvent was evaporated and the crude product purified by flash 
chromatography on silica gel using (30:70 of EtOAc: hexanes) as mobile phase to yield the desired 
methyl acrylate in 77-85% yield. 
Methyl 2-(tert-butoxycarbonylamino)-3-(3,4-dimethoxyphenyl)acrylate . 1H-NMR 
(CDCl3, 400 MHz): 7.20 (s, 1 H), 7.14 (s, 1 H), 7.07 (d, 1J= 8.36 Hz, 1 H), 6.80-6.77 (dd, 1J= 8.36 
Hz, 2J= 1.44 Hz, 1 H), 6.07 (s, br, 1 H), 3.83 (s, 3 H), 3.8 (s, 3 H), 3.77 (s, 3 H), 1.34 (s, 9H). 13C-
NMR (CDCl3, 100 MHz): 166.22, 153.05, 150.15, 148.7, 131.5, 126.87, 124.09, 122.58, 112.28, 
110.86, 80.79, 55.86, 55.73, 52.42, 28.13. MS (ESI) calculated for C17H23NO6, [M+H]+, m/z 
338.15, found for [M+Na]+, m/z 360.12. 
Methyl 2-(tert-butoxycarbonylamino)-3-(2,5-dimethoxyphenyl)acrylate. 1H-NMR 
(CDCl3, 400 MHz): 7.21 (s, 1 H), 7.0 (s, 1H), 6.78 (t, 1J= 0.92 H, 2 H), 6.41 (s, br, 1H), 3.77 (s, 
3H), 3.76 (s, 3H), 3.68 (s, 3H), 1.32 (s, 9H). 13C-NMR (CDCl3, 100 MHz): 166.07, 153.44, 152.81, 
151.51, 126.13, 123.79, 123.47, 116.11, 114.52, 112.61, 80.68, 56.45, 55.7, 52.44, 28.27. MS 
(ESI) calculated for C17H23NO6, [M+H]+, m/z 338.15, found for [M+Na]+, m/z 360.18. 
General procedure for catalytic hydrogenation of α-amino-β-aryl methyl acrylates. 
Methyl acrylate from the above reaction and 10% Pd/C were mixed in ethanol (10 mL). Hydrogen 
gas was then pumped into the mixture at RT. After stirring the solution for 5 h, the catalyst was 
filtered on Celite and the organic filtrate concentrated in vacuo to afford the reduced product in 
~100% yield. 
Methyl 2-(tert-butoxycarbonylamino)-3-(3,4-dimethoxyphenyl)propanoate (11). 1H-
NMR (CDCl3, 400 MHz): 6.72 (d, 1J= 8.08 Hz, 1 H), 6.59 (d, 1J= 8.28 Hz, 1 H), 6.57 (d, 1J= 1.36 
Hz, 1 H), 4.89 (d, 1J= 7 Hz, 1 H), 4.49-4.43 (dd, 1J= 13.24 Hz, 2J= 6.76 Hz, 1 H), 3.79 (s, 3 H), 
3.78 (s, 3 H), 3.65 (s, 3 H), 2.96 (t, 1J= 6.2 Hz, 2 H), 1.35 (s, 9H). 13C-NMR (CDCl3, 100 MHz): 
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172.39, 155.05, 148.91, 148.14, 128.44, 121.38, 112.45, 111.3, 79.89, 55.87, 55.8, 54.50, 52.16, 
37.9, 28.3. MS (ESI) calculated for C17H25NO6, [M+H]+, m/z 340.17, found for [M+Na]+, m/z 
362.33. 
Methyl 2-(tert-butoxycarbonylamino)-3-(2,5-dimethoxyphenyl)propanoate (12). 1H-
NMR (CDCl3, 400 MHz): 6.7-6.68 (m, 2H), 6.605 (d, 1J= 2.76 Hz, 1 H), 5.19 (d, 1J= 7.08 Hz, 1 
H), 4.45-4.39 (dd, 1J= 13.24 Hz, 2J= 7.04 Hz, 1 H), 3.71 (s, 3H), 3.67 (s, 3H), 3.64 (s, 3H), 2.96 (t, 
J= 4.84 Hz, 2H), 1.31 (s, 9H). 13C-NMR (CDCl3, 100 MHz): 172.7, 155.21, 153.5, 151.82, 125.73, 
117.16, 112.7, 111.29, 79.47, 55.77, 55.6, 54.08, 51.97, 32.86, 28.22. MS (ESI) calculated for 
C17H25NO6, [M+H]+, m/z 340.17, found for [M+Na]+, m/z 361.82. 
General procedure for N-Boc deprotection. To a solution of N-Boc β-aryl amino ester 
(1.0 equivalent) in CH2Cl2 (5 mL), trifluoro-acetic acid (TFA, 5 mL) was added drop-wise at 0 0C, 
and the mixture was warmed to RT. After stirring for 4 h, the reaction mixture was diluted with 
CH2Cl2 (25 mL) and neutralized by drop-wise addition of saturated aqueous NaHCO3 (20 mL). 
The organic layer was separated and the aqueous phase was extracted with EtOAc (2 × 25 mL). 
The organic extracts were combined, washed with saturated NaCl solution (25 mL), and dried over 
anhydrous Na2SO4. Removal of the solvent under reduced pressure left a residue, which was 
purified by silica gel chromatography (90:10 of EtOAc:hexanes) to afford the desired β-aryl amino 
ester in ~85% yield. 
Methyl 3,4-dimethoxy phenylalanine. 1H-NMR (CDCl3, 400 MHz): 6.73 (d, J= 7.76 Hz,1 
H), 6.66 (d, 1J = 7.36 Hz, 1 H), 6.65 (s, 1 H), 3.79-3.65 (m, 1 H), 3.79 (s, 3 H), 3.78 (s, 3H), 3.64 
(s, 3H), 2.99-2.95 (dd, 1J= 13.6 Hz, 2J= 4.84 Hz, 1H),  2.79-2.74 (dd, 1J= 13.6 Hz, 2J= 7.64 Hz, 
1H), 1.86 (s, 1 H). 13C-NMR (CDCl3, 100 MHz): 175.22, 148.96, 147.99, 129.49,121.36, 112.4, 
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111.32, 55.87, 55.83, 55.8, 51.99, 40.41. MS (ESI) calculated for C12H17NO4, [M+H]+, m/z 240.12, 
found for [M+Na]+, m/z 262.22. 
Methyl 2,5-dimethoxy phenylalanine. 1H-NMR (CDCl3, 400 MHz): 6.71 (s, 3H), 4.28-
4.25 (dd, 1J= 8 Hz, 2J= 5 Hz, 1H), 3.70 (s, 3H), 3.66 (s, 3H), 3.63 (s, 3H), 3.33-3.28 (dd, 1J= 14.12 
Hz, 2J= 4.95 Hz, 1 H), 3.03-2.97 (dd, 1J= 14.12 Hz, 2J= 8.04 Hz, 1H). 13C-NMR (CDCl3, 100 
MHz): 169.51, 153.41, 151.81, 123.01, 117.87, 113.92, 111.67, 55.77, 53.04, 52.77, 32.01. MS 
(ESI) calculated for C12H17NO4, [M+H]+, m/z 240.12, found for [M+Na]+, m/z 262.15. 
General procedure for Pictet-Spengler reaction of substituted methyl phenylalanine 
esters and substituted phenethylamine. A solution of methyl phenylalanine derivative or 
phenethylamine derivative (1 equivalent) in CH2Cl2 (2 mL) was treated at RT with formaldehyde 
(37% aqueous solution, 1.5 equivalents). TFA (2 equivalent) was then slowly added over 15 min. 
After stirring for 5 h, the reaction mixture was diluted with CH2Cl2 (2 mL) and neutralized with 
saturated NaHCO3 solution (5 mL). The organic layer was separated and the aqueous phase was 
further extracted with CH2Cl2 (3 × 10 mL). The organic extracts were combined, washed with 
saturated NaCl solution (10 mL), and dried over anhydrous Na2SO4. Removal of the solvent under 
reduced pressure left a residue, which was purified by silica gel chromatography (60:40 of EtOAc: 
hexanes) to yield the desired tetrahydroisoquinoline derivative in 70-80 % yield. 
Methyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (13). 1H-NMR 
(CDCl3, 400 MHz): 6.52 (s, 1 H), 6.46 (s, 1 H), 4.08-3.98 (dd, 1J= 25.64 Hz, 2J= 15.67 Hz, 2 H), 
3.79-3.73 (m, 1 H), 3.78 (s, 3 H), 3.77 (s, 3 H), 3.72 (s, 3 H), 3.41 (s, br, 1 H), 3.00-2.95 (dd, 1J= 
16.08 Hz, 2J = 4.76 Hz, 1 H), 2.91-2.84 (dd, 1J= 16 Hz, 2J= 9.68 Hz, 1 H). 13C-NMR (CDCl3, 100 
MHz): 172.73, 147.83, 125.48, 124.35, 111.72, 108.91, 55.93, 55.57, 52.34, 46.37, 30.63. MS 
(ESI) calculated for C13H17NO4, [M+H]+, m/z 252.12, found for [M+Na]+, m/z 274.19. 
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Methyl 5,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (14). 1H-NMR 
(CDCl3, 400 MHz): 6.53-6.52 (m, 2H), 3.94-3.81 (m, 3H), 3.69 (s, 3H), 3.67 (s, 3H), 3.48 (s, 3H), 
3.15-3.06 (m, 1H), 2.87-2.79 (m, 1H). 13C-NMR (CDCl3, 100 MHz): 173.45, 151.16, 150.15, 
124.81, 123.19, 107.12, 56.70, 55.67, 51.21, 45.55, 25.87. MS (ESI) calculated for C13H17NO4, 
[M+H]+, m/z 252.12, found m/z 252.14. 
5,6-Dimethoxy-1,2,3,4-tetrahydroisquinoline (2).  1H-NMR (CDCl3, 400 MHz): 6.67-
6.66 (m, 2 H), 3.75 (s, 3H), 3.73 (s, 3H), 3.59 (s, 1 H), 3.16 (s, 1 H), 2.8 (t, 1J= 5.16 Hz, 2 H), 2.74 
(t, 1J= 5.08 Hz, 2 H). 13C-NMR (CDCl3, 100 MHz): 150.64, 146.63, 129.23, 128.41, 121.92, 
110.41, 59.97, 55.92, 53.99, 48.88, 23.90. MS (ESI) calculated for C11H15NO2, [M+H]+, m/z 
194.11, found for [M+Na]+, m/z 216.11. 
General procedure for N-arylacylation of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic 
acid methyl ester (THIQ3CA ester) and 1,2,3,4-tetrahydroisoquinoline (THIQ). To a stirred 
solution of either 2,5-dimethoxylphenyl acetic, propionic, or butanoic acid (1 equivalent) in 
anhydrous CH2Cl2 (5 mL) was added 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide  (EDCI, 
1.1 equivalents) and DMAP (1.1 equivalents) at RT under nitrogen atmosphere. Dimethoxy-
1,2,3,4-tetrahydroisoquinoline (either 1, 2, 13 or 14) (1.1 equivalents) in anhydrous CH2Cl2 (5 mL) 
was then added drop-wise. After stirring overnight, the reaction mixture was partitioned between 2 
N HCl solution (20 mL) and CH2Cl2 (30 mL). The organic layer was washed further with 2 N HCl 
(2 × 10 mL) and saturated NaCl solution (20 mL), dried using anhydrous Na2SO4, and 
concentrated to give a crude, which purified by silica gel chromatography (50:50 of EtOAc: 
hexanes) to give the desired coupled product in 70 – 95 % yield. 
Methyl 2-(2-(2,5-dimethoxyphenyl)acetyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (15a). 1H-NMR (CDCl3, 400 MHz): 6.80 (d, 1J= 2.64 Hz, 1 H), 6.75-
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6.67 (m, 2 H), 6.56-6.40 (m, 2 H), 5.51-5.49 & 4.94-4.92 (dd & dd, 1J= 3.32 Hz, 2J= 6.04 Hz & 
1J= 2.32 Hz, 2J= 5.76 Hz, 1 H) 4.91-4.30 (m, 2 H), 3.78 (s, 2 H), 3.76 (s, 3 H), 3.75 (s, 3 H), 3.72 
(s, 3 H), 3.66 (s, 3H), 3.50 (d, 1J= 51.52 Hz, 3 H), 3.14-3.06 (m, 1 H), 3.02-2.84 (m, 1 H). 13C-
NMR (CDCl3, 100 MHz): 171.49, 171.36, 153.78, 151.18, 150.55, 148.22, 124.28,  123.92, 
122.83, 115.91, 113.31, 112.90, 111.58, 109.28, 56.1, 55.95, 55.91, 55.73, 52.44, 52.29, 45.47, 
35.30, 31.23. MS (ESI) calculated for C23H27NO7, [M+H]+, m/z 430.18, found for [M+Na]+, m/z 
452.36. 
Methyl 2-(2-(2,5-dimethoxyphenyl)acetyl)-5,8-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (16a). 1H-NMR (CDCl3, 400 MHz): 6.82-6.79 (m, 1 H), 6.73-6.66 
(m, 2 H), 6.60-6.54 (m, 2 H), 5.64-5.62 & 4.96-4.94 (dd & dd, 1J = 2.36 Hz, 2J = 6.80 Hz & 1J = 
1.56 Hz, 2J = 6.44 Hz, 1 H), 5.02-4.14 (m, 2 H), 3.76 (d,1J= 23.76 Hz, 2H),  3.71 (s, 3H), 3.70 (s, 3 
H), 3.67 (s, 3 H), 3.65 (s, 3 H), 3.49 (d, 1J= 46.72 Hz, 3 H), 3.41-3.37 (m, 1 H), 2.78-2.49 (m, 1 
H).13C-NMR (CDCl3, 100 MHz): 171.74, 171.45, 153.64, 151.30, 150.93, 149.57, 124.35, 122.29, 
121.94, 116.04, 113.00, 111.39, 108.13, 107.43, 56.02, 55.83, 55.70, 55.42, 52.24, 49.92, 41.23, 
35.06, 24.27. MS (ESI) calculated for C23H27NO7, [M+H]+, m/z 430.18, found for [M+Na]+, m/z 
452.3. 
Methyl 2-(3-(2,5-dimethoxyphenyl)propanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (15b). 1H-NMR (CDCl3, 400 MHz): 6.72-6.69 (m, 3 H), 6.64-6.45 
(m, 2 H), 5.52-5.50 & 4.87-4.85 (dd & dd, 1J = 3 Hz, 2J = 6.08 Hz & 1J = 2.44 Hz, 2J = 5.76 Hz, 1 
H), 4.88-4.30 (m, 2 H), 3.78 (s, 3 H), 3.75 (s, 3 H), 3.73 (s, 3 H), 3.67 (s, 3 H), 3.56 (s, 3 H), 3.78-
3.09 (m, 1 H), 2.99-2.84 (m, 3 H), 2.70-2.67 (m, 2 H).13C-NMR (CDCl3,100 MHz): 172.77, 
171.62, 153.58, 151.76, 148.26, 147.80,  130.65, 124.10, 123.70, 116.74, 111.71, 111.26, 109.36, 
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108.91, 55.94, 55.91, 55.80, 55.67, 52.77, 50.97, 45.12, 34.18, 30.26, 26.69. MS (ESI) calculated 
for C24H29NO7, [M+H]+, m/z 444.19, found for [M+Na]+, m/z 466.04. 
Methyl 2-(3-(2,5-dimethoxyphenyl)propanoyl)-5,8-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (16b). 1H-NMR (CDCl3, 400 MHz): 6.73-6.54 (m, 5 H), 5.65-5.63 & 
4.96-4.94 (dd & dd, 1J = 2.20 Hz, 2J = 6.76 Hz & 1J = 1.60 Hz, 2J = 6.40 Hz, 1 H), 5.03-4.14 (m, 2 
H), 3.73 (s, 3 H), 3.70 (s, 3 H), 3.69 (s, 3 H), 3.67 (s, 3 H), 3.55 (s, 3 H), 3.54-3.38 (m, 1 H), 2.94-
2.85 (m, 2 H), 2.78-2.53 (m, 3 H). 13C-NMR (CDCl3, 100 MHz): 173.16, 171.58, 153.60, 151.81, 
150.92, 149.59, 130.67, 122.43, 121.71, 116.50, 111.81, 111.20, 108.09, 107.63, 55.83, 55.70, 
55.44, 55.31, 52.31, 49.61, 40.96, 34.16, 26.71, 24.31. MS (ESI) calculated for C24H29NO7, 
[M+H]+, m/z 444.19, found for [M+Na]+, m/z 465.97. 
Methyl 2-(4-(2,5-dimethoxyphenyl)butanoyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (15c). 1H-NMR (CDCl3, 400 MHz): 6.71-6.62 (m, 3 H), 6.55-6.47 (m, 
2 H), 5.52-5.50 & 4.69-4.67 (dd & dd, 1J = 2.88 Hz, 2J =5.92 Hz & 1J = 2.36 Hz, 2J = 5.56 Hz, 1 
H), 4.86-4.44 (m, 2 H), 3.78 (s, 3 H), 3.77 (s, 3 H), 3.69 (s, 3 H), 3.68 (s, 3 H), 3.55 (s, 3 H), 3.17-
3.09 (m, 1 H), 3.04-2.93 (m, 1 H), 2.64 (m, 2 H), 2.44-2.40 (m, 2 H), 1.97-1.89 (m, 2 H). 13C-
NMR (CDCl3, 100 MHz): 173.18, 171.55, 153.50, 151.88, 148.28, 147.84, 131.32, 124.11, 123.60, 
116.45, 111.30, 110.97, 109.38, 108.99, 55.96, 55.94, 55.90, 55.70, 52.30, 50.94, 45.16, 33.10, 
30.27, 29.76, 24.81. MS (ESI) calculated for C25H31NO7, [M+H]+, m/z 458.21, found for [M+Na]+, 
m/z 479.96. 
Methyl 2-(4-(2,5-dimethoxyphenyl)butanoyl)-5,8-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline-3-carboxylate (16c). 1H-NMR (CDCl3, 400 MHz): 6.70-6.55 (m, 5 H), 5.63-5.60 & 
4.72 (dd & d, 1J = 2.32 Hz, 2J = 6.76 Hz & 1J = 4.92 Hz, 1 H), 5.02-4.09 (m, 2 H), 3.71 (s, 3 H), 
3.70 (s, 3 H), 3.69 (s, 3  H), 3.67 (s, 3 H), 3.55 (s, 3 H), 3.40-3.37 (m, 1 H), 2.75-2.68 (m, 1 H), 
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2.66-2.53 (m, 2 H), 2.51-2.31 (m, 2 H), 1.97-1.89 (m, 2 H). 13C-NMR (CDCl3, 100 MHz): 173.44, 
171.62, 153.50, 151.85, 150.93, 149.58, 131.47, 122.5, 121.75, 116.38, 111.48, 111.18, 108.17, 
107.38, 55.83, 55.75, 55.69, 55.40, 52.29, 49.64, 40.89, 33.26, 29.93, 25.12, 24.30. MS (ESI) 
calculated for C25H31NO7, [M+H]+, m/z 458.21, found for [M+Na]+, m/z 480.4. 
1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-(2,5-dimethoxy phenyl) ethanone 
(3). 1H-NMR (CDCl3, 400 MHz): 6.78-6.64 (m, 5H), 4.54 (d, 1J= 48.84 Hz, 2H), 3.76 (s, 3H), 
3.71(s, 3H), 3.69 (s, 3H), 3.67(s, 3H), 3.63-3.60 (m, 3H), 3.58-3.54 (m, 1H), 2.78 (t, 1J = 5.96 Hz, 
1 H), 2.64 (t, 1J = 5.88 Hz, 1 H). 13C-NMR (CDCl3, 100 MHz): 170.40, 153.68, 151.00, 146.18, 
128.52, 126.68, 124.67, 121.98, 117.10, 115.81, 112.94, 111.57, 110.88, 60.28, 56.09, 55.87, 
55.68, 47.17, 43.89, 35.09, 23.64. MS (ESI) calculated for C21H25NO5, [M+H]+, m/z 372.17, found 
for [M+Na]+, m/z 394.33. 
1-(5,6-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-4-(2,5-dimethoxy phenyl) butan-1-
one (4). 1H-NMR (CDCl3, 400 MHz): 6.79-6.60 (m, 5 H), 4.49 (d, 1J= 74.72 Hz, 2 H), 3.77 (s, 
3H), 3.73 (s, 3H), 3.67 (s, 3H), 3.66 (s, 3H), 3.67-3.66 (m, 1 H), 3.50 (t, 1J= 5.68 Hz, 1 H), 2.80-
2.76 (m, 2 H), 2.59 (t, 1J= 7.6 Hz, 2 H), 2.34 (t, 1J= 7.36 Hz, 2 H), 1.92-1.88 (m, 2H). 13C-NMR 
(CDCl3, 100 MHz): 171.92, 153.48, 151.83, 150.88, 146.21, 131.34, 128.44, 126.86, 126.00, 
121.97, 121.27, 116.33, 111.22, 60.34, 55.90, 55.87, 55.68, 46.83, 42.92, 39.34, 33.05, 29.92, 
25.19. MS (ESI) calculated for C23H29NO5, [M+H]+, m/z 400.20, found for [M+Na]+, m/z 422.37. 
General procedure for O-demethylation of N-arylacyl THIQ3CA esters and THIQs. 
To a stirred solution of the protected THIQ3CA ester (or THIQ derivative) in anhydrous CH2Cl2 (5 
mL), BBr3 (1M solution in CH2Cl2, 9-12 equivalents) was added drop-wise at -78 0C under 
nitrogen atmosphere over 10 min. After 2 h, the reaction mixture was brought to RT and allowed 
to equilibrate overnight. A mixture of (1:1) methanol/water (2 mL) was then added slowly at 0 0C 
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and vigorously stirred for 10 min to quench the reaction. The reaction mixture was then 
concentrated and partitioned between EtOAc (25 mL) and saturated solution of NH4Cl (15 mL). 
The aqueous layer was further washed with EtOAc (2 × 20 mL). The combined organic layer was 
washed with brine solution (15 mL), dried using anhydrous Na2SO4 and, and finally concentrated 
in vacuo. The crude was purified by gradient silica gel chromatography using EtOAc in hexanes to 
give the desired poly-phenol of THIQ derivative in 65 – 85 % yield. 
2-(2-(2,5-dihydroxyphenyl)acetyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acid (17a).  1H-NMR (acetone-d6, 400 MHz):  6.65 (d, J= 2.92 Hz, 1 H), 6.54-6.50 (m, 
3 H), 6.47-6.44 (dd, 1J = 2.96 Hz, 2J= 8.56 Hz, 1 H), 5.20-5.18 & 5.15-5.13 (dd & dd, 1J= 3.60 Hz, 
2J = 5.92 Hz & 1J = 2.60 Hz, 2J = 5.68 Hz, 1 H), 4.79-4.19 (m, 2 H), 3.78-3.43 (m, 2 H), 3.07-3.00 
(m, 1 H), 2.88-2.84 (m, 1 H). 13C-NMR (acetone-d6, 100 MHz): 173.3, 172.2, 151.33, 149.87, 
149.53, 145.04, 124.65, 124.52, 123.98, 118.48, 117.87, 115.69, 115.53, 113.83, 56.18, 46.50, 
36.49, 31.68. MS (ESI) calculated for C18H17NO7, [M+H]+, m/z 360.1, found for [M+Na]+, m/z 
382.24. 
2-(2-(2,5-dihydroxyphenyl)acetyl)-5,8-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acid (18a). 1H-NMR (acetone-d6, 400 MHz): 6.64-6.54 (m, 3 H), 6.47-6.42 (m, 2 H), 
5.49-5.47 & 5.26 (dd & d, 1J = 2.20 Hz, 2J = 6.32 Hz & 1J = 5.00 Hz, 1 H), 4.91-4.19 (m, 2 H), 
3.86-3.81 (dd, 1J = 5.84 Hz, 2J = 14.68 Hz, 1 H), 3.72-3.57 (m, 1 H), 3.46-3.41 (m, 1 H), 2.71-2.55 
(m, 1 H).13C-NMR (acetone-d6, 100 MHz): 173.73, 172.51, 151.32, 149.58, 148.19, 147.02, 
123.21, 121.08, 120.82, 118.53, 117.59, 116.68, 115.50, 113.46, 51.13, 42.68, 36.41, 25.43. MS 
(ESI) calculated for C18H17NO7, [M+H]+, m/z 360.1, found for [M+Na]+, m/z 382.21. 
2-(3-(2,5-dihydroxyphenyl)propanoyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline-
3-carboxylic acid (17b). 1H-NMR (400 MHz, acetone-d6): 6.55-6.47 (m, 4 H), 6.40-6.38 (dd, 1J = 
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2.88 Hz, 2J = 8.56 Hz, 1 H), 5.22-5.20 & 4.94-4.93 (dd & dd, 1J = 3.66 Hz, 2J = 6.00 Hz & 1J = 
2.68 Hz, 2J = 5.68 Hz, 1 H), 4.58-4.17 (m, 2 H), 3.07-2.94 (m, 1 H), 2.91-2.80 (m, 1 H), 2.79-2.66 
(m, 4 H).  13C-NMR (100 MHz, acetone-d6): 174.36, 172.4, 151.36, 149.13, 145.02, 144.81, 
129.95, 124.77, 124.58, 117.85, 117.66, 115.69, 114.7, 113.86, 55.41, 45.78, 35.63, 30.93. 26.11. 
MS (ESI) calculated for C19H19NO7, [M+H]+, m/z 374.12, found for [M+Na]+, m/z 396.22. 
2-(3-(2,5-dihydroxyphenyl)propanoyl)-5,8-dihydroxy-1,2,3,4-tetrahydroisoquinoline-
3-carboxylic acid (18b). 1H-NMR (CD3OD, 400 MHz): 6.53-6.47 (m, 2H), 6.43-6.35 (m, 3 H), 
5.34-5.32 & 5.01-5.00 (dd & dd, 1J=  2.80 Hz, 2J= 6.48 Hz & 1J= 2.04 Hz, 2J= 6.12 Hz, 1 H), 4.82-
4.19 (m, 2 H), 3.46-3.31 (m, 1 H), 2.81-2.63 (m, 4 H), 2.56-2.46 (m, 1 H). 13C-NMR (CD3OD, 100 
MHz): 175.91, 174.51, 151.24, 149.26, 148.40, 147.41, 129.59, 124.20, 121.19, 117.75, 117.17, 
114.81, 114.25, 113.79, 52.05, 42.43, 35.20, 30.68, 27.25. MS (ESI) calculated for C19H19NO7, 
[M+H]+, m/z 374.12, found for [M+Na]+, m/z 396.2. 
2-(4-(2,5-dihydroxyphenyl)butanoyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acid (17c). 1H-NMR (acetone-d6, 400 MHz): 6.55-6.46 (m, 4 H), 6.40-6.38 (m,1 H), 
5.25-5.23 & 4.91-4.88 (dd & dd, 1J= 3.44 Hz, 2J= 6.00 Hz & 1J= 2.60 Hz, 2J= 5.52 Hz, 1 H), 4.64-
4.17 (m, 2 H), 3.09-3.00 (m, 1 H), 2.98-2.83 (m, 1H), 2.49-2.17 (m, 4 H), 1.83-1.81 (m, 2 H). 13C-
NMR (acetone-d6, 100 MHz): 174.09, 172.63, 151.06, 149.23, 145.05, 144.98, 129.65, 124.81, 
124.7, 124.1, 117.45, 116.89, 115.73, 114.27, 113.88, 55.39, 45.72, 36.27, 33.12, 31.73, 26.14. MS 
(ESI) calculated for C20H21NO7, [M+H]+, m/z 388.13, found for [M+Na]+, m/z 410.21. 
2-(4-(2,5-dihydroxyphenyl)butanoyl)-5,8-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acid (18c). 1H-NMR (acetone-d6, 400 MHz): 6.53-6.43 (m, 4 H), 6.40-6.36 (m, 1 H), 
5.50-5.48 & 5.03-5.01 (dd & dd, 1J = 2.52 Hz, 2J = 6.68 & 1J = 1.88 Hz, 2J = 6.32 Hz, 1 H), 4.90-
4.14 (m, 2 H), 3.53-3.40 (m, 1 H), 2.81-2.66 (m, 1 H), 2.54-2.33 (m, 4 H), 1.83-1.75 (m, 2 H). 13C-
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NMR (acetone-d6, 100 MHz): 174.17, 172.60, 150.99, 149.15, 148.28, 146.99, 129.62, 121.51, 
117.30, 116.80, 114.17, 113.64, 113.33, 113.18, 54.44, 50.65, 41.81, 33.14, 26.24, 25.38. MS 
(ESI) calculated for C20H21NO7, [M+H]+, m/z 388.13, found for [M+Na]+, m/z 410.34. 
1-(6,7-dihydroxy-3,4-dihydroisoquinolin-2(1H)-yl)-2-(2,5-dihydroxyphenyl) ethanone 
(5). 1H-NMR (acetone-d6, 400 MHz): 6.60-6.53 (m, 2 H), 6.48-6.44 (m, 3 H), 4.5 (d, 1J= 84.0 Hz, 
2 H), 3.72 (t, 1J= 5.72 Hz, 1 H), 3.63 (d, 1J= 6.96 Hz, 2 H), 3.58 (t, 1J= 5.96 Hz, 1 H), 2.56 (t, 1J= 
5.60 Hz, 1 H), 2.51 (t, 1J= 5.88 Hz, 1 H). 13C-NMR (acetone-d6, 100 MHz): 172.25, 151.30, 
150.12, 144.84, 144.65, 126.76, 125.22, 124.87, 123.44, 118.06, 115.84, 115.58, 113.79, 48.14, 
45.17, 36.63, 28.33. MS (ESI) calculated for C17H17NO5, [M+H]+, m/z 316.11, found for [M+Na]+, 
m/z 338.2. 
1-(5,6-dihydroxy-3,4-dihydroisoquinolin-2(1H)-yl)-4-(2,5-dihydroxyyphenyl) butan-1-
one (6). 1H-NMR (CD3OD, 400 MHz): 6.55-6.49 (m, 2 H), 6.46-6.43 (m, 1 H), 6.39-6.32 (m, 2 H), 
4.39 (d, 1J= 43.04 Hz, 2 H),  3.6 (t, 1J= 6.16 Hz, 1 H), 3.49 (t, 1J= 6.04 Hz, 1 H), 2.68 (t, 1J= 5.92 
Hz, 1 H), 2.63 (t, 1J= 6.12 Hz, 1 H), 2.50-2.45 (m, 2 H), 2.35-2.30 (m, 2 H), 1.81-1.74 (m, 2 H). 
13C-NMR (CD3OD, 100 MHz): 174.58, 151.10, 149.33, 144.64, 143.76, 130.19, 126.20, 125.94, 
123.48, 118.24, 117.83, 116.93, 114.50, 45.03, 44.48, 41.11, 33.96, 30.85, 26.77. MS (ESI) 
calculated for C19H21NO5, [M+H]+, m/z 344.14, found for [M+Na]+, m/z 366.23. 
General procedure for O-sulfonation of polyphenolic THIQ3CA and THIQ 
derivatives. An equivolume mixture of anhydrous CH3CN and DMF (3 mL) containing THIQ 
polyphenol and SO3:NMe3 complex (6 equivalents/-OH group of the polyphenol) was heated for 5 
h at 80°C. Following reaction, the solution was cooled and concentrated in vacuo at less than 35 0C 
and the residue taken up in water for loading onto a Sephadex G10 column. The column was 
eluted with deionized water and fractions were combined based on RP-HPLC and/or CE profiles 
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(see above). The eluted fractions were lyophilized and re-loaded onto a SP Sephadex column for 
sodium exchange. Appropriate fractions were pooled, concentrated in vacuo, and lyophilized to 
obtain a white powder of per-sulfated THIQ-based antithrombin activators in 45 – 75 % yield. 
Sodium 2-(2-(2,5-di-O-sulfonato-phenyl)acetyl)-6,7-di-O-sulfonato-1,2,3,4-
tetrahydroisoquinoline-3-carboxylate tetrasodium (19a), 67A225. 1H-NMR (D2O, 400 MHz): 
7.47-7.25 (m, 5 H), 5.02-4.99 & 4.93-4.91 (dd & dd, 1J= 3.68 Hz, 2J = 5.56 Hz & 1J = 2.64 Hz, 2J 
= 5.32 Hz, 1 H), 4.90-4.82 (m, 2 H), 4.27-3.56 (m, 2 H), 3.32-3.12 (m, 2 H). 13C-NMR (D2O, 100 
MHz): 177.74, 172.94, 148.70, 147.52, 141.95, 132.61, 132.16, 131.31, 129.91, 124.43, 122.91, 
122.35, 121.65, 121.05, 55.59, 45.86, 35.39, 31.88. MS (ESI) calculated for C18H12NNa5O19S4, 
[M-H]-, m/z 787.84, found for [M-Na]-, m/z 765.92. 
Sodium 2-(2-(2,5-di-O-sulfonato-phenyl)acetyl)-5,8-di-O-sulfonato-1,2,3,4-
tetrahydroisoquinoline-3-carboxylate tetrasodium (20a), 58A225. 1H-NMR (D2O, 400 MHz): 
7.09-7.32 (m, 5 H), 4.87-5.18 (m, 1 H), 4.66-4.84 (m, 2 H), 3.52-4.14 (m, 2 H), 3.28-3.44 (m, 1 H), 
2.88-2.99 (m, 1 H). 13C-NMR (D2O, 100 MHz): 176.65, 172.60, 148.65, 147.67, 146.05, 144.95, 
129.91, 129.08, 127.82, 124.56, 122.89, 121.59, 120.99, 120.38, 54.08, 41.38, 35.37, 25.88. MS 
(ESI) calculated for C18H12NNa5O19S4, [M-H]-, m/z 787.84, found for [M-Na]-, m/z 766.05. 
Sodium 2-(3-(2,5-di-O-sulfonato-phenyl)propanoyl)-6,7-di-O-sulfonato-1,2,3,4-
tetrahydroisoquinoline-3-carboxylate tetrasodium (19b), 67A325. 1H-NMR (D2O, 400 MHz): 
7.27-7.01 (m, 5 H), 5.16-5.13 & 4.98-4.95 (dd & dd, 1J = 3.76 Hz, 2J = 5.8 Hz & 1J =3.32 Hz, 2J 
5.92 Hz, 1 H), 4.61-4.49 (m, 2 H), 3.18-2.82 (m, 5 H), 2.74-2.52 (m, 1 H). 13C-NMR (D2O, 100 
MHz): 175.25, 174.50, 148.72, 147.26, 141.83, 141.57, 134.95, 132.34, 131.36, 130.93, 123.43, 
122.65, 122.29, 120.97, 57.54, 45.51, 33.49, 30.79. 26.18. MS (ESI) calculated for 
C19H14NNa5O19S4, [M-H]-, m/z 801.85, found for [M-Na]-, m/z 779.97. 
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Sodium 2-(3-(2,5-di-O-sulfonato-phenyl) propanoyl)-5,8-di-O-sulfonato-1,2,3,4-
tetrahydroisoquinoline-3-carboxylate tetrasodium (20b), 58A325. 1H-NMR (D2O, 400 MHz): 
7.45-7.03 (m, 5 H), 5.24-5.03 (m, 1 H), 4.91-4.51 (m, 2 H), 3.52-3.36 (m, 1 H), 3.15-3.08 (m, 3 H), 
3.06-2.64 (m, 2 H). 13C-NMR (D2O, 100 MHz): 175.49, 174.57, 148.73, 147.33, 146.23, 145.17, 
135.04, 128.84, 127.92, 127.56, 123.43, 122.79, 121.30, 120.53, 56.73, 52.42, 41.27, 33.33, 25.90. 
MS (ESI) calculated for C19H14NNa5O19S4, [M-H]-, m/z 801.85, found for [M-Na]-, m/z. 780.07. 
Sodium 2-(4-(2,5-di-O-sulfonato-phenyl)butanoyl)-6,7-di-O-sulfonato-1,2,3,4-
tetrahydroisoquinoline-3-carboxylate tetrasodium (19c), 67A425. 1H-NMR (D2O, 400 MHz): 
7.24-7.02 (m, 5 H), 5.02-4.99 & 4.94-4.91 (t & dd, 1J = 5.64 Hz & 1J = 4.24 Hz, 2J = 5.92 Hz,  1 
H), 4.49-4.35 (m, 2 H), 3.13-2.82 (m, 2 H), 2.66-2.63 (m, 2H), 2.49-2.06 (m, 2 H), 1.93-1.65 (m, 2 
H). 13C-NMR (D2O, 100 MHz): 175.71, 172.92, 148.73, 147.35, 142.24, 141.55, 136.16, 132.29, 
132.16, 123.51, 122.58, 122.04, 120.72, 120.33, 53.13, 45.87, 37.18, 32.33, 29.49, 25.01. MS 
(ESI) calculated for C20H16NNa5O19S4, [M-H]-, m/z 815.87, found for [M-Na]-, m/z 793.7. 
Sodium 2-(4-(2,5-di-O-sulfonato-phenyl)butanoyl)-5,8-di-O-sulfonato-1,2,3,4-
tetrahydro isoquinoline- 3-carboxylate tetrasodium (20c), 58A425. 1H-NMR (D2O, 400 MHz): 
7.42-7.30 (m, 3 H), 7.27-7.16 (m, 2 H), 5.17-4.91 (m, 1 H), 4.88-4.53 (m, 2 H), 3.56-3.33 (m, 1 H), 
3.14-2.83 (m, 1 H), 2.8-2.37 (m, 4 H), 2.0-1.9 (m, 2 H). 13C-NMR (D2O, 100 MHz): 177.65, 
175.86, 148.76, 147.27, 146.08, 144.89, 136.56, 129.31, 128.66, 127.93, 123.43, 122.54, 121.12, 
120.25, 56.58, 41.2, 32.95, 29.1, 26.77, 25.86. MS (ESI) calculated for C20H16NNa5O19S4, [M-H]-, 
m/z 815.87, found for [M-Na]-, m/z 793.92. 
1-(6,7-di-O-sulfonato-3,4-dihydroisoquinolin-2(1H)-yl)-2-(2,5-di-O-sulfonato-phenyl) 
ethanone tetrasodium (7), 67225. 1H-NMR (D2O, 400 MHz): 7.32-7.29 (m, 2 H), 7.18-7.06 (m, 3 
H), 4.59 (d, J= 48.8 Hz, 2 H), 3.84 (s, 2 H), 3.68 (t, 1J = 5.84 Hz, 1 H), 3.63 (t, 1J = 6.00 Hz, 1 H), 
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2.79-2.73 (m, 2 H). 13C-NMR (D2O, 100 MHz): 171.96, 148.73, 147.37, 141.51, 141.37, 133.57, 
131.29, 130.01, 124.11, 122.94, 122.68, 121.6, 120.94, 47.08, 44.23, 35.0, 28.21. MS (ESI) 
calculated for C17H13NNa4O17S4, [M-H]-, m/z 721.87, found for [M-Na]-, m/z 700.08. 
1-(5,6-di-O-sulfonato-3,4-dihydroisoquinolin-2(1H)-yl)-4-(2,5-di-O-sulfonato-
phenyl)butan-1-one tetrasodium (8), 56425. 1H-NMR (D2O, 400 MHz): 7.42-7.16 (m, 5 H), 5.05 
(d, 1J= 8.32 Hz, 2 H), 3.69-3.66 (m, 2 H), 3.07-3.03 (m, 2 H), 2.8-2.74 (m, 2 H), 2.58 (t, 1J = 7.2 
Hz, 1 H), 2.51 (t, 1J = 7.28, 1 H), 1.96-1.92 (m, 2 H).13C-NMR (D2O, 100 MHz): 174.9, 148.73, 
147.32, 143.05, 142.49, 137.64, 136.36, 134.21, 133.61, 130.12, 123.5, 122.52, 120.35, 42.49, 
41.88, 39.87, 32.73, 29.01, 26.80. MS (ESI) calculated for C19H17NNa4O17S4, [M-H]-, m/z 749.9, 
found for [M-Na]-, m/z 727.96. 
4.5.9. Equilibrium Binding Studies— Fluorescence spectroscopy experiments were 
performed using a QM4 fluorometer (Photon Technology International, Birmingham, NJ) in 20 
mM sodium phosphate buffer, pH 6.0, containing 25 mM NaCl, 0.1 mM EDTA, and 0.1 % 
PEG8000 at 25 ºC in a manner following our previous work.110,219 Equilibrium dissociation 
constants (KD) for the interaction of non-saccharide aromatic activators with plasma AT were 
determined by titrating the activator (ACT) into a solution of serpin and monitoring the decrease in 
the fluorescence at 340 nm (λEX = 280 nm). Slit widths were 1 mm on both the excitation and 
emission sides. The saturable decrease in signal was fit to the quadratic equilibrium binding 
equation 5 to obtain the KD of interaction. In this equation, ∆F represents the change in 
fluorescence following each addition of the ACT from the initial fluorescence FO and ∆FMAX 
represents the maximal change in fluorescence observed on saturation of AT. 
∆

= ∆

× ( !"# !"$%)&	'( !"# !"$%)
(&) !# !
*	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		(5)			  
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4.5.10. Factor Xa Inhibition Studies— The kinetics of inhibition of FXa by AT in the 
presence of the designed non-saccharide aromatic activators was measured spectrophotometrically 
under pseudo-first order conditions following our earlier work.83,106,110,219 Briefly, a fixed 
concentration of FXa (20 nM) was incubated with fixed concentrations of plasma AT (1.075 µM) 
and sulfated activators (0 to 100 µM) in 20 mM sodium phosphate buffer, pH 6.0, containing 25 
mM NaCl, 0.1 mM EDTA and 0.1% (w/v) PEG8000 at 25 ºC. At regular time intervals, an aliquot 
of the inhibition reaction was quenched with 900 µL of 100 µM Spectrozyme FXa in 20 mM 
sodium phosphate buffer, pH 7.4, containing 100 mM sodium chloride at 25 ºC. To determine the 
residual FXa activity, the initial rate of substrate hydrolysis was measured from the increase in 
absorbance at 405 nm. The exponential decrease in the initial rate of substrate hydrolysis as a 
function of time was used to determine the observed pseudo-first rate constant of FXa inhibition 
(kOBS). A plot of kOBS at different concentrations of the activator could be described by equation 6 
in which kUNCAT is the second-order rate constant of FXa inhibition by AT alone and kACT is the 
second-order rate constant of FXa inhibition by AT–activator complex. 
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0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CHAPTER 5: POTENT DIRECT FACTOR Xa INHIBITORS BASED ON 
TETRAHYDROISOQUINOLINE SCAFFOLD 
 
5.1. Hypthesis— Anticoagulants represent the basis for treatment and prevention of 
thromboembolic disorders.7 The inhibition of any coagulation enzyme can be expected to reduce 
or prevent clotting, yet most strategies have targeted two serine proteases, factor IIa (FIIa, or 
thrombin) and factor Xa (FXa), which belong to the common pathway of the coagulation 
cascade.17 Of these, thrombin plays a major role in a number of physiologically relevant responses 
that rely on its catalytic activity.225,226 Thus, inhibition of thrombin not only reduces cleavage of 
fibrinogen to fibrin, a key aspect of clotting, but also other processes such as platelet activation, 
platelet aggregation and angiogenesis. On the other hand, FXa has a rather limited role in 
comparison, which is only to generate thrombin. 
Several lines of evidence suggest that FXa may represent a better target for anticoagulation. 
FXa’s contribution to amplification of the coagulation signal is higher than that of thrombin.18,19 Its 
occurrence earlier in the coagulation pathway suggests that a FXa inhibitor may be more effective 
in blocking progression of a coagulation signal than a thrombin inhibitor .227,228 Recent results with 
indirect parenteral and direct oral FXa inhibitors have shown reduced bleeding complications.25 
Also, thrombin inhibitors have been associated with rebound hypercoagulability,24,229 while 
peptidomimetic inhibitors have been shown to inhibit both free as well as clot-bound FXa.142,230 
FXa can be inhibited through two major pathways including an indirect, antithrombin-
dependent pathway 14,231 or a direct FXa targeting pathway.6,232,233 Designing indirect FXa 
inhibitors that activate antithrombin is challenging and has been achieved primarily with heparin-
based molecules,14,234 although efforts are afoot to design effective non-saccharide-based 
antithrombin activators.106,110, 231 In contrast, designing direct inhibitors of FXa has been much 
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more productive and has led to several clinically relevant peptidomimetics, e.g., rivaroxaban,114,125 
apixaban,119 DPC423,235 and others, that target FXa’s active site. 
A large number of scaffolds have been studied for direct inhibition of FXa including the 
aminopiperidines ,236 piperazines,237 diaminocycloalkanes,238 lactams,239,240 oxazolidinones,125 
amino acids (e.g., glycine, proline, and β-aminoproionate),241,242 anthranilamides,243 isoxazoles,244 
pyrazoles,235,245 indazoles,246 indoles,247,248 and dihydropyrazolopyridinones.119,249 The overall 
philosophy in the design of these scaffolds is to have a three-component system, which includes a 
core scaffold and two hydrophobic arms that provide a non-linear geometry considered important 
for FXa recognition. In addition, a key design principle has also been flexibility of the core 
scaffold. The core scaffolds studied to date can be classified into either a highly flexible class or a 
fairly rigid class.  
It is known that trypsin’s active site is much more open than FXa’s, which in turn possesses 
an active site that is more open than that of thrombin. This allows trypsin to work upon practically 
any arginine containing sequence, while thrombin prefers a fairly rigid proline containing 
sequence. Thus, we hypothesized that an intermediate level of flexibility in the core scaffold will 
engineer high selectivity for FXa inhibition. Lastly, having an amino acid–like structure will allow 
us to apply the peptide chemistry in very straightforward manner to establish the SAR for the 
THIQ dicarboxamide class of FXa inhibitors. 
5.2. Results and Discussion— 
5.2.1. Designing the Tetrahydroisoquinoline-3-Carboxylic Acid Scaffold as a Potential 
Factor Xa Inhibitor Scaffold. The glycine and β-aminopropionate-based inhibitors are examples 
of a highly flexible core scaffold, while aromatic scaffolds, e.g., aminobenzoic acids, pyrazoles, 
and indazoles, are examples of fairly rigid scaffolds. An intermediate level of flexibility in the core 
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scaffold has not been studied to date for direct FXa inhibition. A large number of scaffolds possess 
intermediate level of flexibility including tetrahydroisoquinoline (THIQ), tetrahydroquinoline, 
tetrahydroquinazoline, dihydrocoumarin, and dihydroindole. In each of these, the five- or six-
membered rings are flexible, yet full flexibility is restricted due to ring fusion. Of these, we 
focused on the THIQ scaffold, which is a widely explored privileged structure.231,250-252 To enable 
a non-linear structure for FXa recognition, we introduced a carboxylic acid group at the 3-position 
of the THIQ scaffold to arrive at THIQ3CA scaffold. 
The designed THIQ3CA scaffold was first investigated in silico to assess its potential in 
binding in factor Xa active site as well as to identify a potential inhibitor for synthesis. A virtual 
library of THIQ3CA structures was prepared by introducing substituents at positions 2 and 3. A 
large group of aromatic and non-aromatic carboxylic acid and amine arms at positions 2 and 3 
were studied to identify potential ‘hits’. The virtual library of resulting THIQ3CA dicarboxamides 
was then computationally docked into active site of human FXa and scored using genetic 
algorithm-based screening technique developed in our laboratory earlier.231 As positive controls, 
two well-established direct FXa inhibitors, apixaban and rivaroxaban, were also studied in an 
identical manner. 
The GOLD-based docking and scoring strategy identified several hits, of which THIQ3CA 
dicarboxamide 23, containing a 5-chlorothiophen-2-yl moiety (also present in rivaroxaban), was 
identified as a promising candidate. Figure 25 shows a comparison of the predicted bound form of 
23 with apixaban. Both molecules adopted a rather similar binding mode in which the 5-
chlorothiophenyl-carbonyl group was found to be oriented toward the S1 subsite and the 4-
(piperidin–2–one)–N1–methylaniline moiety oriented into the S4 subsite. Comparison of the 
binding geometry with rivaroxaban suggested similar corresponding features. THIQ3CA 
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dicarboxamide 23 was synthesized in three high yield steps and evaluated for its direct human FXa 
inhibition potential. An IC50 of 55.9 µM, corresponding to a KI of 28 µM, was measured, 
validating the potential of the THIQ3CA core scaffold in direct human FXa inhibition 
investigation. 
5.2.2. Synthesis of THIQ3CA-Based Potential FXa Inhibitors. Based on the structure of 
23, a library of THIQ3CA dicarboxamides was designed. The synthesis of the targeted THIQ3CA 
analogs was achieved using a facile three-step strategy of amidation, deprotection, and amidation 
that relied on the availability of the two arms, AN and AC, at positions 2 and 3, respectively.253 
Each AN structure designed as a part of the library was commercially available and was introduced 
using standard amidation reaction (see Scheme 6). In contrast, arm AC at position 3 of THIQ3CA 
required pre-assembly. This arm was synthesized by aromatic nucleophilic substitution in which 
4–bromoaniline derivatives 4a–4c were reacted with either valerolactam 5a or morpholin-3-one 5b 
to quantitatively give the corresponding 4–substituted aniline derivatives 8a – 8g.254 Likewise, 
substituted anilines 8h – 8j containing the piperazine side chain were also included in the study 
(Scheme 6). 
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Figure 25. Virtual screening of a library of potential THIQ3CA-based inhibitors docked and scored onto 
the active site of FXa (PDB: 2P16) using GOLD resulted in the design of 23 (A: GOLD score of 69.3, 
Carbons in pink) that appeared to mimick the binding of well known potent FXa  inhibitors. The virtual 
library of THIQ3CA–based dicarboxamides contained structural  modifications in arms AN and AC. 
Apixaban (GOLD score of 93.7, Carbons in blue) and rivaroxaban (GOLD score of 87.2 , structure not 
shown) were also docked and scored as  positive controls. Sytematic structural modifications led to the 
design of the most potent THIQ3CA dicarboxamide 47 (B: GOLD score of 77.2, Carbons in yellow).  
 
To introduce either arm AN or AC through an amidation reaction, the THIQ3CA core was 
first appropriately protected, which involved either esterification of the 3-carboxylic acid or t-
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butoxycarbonylation (Boc group) or carbonylbenzyloxylation (Cbz group) of the ring nitrogen. For 
example, THIQ3CAs 9 – 11 were amidated using amines 8a – 8g to yield Boc- or Cbz-protected 
THIQ3CA mono-carboxamides 12 – 21 in 73–89% yield (Scheme 7). The Boc or Cbz protecting 
group of 12 – 21 was then removed using either mild acid255 or catalytic hydrogenation,256 
respectively, to afford the corresponding free form in 65-75% yield. The free form of 12 – 21 was 
then amidated at the 2 position with twenty one carboxylic acids in the presence of EDCI to yield 
the targeted THIQ3CA dicarboxamides 22 – 49 in 70–95% yield (Scheme 7). This strategy was 
also exploited for the synthesis of THIQ3CA dicarboxamides 50 – 55, 59, and 62 that contain 
additional variations on arms AN and AC (Schemes 8 and 9). 
To assess the effect of flexibility for FXa inhibition, we targeted three core scaffolds that 
afford greater flexibility than the THIQ3CA scaffold as well as can help assess the importance of 
configurational geometry. These scaffolds were: 1) a ring opened variant of THIQ3CA core, the 
phenylalanine (PA) derivative 62; 2) mono-cyclic dicarboxamides 69 – 73 belonging to the 
piperidine–3–carboxylic acid (P3CA) class; and 3) mono-cyclic dicarboxamides 78, 79 and 81 
belonging to the piperidine–2–carboxylic acid (P2CA) class (Scheme 10). These molecules were 
synthesized in a manner similar to the THIQ3CA scaffold using the amidation, deprotection, and 
amidation strategy. 
To understand the importance of the aromatic ring of the THIQ3CA scaffold, and yet 
mimic its flexibility, we targeted 1) a partially unsaturated, cyclic ring system, i.e., (S)-1,2,3,6–
tetrahydropyridine–2–carboxylic acid (THP2CA) and 2) a bridged system, i.e., (1R,3S,4R)-2-
azabicyclo[2.2.1]heptane-3-carboxylic acid (ABH3CA) (Scheme 11). The synthesis of either 
scaffold started with the Boc-protected carboxylic acid 82 or 85, which was converted in three 
steps to dicarboxamide 84 or 87, respectively, in excellent yield. 
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Overall, we synthesized twenty eight THIQ3CA, one PA, five P3CA, three P2CA, one 
THP2CA and one ABH3CA dicarboxamides using a simple three-step protocol. The molecules 
were purified using standard flash chromatography system and were characterized using 1H and 
13C NMR spectroscopy and ESI-MS.
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Scheme 6. a) Acetic anhydride, pyridine, CH2Cl2, rt/4 h, 92%, b)  LiAlH4, THF, rt/overnight, 60%,  c) Acetone, Titanium (IV) isopropoxide, 
Ethanol, rt/12 h, d) NaBH4, rt/2 h, 75%, e) Piperidin-2-one or morpholin-3-one, CuI, N,N’-Dimethylethylenediamine, K2CO3, Toluene, 
reflux/overnight, 65-90%,  f) For 7a: Acetic anhydride, pyridine, CH2Cl2, rt/4 h, 84%. For 7b: Thiophene-2-carboxylic acid, EDCI, DMAP, 
CH2Cl2, rt/overnight, 70-95%, g) 10% Pd/C, CH3OH/HCl, H2, rt/5 h, 100%. Note: Underlined compounds are commercially available and are not 
products of the designated reactions.
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Scheme 7.   a) Appropriate amine (8a–8g), HOBt.H2O, DMAP, EDCI, CH2Cl2, rt/overnight, 73-89%, b) For Cbz-protected intermediates: 10% 
Pd(OH)2, (1:1) CH3OH: t-butanol, H2, rt/overnight, 65-72%. For Boc-protected intermediates: (1:1) TFA:CH2Cl2, rt/4 h, 75%, c) Appropriate 
organic acid, EDCI, DMAP, CH2Cl2, rt/overnight, 70-95%.
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Scheme 8. a) Appropriate amine (8c, 8h–8j, or 4-Chloroaniline), HOBt.H2O, DMAP, EDCI, CH2Cl2, 
rt/overnight, 73-89%, b) 10% Pd(OH)2, (1:1) CH3OH: t-butanol, H2, rt/overnight, 65-72%, c) 4-(2-
oxopiperidin-1-yl)benzoic acid , EDCI, DMAP, CH2Cl2, rt/overnight, 72%, d) (4-Chlorophenyl) methane 
sulfonyl chloride, pyridine, rt/overnight, 77%. 
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Scheme 9. a) SOCl2, CH3OH, reflux/4 h, 95%, b) 4-Chlorophenyl acetic acid , EDCI, DMAP, CH2Cl2, rt/overnight, 81%, c) LiOH.H2O, CH3OH, 
rt/24 h, 75%, d) 8c, HOBt.H2O, DMAP, EDCI, CH2Cl2, rt/overnight, 73-89%, e) (1:1) TFA:CH2Cl2, rt/4 h. 
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Scheme 10. a) Benzyl chloroformate, Et3N, THF, rt/5 h, 70-73 %, b) 8b or 8c , HOBt.H2O, DMAP, EDCI, CH2Cl2, rt/overnight, 73-89%, c) For 
Cbz-protected intermediates: 10% Pd(OH)2, (1:1) CH3OH: t-butanol, H2, rt/overnight, 65-72%. For Boc-protected intermediates: (1:1) 
TFA:CH2Cl2, rt/4 h,75%, d) Appropriate organic acid, EDCI, DMAP, CH2Cl2, rt/overnight, 70-95%. 
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Scheme 11. a) 8b, HOBt.H2O, DMAP, EDCI, CH2Cl2, rt/overnight, b) (1:1) TFA:CH2Cl2, rt/4 h, c) 4-
Chlorophenyl acetic acid , EDCI, DMAP, CH2Cl2, rt/overnight, 70-95%. 
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5.2.3. Inhibition Potential of the Library of FXa Inhibitors. Direct inhibition of FXa 
was measured by a chromogenic substrate hydrolysis assay in 20 mM TrisHCl buffer, pH 7.4, at 
37 ºC, as reported earlier.257 In this assay, hydrolysis of the substrate by FXa results in a linear 
increase in absorbance at 405 nm, the slope of which corresponds to residual enzyme activity. The 
change in residual enzyme activity as a function of the concentration of the potential inhibitor is 
plotted on a logarithmic scale and fitted by the logistic dose-response relationship 8 to derive the 
potency (IC50), efficacy (∆Y = YM – Y0) and Hill Slope (HS) of inhibition.233,257 Figure 26 shows 
representative inhibition profiles for 20, 47, 49, and 51, which are THIQ3CA derivatives, and 62 
and 81, which are PA and P2CA derivatives, respectively. Similar profiles were measured for other 
THIQ3CA, P2CA, P3CA, THP2CA, and ABH3CA derivatives, except for the variation in potency 
of inhibition. The HS of inhibition was found to be in the range of 0.7 to 1.2, which suggests 
absence of the complications arising from non-specific binding or aggregation. The IC50 values of 
the FXa inhibitors studied in this work were found to exhibit a wide range of activity (high µM to 
nM), which provide valuable SAR. 
5.2.4. Structural Optimization of Arm AC of the THIQ3CA Scaffold. Our early 
molecular modeling studies suggested that arm AC at the 3-position of the THIQ3CA core 
structure bound in the S4 subsite of the FXa active site. An intermediate 13, synthesized early in 
the library and containing N-(N-methylanilin-4-yl)piperidin-2-one as the AC arm, had shown a 
reasonable IC50 of 16.4 µM. This formed the starting point for studying the S4 subsite substitutions 
(Table 7). To optimize the structure of the AC arm, two levels of structural modifications were 
introduced. These included 1) variation in the carboxamide N-substituent and 2) variation in the 
para-substituent of the aniline moiety. Replacing the N-methyl group of 13 with ethyl (inhibitor 
14) and isopropyl (inhibitor 15) groups resulted in no significant change, however, N-
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demethylation as in 12 reduced the IC50 by 1.7–fold suggesting the possibility of the formation of a 
hydrogen bond. This was however not substantiated by molecular modeling (not shown) and we 
speculated that the alkyl group on the nitrogen may be inducing a conformational preference that is 
not favorable for binding in the S4 subsite. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Direct inhibition of FXa by designed THIQ3CA and related dicarboxamides. The inhibition 
of human FXa was determined spectrophotometrically through the chromogenic substrate hydrolysis assay 
at pH 7.4 and 37ºC. Solid lines represent sigmoidal fits to the data to obtain IC50, YM, Y0, and HS, as 
described in the Experimental Methods section. Experiments were performed in duplicate or triplicate (SE < 
20%). 
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Table 7. Optimization of the AC arm (position 3) of THIQ3CA scaffold for FXa inhibition. 
 
Inhibitor R1 R2 IC50 (µM) 
12 -H 
 
9.9 ± 0.2 
13 -CH3 
 
16.4 ± 0.4 
14 -CH2CH3 
 
20 ± 1 
15 -CH(CH3)2 
 
19 ± 2 
18 -CH3 
 
12.8 ± 0.2 
19 -CH2CH3 
 
19 ± 6 
20 -H 
 
6.0 ± 0.8 
50 -H -Cl >500 
53 -H 
 
>500 
54 -H 
 
>500 
55 -H 
 
>500 
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To optimize the para–substituent of the aniline moiety, we relied on the extensive literature 
that abounds in such optimizations.6,7,118 The moieties preferred at this position include the 
piperidone, morpholinone, piperidine, piperazine and other rings. Yet, introducing piperidine and 
piperazine moieties at the para position of the aniline was catastrophic. The piperidine–containing 
derivative 53 and the piperazine–containing derivatives 54 and 55 displayed an un-quantifiable 
IC50 of >500 µM (Table 7). Molecular modeling suggested that the para substituent helps orient 
the adjacent aromatic ring for better interaction with Tyr99, Phe174, and Trp215 of the S4 subsite 
(not shown), in a manner similar to that observed with rivaroxaban and apixaban .119,125 Thus, we 
studied the morpholin-3-one moiety (derivative 20, Table 7), which exhibited a much improved 
IC50 of 6.0 µM. The results indicated a significant contribution of the carbonyl group of 
morpholin-3-one for the THIQ3CA inhibitors. 
5.2.5. Structural Optimization of Arm AN of the THIQ3CA Scaffold. Molecular 
modeling suggested that the AN arm at position 2 of the THIQ3CA core fits into S1 subsite of the 
FXa active site. The initial hit 13 (IC50 = 16.4 µM) containing the Cbz group as the AN arm was 
used as the starting point for studying the S1 subsite substitutions. Considering that the AN arm of 
13 is structurally less defined than its AC arm, we decided to explore a wider range of moieties to 
replace the Cbz group. Thus, the optimal chain length of AN, the nature of its aromatic ring, and 
the position and number of substituents on the aromatic ring were studied. 
Replacing the AN arm of 13 with thiophenyl carbonyl (22), 5-chlorothiophenyl carbonyl 
(23), p-chlorophenyl carbonyl (24), p-methylphenyl carbonyl (25) or p-methoxyphenyl carbonyl 
(26) arm resulted in 1.2 – 12.7-fold reduction in potency (Table 8). Extending the length of the 
linker by one carbon atom resulted in significant improvement in IC50. Dicarboxamide 27 
containing a 4-chlorophenyl acetyl side chain exhibited an IC50 of 1.3 µM, which was the first high 
138 
 
affinity inhibitor (Ki = 0.65 µM) designed in the THIQ3CA series. Yet, most subsequent 
modifications failed to enhance potency further. For example, one or more electron donating        
(–CH3, –OCH3) as well as one or more electron withdrawing (–Cl, –CF3, –NO2) substituents on the 
phenylacetyl side chain weakened the potency by 1 – 262-fold (Table 8). 
Considering the observations made with the AC structural variants, we studied the 
morpholin-3-one containing THIQ3CA derivatives also for optimization of the AN arm. Table 3 
shows the results obtained in the morpholin-3-one series. Replacing the Cbz group of parent 18 
(IC50 = 12.8 µM) with thiophenyl carbonyl (40), p-methoxyphenyl propanoyl (43), or 2,4-
dimethoxyphenyl propanoyl (48) resulted in considerable loss of activity. Yet, as in the piperidone 
series described above, introducing a 4-chlorophenyl acetyl side chain for the Cbz group resulted 
in an IC50 of 1.1 µM. Analysis of the above results indicated that the best inhibitors carried a 7–
atom arm AN (at position 2), e.g., 13, 26, 27, 28, and 41. Within this category, a 7-atom arm 
containing a small, lipophilic electron–withdrawing group (–Cl) is optimal. This group appears to 
be the p-chlorophenylacetyl moiety, as exemplified by a considerable increase in affinity observed 
with 27, 34 and 41, and a loss in affinity for derivative 49 (Tables 8 and 9). Thus, FXa appears to 
preferentially recognize the chlorophenyl moiety in the THIQ3CA series of inhibitors. 
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Table 8. Optimization of the AN arm (position 2) of THIQ3CA scaffold containing the piperidone moiety in 
the AC arm for FXa inhibition. 
 
Inhibitor R3 IC50 (µM) 
16 
 
221 ± 19 
22 
 
42 ± 2 
23 
 
56 ± 2 
24 
 
197 ± 39 
25 
 
209 ± 31  
26 
 
19 ± 2 
27 
 
1.3 ± 0.1 
28 
 
14 ± 3 
29 
 
34 ± 1 
30 
 
85 ± 19 
31 
 
335 ± 50 
32 
 
246 ± 58 
33 
 
18 ± 2 
34 
 
1.3 ± 0.2 
38 
 
103 ± 8 
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Table 9. Optimization of the AN arm (position 2) of THIQ3CA scaffold  containing the morpholinone 
moiety in the AC arm for FXa inhibition. 
 
Inhibitor R1 R3 IC50 (µM) 
40 -CH3 
 
36 ± 3 
41 -CH3 
 
1.1 ± 0.1 
42 -H 
 
5.4 ± 0.9 
43 -CH3 
 
190 ± 16 
45 -CH3 
 
>500 
48 -CH3 
 
>500 
49 -H 
 
2.9 ± 0.4 
 
5.2.6. Rational Design of Analog 47. The majority of inhibitors described above possessed 
(S)-chirality at position 3. To assess whether an (R)-isomer would be better, we studied THIQ3CA 
derivative 35, which is a stereoisomer of 27 (IC50 = 1.3 µM). This stereochemical inversion 
resulted in a 1.5–fold increase in the activity (Table 10). This led to a hypothesis that introducing 
optimal features derived on arms AN and AC into a single THIQ3CA derivative may lead to the 
most potent FXa inhibitor designed so far. Thus, analog 47 was designed, which contained a 
morpholin-3-one moiety, a p-chlorophenylacetyl unit, (R)-chirality at the 3-position, and NH-
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containing carboxamide at the 3-position. THIQ3CA derivative 47 displayed an IC50 of 0.27 µM 
(KI = 0.135 µM) and presents the highest potency observed in the THIQ3CA series. 
The design of 47 reflects a truly additive phenomenon. Inhibitor 47 exhibits ~60–fold 
decrease in IC50 relative to the starting inhibitor 13 (IC50 = 16.4 µM), which can be rationalized 
from the 1.5–fold (morpholin-3-one) × 2–fold (unsubstituted carboxamide) × 1.5–fold 
(stereochemical inversion) × 13–fold (4-chlorophenylacetyl moiety) increases found independently 
earlier. This is an interesting observation and appears to have considerable consistency across the 
series of molecules studied here. 
 
Table 10. Simultaneous optimization of both AN AC arms of THIQ3CA scaffold for optimal FXa inhibition. 
 
Inhibitor R1 X Y R3 Chirality (*) IC50 (µM) 
35 -CH3 -CH2- -C(O)- 
 
(R)- 0.9 ± 0.1 
36 -CH3 -CH2- -C(O)- 
 
(R)- 311 ± 56 
37 -H -CH2- -C(O)- 
 
(S)- 13.3 ± 1.4 
46 -CH2CH3 -O- -C(O)- 
 
(S)- 1.6 ± 0.2 
47 -H -O- -C(O)- 
 
(R)- 0.27 ± 0.03 
52 -CH3 -CH2- -SO2- 
 
(S)- 151 ± 36 
 
 
 
142 
 
5.2.7. THIQ3CA Core is the Most Optimal Scaffold. Based on the number of flexible 
carbons constituting the core scaffold, we reasoned that the open-chain PA core will be more 
flexible than the six-membered cyclic P2CA and P3CA cores, which in turn will exhibit greater 
flexibility than the unsaturated or bridged THP2CA and ABH3CA cores. The THIQ3CA core was 
likely to be similar to the unsaturated or bridged cores in terms of conformational flexibility. Table 
5 displays the potency of selected PA, P2CA, P3CA, THP2CA, ABH3CA, and THIQ3CA 
inhibitors. Overall, the potencies of PA, P2CA, and P3CA dicarboxamide inhibitors were found to 
be weak (23 – 371 µM), while those for THP2CA, ABH3CA and THIQ3CA inhibitors were higher 
(0.27 – 56 µM). Comparison of the unsaturated or bridged six-membered scaffold with the 
THIQ3CA scaffold shows that the latter is the optimal structure. For example, THP2CA derivative 
84 and ABH3CA derivative 87 exhibit IC50s of 9.1 and 10 µM, which are 33–37-fold greater than 
the 0.27 µM IC50 of the corresponding THIQ3CA derivative 47 (Table 11). 
Within these broad results, we noticed interesting structure-activity dependence across the 
different core scaffolds studied here. Nearly all 5-chloro-thiophenyl containing derivatives, e.g., 23 
and 40, display weak inhibition potency in comparison to most p-chlorophenyl containing 
derivatives, e.g., 27 and 41 (Tables 8 and 9). This was against our expectation based on the well 
established high affinity of rivaroxaban, which contains the 5-chloro-thiophenyl side chain [22, 
30]. Another interesting observation was that the morpholin-3-one ring consistently induces higher 
potency than the piperid-2-one ring. For example, morpholin-3-one-containing THIQ3CA 
derivatives 18, 20, and 40 have better activity than the corresponding piperid-2-one-containing 
derivatives 13, 12, and 23, respectively (see Tables 7, 8 and 9). 
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Table 11. Comparison of the FXa inhibition potential of different scaffolds. 
 
Inhibitor A IC50 (µM) 
 
Inhibitor B IC50 (µM) 
 
Inhibitor C IC50 (µM) 
27 
 
1.3 ± 0.1 23 
 
56 ± 2 47 
 
0.27 ± 0.03 
59 
 
7.8 ± 0.4  78 
 
358 ± 16  81 
 
23 ± 2 
62 
 
54 ± 5  79 
 
99 ± 7  84 
 
9 ± 2 
72 
 
371 ± 59  69 
 
69 ± 7  87 
 
10 ± 3 
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The above results suggest that the THIQ3CA core scaffold was the optimal for FXa 
inhibition following optimization of its two arms AN and AC. Yet, the THP2CA and ABH3CA 
scaffolds are interesting. These scaffolds are new, readily synthesizable and are relatively 
unexplored. Screening of a wider chemical space would help better understand their true potential 
for FXa inhibition. 
5.2.8. Dicarboxamide 47 Selectively Inhibits Factor Xa in Comparison to Other 
Proteases of the Coagulation and Digestive Systems. A critical goal of the molecular modeling-
based rational design of THIQ3CA inhibitors was selectivity for targeting factor Xa. This enzyme 
is a trypsin-like serine protease with considerable homology with enzymes of the coagulation and 
digestive systems including FIIa, FVIIa, FIXa, FXIa, FXIIa, trypsin and chymotrypsin. 
Chromogenic substrate hydrolysis assays for each of these enzymes were performed in a manner 
similar to that for FXa. The assays were conducted at 37 ºC using literature reported buffer 
systems that are as close to physiological conditions as possible. Initial screening was performed at 
a high, fixed concentration of the inhibitor (100 – 1000 µM) and fractional residual enzyme 
activity was measured from the initial rate of hydrolysis in the presence of the inhibitor to that in 
its absence. 
The THIQ3CA inhibitors showed high selectivity for FXa inhibition. No coagulation 
enzyme was found to be inhibited by THIQ3CA inhibitors at concentrations less than 100 µM. 
With regard to digestive enzymes, moderate inhibition of chymotrypsin (IC50 = 5–100 µM) was 
noted with 4-chlorophenyl side chain containing inhibitors. The most potent FXa inhibitor 47 
demonstrated a selectivity of at least 1852–fold over FIIa, FVIIa, FIXa, FXIa, and FXIIa (Table 
12). Against trypsin and chymotrypsin, the selectivity of 47 was found to be at least 370- and 279-
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fold, respectively. Few rationally designed inhibitors have been able to achieve such high 
selectivity for factor Xa against other homologous enzymes.258,259 
 
Table 12. Selectivity of inhibition by THIQ3CA dicarboxamide 47. 
 
Protease IC50 (µM) Selectivity Index 
 
Human FIIa 
 
>500 
 
>1852 
 
Human FVIIa 
 
>1000 
 
>3703 
 
Human FIXa 
 
>1000 
 
>3703 
 
Human FXIa 
 
>500 
 
>1852 
 
Human FXIIa 
 
>500 
 
>1852 
 
Bovine Trypsin 
 
>100 
 
>370 
 
Bovine Chymotrypsin 
 
75 ± 13 
 
279 
 
5.2.9. Prolongation of Plasma Clotting Times by THIQ3CA, THP2CA and ABH3CA 
Inhibitors. Clotting assays, prothrombin and activated partial thromboplastin time (PT and aPTT, 
respectively), are routinely used to assess anticoagulation potential of new enzyme inhibitors in an 
in vitro setting.233,260,261 Whereas PT measures the effect of an inhibitor on the extrinsic pathway of 
coagulation, aPTT measures the effect on the intrinsic pathway. The prolongation of the human 
plasma clotting time as a function of the concentration of the inhibitors followed a pattern typical 
of other well-studied anticoagulants, except for the range of active concentrations. Table 13 lists 
the concentrations of selected potent FXa inhibitors required to double the PT and aPTT. Overall, 
for the inhibitors studied, doubling the PT required 17–2347 µM concentration, while doubling of 
aPTT required 20–810 µM, suggesting that most inhibitors essentially affect both pathways 
equally (Figure 27). This is to be expected because of their selectivity for targeting FXa, which is 
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an enzyme of the common pathway. The inhibitors studied included THIQ3CA derivatives 20, 27, 
34, 42, 47, and 49, and THP2CA/ ABH3CA derivatives 84 and 87. Inhibitor 47 doubled the PT 
clotting time at 17.1 µM, which is comparable to razaxaban (3.8 µM) and DPC423 (4.9 µM), two 
direct FXa inhibitors being pursued in clinical trials.258 
 
Table 13. Effect of designed FXa dicarboxamide inhibitors on human plasma clotting time. 
 
Inhibitor PT (µM) aPTT (µM) 
20 1387 NDa 
27 71 80 
34 219 260 
42 2160 NDa 
47 17.1 20.2 
49 645 614 
84 952 810 
87 2347 NDa 
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Figure 27. Prolongation of clotting time as a function of concentration of designed THIQ3CA and 
related dicarboxamides in either prothrombin time assay (PT) (A) or activated partial thromboplastin time 
assay (aPTT) (B). Solid lines are trend lines from which the concentration necessary to double clotting time 
was deduced. Clotting assays were performed in duplicate (SE ≤ 10%) as described in Experimental 
Methods. 
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5.3. Conclusion— Direct inhibition of FXa carries significant promise for developing 
effective and safe anticoagulants. Although a large number of FXa inhibitors have been studied, 
each can be classified as either possessing a highly flexible or a rigid core scaffold. We reasoned 
that an intermediate level of flexibility will provide high selectivity for FXa considering that its 
active site is less constrained in comparison to thrombin and more constrained as compared to 
trypsin. We studied several core scaffolds including 1,2,3,4-tetrahydroisoquinoline-3-carboxylic 
acid for direct FXa inhibition. Using docking and scoring with GOLD, a promising candidate 23 
was identified, synthesized, and found to inhibit FXa with a Ki of 28 µM. Optimization of 
derivative 23 resulted in the design of a potent dicarboxamide 47, which displayed a Ki of 0.135 
µM. Dicarboxamide 47 displayed at least 1852-fold selectivity for FXa inhibition over other 
coagulation enzymes and doubled PT and aPTT of human plasma at 17.1 µM and 20.2 µM, 
respectively, which are comparable to those of clinically relevant agents. Dicarboxamide 47 is 
expected to serve as an excellent lead for further anticoagulant discovery. 
5.4. Experimental Section— 
5.4.1. Chemicals, Reagents, and Analytical Chemistry. Anhydrous CH2Cl2, THF, 
CH3CN, DMF, toluene, and acetone were purchased from Sigma-Aldrich (Milwaukee, WI) or 
Fisher (Pittsburgh, PA) and used as such. Other solvents used were of reagent gradient and used as 
purchased. Analytical TLC was performed using UNIPLATETM silica gel GHLF 250 µm pre-
coated plates (ANALTECH, Newark, DE). Column chromatography was performed using silica 
gel (200-400 mesh, 60 Å) from Sigma-Aldrich. Chemical reactions sensitive to air or moisture 
were carried out under nitrogen atmosphere in oven-dried glassware. Reagent solutions, unless 
otherwise noted, were handled under a nitrogen atmosphere using syringe techniques. Flash 
chromatography was performed using Teledyne ISCO (Lincoln, NE) Combiflash RF system and 
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disposable normal silica cartridges of 30–50 µm particle size, 230–400 mesh size and 60 Å pore 
size. The flow rate of the mobile phase was in the range of 18 to 35 mL/min and mobile phase 
gradients of ethyl acetate/hexanes and CH2Cl2/CH3OH were used to elute compounds. 
5.4.2. Chemical Characterization of Compounds. 1H and 13C NMR were recorded on 
Bruker-400 MHz spectrometer in either CDCl3, CD3OD, or acetone-d6. Signals, in part per million 
(ppm), are either relative to the internal standard (tetramethyl silane, TMS) or to the residual peak 
of the solvent. The NMR data are reported as chemical shift (ppm), multiplicity of signal (s= 
singlet, d= doublet, t= triplet, q= quartet, dd= doublet of doublet, m= multiplet), coupling constants 
(Hz), and integration. Compounds with dicarboxamide functionalities exhibit amide rotamerism 
resulting in complexity of NMR signals. ESI-MS of compounds were recorded using Waters 
Acquity TQD MS spectrometer in positive ion mode. Samples were dissolved in methanol and 
infused at a rate of 20 µL/min. Mass scans were obtained in the range of 200-700 amu with a scan 
time of 1 s and a scan rate of 500 amu/s. The capillary voltage was varied between 3 and 4 kV, 
while the cone voltage ranged from 38 to 103 V. Ionization conditions were optimized for each 
compound to maximize the ionization of the parent ion. Generally, the extractor voltage was set to 
3 V, the Rf lens voltage was 0.1 V, the source block temperature was set to 150 ºC, and the 
desolvation temperature was about 250 ºC. The purity of each final compound was greater than 
95% as determined by uPLC-MS. 
5.4.3. Proteins. Human plasma proteinases including FIIa, FXa, FXIa, FIXa, FVIIa, and 
recombinant tissue factor was obtained from Haematologic Technologies (Essex Junction, VT). 
FXIIa was purchased from Enzyme Research Laboratories (South Bend, IN). Bovine α-
chymotrypsin and bovine trypsin were obtained from Sigma-Aldrich (St. Louis, MO). The 
substrates Spectrozyme TH, Spectrozyme FXa, Spectrozyme FXIIa, Spectrozyme FIXa, 
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Spectrozyme VIIa, and Spectrozyme CTY were obtained from American Diagnostica (Greenwich, 
CT). Factor IXa substrate, S-2366, trypsin substrate, S-2222, were obtained from Diapharma (West 
Chester, OH). Factor Xa and FVIIa were prepared in 20 mM TrisHCl buffer, pH 7.4, containing 
100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG8000, and 0.02% Tween80. FIXa was prepared in 20 
mM TrisHCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG8000, 0.02% 
Tween80, and 33% v/v Ethylene glycol. Other enzymes were prepared in 50 mM TrisHCl buffer, 
pH 7.4, containing 150 mM NaCl, 0.1% PEG8000, and 0.02% Tween80. 
5.4.4. Modeling Factor Xa and the Virtual Library of (S)-THIQ3CA Dicarboxamides. 
Sybyl 8.1 (Tripos Associates, St. Louis, MO) was used for modeling of FXa–inhibitor complexes. 
The structure of human FXa (ID: 2P16)119 was acquired from the Protein Data Bank 
(www.rcsb.org). To prepare the protein structure for modeling experiments, hydrogen atoms were 
added, while inorganic ions and water molecules were removed. Individual atoms were assigned 
Gasteiger –Hückel charges. Energy minimization was then performed using a Tripos force field so 
as to reach a terminating gradient of 0.5 kcal/mol Å2 or a maximum of 100,000 iterations. 
(S)–THIQ3CA was modified in silico at positions 2 and 3 with appropriate substituents to 
“synthesize” a virtual chemical library of nearly 150 dicarboxamide derivatives. The different 
combinations at 2- and 3-positions included substituted derivatives of aromatic carboxylic acids 
and aromatic amines, respectively. These acids and amines were further substituted at varying 
positions with halogen, t–butyl, cyclopropyl, methoxy, amino–methyl, substituted phenyl, 
substituted imidazole, pyridine, pyridine–2–one, N–oxide pyridine, N-methyl piperazine, or cyclic 
amides such as piperidone and morpholinone. The resulting molecules were assigned Gasteiger – 
Hückel charges and were then energetically minimized using a Tripos force field until a 
terminating gradient of 0.5 kcal/mol Å2 or a maximum of 100,000 iterations. 
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5.4.5. Docking and Scoring. Docking of the (S)-THIQ3CA dicarboxamides onto the active 
site of FXa was performed with GOLD 5.1 (Cambridge Crystallographic Data Center, UK). The 
docking experiment was performed as reported earlier.231 The binding site in human FXa was 
defined to include all atoms within 6 Å of the co–crystallized ligand. The docking protocol was 
validated by docking a ligand for which the adopted docking pose was found to have RMSD < 1 Å 
relative to that reported in the crystal structure.119 Docking was driven by the GOLD scoring 
function, while for ranking the docked solutions; a linear, modified form of the same scoring 
function  equation 7 was used, as reported earlier.231 In this equation, HBEXT and VDWEXT are the 
“external” (nonbonded interactions taking place between the ligand and the target protein) 
hydrogen bonding and van der Waals terms, respectively. 
GOLDScore = HBEXT + 1.375 × VDWEXT              (7) 
5.4.6. FXa Inhibition Studies. Direct inhibition of FXa was measured by a chromogenic 
substrate hydrolysis assay, as reported earlier 257 using a microplate reader (FlexStation III, 
Molecular Devices) at a wavelength of 405 nm and incubating temperature of 37 ºC. Generally, 
each well of the 96-well microplate had 185 µL pH 7.4 buffer to which 5 µL potential FXa 
inhibitor (or solvent reference) was added, to which 5 µL FXa (stock conc. 43.5 nM) was further 
added. After 10 min incubation at 37 ºC, 5 µL FXa substrate (stock conc. 5 mM) was rapidly 
added and the residual FXa activity was measured from the initial rate of increase in absorbance at 
405 nm. The concentration of the organic solvent in which the inhibitors were dissolved was 
maintained constant and was less than 2.5% (v/v). Stocks of FXa inhibitors were prepared at 20 
mM concentration and then serially diluted to give twelve different aliquots spanning a range of 
0.015-500 µM in the plate wells. Each inhibitor was studied in duplicate or triplicate at each 
concentration. Relative residual FXa activity at each concentration of the inhibitor was calculated 
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from the ratio of FXa activity in the presence and absence of the inhibitor. Logistic Eq. 8 was used 
to fit the dose-dependence of residual proteinase activity to obtain the potency (IC50) and efficacy 
(∆Y) of inhibition. In this equation, Y is the ratio of residual factor Xa activity in the presence of 
inhibitor to that in its absence (fractional residual activity), YM and Y0 are the maximum and 
minimum possible values of the fractional residual proteinase activity, IC50 is the concentration of 
the inhibitor that results in 50% inhibition of enzyme activity, and HS is the Hill slope (which was 
between 0.7 and 1.2 in all measurements). Nonlinear curve fitting resulted in YM, Y0, IC50 and HS 
values. The reported IC50 is an average of the two or three measurements with standard error (SE) 
of <20%. The efficacy of inhibition ∆Y was found to be >80% for each studied FXa inhibitor. 
8 = 81 +
89 − 81
1 + 10(=>?!&=>	?#@)(A/)
									(8) 
5.4.7. Inhibition of Proteases of the Coagulation and Digestive Systems. The potential 
of the FXa inhibitors against coagulation enzymes including FIIa, FVIIa, FIXa, FXIa, and FXIIa, 
and digestive enzymes including trypsin and chymotrypsin was performed using chromogenic 
substrate hydrolysis assays reported in the literature.262 These assays were performed using 
substrates appropriate for the enzyme being studied under conditions closest to the physiological 
condition (37 ºC and pH 7.4), except for FIIa, which was performed at 25 ºC and pH 7.4. For 
selectivity analysis, single concentration point assay was utilized in which 0.5 – 1 mM FXa 
inhibitor was tested in duplicate. The fractional residual enzyme activity was measured and if 
found to be less than 50%, the inhibition profile was measured over a range of inhibitor 
concentrations to determine the IC50 of the enzyme–inhibitor complex. The KM of the substrate for 
its enzyme was used to identify the concentration of the substrate to be used for inhibition studies. 
The concentrations of enzymes and substrates in microplate cells were: 6 nM and 50 µM for FIIa; 
0.765 nM and 345 µM for FXIa; 5 nM and 125 µM for FXIIa; 89 nM and 850 µM for FIXa; 8 nM 
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and 1000 µM for FVIIa (along with 40 nM recombinant tissue factor); 72.5 ng/ml and 80 µM for 
bovine trypsin; and 500 ng/ml and 240 µM for bovine chymotrypsin. 
5.4.8. Prothrombin Time (PT) and Activated Partial ThromboplastinTime (aPTT). 
Clotting time was measured in a standard one-stage recalcification assay with a BBL Fibrosystem 
fibrometer (Becton-Dickinson, Sparles, MD), as described previously.233 For PT assays, 
thromboplastin was reconstituted according to the manufacturer’s directions and warmed to 37 ºC. 
A 10 µL sample of the FXa inhibitor, to give the desired concentration, was brought up to 100 µL 
with citrated human plasma, incubated for 30 s at 37º C followed by addition of 200 µL of 
prewarmed thromboplastin. For the aPTT assay, 10 µL of inhibitor was mixed with 90 µL of 
citrated human plasma and 100 µL of prewarmed aPTT reagent (0.2% ellagic acid). After 
incubation for 4 min at 37 ºC, clotting was initiated by adding 100 µL of prewarmed 25 mM CaCl2 
and time to clot noted. The data were fit to a quadratic trendline, which was used to determine the 
concentration of the inhibitor necessary to double the clotting time. Clotting time in the absence of 
an anticoagulant was determined in similar fashion using 10 µL of deionized water and/or 
appropriate organic vehicle and was found to be 21.0 s for PT and 46.4 s for aPTT. 
5.4.9. General Synthetic Procedures and Spectral Characterization Data— 
N-(4-bromophenyl)acetamide (2). To a stirred solution of 4-bromoaniline (1) (1 mmol) in 
anhydrous CH2Cl2 (4 mL) was added anhydrous pyridine (2 mmol) at RT, followed by drop-wise 
addition of acetic anhydride (1.5 mmol). After 4 h, the reaction mixture was diluted with CH2Cl2 
(10 mL) and washed with 2.0 N HCl aqueous solution (2 × 10 mL). The organic phase was then 
concentrated by rotary evaporator and the resulting crude was purified by flash chromatography 
using gradient of EtOAc/hexanes as mobile phase to provide the titled acetylated product as violet 
solid in 92% yield. 1H-NMR (CDCl3, 400 MHz): 7.42 (d, J = 9.12 Hz, 2 H), 7.39 (d, J =  9.24 Hz, 
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2 H), 2.17 (s, 3 H). 13C-NMR (CDCl3, 100 MHz):  168.22, 136.94, 131.96, 121.37, 116.88, 24.57. 
MS (ESI) calculated for C8H8BrNO, [M+H]+, m/z 213.99, found for [M+H]+, m/z 214.11. 
N-ethyl-4-bromoaniline (4b). To a stirred solution of N-(4-bromophenyl)acetamide  (2) (1 
mmol) in anhydrous THF (5 mL) was added LiAlH4 (2.0 M in THF, 3 mmol) at 0 0C under 
nitrogen atmosphere. The reaction mixture was allowed to warm up to RT and was kept stirring 
overnight. The reaction mixture was then diluted with THF (10 mL). Water (1 mL) was added 
slowly, followed by 10% aqueous NaOH (2 mL), and followed finally by water (3 mL). The 
precipitating aluminum salts were filtered off on a pressed plug of Celite. The filtrate was 
concentrated in vacuo and purified by flash chromatography using gradient of EtOAc/hexanes to 
provide the titled product as brown solid in 60% yield. 1H-NMR (CDCl3, 400 MHz): 7.24 (d, J = 
8.88 Hz, 2 H),  6.47 (d, J = 8.88 Hz, 2 H),  3.14 (d,  J = 7.12 Hz, 1 H), 3.10 (d, J = 7.12 Hz, 1 H), 
1.24 (t, J = 7.12 Hz, 3 H). 13C-NMR (CDCl3, 100 MHz):  147.39, 131.90, 114.26, 112.27, 38.49, 
14.72. MS (ESI) calculated for C8H10BrN, [M+H]+, m/z 200.01, found for [M+H]+, m/z 200.1. 
4-bromo-N-isopropylaniline (4c). A mixture of 4-bromoaniline (1) (1 mmol), acetone (1.5 
mmol), titanium (IV) isopropoxide (1 mmol), and ethanol (4 mL) was stirred for 12 h at RT to give 
the brown solution of imine (3). To the light brown solution was added sodium borohydride 
(NaBH4, 2 mmol) portion-wise over 10 min, and then the resulting solution was stirred for 2 h. The 
reaction mixture was cooled to 0 °C and quenched with 2.0 N aqueous NH3 (10 mL). The resulting 
precipitate was filtered off and further washed with ether. The filtrate volume was reduced by 
rotary evaporator and extracted by ether (3 X 20 mL). The organic extracts were combined, 
washed with brine solution, dried over anhydrous Na2SO4, and finally filtered. The organic filtrate 
was concentrated in vacuo and the residue was purified by flash chromatography using gradient 
mobile phase of EtOAc/hexanes to afford the titled compound as brown solid in 75% yield. 1H-
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NMR (CDCl3, 400 MHz): 7.22 (d, J = 8.92 Hz,  2 H), 6.44 (d, J = 8.92 Hz, 2 H), 3.59-3.53 (m, 1 
H), 1.18 (d, J = 6.28 Hz, 6 H). 13C-NMR (CDCl3, 100 MHz): 146.52, 131.93, 114.76, 108.35, 
44.32, 22.83. MS (ESI) calculated for C9H12BrN, [M+H]+, m/z 214.02, found for [M+H]+, m/z 
214.11. 
1-(4-(4-nitrophenyl)piperazin-1-yl)ethanone (7a). To a stirred solution of 1-(4-
nitrophenyl) piperazine (6) (1 mmol) in anhydrous CH2Cl2 (4 mL) was added anhydrous pyridine 
(2 mmol) at RT, followed by drop-wise addition of acetic anhydride (1.5 mmol). After 4 h, the 
reaction mixture was diluted with CH2Cl2 (10 mL) and washed with 2.0 N HCl aqueous solution (2 
X10 mL). The organic phase was then concentrated by rotary evaporator and the resulting crude 
was purified by flash chromatography using gradient of EtOAc/hexanes as mobile phase to provide 
the titled acetylated product in 84% yield. 1H-NMR (CDCl3, 400 MHz): 8.08 (d, J = 9.36 Hz, 2 H), 
6.78 (d, J = 9.36 Hz, 2 H), 3.75-3.60 (m, 4 H), 3.40-3.37 (m, 4 H), 2.09 (s, 3 H). 13C-NMR (CDCl3, 
100 MHz):  169.21, 154.19, 139.39, 125.95, 113.24, 47.15, 21.25. MS (ESI) calculated for 
C12H15N3O3, [M+H]+, m/z 250.27, found for [M+H]+, m/z 250.12. 
(4-(4-nitrophenyl)piperazin-1-yl)(thiophen-2-yl)methanone (7b). 1H-NMR (CDCl3, 400 
MHz): 8.07 (d, J = 9.40 Hz, 2 H), 7.44-7.42 (dd, J = 1.04 Hz, J = 5 Hz, 1 H), 7.30-7.29 (dd, J = 
1.08 Hz, J = 3.68 Hz, 1 H), 3.03-3.01 (m, 1 H), 6.77 (d, J =  9.4 Hz, 2 H),  3.89 (t, J = 5.24 Hz, 4 
H), 3.45 (t, J = 5.44 Hz, 4 H). 13C-NMR (CDCl3, 100 MHz):  163.81, 154.16, 139.39, 136.45, 
129.39, 129.33, 126.95, 126.04, 125.96, 113.20, 112.55, 47.21, 46.25. MS (ESI) calculated for 
C15H15N3O3S, [M+H]+, m/z 318.76, found for [M+H]+, m/z 3.18.09. 
 
General Procedure for Nucleophilic Amidation of Halogenated Aniline Derivatives 
8a-8g. An oven-dried, two-neck round bottom flask fitted with a condenser was charged with CuI 
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(0.05 mmol) and K2CO3 (2.0 mmol) under nitrogen atmosphere. N, N’-dimethylethylenediamine 
(0.10 mmol), 4-haloaniline derivative (4a–4c) (1.0 mmol), piperidin-2-one (5a) or morpholin-3-
one (5b) (1.5 mmol), and anhydrous toluene (1 mL) were added. The reaction mixture was stirred 
and refluxed overnight. The resulting mixture was allowed to reach RT and filtered through Celite, 
which was further washed with methanol (10 mL). The organic filtrate was concentrated in vacuo 
and the residue was purified by flash chromatography using gradient mobile phase of 
EtOAc/hexanes to afford the corresponding para-amidated aniline derivatives (8a–8g) as solid 
products in 65-90% yield.  
1-(4-aminophenyl)piperidin-2-one (8a). 1H-NMR (CDCl3, 400 MHz): 7.00 (d, J = 8.76 
Hz, 2 H),  6.56 (d, J = 8.76 Hz, 2 H), 3.56 (t, J = 5.44 Hz, 2 H), 2.52 (t, J = 5.24 Hz, 2 H), 1.92-
1.89 (m, 4 H). 13C-NMR (CDCl3, 100 MHz): 170.11, 146.25, 132.89, 127.19, 113.35, 52.17, 
32.88, 23.04, 21.20. MS (ESI) calculated for C11H14N2O, [M+H]+, m/z 191.25, found for [M+H]+, 
m/z 191.98. 
4-(4-aminophenyl)morpholin-3-one (8b). 1H-NMR (CDCl3, 400 MHz): 7.00 (d, J= 8.64 
Hz, 2 H), 6.62 (d, J= 8.68 Hz, 2 H), 4.24 (s, 2 H), 3.93 (t, J= 5.2 Hz, 2 H), 3.61 (t, J = 5.24 Hz, 2 
H). 13C-NMR (CDCl3, 100 MHz): 166.85, 147.59, 130.92, 127.00, 126.71, 113.25, 112.98, 68.62, 
64.25, 50.27. MS (ESI) calculated for C10H12N2O2, [M+H]+, m/z 193.22, found for [M+H]+, m/z  
193.26. 
1-(4-(methylamino)phenyl)piperidin-2-one (8c). 1H-NMR (acetone-d6, 400 MHz): 6.84 
(d, J= 8.68 Hz, 2 H), 6.42 (d, J = 8.72 Hz, 2 H), 3.43 (t, J = 5.44 Hz, 2 H), 2.62 (s, 3 H), 2.22 (t, J = 
6.44 Hz, 2 H), 1.76-1.73 (m, 4 H). 13C-NMR (acetone-d6, 100 MHz): 169.23, 149.28, 134.28, 
127.94, 112.57, 52.57, 33.66, 29.60, 24.51, 22.39. MS (ESI) calculated for C12H16N2O, [M+H]+, 
m/z 205.28, found for [M+H]+, m/z 205.48. 
157 
 
4-(4-(methylamino)phenyl)morpholin-3-one (8d). 1H-NMR (CDCl3, 400 MHz): 7.10-
7.08 (dd, J =  2.00 Hz, J = 8.60 Hz, 2 H), 6.62-6.59 (dd, J = 2.00 Hz, J = 8.60 Hz, 2 H),  4.31 (s, 2 
H), 4.00 (t, J = 3.88 Hz, 2 H), 3.69 (t, J = 3.28 Hz, 2 H), 2.83 (s, 3 H). 13C-NMR (CDCl3, 100 
MHz): 166.94, 148.50, 132.16, 130.94, 115.04, 68.57, 64.21, 50.27, 30.70.  MS (ESI) calculated 
for C11H14N2O2, [M+H]+, m/z 207.25, found for [M+H]+, m/z 207.57. 
1-(4-(ethylamino)phenyl)piperidin-2-one (8e). 1H-NMR (CDCl3, 400 MHz): 7.08 (d, J= 
8.64 Hz, 2 H), 6.97 (d, J= 8.64 Hz, 2 H), 3.23 (t, J= 5.12 Hz, 2 H), 3.16-3.11 (q, J = 7.16 Hz, J = 
14.28 Hz, 2 H), 2.27 (t, J= 6.36 Hz, 2 H), 1.73-1.67 (m, 4 H), 1.24 (t, J = 7.20 Hz, 3 H).  13C-NMR 
(CDCl3, 100 MHz): 169.35, 141.14, 126.33, 125.41, 117.35, 50.85, 41.96, 31.83, 22.52, 21.19, 
12.55. MS (ESI) calculated for C13H18N2O, [M+H]+, m/z 219.30, found for [M+H]+, m/z 219.15. 
4-(4-(ethylamino)phenyl)morpholin-3-one (8f). 1H-NMR (CDCl3, 400 MHz): 7.01 (d, J= 
8.76 Hz, 2 H), 6.53 (d, J =  8.72 Hz, 2 H), 4.24 (s, 2 H), 3.92 (t, J= 4.92 Hz, 2 H), 3.61 (t, J = 5.28 
Hz, 2 H), 3.10-3.05 (q, J = 7.12 Hz, J = 14.28 Hz, 2 H), 1.18 (t, J = 7.16 Hz, 3 H). 13C-NMR 
(CDCl3, 100 MHz): 166.85, 147.59, 130.92, 127.00, 126.71, 113.25, 112.98, 68.62, 64.25, 50.27, 
38.49, 41.83. MS (ESI) calculated for C12H16N2O2, [M+H]+, m/z 221.28, found for [M+H]+, m/z 
221.26. 
1-(4-(isopropylamino)phenyl)piperidin-2-one (8g). 1H-NMR (acetone-d6, 400 MHz): 
6.82 (d, J= 8.84 Hz, 2 H), 6.43 (d, J =  8.84 Hz, 2 H), 3.52-3.50 (m, 1 H), 3.45 (t, J = 5.00 Hz, 2 
H), 2.24 (t, J= 6.68 Hz, 2 H), 1.84-1.70 (m, 4 H), 1.11 (d, J = 6.32 Hz, 6 H). 13C-NMR (acetone-d6, 
100 MHz): 169.63, 147.32, 134.14, 127.64, 113.52, 52.54, 44.70, 33.78, 24.51, 22.99, 22.37. MS 
(ESI) calculated for C14H20N2O, [M+H]+, m/z 233.33, found for [M+H]+, m/z 233.08. 
General Procedure for Catalytic Hydrogenation of Nitro Group for Synthesis of 8i 
and 8j. 4-Nitrophenylpiperazine (7a or 7b) and 10% Pd/C was mixed in methanol (10 mL) 
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containing concentrated HCl (2 mL). Hydrogen gas was then pumped into the mixture at RT. After 
stirring the solution for 5 h, the catalyst was filtered on Celite and the organic filtrate concentrated 
in vacuo to afford the corresponding aniline derivative (8i and 8j) in ~100% yield. 
1-(4-(4-aminophenyl)piperazin-1-yl)ethanone (8i). 1H-NMR (CDCl3, 400 MHz): 6.81 (d, 
J = 8.76 Hz, 2 H), 6.66 (d, J = 8.76 Hz, 2 H), 3.75 (t, J = 5.08 Hz, 2 H), 3.60 (t, J = 4.92 Hz, 2 H), 
3.01 (t, J = 5.20 Hz, 2 H), 2.98 (t, J = 5.12 Hz, 2 H), 2.13 (s, 3 H). 13C-NMR (CDCl3, 100 MHz): 
168.98, 144.04, 140.90, 119.32, 116.17, 51.55, 51.14, 46.51, 41.61, 21.33.  MS (ESI) calculated 
for C12H17N3O, [M+H]+, m/z 220.29, found for [M+]+, m/z 220.15. 
(4-(4-aminophenyl)piperazin-1-yl)(thiophen-2-yl)methanone (8j). 1H-NMR (acetone-d6, 
400 MHz): 7.57 (d, J = 4.96 Hz, 1 H), 7.34 (d, J = 3.56 Hz, 1 H), 7.03 (d, J = 4.32 Hz, 1 H),  6.86 
(d, J = 8.64 Hz, 2 H), 6.54 (d, J =  8.60 Hz, 2 H),  3.77 (t, J = 4.96 Hz, 4 H), 3.08 (t, J = 5.16 Hz, 4 
H). 13C-NMR (acetone-d6, 100 MHz):  163.60, 148.27, 138.75, 129.72, 127.70, 122.94, 121.33, 
120.06, 118.43, 116.14, 52.39, 51.20. MS (ESI) calculated for C15H17N3OS, [M+H]+, m/z 288.39, 
found for [M+H]+, m/z 288.25. 
General Procedure for Deprotection of t-Butyloxycarbonyl (Boc) Group of 16, 17, 21, 
61, 76, 77, 80, 83, or 86. To a solution of 1,2,3,4-tetrahydroisoquinoline carboxamides (16, 17, 
21), phenylalanine carboxamide (61), piperidine-2-carboxamides (76, 77, 80), 1,2,3,6-
tetrahydropyridine-2-carboxamides (83), or 2-azabicyclo[2.2.1] heptane-3-carboxamides (86) (1.0 
mmol) in CH2Cl2 (5 mL), trifluoroacetic acid (TFA, 5 mL) was added drop-wise at 0 ºC, and the 
mixture was warmed to RT. After stirring for 4 h, the reaction mixture was diluted with CH2Cl2 
(25 mL) and neutralized by drop-wise addition of saturated aqueous NaHCO3 (20 mL). The 
organic layer was separated and the aqueous phase was extracted with EtOAc (2 × 25 mL). The 
organic extracts were combined, washed with saturated NaCl solution (25 mL), and dried over 
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anhydrous Na2SO4. Removal of the solvent under reduced pressure afforded the desired 
unprotected carboxamides in quantitative yields and sufficient purity (as indicated by TLC) to be 
directly used in the next reactions without any further treatment.  
(S)-tert-butyl 3-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)-3,4-dihydro-
isoquinoline-2(1H)-carboxylate (16). 1H-NMR (CDCl3, 400 MHz): 7.37-7.27 (m, 4 H), 7.12-6.92 
(m, 4 H), 7.15-7.11 (m, 3 H), 4.91-7.37 (m, 3 H), 3.62 (t, J= 5.44 Hz, 2 H), 3.14 (s, 3 H), 2.8-2.65 
(m, 1 H), 2.50 (t, J= 6.44 Hz, 2 H), 2.0-1.90 (m, 4 H), 1.42 (s, 9 H) . 13C-NMR (CDCl3, 100 MHz): 
171.99, 170.05, 154.30, 142.71, 141.31, 134.73, 132.21, 128.13, 127.69, 127.27, 126.63, 125.74, 
79.98, 51.39, 45.49, 38.05, 32.88, 31.29, 29.65, 28.52, 23.48, 21.33. MS (ESI) calculated for 
C27H33N3O4 , [M+H]+, m/z 464.58, found for [M+Na]+, m/z 486.29. 
(R)-tert-butyl 3-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)-3,4-dihydro-
isoquinoline-2(1H)-carboxylate (17). 1H-NMR (CDCl3, 400 MHz): 7.37-7.25 (m, 4 H), 7.12-6.90 
(m, 4 H), 7.17-7.11 (m, 3 H), 4.91-7.37 (m, 3 H), 3.62 (t, J= 5.45 Hz, 2 H), 3.14 (s, 3 H), 2.82-2.65 
(m, 1 H), 2.50 (t, J= 6.42 Hz, 2 H), 2.1-1.911 (m, 4 H), 1.41 (s, 9 H) . 13C-NMR (CDCl3, 100 
MHz): 172.01, 170.09, 154.30, 142.71, 141.31, 134.72, 132.21, 128.15, 127.69, 127.27, 126.63, 
125.74, 79.98, 51.39, 45.49, 38.05, 32.87, 31.29, 29.65, 28.52, 23.51, 21.35. MS (ESI) calculated 
for C27H33N3O4 , [M+H]+, m/z 464.58, found for [M+Na]+, m/z 486.29. 
(R)-tert-butyl 3-(4-(3-oxomorpholino)phenylcarbamoyl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (21). 1H-NMR (CDCl3, 400 MHz):  7.50-7.30 (m, 2 H), 7.28-7.10 (m, 6 H), 
5.00-4.45 (m, 3 H), 4.31 (s, 2 H), 4.00 (t, J = 4.84 Hz, 2 H), 3.69 (t, J = 5.68 Hz, 2 H), 3.40-3.27 
(m, 1 H), 3.23-3.00 (m, 1 H), 1.50 (s, 9 H).  13C-NMR (CDCl3, 100 MHz):  171.40, 166.73, 
155.65, 133.77, 128.13, 126.73, 126.08, 120.57, 81.81, 68.57, 64.13, 49.75, 44.85, 28.38.  MS 
(ESI) calculated for C28H27N3O5, [M+H]+, m/z 452.52, found for [M+Na]+, m/z 474.37.  
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(S)-tert-butyl 1-(methyl(4-(2-oxopiperidin-1-yl)phenyl)amino)-1-oxo-3-phenylpropan-
2-ylcarbamate (61). 1H-NMR (CDCl3, 400 MHz): 7.30-7.12 (m, 5 H), 6.86-6.76 (m, 2 H), 6.75-
6.66 (m, 2 H), 4.49-4.44 (q, J = 7.16 Hz,  J = 15.08 Hz, 1 H), 3.60 (t, J = 4.84 Hz, 2 H), 3.12 (s, 3 
H), 2.83-2.77 (dd, J = 7.60 Hz, J = 13.12, 1 H), 2.66-2.61 (dd, J = 6.20 Hz, J = 12.52 Hz, 1 H), 
2.50 (t,  J = 6.36, 2 H), 1.90-1.85 (m, 4 H), 1.31 (s, 9 H). 13C-NMR (CDCl3, 100 MHz): 171.79, 
170.00, 154.82, 142.77, 140.39, 136.59, 129.38, 128.35, 127.92, 127.10, 126.68, 79.46, 52.27, 
51.69, 39.86, 37.45, 32.30, 28.30, 23.53, 21.39.  MS (ESI) calculated for C26H33N3O4, [M+H]+, 
m/z 452.57, found for [M+H]+, m/z 452.42. 
(S)-tert-butyl 2-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)piperidine-1-
carboxylate  (76). 1H-NMR (CDCl3, 400 MHz): 7.36-7.31 (m, 4 H),  7.06 (d, J = 3.04 Hz, 1 H), 
6.83 (d, J = 3.92 Hz, 1 H), 4.85-4.86 (m, 1 H), 3.85-3.72 (m, 1 H), 3.60 (t, J = 5.16 Hz, 2 H), 3.55-
3.46 (m, 1 H), 3.17 (s, 3 H), 2.50 (t, J = 5.76 Hz, 2 H), 1.89-1.84 (m, 4 H), 1.59-1.54 (m, 2 H), 
1.53-1.38 (m, 2 H), 1.38 (s, 9 H), 1.26-1.18 (m, 2 H). 13C-NMR (CDCl3, 100 MHz): 172.98, 
170.04, 154.20, 142.50, 141.49, 127.96, 127.13, 79.57, 51.41, 45.26, 42.43, 38.05, 32.92, 28.52, 
26.62, 24.80, 23.60, 21.50, 19.49. MS (ESI) calculated for C23H33N3O4, [M+H]+, m/z 416.53, 
found for [M+Na]+, 438.29 m/z. 
(R)- tert-butyl 2-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)piperidine-1-
carboxylate (77). 1H-NMR (CDCl3, 400 MHz): 7.35-7.29 (m, 4 H),  7.06 (d, J = 3.05 Hz, 1 H), 
6.84 (d, J = 3.91 Hz, 1 H), 4.85-4.86 (m, 1 H), 3.85-3.71 (m, 1 H), 3.60 (t, J = 5.15 Hz, 2 H), 3.55-
3.46 (m, 1 H), 3.17 (s, 3 H), 2.50 (t, J = 5.75 Hz, 2 H), 1.90-1.85 (m, 4 H), 1.59-1.54 (m, 2 H), 
1.54-1.38 (m, 2 H), 1.40 (s, 9 H), 1.26-1.18 (m, 2 H). 13C-NMR (CDCl3, 100 MHz): 172.95, 
170.04, 154.20, 142.50, 141.49, 128.01, 127.13, 79.57, 51.41, 45.26, 42.43, 38.1, 32.92, 28.52, 
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26.63, 24.80, 23.60, 21.51, 19.50. MS (ESI) calculated for C23H33N3O4, [M+H]+, m/z 416.53, 
found for [M+Na]+, 438.24 m/z. 
(R)-tert-butyl 2-(4-(3-oxomorpholino)phenylcarbamoyl)piperidine-1-carboxylate (80). 
1H-NMR (CDCl3, 400 MHz): 7.46 (d, J = 8.80 Hz, 2 H), 7.19 (d, J = 8.36 Hz, 2 H), 4.80-4.72 (m, 
1 H), 4.26 (s, 2 H), 4.14-4.04 (m, 2 H), 3.99 (t, J = 4.88 Hz, 2 H), 3.85 (t, J = 4.44 Hz, 2 H), 2.76 
(t, J =  12.44 Hz, 1 H), 2.26-2.23 (m, 1 H), 1.77-1.50 (m, 4 H), 1.48 (s, 9 H). 13C-NMR (CDCl3, 
100 MHz): 169.88, 166.88, 157.58, 137.04, 136.90, 126.27, 120.48, 81.26, 68.63, 64.16, 55.00, 
49.92, 42.53, 28.42, 25.06, 20.37. MS (ESI) calculated for C21H29N3O5, [M+H]+, m/z 404.48, 
found for [M+Na]+, 426.34 m/z . 
(S)-tert-butyl 6-(4-(3-oxomorpholino)phenylcarbamoyl)-5,6-dihydropyridine-1(2H)-
carboxylate (83). 1H-NMR (CDCl3, 400 MHz): 7.50 (d, J = 8.80 Hz, 2 H), 7.22 (d, J = 8.64 Hz, 2 
H), 5.85-5.80 (m, 1 H), 4.65-4.60 (m, 1 H), 5.00-4.93 (m, 1 H), 4.28 (s, 2 H), 4.20-4.07 (m, 1 H), 
3.94 (t, J = 4.95 Hz, 2 H), 3.65 (t, J = 4.40 Hz, 2 H), 3.60-3.63 (m, 1 H), 2.60-3.72 (m, 1 H), 2.34-
2.28 (m, 1 H).  13C-NMR (CDCl3, 100 MHz): 169.54, 166.82, 156.90, 137.99, 126.12, 123.36, 
122.20, 120.36, 81.41, 68.54, 64.11, 61.4, 49.79, 41.50, 28.39, 24.10. MS (ESI) calculated for 
C22H29N3O5, [M+H]+, m/z 402.46, found for [M+Na]+, m/z 424.36. 
(1R, 3S, 4R)-tert-butyl 3-(4-(3-oxomorpholino)phenylcarbamoyl)-2-azabicyclo[2.2.1] 
heptane -2-carboxylate (86). 1H-NMR (CDCl3, 400 MHz): 7.57 (d, J = 8.36 Hz, 2 H), 7.25 (d, J = 
7.60 Hz, 2 H), 4.32 (s, 3 H), 4.14-4.11 (m, 1 H), 4.02 (t, J = 4.96 Hz, 2 H), 3.93-3.85 (m, 1 H), 
3.73 (t, J = 4.84 Hz, 2 H), 3.03-2.96 (m, 1 H), 1.80-1.77 (m, 2 H), 1.67-1.65 (m, 2 H), 1.50 (s, 9 
H), 1.39-1.36 (m, 2 H).   13C-NMR (CDCl3, 100 MHz): 169.30, 166.76, 157.58, 137.26, 136.90, 
126.07, 120.42, 81.17, 68.57, 67.06, 64.35, 58.23, 49.78, 39.25, 36.65, 29.97, 28.43, 26.40. MS 
(ESI) calculated for C22H29N3O5, [M+H]+, m/z 416.49, found for [M+Na]+, m/z 438.20. 
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General Procedure for Deprotection of Carbobenzyloxy (Cbz) Group of 12-15, 18–20, 
50, 67 or 68. 1,2,3,4-tetrahydroisoquinoline carboxamides (12-15, 18, 19, 50) or piperidine-3-
carboxamides (67 or 68) and 10% Pd(OH)2 on activated charcoal were mixed in CH3OH: tert-
butanol (1:1) mixture (10 mL). Hydrogen gas was then pumped into the mixture at RT. After 
stirring the solution overnight, the catalyst was filtered on Celite and the organic filtrate 
concentrated in vacuo to afford the corresponding desired unprotected carboxamides in 
quantitative yields and sufficient purity (as indicated by TLC) to be directly used in the next 
reactions without any further treatment.  
(S)-benzyl 3-(4-(2-oxopiperidin-1-yl)phenylcarbamoyl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (12). 1H-NMR (CDCl3, 400 MHz): 7.50-7.27 (m, 6 H), 7.25-7.08 (m, 5 H), 
7.06 (d, J = 8.44, 2 H), 5.23-5.12 (m, 2 H), 4.96-4.54 (m, 3 H), 3.55 (t, J = 5.00 Hz, 2 H), 3.40-3.30 
(m, 1 H), 3.20-3.09 (m, 1 H), 2.52 (t, J = 5.00 Hz, 2 H), 2.00-1.87 (m, 4 H).  13C-NMR (CDCl3, 
100 MHz): 170.23, 169.22, 156.94, 139.31, 136.09, 135.47, 134.33, 133.32,128.64, 128.32, 
128.07, 127.76, 127.23, 126.90, 126.58,125.99, 120.87, 68.04, 64.35, 51.75, 45.08, 32.82, 30.31, 
23.51, 21.41.  MS (ESI) calculated for C29H29N3O4, [M+H]+, m/z 484.57, found for [M+Na]+, m/z 
506.3. 
(S)-benzyl 3-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)-3,4-dihydroiso-
quinoline-2(1H)-carboxylate (13).1H-NMR (CDCl3, 400 MHz): 7.47 (d, J = 7.64 Hz, 1 H), 7.39-
7.31 (m, 6 H), 7.18 (m, 4 H), 7.06-6.82 (m, 2 H), 5.23 (d, J = 45.56 Hz, 1 H), 5.16 (d, J = 19.68 
Hz, 1 H), 5.03-4.50 (m, 3 H), 3.67 (t, J = 5.20 Hz, 1 H), 3.59 (t, J = 5.20 Hz, 1 H), 3.17 (d, J = 
50.36 Hz, 3 H), 2.87-2.83 (m, 2 H), 2.58 (t, J = 6.20 Hz, 2 H), 2.00-1.93 (m, 4 H).  13C-NMR 
(CDCl3, 100 MHz): 170.91, 169.46, 154.74, 141.69, 140.31, 139.82, 135.47, 134.33, 133.44, 
131.75, 128.01, 127.60, 127.23, 126.78, 126.12, 125.97, 124.88, 66.92, 52.41, 50.50, 44.23, 37.01, 
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31.70, 30.81, 22.42, 20.22. MS (ESI) calculated for C30H31N3O4, [M+H]+, m/z 498.59, found for 
[M+Na]+, m/z 520.32. 
(S)-benzyl 3-(ethyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)-3,4-dihydroiso-
quinoline-2(1H)-carboxylate (14).  1H-NMR (CDCl3, 400 MHz): 7.44-7.41 (m, 1 H), 7.38-7.32 
(m, 6 H), 7.21-7.10 (m, 4 H), 7.05-6.70 (m, 2 H), 5.20-5.02 (m, 2 H), 4.93-4.44 (m, 3 H), 3.83-3.76 
(m, 1 H), 3.66-3.60 (m, 2 H), 3.58-3.46 (m, 1 H), 2.86-2.81 (dd, J = 3.76 Hz, J =  6.76 Hz, 2 H), 
2.59 (d,  J = 5.48 Hz, 2 H), 2.00-1.90 (m, 4 H), 1.11-0.97 (m, 3 H). 13C-NMR (CDCl3, 100 MHz):  
171.33, 170.51, 155.70, 142.68, 139.79, 139.30, 136.53, 135.43, 134.52, 132.79, 132.35, 129.19, 
128.63, 127.77, 127.14, 126.94, 125.89, 67.91, 60.38, 52.58, 51.47, 45.29, 32.66, 29.70, 23.41, 
21.18, 12.84.  MS (ESI) calculated for C31H33N3O4, [M+H]+, m/z 512.62, found for [M+Na]+, m/z 
534.33. 
(S)-benzyl 3-(isopropyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)-3,4-dihydro-
isoquinoline-2(1H)-carboxylate (15). 1H-NMR (CDCl3, 400 MHz): 7.45-7.28 (m, 7 H), 7.24-7.08 
(m, 4 H),  7.02-6.46 (m, 2 H), 5.16-5.03 (m, 2 H), 4.93-4.27 (m, 4 H), 3.68 (t, J = 5.90 Hz, 1 H), 
3.62 (t, J = 5.92 Hz, 1 H), 2.89-2.82 (m, 2 H), 2.54 (d, J = 7.12 Hz, 2 H), 1.96-1.85 (m, 4 H), 1.20-
0.80 (m, 6 H).  13C-NMR (CDCl3, 100 MHz): 171.43, 170.05, 155.26, 143.37, 136.59, 135.68, 
135.23, 132.94, 131.15, 130.19, 129.05, 128.64, 127.77, 127.13, 126.82, 126.46, 125.87, 67.83, 
60.37, 53.06, 51.34, 46.99, 32.96, 31.94, 23.65, 21.52, 20.39.  MS (ESI) calculated for 
C32H35N3O4, [M+H]+, m/z 526.65, found for [M+Na]+, m/z 548.35. 
(S)-benzyl 3-(methyl(4-(3-oxomorpholino)phenyl)carbamoyl)-3,4-dihydroiso-
quinoline-2(1H)-carboxylate (18). 1H-NMR (CDCl3, 400 MHz):  7.51-7.44 (dd, J = 6.68 Hz, J = 
20.32, 2 H), 7.38-7.36 (m, 4 H), 7.34-7.30 (m, 1 H), 7.22-7.09 (m, 4 H), 7.06-6.84 (m, 2 H), 5.24 
(d, J = 28.32 Hz, 1 H), 5.16 (d, J = 5.88 Hz, 1 H), 5.03-4.63 (m, 3 H), 4.34 (d, J = 6.72 Hz, 2 H), 
164 
 
4.02 (t, J = 4.80 Hz, 2 H), 3.79 (t, J = 4.72 Hz, 1 H), 3.72 (t, J = 3.76 Hz, 1 H), 3.17 (d, J = 51.12 
Hz, 3 H), 2.90-2.83 (m, 2 H). 13C-NMR (CDCl3, 100 MHz): 171.92, 166.71, 155.76, 141.64, 
140.80, 136.46, 135.32, 132.69, 129.05, 128.64, 128.14, 127.79, 12718, 127.00,  126.92, 126.51, 
125.93, 68.58, 67.43, 64.09, 52.40, 49.42, 45.24, 37.96, 31.83.  MS (ESI) calculated for 
C29H29N3O5, [M+H]+, m/z 500.57, found for [M+Na]+, m/z 522.30. 
(S)-benzyl 3-(ethyl(4-(3-oxomorpholino)phenyl)carbamoyl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (19). 1H-NMR (CDCl3, 400 MHz): 7.48-7.44 (m, 2 H), 7.42-7.34 (m, 4 H), 
7.33-7.30 (m, 1 H), 7.25-7.10 (m, 4 H), 7.09-6.80 (m, 2 H), 5.20-5.04 9m, 2 H), 4.94-4.44 (m, 3 
H), 4.35 (d, J = 5.28 Hz, 2 H), 4.03 (t, J = 4.04 Hz, 2 H), 3.81-3.72 (m, 2 H), 3.67-3.47 (m, 2 H), 
2.87-2.83 (m, 2 H), 1.12-0.97 (m, 3 H). 13C-NMR (CDCl3, 100 MHz):  171.31, 166.65, 155.71, 
140.90, 139.99, 136.52, 135.40, 134.52, 132.72, 129.31, 128.65, 128.01, 127.77, 127.16, 126.90, 
126.28, 125.92, 68.60, 67.92, 64.10, 60.37, 52.56, 49.40, 45.28, 31.44, 12.83. MS (ESI) calculated 
for C30H31N3O5, [M+H]+, m/z 514.59, found for [M+Na]+, m/z 537.37. 
(S)-benzyl 3-(4-(3-oxomorpholino)phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (20). 1H-NMR (acetone-d6, 400 MHz): 7.55 (d, J = 8.92 Hz, 2 H), 7.49-7.34 (m, 4 H), 
7.29 (d, J =  8.80, 2 H), 7.27-7.22 (m, 5 H), 5.25-5.09 (m, 2 H), 5.01-4.61 (m, 3 H), 4.18 (s, 2 H), 
3.76 (s, br, 2 H), 3.32 (t, J = 4.00 Hz, 2 H), 3.29-3.24 (m, 2 H).  13C-NMR (CDCl3, 100 MHz): 
171.95, 166.73, 155.76, 141.65, 140.78, 136.46, 135.31, 132.69, 129.05, 128.66, 128.14, 127.79, 
127.18, 127.00,  126.92, 126.51, 125.95, 68.61, 67.43, 64.09, 52.40, 49.42, 45.24, 31.80. MS (ESI) 
calculated for C28H27N3O5, [M+H]+, m/z 486.20, found for [M+Na]+, m/z 508.18. 
(S)-benzyl 3-(4-chlorophenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(50). 1H-NMR (CDCl3, 400 MHz): 7.50-7.35 (m, 3 H), 7.34-7.26 (m, 2 H), 7.25-7.18 (m, 4 H), 
7.17-7.00 (m, 4 H), 5.39-5.10 (m, 2 H), 4.96-4.49 (m, 3 H), 3.35-3.21 (m, 1 H), 3.20-3.3.03 (m, 1 
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H). 13C-NMR (CDCl3, 100 MHz): 169.12, 157.30, 136.24, 135.95, 133.44, 132.70, 129.08, 128.81, 
128.70, 128.57, 128.43, 128.11, 127.77, 126.78, 125.94, 121.13, 68.19, 57.04, 45.11, 28.30. MS 
(ESI) calculated for C24H21ClN2O3, [M+H]+, m/z 421.90, found for [M+Na]+, m/z 443.26. 
(S)-benzyl 3-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)piperidine-1-
carboxylate (67).1H-NMR (CDCl3, 400 MHz): 7.40-7.34 (m, 2 H), 7.33-7.31 (m, 2 H), 7.30-7.23 
(m, 2 H), 7.22-7.04 (m, 3 H),  5.20-5.00 (m, 2 H), 4.14 (t, J = 6.60 Hz, 1 H), 4.06 (t, J = 6.72 Hz, 1 
H), 3.70-3.50 (m, 2 H), 3.21 (s, 3 H), 2.99 (t, J = 11.92 Hz, 1 H), 2.76 (t, J = 11.84 Hz, 1 H), 2.58 
(t, J = 6.00 Hz, 2 H), 2.50-2.40 (m, 1 H), 2.00-1.94 (m, 4 H), 1.76-1.71 (m, 2 H), 1.61-1.58 (m, 1 
H), 1.27-1.24 (m, 1 H).  13C-NMR (CDCl3, 100 MHz):  173.22, 170.26, 154.96, 142.71, 141.40, 
136.80, 128.46, 127.98, 127.80, 127.64, 127.25, 67.04, 51.41, 46.60, 44.08, 39.71, 37.50, 32.84, 
27.77, 24.12, 23.48, 21.32. MS (ESI) calculated for C26H31N3O4, [M+H]+, m/z 450.55, found for 
[M+Na]+, m/z 472.35. 
(R)-benzyl 3-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)piperidine-1-
carboxylate (68).1H-NMR (CDCl3, 400 MHz):  13C-NMR (CDCl3, 100 MHz): 1H-NMR (CDCl3, 
400 MHz): 7.40-7.34 (m, 2 H), 7.33-7.31 (m, 2 H), 7.30-7.23 (m, 2 H), 7.22-7.04 (m, 3 H),  5.20-
5.00 (m, 2 H), 4.14 (t, J = 6.60 Hz, 1 H), 4.06 (t, J = 6.72 Hz, 1 H), 3.70-3.50 (m, 2 H), 3.21 (s, 3 
H), 2.99 (t, J = 11.92 Hz, 1 H), 2.76 (t, J = 11.84 Hz, 1 H), 2.58 (t, J = 6.00 Hz, 2 H), 2.50-2.40 (m, 
1 H), 2.00-1.94 (m, 4 H), 1.76-1.71 (m, 2 H), 1.61-1.58 (m, 1 H), 1.27-1.24 (m, 1 H).  13C-NMR 
(CDCl3, 100 MHz):  173.22, 170.26, 154.96, 142.71, 141.40, 136.80, 128.46, 127.98, 127.80, 
127.64, 127.25, 67.04, 51.41, 46.60, 44.08, 39.71, 37.50, 32.84, 27.77, 24.12, 23.48, 21.32. MS 
(ESI) calculated for C26H31N3O4, [M+H]+, m/z 450.55, found for [M+Na]+, m/z 472.35. 
General Procedure for Amine Protection by Carbobenzyloxy (Cbz) Group in the 
Synthesis of 65 or 66. Piperidine-3-carboxylic acid (63 or 64) (1 mmol) was dissolved in dry THF 
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(10 mL) and stirred at RT. Tri-ethylamine (Et3N) (2 mmol) was then added followed by benzyl 
chloroformate (1.5 mmol). The reaction mixture became initially cloudy and turned to clear 
solution after 5 h. The reaction mixture was then partitioned between acidified water (15 mL) and 
EtOAc (20 mL). The aqueous layer was further washed with EtOAc (2 × 20 mL). The organic 
extracts were combined, dried over anhydrous Na2SO3, filtered, and concentrated in vacuo. The N-
Cbz protected product (65 or 66) was isolated as white solids by flash chromatography using 
gradient of EtOAc/hexanes as eluant in 70-73 % yield.  
(S)-1-(benzyloxycarbonyl)piperidine-3-carboxylic acid (65). 1H-NMR (acetone-d6, 400 
MHz): 7.43-7.30 (m, 5 H), 5.15 (s, 2 H), 4.35-4.04 (m, 1 H), 3.93 (d, J = 12.08 Hz, 1 H), 3.18-3.02 
(m, 1 H), 3.01-2.92 (m, 1 H), 2.53-2.46 (m, 1 H), 2.09-2.062 (m, 1 H), 1.75-1.66 (m, 2 H), 1.53-
1.45 (m, 1 H). 13C-NMR (acetone-d6, 100 MHz): 174.88, 155.77, 138.25, 129.30, 128.70, 128.60, 
67.49, 46.62, 44.90, 41.64, 27.87, 24.98. MS (ESI) calculated for C14H17NO4, [M+H]+, m/z 264.30, 
found for [M+H]+, m/z 264.37. 
(R)-1-(benzyloxycarbonyl)piperidine-3-carboxylic acid (66). 1H-NMR (acetone-d6, 400 
MHz): 7.43-7.30 (m, 5 H), 5.15 (s, 2 H), 4.35-4.04 (m, 1 H), 3.93 (d, J = 12.08 Hz, 1 H), 3.18-3.02 
(m, 1 H), 3.01-2.92 (m, 1 H), 2.53-2.46 (m, 1 H), 2.09-2.062 (m, 1 H), 1.75-1.66 (m, 2 H), 1.53-
1.45 (m, 1 H). 13C-NMR (acetone-d6, 100 MHz): 174.88, 155.77, 138.25, 129.30, 128.70, 128.60, 
67.49, 46.62, 44.90, 41.64, 27.87, 24.98. MS (ESI) calculated for C14H17NO4, [M+H]+, m/z 264.30, 
found for [M+Na]+, m/z 286.28. 
 General Procedure for Amidation of 3-Carboxylic Acid to Yield 12-21, 50, 53-55, 59, 
61, 67, 68, 76, 77, 80, 83, or 86. To a stirred solution of the free carboxylic acid of (9-11, 58, 60, 
65, 66, 74, 75, 82, or 85) (1.0 mmol) in anhydrous CH2Cl2 (5 mL) was added hydrated N-
hydroxybenzotrizole (HOBT.H2O, 1.1 mmol), DMAP (1.1 mmol), and 1-ethyl-3-(3-dimethyl 
167 
 
aminopropyl)carbodiimide (EDCI, 1.1 mmol) at RT under nitrogen atmosphere. Appropriate 
amine (8a – 8j or 4-chloroaniline) (1.1 mmol) in anhydrous CH2Cl2 (5 mL) was then added 
dropwise. After stirring overnight, the reaction mixture was partitioned between 2.0 N HCl 
solution (20 mL) and CH2Cl2 (30 mL). The organic layer was washed further with 2 N HCl (2 × 10 
mL) and saturated NaCl solution (20 mL), dried using anhydrous Na2SO4, and concentrated to give 
a crude, which purified by flash chromatography using gradient of CH2Cl2/CH3OH as eluant to 
give the desired carboxamide product  in 73 – 89 % yield.  
(S)-benzyl 3-(4-(2-oxopiperidin-1-yl)phenylcarbamoyl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (12). 1H-NMR (CDCl3, 400 MHz): 7.50-7.27 (m, 6 H), 7.25-7.08 (m, 5 H), 
7.06 (d, J = 8.44, 2 H), 5.23-5.12 (m, 2 H), 4.96-4.54 (m, 3 H), 3.55 (t, J = 5.00 Hz, 2 H), 3.40-3.30 
(m, 1 H), 3.20-3.09 (m, 1 H), 2.52 (t, J = 5.00 Hz, 2 H), 2.00-1.87 (m, 4 H).  13C-NMR (CDCl3, 
100 MHz): 170.23, 169.22, 156.94, 139.31, 136.09, 135.47, 134.33, 133.32,128.64, 128.32, 
128.07, 127.76, 127.23, 126.90, 126.58,125.99, 120.87, 68.04, 64.35, 51.75, 45.08, 32.82, 30.31, 
23.51, 21.41.  MS (ESI) calculated for C29H29N3O4, [M+H]+, m/z 484.57, found for [M+Na]+, m/z 
506.3. 
(S)-benzyl 3-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)-3,4-
dihydroisoquinoline-2(1H)-carboxylate (13).1H-NMR (CDCl3, 400 MHz): 7.47 (d, J = 7.64 Hz, 
1 H), 7.39-7.31 (m, 6 H), 7.18 (m, 4 H), 7.06-6.82 (m, 2 H), 5.23 (d, J = 45.56 Hz, 1 H), 5.16 (d, J 
= 19.68 Hz, 1 H), 5.03-4.50 (m, 3 H), 3.67 (t, J = 5.20 Hz, 1 H), 3.59 (t, J = 5.20 Hz, 1 H), 3.17 (d, 
J = 50.36 Hz, 3 H), 2.87-2.83 (m, 2 H), 2.58 (t, J = 6.20 Hz, 2 H), 2.00-1.93 (m, 4 H).  13C-NMR 
(CDCl3, 100 MHz): 170.91, 169.46, 154.74, 141.69, 140.31, 139.82, 135.47, 134.33, 133.44, 
131.75, 128.01, 127.60, 127.23, 126.78, 126.12, 125.97, 124.88, 66.92, 52.41, 50.50, 44.23, 37.01, 
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31.70, 30.81, 22.42, 20.22. MS (ESI) calculated for C30H31N3O4, [M+H]+, m/z 498.59, found for 
[M+Na]+, m/z 520.32. 
(S)-benzyl 3-(ethyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)-3,4-dihydroiso-
quinoline-2(1H)-carboxylate (14).  1H-NMR (CDCl3, 400 MHz): 7.44-7.41 (m, 1 H), 7.38-7.32 
(m, 6 H), 7.21-7.10 (m, 4 H), 7.05-6.70 (m, 2 H), 5.20-5.02 (m, 2 H), 4.93-4.44 (m, 3 H), 3.83-3.76 
(m, 1 H), 3.66-3.60 (m, 2 H), 3.58-3.46 (m, 1 H), 2.86-2.81 (dd, J = 3.76 Hz, J =  6.76 Hz, 2 H), 
2.59 (d,  J = 5.48 Hz, 2 H), 2.00-1.90 (m, 4 H), 1.11-0.97 (m, 3 H). 13C-NMR (CDCl3, 100 MHz):  
171.33, 170.51, 155.70, 142.68, 139.79, 139.30, 136.53, 135.43, 134.52, 132.79, 132.35, 129.19, 
128.63, 127.77, 127.14, 126.94, 125.89, 67.91, 60.38, 52.58, 51.47, 45.29, 32.66, 29.70, 23.41, 
21.18, 12.84.  MS (ESI) calculated for C31H33N3O4, [M+H]+, m/z 512.62, found for [M+Na]+, m/z 
534.33. 
(S)-benzyl 3-(isopropyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)-3,4-dihydro-
isoquinoline-2(1H)-carboxylate (15). 1H-NMR (CDCl3, 400 MHz): 7.45-7.28 (m, 7 H), 7.24-7.08 
(m, 4 H),  7.02-6.46 (m, 2 H), 5.16-5.03 (m, 2 H), 4.93-4.27 (m, 4 H), 3.68 (t, J = 5.90 Hz, 1 H), 
3.62 (t, J = 5.92 Hz, 1 H), 2.89-2.82 (m, 2 H), 2.54 (d, J = 7.12 Hz, 2 H), 1.96-1.85 (m, 4 H), 1.20-
0.80 (m, 6 H).  13C-NMR (CDCl3, 100 MHz): 171.43, 170.05, 155.26, 143.37, 136.59, 135.68, 
135.23, 132.94, 131.15, 130.19, 129.05, 128.64, 127.77, 127.13, 126.82, 126.46, 125.87, 67.83, 
60.37, 53.06, 51.34, 46.99, 32.96, 31.94, 23.65, 21.52, 20.39.  MS (ESI) calculated for 
C32H35N3O4, [M+H]+, m/z 526.65, found for [M+Na]+, m/z 548.35. 
(S)-tert-butyl 3-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)-3,4-dihydro-
isoquinoline-2(1H)-carboxylate (16). 1H-NMR (CDCl3, 400 MHz): 7.37-7.27 (m, 4 H), 7.12-6.92 
(m, 4 H), 7.15-7.11 (m, 3 H), 4.91-7.37 (m, 3 H), 3.62 (t, J= 5.44 Hz, 2 H), 3.14 (s, 3 H), 2.8-2.65 
(m, 1 H), 2.50 (t, J= 6.44 Hz, 2 H), 2.0-1.90 (m, 4 H), 1.42 (s, 9 H) . 13C-NMR (CDCl3, 100 MHz): 
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171.99, 170.05, 154.30, 142.71, 141.31, 134.73, 132.21, 128.13, 127.69, 127.27, 126.63, 125.74, 
79.98, 51.39, 45.49, 38.05, 32.88, 31.29, 29.65, 28.52, 23.48, 21.33. MS (ESI) calculated for 
C27H33N3O4 , [M+H]+, m/z 464.58, found for [M+Na]+, m/z 486.29. 
(R)-tert-butyl 3-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)-3,4-dihydro-
isoquinoline-2(1H)-carboxylate (17). 1H-NMR (CDCl3, 400 MHz): 7.37-7.25 (m, 4 H), 7.12-6.90 
(m, 4 H), 7.17-7.11 (m, 3 H), 4.91-7.37 (m, 3 H), 3.62 (t, J= 5.45 Hz, 2 H), 3.14 (s, 3 H), 2.82-2.65 
(m, 1 H), 2.50 (t, J= 6.42 Hz, 2 H), 2.1-1.911 (m, 4 H), 1.41 (s, 9 H) . 13C-NMR (CDCl3, 100 
MHz): 172.01, 170.09, 154.30, 142.71, 141.31, 134.72, 132.21, 128.15, 127.69, 127.27, 126.63, 
125.74, 79.98, 51.39, 45.49, 38.05, 32.87, 31.29, 29.65, 28.52, 23.51, 21.35. MS (ESI) calculated 
for C27H33N3O4 , [M+H]+, m/z 464.58, found for [M+Na]+, m/z 486.29. 
 (S)-benzyl 3-(methyl(4-(3-oxomorpholino)phenyl)carbamoyl)-3,4-dihydroiso-
quinoline-2(1H)-carboxylate (18). 1H-NMR (CDCl3, 400 MHz):  7.51-7.44 (dd, J = 6.68 Hz, J = 
20.32, 2 H), 7.38-7.36 (m, 4 H), 7.34-7.30 (m, 1 H), 7.22-7.09 (m, 4 H), 7.06-6.84 (m, 2 H), 5.24 
(d, J = 28.32 Hz, 1 H), 5.16 (d, J = 5.88 Hz, 1 H), 5.03-4.63 (m, 3 H), 4.34 (d, J = 6.72 Hz, 2 H), 
4.02 (t, J = 4.80 Hz, 2 H), 3.79 (t, J = 4.72 Hz, 1 H), 3.72 (t, J = 3.76 Hz, 1 H), 3.17 (d, J = 51.12 
Hz, 3 H), 2.90-2.83 (m, 2 H). 13C-NMR (CDCl3, 100 MHz): 171.92, 166.71, 155.76, 141.64, 
140.80, 136.46, 135.32, 132.69, 129.05, 128.64, 128.14, 127.79, 12718, 127.00,  126.92, 126.51, 
125.93, 68.58, 67.43, 64.09, 52.40, 49.42, 45.24, 37.96, 31.83.  MS (ESI) calculated for 
C29H29N3O5, [M+H]+, m/z 500.57, found for [M+Na]+, m/z 522.30. 
(S)-benzyl 3-(ethyl(4-(3-oxomorpholino)phenyl)carbamoyl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (19). 1H-NMR (CDCl3, 400 MHz): 7.48-7.44 (m, 2 H), 7.42-7.34 (m, 4 H), 
7.33-7.30 (m, 1 H), 7.25-7.10 (m, 4 H), 7.09-6.80 (m, 2 H), 5.20-5.04 9m, 2 H), 4.94-4.44 (m, 3 
H), 4.35 (d, J = 5.28 Hz, 2 H), 4.03 (t, J = 4.04 Hz, 2 H), 3.81-3.72 (m, 2 H), 3.67-3.47 (m, 2 H), 
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2.87-2.83 (m, 2 H), 1.12-0.97 (m, 3 H). 13C-NMR (CDCl3, 100 MHz):  171.31, 166.65, 155.71, 
140.90, 139.99, 136.52, 135.40, 134.52, 132.72, 129.31, 128.65, 128.01, 127.77, 127.16, 126.90, 
126.28, 125.92, 68.60, 67.92, 64.10, 60.37, 52.56, 49.40, 45.28, 31.44, 12.83. MS (ESI) calculated 
for C30H31N3O5, [M+H]+, m/z 514.59, found for [M+Na]+, m/z 537.37. 
(S)-benzyl 3-(4-(3-oxomorpholino)phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (20). 1H-NMR (acetone-d6, 400 MHz): 7.55 (d, J = 8.92 Hz, 2 H), 7.49-7.34 (m, 4 H), 
7.29 (d, J =  8.80, 2 H), 7.27-7.22 (m, 5 H), 5.25-5.09 (m, 2 H), 5.01-4.61 (m, 3 H), 4.18 (s, 2 H), 
3.76 (s, br, 2 H), 3.32 (t, J = 4.00 Hz, 2 H), 3.29-3.24 (m, 2 H).  13C-NMR (CDCl3, 100 MHz): 
171.95, 166.73, 155.76, 141.65, 140.78, 136.46, 135.31, 132.69, 129.05, 128.66, 128.14, 127.79, 
127.18, 127.00,  126.92, 126.51, 125.95, 68.61, 67.43, 64.09, 52.40, 49.42, 45.24, 31.80. MS (ESI) 
calculated for C28H27N3O5, [M+H]+, m/z 486.20, found for [M+Na]+, m/z 508.18. 
(R)-tert-butyl 3-(4-(3-oxomorpholino)phenylcarbamoyl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (21). 1H-NMR (CDCl3, 400 MHz):  7.50-7.30 (m, 2 H), 7.28-7.10 (m, 6 H), 
5.00-4.45 (m, 3 H), 4.31 (s, 2 H), 4.00 (t, J = 4.84 Hz, 2 H), 3.69 (t, J = 5.68 Hz, 2 H), 3.40-3.27 
(m, 1 H), 3.23-3.00 (m, 1 H), 1.50 (s, 9 H).  13C-NMR (CDCl3, 100 MHz):  171.40, 166.73, 
155.65, 133.77, 128.13, 126.73, 126.08, 120.57, 81.81, 68.57, 64.13, 49.75, 44.85, 28.38.  MS 
(ESI) calculated for C28H27N3O5, [M+H]+, m/z 452.52, found for [M+Na]+, m/z 474.37.  
(S)-benzyl 3-(4-chlorophenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(50). 1H-NMR (CDCl3, 400 MHz): 7.50-7.35 (m, 3 H), 7.34-7.26 (m, 2 H), 7.25-7.18 (m, 4 H), 
7.17-7.00 (m, 4 H), 5.39-5.10 (m, 2 H), 4.96-4.49 (m, 3 H), 3.35-3.21 (m, 1 H), 3.20-3.3.03 (m, 1 
H). 13C-NMR (CDCl3, 100 MHz): 169.12, 157.30, 136.24, 135.95, 133.44, 132.70, 129.08, 128.81, 
128.70, 128.57, 128.43, 128.11, 127.77, 126.78, 125.94, 121.13, 68.19, 57.04, 45.11, 28.30. MS 
(ESI) calculated for C24H21ClN2O3, [M+H]+, m/z 421.90, found for [M+Na]+, m/z 443.26. 
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(S)-benzyl 3-(4-(piperidin-1-yl)phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (53). 1H-NMR (CDCl3, 400 MHz): 7.39-7.26 (m, 5 H), 7.26-7.22 (m, 4 H), 7.12-7.04 
(m, 2 H), 6.87-6.85 (m, 2 H), 5.25-5.14 (m, 2 H), 5.00-4.49 (m, 3 H), 3.39-3.31 (m, 1 H), 3.25-3.07 
(m, 1 H), 3.08 (t, J = 5.36 Hz, 4 H), 1.73-1.70 (m, 4 H), 1.56 (t, J = 5.24 Hz, 2 H).  13C-NMR 
(CDCl3, 100 MHz): 169.41, 157.01, 148.18, 136.07, 133.54, 132.71, 128.65, 128.30, 128.05, 
127.65, 127.09, 126.65, 125.89, 121.57, 121.26, 117.39, 68.01, 56.84, 51.75, 45.07, 31.91, 25.54, 
23.99. MS (ESI) calculated for C29H31N3O3, [M+H]+, m/z 470.58, found for [M+Na]+, m/z 492.35. 
(S)-benzyl 3-(4-(4-acetylpiperazin-1-yl)phenylcarbamoyl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (54). 1H-NMR (CDCl3, 400 MHz): 7.39-7.26 (m, 5 H), 7.26-7.22 (m, 4 H), 
7.12-7.04 (m, 2 H), 6.87-6.85 (m, 2 H), 5.23-5.11 (m, 2 H), 4.97-4.56 (m, 3 H), 3.84-3.80 (m, 2 H), 
3.71-3.68 (m, 2 H), 3.33-3.30 (m, 1 H), 3.17-3.14 (m, 1 H), 3.15-3.09  (m, 4 H), 2.09 (s, 3 H). 13C-
NMR (CDCl3, 100 MHz): 169.36, 168.99, 156.97, 145.20, 136.09, 133.35, 132.93, 128.64, 128.30, 
127.98, 127.63, 126.81, 125.97, 121.65, 121.35, 118.44, 67.99, 55.45, 51.69, 45.14, 40.55, 30.54, 
21.26. MS (ESI) calculated for C30H32N4O4, [M+H]+, m/z 513.61, found for [M+Na]+, m/z 535.33. 
(S)-benzyl 3-(4-(4-(thiophene-2-carbonyl)piperazin-1-yl)phenylcarbamoyl)-3,4-
dihydro-isoquinoline-2(1H)-carboxylate (55). 1H-NMR (CDCl3, 400 MHz): 7.47-7.45 (dd, J = 
0.92 Hz, J = 4.96 Hz, 1 H), 7.42-7.27 (m, 6 H), 7.25-7.19 (m, 3 H), 7.18-7.08 (m, 2 H), 7.07-7.04 
(m, 2 H), 6.99-6.85 (m, 2 H), 5.29-5.10 (m, 2 H), 5.05-4.53 (m, 3 H), 3.95-3.85 (m, 4 H), 3.35-3.20 
(m, 2 H), 3.16-3.10 (m, 4 H).  13C-NMR (CDCl3, 100 MHz):  168.92, 163.65, 155.85, 145.20, 
136.75, 136.04, 133.59, 133.17, 132.95, 129.11, 128.92, 128.53, 128.06, 127.99, 126.91, 126.48, 
126.05, 125.92, 121.44, 117.71, 116.86, 68.05, 58.45, 55.37, 50.72, 45.09, 31.80. MS (ESI) 
calculated for C33H32N4O4S, [M+H]+, m/z 581.70, found for [M+Na]+, m/z 603.36. 
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(S)-2-(2-(4-chlorophenyl)acetyl)-6,7-dimethoxy-N-methyl-N-(4-(2-oxopiperidin-1-
yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (59). 1H-NMR (CDCl3, 400 MHz): 
7.45 (d, J = 7.80 Hz, 2 H), 7.29 (d, J = 8.48 Hz, 2 H), 7.11 (d, J =  8.80 Hz, 2 H), 6.49 (s, 1 H), 
6.31 (s, 1 H),  4.97 (t, J= 6.16 Hz, 1 H), 4.60-4.40 (dd, J =  14.60 Hz, J = 64.28 Hz, 2 H), 3.76 (s, 3 
H), 3.75 (s, 2 H), 3.72 (s, 3 H),  3.59 (t, J = 5.48 Hz, 2 H), 3.17 (s, 3 H), 2.72 (t, J = 6.24 Hz, 2 H), 
2.51 (t, J = 6.20 Hz, 2 H), 1.90-1.85 (m, 4 H). 13C-NMR (CDCl3, 100 MHz):  171.85, 170.27, 
170.06, 148.22, 147.81, 142.82, 141.19, 133.25, 132.71, 130.37, 128.83, 127.93, 125.75, 124.55, 
56.05, 55.95, 51.54, 51.44, 46.77, 40.76, 38.09, 32.87, 30.09, 23.50, 21.33. MS (ESI) calculated 
for C32H34ClN3O5, [M+H]+, m/z 577.09, found for [M+Na]+, m/z 598.37. 
(S)-tert-butyl 1-(methyl(4-(2-oxopiperidin-1-yl)phenyl)amino)-1-oxo-3-phenylpropan-
2-ylcarbamate (61). 1H-NMR (CDCl3, 400 MHz): 7.30-7.12 (m, 5 H), 6.86-6.76 (m, 2 H), 6.75-
6.66 (m, 2 H), 4.49-4.44 (q, J = 7.16 Hz,  J = 15.08 Hz, 1 H), 3.60 (t, J = 4.84 Hz, 2 H), 3.12 (s, 3 
H), 2.83-2.77 (dd, J = 7.60 Hz, J = 13.12, 1 H), 2.66-2.61 (dd, J = 6.20 Hz, J = 12.52 Hz, 1 H), 
2.50 (t,  J = 6.36, 2 H), 1.90-1.85 (m, 4 H), 1.31 (s, 9 H). 13C-NMR (CDCl3, 100 MHz): 171.79, 
170.00, 154.82, 142.77, 140.39, 136.59, 129.38, 128.35, 127.92, 127.10, 126.68, 79.46, 52.27, 
51.69, 39.86, 37.45, 32.30, 28.30, 23.53, 21.39.  MS (ESI) calculated for C26H33N3O4, [M+H]+, 
m/z 452.57, found for [M+H]+, m/z 452.42. 
 (S)-benzyl 3-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)piperidine-1-
carboxylate (67).1H-NMR (CDCl3, 400 MHz): 7.40-7.34 (m, 2 H), 7.33-7.31 (m, 2 H), 7.30-7.23 
(m, 2 H), 7.22-7.04 (m, 3 H),  5.20-5.00 (m, 2 H), 4.14 (t, J = 6.60 Hz, 1 H), 4.06 (t, J = 6.72 Hz, 1 
H), 3.70-3.50 (m, 2 H), 3.21 (s, 3 H), 2.99 (t, J = 11.92 Hz, 1 H), 2.76 (t, J = 11.84 Hz, 1 H), 2.58 
(t, J = 6.00 Hz, 2 H), 2.50-2.40 (m, 1 H), 2.00-1.94 (m, 4 H), 1.76-1.71 (m, 2 H), 1.61-1.58 (m, 1 
H), 1.27-1.24 (m, 1 H).  13C-NMR (CDCl3, 100 MHz):  173.22, 170.26, 154.96, 142.71, 141.40, 
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136.80, 128.46, 127.98, 127.80, 127.64, 127.25, 67.04, 51.41, 46.60, 44.08, 39.71, 37.50, 32.84, 
27.77, 24.12, 23.48, 21.32. MS (ESI) calculated for C26H31N3O4, [M+H]+, m/z 450.55, found for 
[M+Na]+, m/z 472.35. 
(R)-benzyl 3-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)piperidine-1-
carboxylate (68).1H-NMR (CDCl3, 400 MHz):  13C-NMR (CDCl3, 100 MHz): 1H-NMR (CDCl3, 
400 MHz): 7.40-7.34 (m, 2 H), 7.33-7.31 (m, 2 H), 7.30-7.23 (m, 2 H), 7.22-7.04 (m, 3 H),  5.20-
5.00 (m, 2 H), 4.14 (t, J = 6.60 Hz, 1 H), 4.06 (t, J = 6.72 Hz, 1 H), 3.70-3.50 (m, 2 H), 3.21 (s, 3 
H), 2.99 (t, J = 11.92 Hz, 1 H), 2.76 (t, J = 11.84 Hz, 1 H), 2.58 (t, J = 6.00 Hz, 2 H), 2.50-2.40 (m, 
1 H), 2.00-1.94 (m, 4 H), 1.76-1.71 (m, 2 H), 1.61-1.58 (m, 1 H), 1.27-1.24 (m, 1 H).  13C-NMR 
(CDCl3, 100 MHz):  173.22, 170.26, 154.96, 142.71, 141.40, 136.80, 128.46, 127.98, 127.80, 
127.64, 127.25, 67.04, 51.41, 46.60, 44.08, 39.71, 37.50, 32.84, 27.77, 24.12, 23.48, 21.32. MS 
(ESI) calculated for C26H31N3O4, [M+H]+, m/z 450.55, found for [M+Na]+, m/z 472.35. 
 (S)-tert-butyl 2-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)piperidine-1-
carboxylate  (76). 1H-NMR (CDCl3, 400 MHz): 7.36-7.31 (m, 4 H),  7.06 (d, J = 3.04 Hz, 1 H), 
6.83 (d, J = 3.92 Hz, 1 H), 4.85-4.86 (m, 1 H), 3.85-3.72 (m, 1 H), 3.60 (t, J = 5.16 Hz, 2 H), 3.55-
3.46 (m, 1 H), 3.17 (s, 3 H), 2.50 (t, J = 5.76 Hz, 2 H), 1.89-1.84 (m, 4 H), 1.59-1.54 (m, 2 H), 
1.53-1.38 (m, 2 H), 1.38 (s, 9 H), 1.26-1.18 (m, 2 H). 13C-NMR (CDCl3, 100 MHz): 172.98, 
170.04, 154.20, 142.50, 141.49, 127.96, 127.13, 79.57, 51.41, 45.26, 42.43, 38.05, 32.92, 28.52, 
26.62, 24.80, 23.60, 21.50, 19.49. MS (ESI) calculated for C23H33N3O4, [M+H]+, m/z 416.53, 
found for [M+Na]+, 438.29 m/z. 
(R)- tert-butyl 2-(methyl(4-(2-oxopiperidin-1-yl)phenyl)carbamoyl)piperidine-1-
carboxylate (77). 1H-NMR (CDCl3, 400 MHz): 7.35-7.29 (m, 4 H),  7.06 (d, J = 3.05 Hz, 1 H), 
6.84 (d, J = 3.91 Hz, 1 H), 4.85-4.86 (m, 1 H), 3.85-3.71 (m, 1 H), 3.60 (t, J = 5.15 Hz, 2 H), 3.55-
174 
 
3.46 (m, 1 H), 3.17 (s, 3 H), 2.50 (t, J = 5.75 Hz, 2 H), 1.90-1.85 (m, 4 H), 1.59-1.54 (m, 2 H), 
1.54-1.38 (m, 2 H), 1.40 (s, 9 H), 1.26-1.18 (m, 2 H). 13C-NMR (CDCl3, 100 MHz): 172.95, 
170.04, 154.20, 142.50, 141.49, 128.01, 127.13, 79.57, 51.41, 45.26, 42.43, 38.1, 32.92, 28.52, 
26.63, 24.80, 23.60, 21.51, 19.50. MS (ESI) calculated for C23H33N3O4, [M+H]+, m/z 416.53, 
found for [M+Na]+, 438.24 m/z. 
 (R)-tert-butyl 2-(4-(3-oxomorpholino)phenylcarbamoyl)piperidine-1-carboxylate 
(80). 1H-NMR (CDCl3, 400 MHz): 7.46 (d, J = 8.80 Hz, 2 H), 7.19 (d, J = 8.36 Hz, 2 H), 4.80-4.72 
(m, 1 H), 4.26 (s, 2 H), 4.14-4.04 (m, 2 H), 3.99 (t, J = 4.88 Hz, 2 H), 3.85 (t, J = 4.44 Hz, 2 H), 
2.76 (t, J =  12.44 Hz, 1 H), 2.26-2.23 (m, 1 H), 1.77-1.50 (m, 4 H), 1.48 (s, 9 H). 13C-NMR 
(CDCl3, 100 MHz): 169.88, 166.88, 157.58, 137.04, 136.90, 126.27, 120.48, 81.26, 68.63, 64.16, 
55.00, 49.92, 42.53, 28.42, 25.06, 20.37. MS (ESI) calculated for C21H29N3O5, [M+H]+, m/z 
404.48, found for [M+Na]+, 426.34 m/z . 
 (S)-tert-butyl 6-(4-(3-oxomorpholino)phenylcarbamoyl)-5,6-dihydropyridine-1(2H)-
carboxylate (83). 1H-NMR (CDCl3, 400 MHz): 7.50 (d, J = 8.80 Hz, 2 H), 7.22 (d, J = 8.64 Hz, 2 
H), 5.85-5.80 (m, 1 H), 4.65-4.60 (m, 1 H), 5.00-4.93 (m, 1 H), 4.28 (s, 2 H), 4.20-4.07 (m, 1 H), 
3.94 (t, J = 4.95 Hz, 2 H), 3.65 (t, J = 4.40 Hz, 2 H), 3.60-3.63 (m, 1 H), 2.60-3.72 (m, 1 H), 2.34-
2.28 (m, 1 H).  13C-NMR (CDCl3, 100 MHz): 169.54, 166.82, 156.90, 137.99, 126.12, 123.36, 
122.20, 120.36, 81.41, 68.54, 64.11, 61.4, 49.79, 41.50, 28.39, 24.10. MS (ESI) calculated for 
C22H29N3O5, [M+H]+, m/z 402.46, found for [M+Na]+, m/z 424.36. 
 (1R, 3S, 4R)-tert-butyl 3-(4-(3-oxomorpholino)phenylcarbamoyl)-2-azabicyclo[2.2.1] 
heptane -2-carboxylate (86). 1H-NMR (CDCl3, 400 MHz): 7.57 (d, J = 8.36 Hz, 2 H), 7.25 (d, J = 
7.60 Hz, 2 H), 4.32 (s, 3 H), 4.14-4.11 (m, 1 H), 4.02 (t, J = 4.96 Hz, 2 H), 3.93-3.85 (m, 1 H), 
3.73 (t, J = 4.84 Hz, 2 H), 3.03-2.96 (m, 1 H), 1.80-1.77 (m, 2 H), 1.67-1.65 (m, 2 H), 1.50 (s, 9 
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H), 1.39-1.36 (m, 2 H).   13C-NMR (CDCl3, 100 MHz): 169.30, 166.76, 157.58, 137.26, 136.90, 
126.07, 120.42, 81.17, 68.57, 67.06, 64.35, 58.23, 49.78, 39.25, 36.65, 29.97, 28.43, 26.40. MS 
(ESI) calculated for C22H29N3O5, [M+H]+, m/z 416.49, found for [M+Na]+, m/z 438.20. 
General Procedure for Amidation at the Ring Nitrogen of the Core Structure to Yield 
7b, 22-49, 51, 58, 62, 69-73, 78, 79, 81, 84, or 87. To a stirred solution of organic acid (1.0 mmol) 
in anhydrous CH2Cl2 (5 mL) was added 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI, 
1.1 mmol) and DMAP (1.1 mmol) at RT under nitrogen atmosphere. The unprotected form (free 
amine) of (6, 12-21, 50, 57, 61, 67, 68, 76, 77, 80, 83, or 86) (1.1 mmol) in anhydrous CH2Cl2 (5 
mL) was then added drop-wise. After stirring overnight, the reaction mixture was partitioned 
between 2.0 N HCl solution (20 mL) and CH2Cl2 (30 mL). The organic layer was washed further 
with 2 N HCl (2 × 10 mL) and saturated NaCl solution (20 mL), dried using anhydrous Na2SO4, 
and concentrated to give a crude, which purified by flash chromatography using gradient of 
CH2Cl2/CH3OH as eluting phase to give the desired dicarboxamide product in 70 – 95 % yield.  
 (4-(4-nitrophenyl)piperazin-1-yl)(thiophen-2-yl)methanone (7b). 1H-NMR (CDCl3, 400 
MHz): 8.07 (d, J = 9.40 Hz, 2 H), 7.44-7.42 (dd, J = 1.04 Hz, J = 5 Hz, 1 H), 7.30-7.29 (dd, J = 
1.08 Hz, J = 3.68 Hz, 1 H), 3.03-3.01 (m, 1 H), 6.77 (d, J =  9.4 Hz, 2 H),  3.89 (t, J = 5.24 Hz, 4 
H), 3.45 (t, J = 5.44 Hz, 4 H). 13C-NMR (CDCl3, 100 MHz):  163.81, 154.16, 139.39, 136.45, 
129.39, 129.33, 126.95, 126.04, 125.96, 113.20, 112.55, 47.21, 46.25. MS (ESI) calculated for 
C15H15N3O3S, [M+H]+, m/z 318.76, found for [M+H]+, m/z 318.09. 
(S)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-2-(thiophene-2-carbonyl)-1,2,3,4-
tetrahydroisoquinoline-3-carboxamide (22). 1H-NMR (CDCl3, 400 MHz): 7.51-7.42 (m, 2 H), 
7.41 (d, J = 0.88 Hz, 1 H), 7.4-7.39 (m, 1 H), 7.37 (d, J = 20.08 Hz, 2 H), 7.12-7.09 (m, 2 H), 7.04-
7.00 (m, 3 H), 4.97-4.76 (dd,  J = 14.96 Hz, J = 69.36 Hz, 2 H), 4.9-4.82 (m, 1 H), 3.55 (t, J= 5.44 
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Hz, 2 H), 3.21 (s, 3 H), 2.98-2.85 (m, 2 H), 2.50 (t, J= 6.44 Hz, 2 H), 1.90-1.84 (m, 4 H) . 13C-
NMR (CDCl3, 100 MHz): 171.32, 170.07, 162.67, 142.93, 141.12, 137.40, 134.54, 133.10, 129.36, 
129.01, 128.17, 127.60, 127.36, 126.88, 126.74, 125.48, 53.06, 51.37, 48.92, 38.00, 32.90, 31.24, 
23.50, 21.36. MS (ESI) calculated for C27H27N3O3S, [M+H]+, m/z 474.59, found for [M+Na]+, m/z 
496.21. 
(S)-2-(5-chlorothiophene-2-carbonyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-
1,2,3,4-tetrahydroisoquinoline-3-carboxamide (23). 1H-NMR (CDCl3, 400 MHz): 7.51-7.35 (m, 
2 H), 7.28 (d, J = 8.28 Hz, 2 H), 7.15-7.11 (m, 3 H), 7.04-7.02 (m, 2 H), 6.83 (d, J= 3.92 Hz, 1 H), 
4.95-4.76 (dd, J = 14.84 Hz, J = 63.4 Hz, 2 H), 4.90-4.80 (m, 1 H), 3.56 (t, J= 5.44 Hz, 2 H), 3.19 
(s, 3 H), 3.00-2.94 (dd, J = 8.4 Hz, J = 15.24, 1 H), 2.89-2.84 (dd, J = 5.96 Hz, J = 15.16 Hz, 1 H), 
2.50 (t, J= 6.44 Hz, 2 H), 1.92-1.80 (m, 4 H) . 13C-NMR (CDCl3, 100 MHz): 171.07, 170.05, 
162.65, 143.0, 141.0, 136.22, 134.49, 134.17, 129.09, 128.09, 127.64, 127.37, 126.97, 126.11, 
125.48, 53.16, 51.36, 48.71, 38.02, 32.92, 31.20, 23.51, 21.37. MS (ESI) calculated for 
C27H26ClN3O3S, [M+H]+, m/z 509.04, found for [M+Na]+, m/z 530.17. 
(S)-2-(4-chlorobenzoyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-1,2,3,4-
tetrahydro-isoquinoline-3-carboxamide (24). 1H-NMR (CDCl3, 400 MHz): 7.53 (d, J = 6.04 Hz, 
2 H), 7.39-7.29 (m, 5 H), 7.15-7.09 (m, 3 H), 7.06 (d,  J = 10.24 Hz, 1 H), 6.87 (d, J = 7.00 Hz, 1 
H), 4.71 (t, J = 7.40 Hz, 1 H), 4.59-4.39 (dd,  J = 14.84 Hz, J = 63.76 Hz, 2 H), 3.60 (t, J= 5.28 Hz, 
2 H), 3.26 (s, 3 H), 3.03-2.97 (dd, J = 9.60 Hz, J = 14.84 Hz, 1 H), 2.91-2.86 (dd, J = 5.88 Hz, J = 
14.92 Hz, 1 H), 2.57 (t, J = 5.92 Hz, 2 H), 1.90-1.84 (m, 4 H). 13C-NMR (CDCl3, 100 MHz): 
171.92, 171.69, 170.36, 142.52, 141.47, 136.38, 134.60, 133.75, 133.53, 131.45, 128.91, 128.70, 
128.41, 127.96, 127.53, 127.10, 125.24, 51.74, 49.05, 38.11, 32.24, 31.19, 29.69, 23.22, 20.92. MS 
(ESI) calculated for C29H28ClN3O3, [M+H]+, m/z 503.01, found for [M+Na]+, m/z 524.22 . 
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(S)-N-methyl-2-(4-methylbenzoyl)-N-(4-(2-oxopiperidin-1-yl)phenyl)-1,2,3,4-
tetrahydro-isoquinoline-3-carboxamide (25). 1H-NMR (CDCl3, 400 MHz): 7.53 (d, J = 6.76 Hz, 
2 H), 7.30-7.26 (m, 4 H), 7.17-7.07 (m, 4 H), 7.03 (d,  J = 6.52 Hz, 1 H), 6.87 (d, J = 6.84 Hz, 1 
H), 4.76 (t, J = 8.08 Hz, 1 H), 4.60-4.48 (dd,  J = 14.72 Hz, J = 33.24 Hz, 2 H), 3.58 (t, J= 5.28 Hz, 
2 H), 3.24 (s, 3 H), 3.02-2.96 (dd, J = 9.12 Hz, J = 15.00 Hz, 1 H), 2.91-2.85 (dd, J = 5.80 Hz, J = 
14.72 Hz, 1 H), 2.52 (t, J = 5.92 Hz, 2 H), 2.33 (s, 3 H), 1.90-1.84 (m, 4 H). 13C-NMR (CDCl3, 100 
MHz): 170.94, 170.21, 169.63, 141.73, 140.36, 139.17, 134.11, 132.99, 131.58, 129.06, 128.07, 
127.35, 126.63, 126.49, 126.28, 125.84, 124.22, 51.68, 50.51, 47.95, 36.98, 31.64, 30.25, 28.78, 
22.39, 20.19. MS (ESI) calculated for C30H31N3O3, [M+H]+, m/z 482.59, found for [M+Na]+, m/z 
504.27. 
(S)-2-(4-methoxybenzoyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-1,2,3,4-
tetrahydroisoquinoline-3-carboxamide (26). 1H-NMR (CDCl3, 400 MHz): 7.51 (d, J = 6.76 Hz, 
2 H), 7.35 (d, J = 7.52 Hz, 2 H), 7.28 (d, J = 6.08 Hz, 2 H), 7.11-7.02 (m, 4 H), 6.86 (d, J = 8.68 
Hz, 2 H), 4.79 (t, J = 7.12 Hz, 1 H), 4.63-4.52 (dd,  J = 14.44 Hz, J = 31.08 Hz, 2 H), 3.78 (s, 3 H), 
3.57 (t, J= 5.28 Hz, 2 H), 3.24 (s, 3 H), 3.02-2.96 (m,1 H), 2.90-2.86 (dd, J = 5.76 Hz, J = 14.64 
Hz, 1 H), 2.50 (t, J = 5.92 Hz, 2 H), 1.90-1.84 (m, 4 H). 13C-NMR (CDCl3, 100 MHz): 171.92, 
170.66, 170.08, 160.90, 142.90, 141.27, 135.23, 134.12, 129.26, 128.28, 128.04, 127.54, 127.29, 
126.79, 125.22, 113.70, 55.36, 52.59, 51.39, 49.06, 37.94, 32.90, 31.28, 23.51, 21.36. MS (ESI) 
calculated for C30H31N3O4, [M+H]+, m/z 498.59, found for [M+Na]+, m/z 520.29. 
(S)-2-(2-(4-chlorophenyl)acetyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-1,2,3,4-
tetrahydroisoquinoline-3-carboxamide (27). 1H-NMR (CDCl3, 400 MHz): 7.47 (d, J = 7.76 Hz, 
2 H), 7.28 (d, J = 8.32 Hz, 2 H), 7.20 (d, J = 8.24 Hz, 2 H), 7.12-7.07 (m, 4 H), 6.98 (d, J = 6.08 
Hz, 1 H), 6.86 (d, J = 6.44 Hz, 1 H), 4.86 (t, J = 6.68 Hz, 1 H), 4.63-4.48 (dd, J = 14.68 Hz, J = 
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47.76 Hz, 2 H), 3.74 (s, 2 H), 3.58 (t, J = 5.08 Hz, 2 H), 3.16 (s, 3 H), 2.85-2.73 (m,  2 H), 2.51 (t, 
J = 5.92 Hz, 2 H), 1.90-1.85 (m, 4 H) . 13C-NMR (CDCl3, 100 MHz): 170.71, 169.17, 168.99, 
141.86, 140.16, 133.14, 132.16, 131.93, 129.39, 127.80, 127.56, 126.88, 126.23, 125.85, 124.92, 
50.97, 50.41, 46.16, 39.60, 36.98, 31.86, 30.15, 22.48, 20.32. MS (ESI) calculated for 
C30H30ClN3O3, [M+H]+, m/z 517.04, found for [M+Na]+, m/z 538.23. 
(S)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-2-(2-p-tolylacetyl)-1,2,3,4-tetrahydro-
isoquinoline-3-carboxamide (28). 1H-NMR (CDCl3, 400 MHz): 7.45 (d, J = 7.32 Hz, 2 H), 7.26 
(d, J = 8.20 Hz, 2 H), 7.09-6.95 (m, 7 H), 6.82 (d, J = 6.92 Hz, 1 H), 4.85 (t, J = 6.56 Hz, 1 H), 
4.60-4.53 (m, 2 H), 3.73 (s, 2 H), 3.58 (t, J = 5.28 Hz, 2 H), 3.16 (s, 3 H), 2.84-2.75 (m,  2 H), 2.50 
(t, J = 5.92 Hz, 2 H), 2.23 (s, 3 H), 1.90-1.85 (m, 4 H) . 13C-NMR (CDCl3, 100 MHz): 172.80, 
171.87, 170.34, 142.77, 141.27, 136.47, 135.29, 134.40, 133.17, 132.66, 131.52, 129.47, 128.73, 
127.94, 126.85, 126.74, 125.94, 51.83, 47.11, 46.12, 40.07, 37.89, 32.74, 31.21, 30.70, 23.36, 
21.06. MS (ESI) calculated for C31H33N3O3, [M+H]+, m/z 496.62, found for [M+Na]+, m/z 518.36. 
(S)-2-(2-(4-methoxyphenyl)acetyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-
1,2,3,4-tetrahydroisoquinoline-3-carboxamide (29). 1H-NMR (CDCl3, 400 MHz): 7.47 (d, J = 
7.76 Hz, 2 H), 7.28 (d, J = 8.36 Hz, 2 H), 7.11-7.03 (m, 4 H), 6.97 (d, J = 6.72 Hz, 1 H), 6.84 (d, J 
= 6.8 Hz, 1 H), 6.77 (d, J= 8.64 Hz, 2 H), 4.88 (t, J = 6.80 Hz, 1 H), 4.63-4.52 (dd, J = 14.76 Hz, J 
= 30.56 Hz, 2 H), 3.72 (s, 2 H), 3.70 (s, 3 H), 3.59 (t, J = 5.28 Hz, 2 H), 3.17 (s, 3 H), 2.81-2.73 
(m,  2 H), 2.50 (t, J = 5.92 Hz, 2 H), 1.90-1.85 (m, 4 H) . 13C-NMR (CDCl3, 100 MHz): 170.82, 
169.75, 169.06, 157.43, 141.84, 140.26, 133.41, 132.16, 128.81, 127.30, 126.46, 126.37, 125.75, 
124.39, 113.19, 54.25, 50.83, 50.41, 46.11, 39.60, 36.96, 31.90, 30.21, 22.51, 20.37. MS (ESI) 
calculated for C31H33N3O4, [M+H]+, m/z 512.62, found for [M+Na]+, m/z 534.3. 
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(S)-N-methyl-2-(2-(4-nitrophenyl)acetyl)-N-(4-(2-oxopiperidin-1-yl)phenyl)-1,2,3,4-
tetrahydroisoquinoline-3-carboxamide (30). 1H-NMR (CDCl3, 400 MHz): 8.12 (d, J = 8.72 Hz, 
2 H), 7.44 (d, J = 8.44 Hz, 2 H), 7.38 (d, J = 8.72 Hz, 2 H), 7.29 (d, J = 8.52 Hz, 2 H), 7.19-7.07 
(m, 2 H), 7.00 (d, J= 7.04 Hz, 1 H), 6.92 (d, J = 6.60 Hz, 1 H), 4.90 (t, J = 6.92 Hz, 1 H), 4.69-4.49 
(dd, J = 14.72 Hz, J = 63.36 Hz, 2 H), 3.93-3.83 (dd, J = 16.12 Hz, J = 22.80, 2 H), 3.59 (t, J = 5.64 
Hz, 2 H), 3.17 (s, 3 H), 2.85-2.77 (m,  2 H), 2.50 (t, J = 6.00 Hz, 2 H), 1.90-1.85 (m, 4 H) . 13C-
NMR (CDCl3, 100 MHz): 171.53, 170.09, 168.99, 147.01, 142.98, 141.06, 133.86, 132.99, 130.75, 
130.13, 129.84, 128.21, 127.72, 127.51, 127.18, 126.98, 125.81, 123.85, 123.52, 51.40, 47.31, 
40.85, 38.02, 32.93, 31.13, 29.70, 23.52, 21.38. MS (ESI) calculated for C30H30N4O5, [M+H]+, m/z 
527.59, found for [M+Na]+, m/z 549.34. 
(S)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-2-(2-(4-(trifluoromethyl) 
phenyl)acetyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (31). 1H-NMR (CDCl3, 400 
MHz): 7.49 (d, J = 8.80 Hz, 2 H), 7.45 (d, J = 8.32 Hz, 2 H), 7.31, (d, J = 8.4 Hz, 2 H), 7.29 (d, J = 
9.88 Hz, 2 H), 7.10-7.03 (m, 2 H), 6.98  (d, J = 7.84 Hz, 1 H), 6.85 (d, J = 6.72 Hz, 1 H), 4.89 (t, J 
= 6.88 Hz, 1 H), 4.66-4.48 (dd, J = 14.76 Hz, J = 55.44 Hz, 2 H), 3.84 (s, 2 H), 3.59 (t, J = 5.44 
Hz, 2 H), 3.17 (s, 3 H), 2.82-2.71 (m,  2 H), 2.50 (t, J = 6.00 Hz, 2 H), 1.91-1.85 (m, 4 H). 13C-
NMR (CDCl3, 100 MHz): 171.64, 170.08, 169.56, 142.94, 141.13, 138.82, 134.08, 133.06, 130.48, 
129.65, 129.40, 129.21, 128.25, 127.82, 127.35, 126.89, 125.65, 125.32, 60.39, 51.41, 47.25, 
41.05, 37.41, 32.93, 31.16, 23.52, 21.38.  MS (ESI) calculated for C31H30F3N3O3, [M+H]+, m/z 
550.59, found for [M+Na]+, m/z 572.32. 
(S)-2-(2-(3,4-dimethoxyphenyl)acetyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-
1,2,3,4-tetrahydroisoquinoline-3-carboxamide (32). 1H-NMR (CDCl3, 400 MHz): 7.47 (d, J = 
6.64 Hz, 2 H), 7.27 (d, J = 7.76 Hz, 2 H), 7.09-6.97 (m, 3 H), 6.84 (d, J = 6.84 Hz, 1 H), 6.75-6.69 
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(m, 3 H), 4.85 (t, J = 6.80 Hz, 1 H), 4.60-4.50 (dd, J = 14.68 Hz, J = 26.08 Hz, 2 H), 3.78 (s, 3 H), 
3.75 (s, 3 H), 3.73 (s, 2 H), 3.58 (t, J = 5.28 Hz, 2 H), 3.16 (s, 3 H), 2.85-2.73 (m, 2 H), 2.51 (t, J = 
5.92 Hz, 2 H), 1.90-1.85 (m, 4 H). 13C-NMR (CDCl3, 100 MHz): 170.86, 169.74, 169.33, 148.18, 
146.87, 141.79, 140.26, 133.44, 132.20, 131.55, 127.43, 126.99, 126.32, 125.78, 124.39, 120.53, 
119.90, 110.98, 110.48, 54.94, 54.86, 50.89, 46.20, 45.16, 39.95, 36.96, 31.80, 30.18, 22.46, 20.29. 
MS (ESI) calculated for C32H35N3O5, [M+H]+, m/z 542.27, found for [M+Na]+, m/z 564.33. 
(S)-2-(2-(3,4-dichlorophenyl)acetyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-
1,2,3,4-tetrahydroisoquinoline-3-carboxamide (33). 1H-NMR (CDCl3, 400 MHz): 7.47 (d, J = 
7.76 Hz, 2 H), 7.37-7.28 (m, 4 H), 7.11-6.99 (m, 4 H), 6.91 (d, J = 8.36 Hz, 1 H),  4.87 (t, J = 6.88 
Hz, 1 H), 4.65-4.47 (dd, J = 14.64 Hz, J = 59.20 Hz, 2 H), 3.71 (s, 2 H), 3.59 (t, J = 5.56 Hz, 2 H), 
3.16 (s, 3 H), 2.87-2.78 (m,  2 H), 2.53 (t, J = 5.92 Hz, 2 H), 1.90-1.85 (m, 4 H). 13C-NMR 
(CDCl3, 100 MHz): 170.66, 170.38, 169.46, 142.84, 141.10, 135.16, 134.73, 133.94, 132.52, 
131.74, 131.07, 130.56, 128.61, 128.21, 127.61, 127.11, 126.77, 125.39, 123.61, 51.46, 47.17, 
40.8, 38.05, 32.78, 31.73, 30.66, 23.45, 21.29. MS (ESI) calculated for C30H29Cl2N3O3, [M+H]+, 
m/z 551.48, found for [M+Na]+, m/z 572.27. 
(S)-2-(2-(2,4-dichlorophenyl)acetyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-
1,2,3,4-tetrahydroisoquinoline-3-carboxamide (34). 1H-NMR (CDCl3, 400 MHz): 7.47 (d, J = 
7.76 Hz, 2 H), 7.28-7.19 (m, 4 H), 7.14-7.07 (m, 3 H), 6.99-6.93 (m, 2 H), 4.93 (t, J = 6.52 Hz, 1 
H), 4.66-4.48 (dd, J = 14.80 Hz, J = 56.84 Hz, 2 H), 3.88-3.76 (dd, J = 16.24 Hz, J = 31 Hz, 2 H), 
3.58 (t, J = 5.24 Hz, 2 H), 3.16 (s, 3 H), 2.85-2.75 (m,  2 H), 2.50 (t, J = 6.12 Hz, 2 H), 1.90-1.85 
(m, 4 H) . 13C-NMR (CDCl3, 100 MHz): 171.57, 170.07, 169.21, 142.90, 141.15, 134.58, 134.05, 
133.47, 132.94, 131.72, 129.14, 128.25, 127.58, 127.54, 127.50, 127.35, 126.91, 125.46.  MS 
(ESI) calculated for C30H29Cl2N3O3, [M+H]+, m/z 551.48, found for [M+Na]+, m/z 572.27. 
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(R)-2-(2-(4-chlorophenyl)acetyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-1,2,3,4-
tetrahydroisoquinoline-3-carboxamide (35). 1H-NMR (CDCl3, 400 MHz): 7.47 (d, J = 7.75 Hz, 
2 H), 7.28 (d, J = 8.30 Hz, 2 H), 7.20 (d, J = 8.25 Hz, 2 H), 7.13-7.07 (m, 4 H), 6.98 (d, J = 6.08 
Hz, 1 H), 6.86 (d, J = 6.45 Hz, 1 H), 4.86 (t, J = 6.70 Hz, 1 H), 4.64-4.48 (dd, J = 14.70 Hz, J = 
47.80 Hz, 2 H), 3.74 (s, 2 H), 3.58 (t, J = 5.09 Hz, 2 H), 3.16 (s, 3 H), 2.85-2.72 (m,  2 H), 2.51 (t, 
J = 5.91 Hz, 2 H), 1.90-1.85 (m, 4 H) . 13C-NMR (CDCl3, 100 MHz): 170.71, 169.17, 169.0, 
141.86, 140.16, 133.14, 132.20, 131.93, 129.39, 127.80, 127.57, 126.88, 126.23, 125.85, 124.92, 
50.97, 50.40, 46.16, 39.60, 36.98, 31.87, 30.15, 22.48, 20.32. MS (ESI) calculated for 
C30H30ClN3O3, [M+H]+, m/z 517.04, found for [M+Na]+, m/z 538.28. 
(R)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-2-(2-(4-(trifluoromethyl)phenyl) 
acetyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (36). 1H-NMR (CDCl3, 400 MHz): 7.45-
7.31 (m, 4 H), 7.28-7.21 (m, 4 H), 7.17-7.08 (m, 2 H), 7.06-6.84 (m, 2 H), 4.87 (m, 1 H), 4.63-4.47 
(dd, J = 14.80 Hz, J = 47.72 Hz, 2 H), 3.84 (d, J = 5.32 Hz, 2 H), 3.59 (t, J = 5.32 Hz, 2 H), 3.18 (s, 
3 H), 2.86-2.75 (m,  2 H), 2.50 (t, J = 6.00 Hz, 2 H), 1.90-1.85 (m, 4 H) . 13C-NMR (CDCl3, 100 
MHz): 171.67, 170.87, 169.87, 142.66, 141.30, 138.62, 133.87, 133.04, 129.72, 129.08, 128.31, 
127.69, 127.45, 126.93, 125.67, 125.51, 122.81, 51.57, 47.24, 40.93, 38.06, 32.57, 31.06, 29.70, 
23.36, 21.15. MS (ESI) calculated for C30H30N4O5, [M+H]+, m/z 550.59, found for [M+Na]+, m/z 
572.32. 
(S)-N-(4-(2-oxopiperidin-1-yl)phenyl)-2-(4-(trifluoromethyl)benzoyl)-1,2,3,4-
tetrahydro-isoquinoline-3-carboxamide (37). 1H-NMR (CDCl3, 400 MHz): 8.97 (s, 1 H), 7.73 
(d, J = 7.88Hz, 2 H), 7.57 (d, J = 11.45 Hz, 2 H), 7.55 (d, J = 8.12 Hz, 2 H),  7.35-7.27 (m, 3 H), 
7.24-7.18 (m, 2 H), 6.94 (d, J = 7.00 Hz, 1 H), 5.25 (t, J = 6.64 Hz, 1 H), 4.51-4.40 (dd, J = 15.16 
Hz, J = 27.04 Hz, 2 H), 4.32 (s, 2 H), 4.02 (t, J = 4.80 Hz, 2 H), 3.72 (t, J =5.00 Hz, 2 H), 3.61-
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3.55 (dd, J = 6.96 Hz, J = 16.40 Hz, 1 H), 3.22-3.17 (dd, J = 6.68 Hz, J = 15.68 Hz, 1 H).  13C-
NMR (CDCl3, 100 MHz):  171.24, 168.26, 166.89, 138.58, 136.83, 133.83, 133.25, 132.30, 
128.33, 128.24, 127.56, 126.18, 125.84, 125.21, 124.98, 120.69, 68.58, 64.37, 54.46, 49.81, 48.28, 
29.02. MS (ESI) calculated for C28H24F3N3O4, [M+H]+, m/z 524.51, found for [M+Na]+, m/z 
546.30. 
 (S)-2-(3-(5-(4-chlorophenyl)oxazol-2-yl)propanoyl)-N-methyl-N-(4-(2-oxopiperidin-1-
yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (38). 1H-NMR (CDCl3, 400 MHz): 
7.50 (d, J = 7.32 Hz, 2 H), 7.41 (d, J = 8.20 Hz, 2 H), 7.31-7.19 (m, 4 H), 7.12-7.07 (m, 3 H), 7.05-
6.95 (m, 2 H), 4.97 (t, J = 5.88 Hz, 1 H), 4.71-4.62 (dd, J = 14.48 Hz, J = 21.64 Hz, 2 H), 3.59 (t, J 
= 5.28 Hz, 2 H), 3.59-2.90 (m, 4 H), 3.14 (s, 3 H), 2.84-2.74 (m,  2 H), 2.50 (t, J = 5.92 Hz, 2 
H),1.90-1.85 (m, 4 H) . 13C-NMR (CDCl3, 100 MHz): 171.64, 170.25, 164.13, 150.50, 142.87, 
141.13, 134.34, 133.82, 132.80, 131.76, 129.49, 129.19, 128.63, 127.89, 127.45, 126.92, 125.68, 
125.37, 123.68, 51.62, 46.55, 38.04, 32.86, 31.07, 30.53, 29.1, 27.30, 23.49, 21.33. MS (ESI) 
calculated for C34H33N4O4, [M+H]+, m/z 598.11, found for [M+Na]+, m/z 619.33. 
(S,E)-2-(3-(2,4-dimethoxyphenyl)acryloyl)-N-methyl-N-(4-(2-oxopiperidin-1-
yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (39). 1H-NMR (CDCl3, 400 MHz): 
7.77 (d, J = 15.52 Hz,1 H), 7.55-7.43 (m, 2 H), 7.38 (d, J = 8.48 Hz, 1 H), 7.36-7.27 (m, 2 H), 
7.11-7.02 (m, 4 H),  6.89 (d, J= 15.52 Hz, 1 H), 6.45-6.42 (dd, J = 2 Hz, J = 8.56 Hz, 1 H), 6.39 (s, 
1 H), 5.08-5.06 (m, 1 H), 4.78 (s, 3 H), 3.79 (s, 3 H), 3.77 (s, 3 H), 3.64 (t, J = 5.44 Hz, 2 H), 3.17 
(s, 3 H), 2.93-2.87 (dd, J = 6.48 Hz, J = 15.56 Hz, 1 H), 2.83-2.78 (dd, J = 4.76 Hz, J = 14.76 Hz, 
1H), 2.49 (t, J = 6.44 Hz, 2 H), 1.88-1.80 (m, 4 H) . 13C-NMR (CDCl3, 100 MHz): 170.73, 169.04, 
166.33, 161.16, 158.71, 140.36, 137.42, 133.22, 132.22, 129.39, 127.23, 126.68, 126.29, 125.72, 
124.61, 116.53, 115.03, 104.13, 97.50, 54.47, 54.44, 50.64, 50.40, 45.86, 36.96, 31.90, 30.25, 
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22.49, 20.37. MS (ESI) calculated for C33H35N3O5, [M+H]+, m/z 554.66, found for [M+Na]+, m/z 
576.3. 
(S)-2-(5-chlorothiophene-2-carbonyl)-N-methyl-N-(4-(3-oxomorpholino)phenyl)-
1,2,3,4-tetra-hydroisoquinoline-3-carboxamide (40). 1H-NMR (CDCl3, 400 MHz): 7.49-7.44 
(m, 2 H), 7.37 (d, J = 8.16 Hz, 2 H), 7.14-7.11 (m, 3 H), 7.04-7.02 (m, 2 H), 6.84 (d, J= 3.96 Hz,1 
H), 4.96-4.76 (dd, J = 14.80 Hz, J = 65.08 Hz, 2 H), 4.82-4.79 (m, 1 H), 4.28 (s, 2 H), 3.96 (t, J= 
5.36 Hz, 2 H), 3.69 (t, J = 5.20 Hz, 2H), 3.20 (s, 3 H), 3.01-2.95 (dd, J = 8.36 Hz, J = 15.28, 1 H), 
2.89-2.84 (dd, J = 5.56 Hz, J = 15.16 Hz, 1 H). 13C-NMR (CDCl3, 100 MHz): 171.11, 166.68, 
162.71, 141.48, 140.94, 136.12, 134.62, 134.17, 133.41, 129.12, 128.31, 127.72, 127.61, 127.02, 
126.51, 126.12, 125.50, 68.58, 64.08, 55.99, 53.16, 49.38, 38.03, 31.23. MS (ESI) calculated for 
C26H24ClN3O4S, [M+H]+, m/z 511.01, found for [M+Na]+, m/z 532.22. 
(S)-2-(2-(4-chlorophenyl)acetyl)-N-methyl-N-(4-(3-oxomorpholino)phenyl)-1,2,3,4-
tetrahydroisoquinoline-3-carboxamide (41). 1H-NMR (CDCl3, 400 MHz): 7.49 (d, J = 7.76 Hz, 
2 H), 7.37 (d, J = 8.44 Hz, 2 H), 7.22 (d, J= 8.00 Hz, 2 H), 7.14-7.06 (m, 4 H), 6.98 (d, J = 5.80 
Hz, 1 H), 6.87 (d, J = 6.28 Hz, 1 H), 4.85 (t, J = 6.90 Hz, 1 H), 4.64-4.49 (dd, J = 14.68 Hz,  J = 
46.6 Hz, 2 H), 4.28  (s, 2 H), 3.97 (t, J = 4.72 Hz, 2 H), 3.75 (s, 2 H), 3.71 (t, J = 5.20 Hz, 2 H), 
3.17 (s, 3 H), 2.85-2.74 (m, 2 H). 13C-NMR (CDCl3, 100 MHz): 171.08, 170.00, 166.70, 141.64, 
140.95, 134.16, 133.12, 133.04, 132.76, 130.31, 129.35, 128.84, 128.47, 127.52, 126.91, 126.45, 
125.37, 68.59, 64.09, 51.96, 49.41, 47.18, 40.63, 37.99, 31.19, 21.02. MS (ESI) calculated for 
C29H28ClN3O4, [M+H]+, m/z 519.01, found for [M+Na]+, m/z 540.25. 
(S)-2-(5-chloro-3-methylbenzo[b]thiophene-2-carbonyl)-N-(4-(3-oxomorpholino) 
phenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (42). 1H-NMR (CDCl3, 400 MHz):  
7.69–7.65 (m, 2 H), 7.43–7.32 (m, 3H), 7.18–6.91 (m, 6 H), 6.17–5.15 (m, 1H), 4.65–4.42 (m, 
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2H), 4.24 (s, 2 H), 3.94 (t, J = 4.8 Hz, 2 H), 3.62 (t, J = 4.92 Hz, 2 H), 3.44–3.39 (dd, J = 5.88 Hz, J 
= 16.16 Hz, 1 H), 3.16–3.11 (dd, J = 6.6 Hz, J = 15.88 Hz, 1 H), 2.32 (s, 3 H). 13C-NMR (CD3OD, 
100 MHz):168.33, 166.89, 166.45, 140.60, 137.36, 136.65, 132.83, 132.05, 131.31, 128.68, 
128.39, 128.17, 127.98, 126.88, 126.36, 126.06, 125.94, 125.65, 123.70, 122.53, 120.81, 68.55, 
64.11, 55.96, 49.80, 47.20, 29.92, 12.77.MS (ESI) calculated for C30H26ClN3O4S, [M+H]+, m/z 
560.14, found for [M+Na]+, m/z 582.33. 
(S)-2-(3-(4-methoxyphenyl)propanoyl)-N-methyl-N-(4-(3-oxomorpholino)phenyl)-
1,2,3,4-tetra-hydroisoquinoline-3-carboxamide (43). 1H-NMR (CDCl3, 400 MHz): 7.51 (d, J = 
7.40 Hz, 2 H), 7.40 (d, J = 8.20 Hz, 2 H),  7.12-7.09 (m, 2 H), 7.07 (d, J = 8.56 Hz, 2 H), 7.00-6.98 
(m, 2 H),  6.76 (d, J= 8.56 Hz, 1 H), 4.90 (t, J = 6.90 Hz, 1 H), 4.64-4.47 (dd, J = 14.88 Hz, J = 
54.92 Hz, 2 H), 4.29 (s, 2 H), 3.98 (t, J = 4.60 Hz, 2 H), 3.73 (t, J = 5.04 Hz, 2 H), 3.71 (s, 3 H), 
3.18 (s, 3 H), 2.88-2.73 (m, 4 H), 2.71-2.62 (m, 2 H). 13C-NMR (CDCl3, 100 MHz): 171.90, 
171.84, 166.70, 158.08, 141.73, 140.80, 134.22, 133.24, 133.00, 129.29, 128.45, 127.60, 127.44, 
126.86, 126.45, 125.49, 114.00, 68.60, 64.10, 55.28, 51.50, 49.43, 46.66, 37.97, 36.36, 31.18, 
30.27. MS (ESI) calculated for C31H33N3O5, [M+H]+, m/z 528.62, found for [M+Na]+, m/z 550.34. 
(S,E)-2-(3-(2,4-dimethoxyphenyl)acryloyl)-N-methyl-N-(4-(3-oxomorpholino)phenyl)-
1,2,3,4-tetrahydroisoquinoline-3-carboxamide (44). 1H-NMR (CDCl3, 400 MHz): 7.77 (d, J = 
15.52 Hz,1 H), 7.54 (d, J = 6.84 Hz, 2 H), 7.38 (d, J = 8.48 Hz, 3 H), 7.13-7.06 (m, 3 H), 7.03 (d, J 
= 4.76 Hz, 1 H),  6.89 (d, J= 15.56 Hz, 1 H), 6.45-6.43 (dd, J = 2.28 Hz, J = 8.48 Hz, 1 H), 6.39 (d, 
J = 2.28 Hz, 1 H), 5.08-5.06 (m, 1 H), 4.77 (s, 2 H), 4.27 (s, 2 H), 3.93 (t, J = 2.72 Hz, 2 H), 3.80 
(s, 3 H), 3.77 (s, 3 H), 3.71 (t, J = 4.72 Hz, 2 H), 3.18 (s, 3 H), 2.94-2.89 (dd, J = 7.08 Hz, J = 
15.56 Hz, 1 H), 2.86-2.80 (dd, J = 4.44 Hz, J = 14.04 Hz, 1H). 13C-NMR (CDCl3, 100 MHz): 
170.69, 166.34, 165.65, 161.19, 158.70, 140.79, 137.48, 133.15, 132.17, 129.40, 127.38, 126.67, 
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126.30, 125.76, 125.46, 124.62, 116.44, 114.89, 104.13, 97.49, 67.55, 63.06, 54.47, 54.44, 50.68, 
48.41, 45.83, 36.98, 30.23. MS (ESI) calculated for C32H33N3O5, [M+H]+, m/z 556.63, found for 
[M+Na]+, m/z 578.34. 
(S)-2-(4-(4-bromophenyl)thiophene-2-carbonyl)-N-methyl-N-(4-(3-oxomorpholino) 
phenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (45). 1H-NMR (CDCl3, 400 MHz): 7.59-
7.47 (m, 7 H), 7.38 (d, J = 8.44 Hz, 2 H), 7.16-7.10 (m, 2 H), 7.05-7.02 (m, 2 H), 5.00-4.79 (m, 3 
H), 4.27 (s, 2 H), 3.94 (t,  J = 4.92 Hz, 2 H), 3.67 (t, J = 5.01, 2 H), 3.22 (s, 3 H), 2.98-2.97 (m, 1 
H), 2.92-2.87 (dd, J= 5.88 Hz, J = 15.0 Hz, 1 H). 13C-NMR (CDCl3, 100 MHz):171.30, 166.69, 
163.76, 141.54, 140.94, 140.82, 138.26, 134.46, 134.0, 132.12, 128.41, 127.90, 127.75, 127.58, 
127.03, 126.50, 125.50, 123.99, 121.63, 68.58, 64.07, 53.26, 49.36, 38.03, 31.32, 26.50. MS (ESI) 
calculated for C32H28BrN3O4S, [M+H]+, m/z 631.56, found for [M+Na]+, m/z 652.24. 
(S)-2-(2-(4-chlorophenyl)acetyl)-N-ethyl-N-(4-(3-oxomorpholino)phenyl)-1,2,3,4-
tetrahydroisoquinoline-3-carboxamide (46). 1H-NMR (CDCl3, 400 MHz): 7.49 (d, J = 7.76 Hz, 
2 H), 7.37 (d, J = 8.44 Hz, 2 H), 7.22 (d, J= 8.00 Hz, 2 H), 7.14-7.06 (m,  4 H), 6.98 (d, J = 5.80 
Hz, 1 H), 6.87 (d, J = 6.28 Hz, 1 H), 4.77 (t, J = 6.88 Hz, 1 H), 4.63-4.48 (dd, J = 14.76 Hz,  J = 
47.08 Hz, 2 H), 4.28  (s, 2 H), 3.96 (t, J = 4.72 Hz, 2 H), 3.74 (s, 2 H), 3.71 (t, J = 5.12 Hz, 2 H), 
3.74-3.25 (m, 2 H), 2.80-2.69 (m, 2 H), 1.04 (t, J = 7.08 Hz, 3 H). 13C-NMR (CDCl3, 100 MHz): 
171.08, 169.90, 166.67, 140.95, 140.01, 134.21, 133.19, 132.72, 130.64, 130.46, 130.29, 129.35, 
128.97, 128.74, 127.52, 126.87, 125.36, 68.59, 64.09, 52.15, 49.39, 47.22, 45.02, 40.67, 31.24, 
30.05, 12.93. MS (ESI) calculated for C30H30ClN3O4, [M+H]+, m/z 533.04, found for [M+Na]+, 
m/z 556.35. 
(R)-2-(2-(4-chlorophenyl)acetyl)-N-(4-(3-oxomorpholino)phenyl)-1,2,3,4-tetrahydro-
isoquinoline-3-carboxamide (47). 1H-NMR (CDCl3, 400 MHz):  7.57-7.30 (m, 2 H), 7.26-7.20 
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(m, 2 H), 7.19-7.17 (m, 2 H), 7.16-7.00 (m, 4 H), 6.99-6.68 (m, 2 H). 5.14-4.12 (m, 1 H), 4.75-4.50 
(m, 2 H), 4.25  (s, 2 H), 3.95 (t, J = 4.72 Hz, 2 H), 3.81 (d, J = 10.40 Hz, 2 H), 3.66 (t, J = 5.20 Hz, 
2 H), 3..38-3.29 (m, 1 H), 3.14-2.92 (m, 1 H).  13C-NMR (CDCl3, 100 MHz): 172.23, 169.13, 
167.34, 136.97, 136.81, 133.53, 133.09, 132.45, 130.72, 130.28, 130.11, 129.54, 129.00, 128.01, 
127.46, 126.75, 125.95, 125.39, 124.21, 122.79, 120.63, 68.29, 63.94, 60.56, 52.53, 49.78, 46.88, 
40.45, 28.12. MS (ESI) calculated for C28H26ClN3O4, [M+H]+, m/z 504.98, found for [M+Na]+, 
m/z 526.21. 
(S)-2-(3-(2,4-dimethoxyphenyl)propanoyl)-N-methyl-N-(4-(3-oxomorpholino)phenyl)-
1,2,3,4-tetrahydroisoquinoline-3-carboxamide (48). 1H-NMR (CDCl3, 400 MHz): 7.51 (d, J = 
6.24 Hz, 2 H), 7.39 (d, J = 8.2 Hz, 2 H), 7.12-7.09 (m, 2 H), 7.02-6.97 (m, 3 H), 6.38 (d, J = 23.20 
Hz, 1 H),  6.35-6.33 (dd, J= 2.36 Hz, J = 8.20 Hz, 1 H), 4.86 (t, J = 6.80 Hz, 1 H), 4.61 (s, 2 H), 
4.28 (s, 2 H), 3.97 (t, J = 4.72 Hz, 2 H), 3.75 (s, 2 H), 3.72 (s, 6 H), 3.18 (s, 3 H), 2.86-2.74 (m, 4 
H), 2.72-2.61 (m, 1 H). 13C-NMR (CDCl3, 100 MHz):  172.41, 172.01, 166.70, 159.58, 158.37, 
141.73, 140.80, 134.64, 133.24, 130.43, 128.50, 127.58, 126.99, 126.45, 125.83, 121.77, 103.99, 
98.60, 68.59, 64.10, 55.38, 55.23, 51.46, 49.44, 46.56, 37.94, 34.93, 31.22, 26.02. MS (ESI) 
calculated for C32H35N3O6, [M+H]+, m/z 558.64, found for [M+Na]+, m/z 580.29. 
(S)-2-(4-(chloromethyl)benzoyl)-N-(4-(2-oxopiperidin-1-yl)phenyl)-1,2,3,4-tetrahydro-
isoquinoline-3-carboxamide (49). 1H-NMR (CDCl3, 400 MHz):7.60-7.42 (m, 6 H), 7.28-7.05 (m, 
6 H), 5.21-5.15 (m, 1 H), 4.80 (s, 2 H), 4.74 (s, 2 H), 3.65 (t, J = 6.00 Hz, 2 H), 3.42-3.33 (m, 2 H), 
2.41 (t, J = 6.52 Hz, 2 H), 1.95-1.90 (m, 4 H). 13C-NMR (CDCl3, 100 MHz): 171.47, 170.05, 
169.52, 140.56, 138.8, 137.81, 135.11, 129.67, 128.87, 128.73, 128.22, 127.48, 127.31, 126.47, 
120.69, 55.75, 52.05, 49.12, 46.25, 33.63, 31.38, 24.34, 22.22. MS (ESI) calculated for 
C29H28ClN3O3, [M+H]+, m/z 503.01, found for [M+Na]+, m/z 526.30. 
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(S)-N-(4-chlorophenyl)-2-(4-(2-oxopiperidin-1-yl)benzoyl)-1,2,3,4-tetrahydro-
isoquinoline-3-carboxamide (51). 1H-NMR (CDCl3, 400 MHz): 8.00-7.39 (m, 4 H), 7.31-7.12 
(m, 6 H), 7.02-6.90 (m, 2 H), 5.23-5.22 (m, 1 H),  4.65-4.37 (dd, J= 15.44 Hz, J = 95.12 Hz, 2 H), 
3.61 (t, J = 5.24 Hz, 2 H), 3.52-3.47 (dd, J = 3.60 Hz, J = 15.52 Hz, 2 H), 3.14-3.09 (dd, J = 5.72 
Hz, J = 15.16 Hz, 2 H), 2.53 (t, J = 5.10 Hz, 2 H), 1.90-1.88 (m, 4 H). 13C-NMR (CDCl3, 100 
MHz):  172.05, 170.43, 168.57, 147.54, 145.18, 138.05, 133.91, 133.36, 130.99, 128.91, 128.27, 
127.93, 127.81, 126.68, 126.14, 125.14, 125.41, 124.24, 119.92, 54.50, 51.43, 48.35, 32.81, 29.70, 
23.41, 21.25. MS (ESI) calculated for C28H26ClN3O3, [M+H]+, m/z 488.99, found for [M+Na]+, 
m/z 510.32. 
(S)-methyl 2-(2-(4-chlorophenyl)acetyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-
3-carboxylate (58). To a stirred solution of methyl esters (57) (1.0 mmol) in CH3OH (20 mL) was 
added LiOH-H2O (5.0 mmol) at RT.  Water (5 mL) was added after 24 to the reaction mixture 
which was kept stirring for further 30 min.  The reaction mixture was then concentrated in vacuo 
to about 10 mL and acidified by 1.0 N HCl.  The mixture was extracted with EtOAc (2 × 10 mL). 
The organic extracts were combined, dried over anhydrous Na2SO4, filtered, and finally 
concentrated by rotary evaporation. The corresponding carboxylic acid derivative was obtained as 
yellowish white solid in ~75% yield and high purity (as indicated by TLC) and accordingly it was 
used directly in the next reaction (General procedure for amidation at the carboxylic group of the 
core structure) without any further treatment to afford the titled compound. 1H-NMR (CDCl3, 400 
MHz): 7.23-7.11 (m, 4 H), 6.56 (s, 1 H), 6.40  (s, 1 H), 5.48-5.46 & 4.74-4.72 (dd, J = 3.32 Hz, J = 
6.04 Hz & J = 2.36 Hz, J = 5.72 Hz, 1 H), 4.89-4.32 (m, 2 H),  3.78 (s, 3 H), 3.76 (s, 2 H), 3.75 (s, 
3 H), 3.55-3.46 (d, 3 H), 3.14-3.05 (m, 1 H), 3.01-2.83 (m, 1 H). 13C-NMR (CDCl3, 100 MHz): 
171.31, 170.57, 148.22, 147.88, 132.94, 132.83, 130.32, 128.87, 124.04, 123.29, 111.23, 108.85, 
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55.95, 55.90, 52.39, 51.39, 45.66, 40.50, 29.69. MS (ESI) calculated for C21H22ClNO4, [M+H]+, 
m/z 404.86, found for [M+Na]+, m/z 422.16. 
(S)-2-(2-(4-chlorophenyl)acetamido)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-3-
phenyl propanamide (62). 1H-NMR (CDCl3, 400 MHz): 7.30-7.22 (m, 4 H), 7.21-7.19 (m, 3 H), 
7.11 (d, J= 8.36 Hz, 2 H), 6.93 (d, J = 7.72 Hz, 2 H), 6.84 (d, J = 7.12 Hz, 2 H), 4.87-4.82 (q, J = 
7.16 Hz,  J = 15.08 Hz, 1 H), 3.69 (t, J = 4.96 Hz, 2 H), 3.47 (s, 2 H), 3.22 (s, 3 H), 2.90-2.85 (dd, J 
= 7.16 Hz, J = 13.32, 1 H), 2.71-2.66 (dd, J = 7.00 Hz, J = 13.36 Hz, 1 H), 2.59 (t,  J = 6.40, 2 H), 
2.05-1.95 (m, 4 H) . 13C-NMR (CDCl3, 100 MHz): 171.30, 170.07, 169.63, 143.01, 140.21, 
136.00, 133.15, 130.62, 129.24, 128.95, 128.44, 127.95, 127.25, 126.90, 51.42, 51.19, 42.76, 
38.91, 37.60, 32.93, 23.53, 21.40.  MS (ESI) calculated for C29H30ClN3O3, [M+H]+, m/z 505.03, 
found for [M+Na]+, m/z 526.33. 
(R)-1-(5-chlorothiophene-2-carbonyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl) 
piperidine-3-carboxamide (69). 1H-NMR (CDCl3, 400 MHz): 7.32 (d, J = 8.28 Hz, 2 H), 7.14 (d, 
J = 6.68 Hz, 2 H), 6.94 (d, J = 3.36 Hz, 1 H), 6.85 (d, J = 3.84 Hz, 1 H), 4.40-4.20 (m, 2 H), 3.71 
(t, J = 5.44 Hz, 2 H), 3.22 (s, 3 H), 3.21-3.16 (m, 1 H), 3.01-2.89 (m, 1 H), 2.58 (t, J = 6.52 Hz, 2 
H), 2.56-2.48 (m, 1 H), 2.05-1.95 (m, 4 H), 1.92-1.84 (m, 2 H), 1.73-1.63 (m, 1 H), 1.39-1.22 (m, 1 
H).  13C-NMR (CDCl3, 100 MHz):  172.69, 170.14, 162.20, 143.02, 141.07, 135.98, 133.58, 
128.14, 127.58, 127.36, 125.86, 51.36, 46.60, 44.08, 39.71, 37.55, 32.94, 27.82, 24.33,23.52, 
21.37. MS (ESI) calculated for C23H26ClN3O3S, [M+H]+, m/z 461.00, found for [M+Na]+, m/z 
482.23. 
(R)-1-(2-(4-methoxyphenyl)acetyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl) 
piperidine-3-carboxamide (70).  1H-NMR (CDCl3, 400 MHz):  7.36-7.30 (dd, J = 8.32 Hz, J = 
15.04 Hz, 2 H), 7.23 (d, J = 8.48 Hz, 1 H), 7.08 (d, J = 8.28 Hz, 1 H), 7.02 (t, J = 6.72 Hz, 2 H), 
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6.85-6.78 (dd, J = 8.48 Hz, J = 19.72 Hz, 2 H), 4.60-4.52 (m, 1 H), 3.79 (d, J = 18.6 Hz, 3 H), 
3.75-3.68 (m, 1 H), 3.66 (t, J = 5.72 Hz, 2 H), 3.56-3.46 (m, 2 H), 3.14 (d, J = 14.96 Hz, 3 H), 
3.18-2.89 (m, 1 H), 2.79-2.43 (m, 1 H), 2.58 (t, J =  5.70 Hz, 2 H), 2.39-2.16 (m, 1 H), 2.00-1.90 
(m, 4 H),  1.77-1.54 (m, 4 H). 13C-NMR (CDCl3, 100 MHz): 173.19, 170.14, 169.54, 158.40, 
143.08, 141.35, 129.60, 127.71, 127.30, 114.24, 55.32, 51.42, 48.47, 46.36, 44.62, 42.03, 40.32, 
39.47, 37.53, 32.93, 23.52, 21.37.  MS (ESI) calculated for C27H33N3O4, [M+H]+, m/z 464.58, 
found for [M+Na]+, m/z 486.33. 
(R)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl)-1-(2-(4-(trifluoromethyl)phenyl) 
acetyl) piperidine-3-carboxamide (71).1H-NMR (CDCl3, 400 MHz): 7.56-7.51 (dd, J = 7.96 Hz, 
J = 14.60 Hz, 2 H), 7.33 (t, J = 8.12 Hz, 2 H), 7.27 (t, J = 7.12 Hz, 2 H), 7.22 (d, J = 8.40 Hz, 1 H), 
7.07 (d, J = 8.24 Hz, 1 H), 4.57-4.49 (m, 1 H), 3.77-3.51 (m, 5 H), 2.39-2.95 (m, 1 H), 3.21 (d, J = 
6.96 Hz, 3 H), 2.85-2.49 (m, 1 H), 2.57 (t, J = 5.88 Hz, 2 H),2.41-2.28 (m, 1 H), 2.00-1.86 (m, 4 
H), 1.76-1.62 (m, 4 H).  13C-NMR (CDCl3, 100 MHz): 172.98, 170.21, 168.73, 142.86, 141.32, 
139.26, 129.52, 128.88, 127.64, 127.34, 125.53, 122.84, 51.39, 48.51, 46.32, 44.66, 42.19, 40.24, 
39.34, 37.54, 32.89, 23.47, 21.33.  MS (ESI) calculated for C27H30F3N3O3, [M+H]+, m/z 502.55, 
found for [M+Na]+, m/z 524.35. 
(S)-1-(2-(4-chlorophenyl)acetyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl) 
piperidine-3-carboxamide (72). 1H-NMR (CDCl3, 400 MHz): 7.28 (d, J = 5.28 Hz, 1 H), 7.26 (d, 
J = 9.32 Hz, 1 H), 7.21-7.19 (m, 1 H), 7.16 (d, J = 8.04 Hz, 2 H),  7.03 (d, J = 8.40 Hz, 1 H), 7.00 
(d, J = 8.24 Hz, 1 H), 6.94 (d, J = 8.28 Hz, 1 H), 4.48 (t, J = 12.32 Hz, 1 H), 3.64 (t, J = 16.08 Hz, 
1 H), 3.60 (t, J = 5.72 Hz, 2 H), 3.50 (d, J = 17.60 Hz, 2 H), 3.21-2.85 (m, 1 H), 3.14 (d, J = 14.96 
Hz, 3 H), 2.75-2.29 (m, 1 H), 2.52 (t, J =  5.70 Hz, 2 H), 2.24-2.08 (m, 1 H), 1.90-1.85 (m, 4 H), 
1.72-1.54 (m, 4 H).  13C-NMR (CDCl3, 100 MHz): 173.04, 170.14, 168.69, 143.08, 140.87, 
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133.72, 132.53, 130.14, 128.85, 127.29, 51.42, 48.44, 46.33, 44.61, 42.03, 40.28, 39.38, 37.55, 
32.95, 23.51, 21.36.  MS (ESI) calculated for C26H30ClN3O3, [M+H]+, m/z 469.00, found for 
[M+Na]+, m/z 490.33. 
(S)-1-(4-(4-bromophenyl)thiophene-2-carbonyl)-N-methyl-N-(4-(2-oxopiperidin-1-
yl)phenyl) piperidine-3-carboxamide (73).  1H-NMR (CDCl3, 400 MHz):  7.51 (d, J = 8.20 Hz, 2 
H), 7.49 (s, 1 H), 7.41 (d, J = 8.88Hz, 2 H),  7.40 (s, 1 H), 7.24-7.20 (m, 2 H), 7.13-7.09 (m, 2 H), 
3.62-4.10 (m, 2 H), 3.62 (t, J = 5.28 Hz, 2 H), 3.20-2.95 (m, 2 H), 3.19 (s, 3 H), 2.55 (t, J = 5.28 
Hz, 2 H), 2.54-2.50 (m, 1 H), 1.95-1.85 (m, 4 H), 1.84-1.81 (m, 2 H), 1.73-1.69 (m, 1 H), 1.39-
1.33 (m, 1 H).  13C-NMR (CDCl3, 100 MHz): 172.83, 170.09, 163.19, 142.93, 141.11, 140.74, 
138.05, 134.09, 132.07, 127.98, 127.53, 127.34, 123.12, 121.59, 51.34, 41.00, 40.05, 37.57, 32.94, 
27.93, 24.46, 23.51, 21.37. MS (ESI) calculated for C29H30BrN3O3S, [M+H]+, m/z 581.54, found 
for [M+Na]+, m/z 602.24. 
(S)-1-(5-chlorothiophene-2-carbonyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl) 
piperidine -2-carboxamide (78). 1H-NMR (CDCl3, 400 MHz): 7.36-7.34 (m, 2 H), 7.31(d, J = 
8.36 Hz, 2 H),  7.06 (d, J = 3.04 Hz, 1 H), 6.83 (d, J = 3.92 Hz, 1 H), 5.15-5.08 (m, 1 H), 4.04-3.87 
(m, 2 H), 3.57 (t, J = 5.32 Hz, 2 H), 3.18 (s, 3 H), 2.50 (t, J = 5.80 Hz, 2 H), 1.89-1.84 (m, 4 H), 
1.78-1.74 (m, 1 H), 1.69-1.60 (m, 2 H), 1.54-1.51 (m, 1 H), 1.50-1.45 (m, 2 H). 13C-NMR (CDCl3, 
100 MHz): 170.92, 169.07, 162.84, 141.79, 140.07, 135.21, 132.76, 127.61, 127.02, 126.28, 
124.88, 50.37, 44.40, 36.97, 31.89, 28.68, 25.45, 24.07, 22.50, 20.36, 18.42. MS (ESI) calculated 
for C23H26ClN3O3S, [M+H]+, m/z 461.00, found for [M+Na]+, m/z 482.20. 
(R)-1-(5-chlorothiophene-2-carbonyl)-N-methyl-N-(4-(2-oxopiperidin-1-yl)phenyl) 
piperidine-2-carboxamide (79). 1H-NMR (CDCl3, 400 MHz): 7.38-7.30 (m, 4 H), 7.06 (d, J = 
3.08 Hz, 1 H),  6.82 (d, J = 3.92 Hz, 1 H), 5.15-5.08 (m, 1 H), 4.04-3.88 (m, 2 H), 3.57 (t, J = 5.28 
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Hz, 2 H), 3.18 (s, 3 H), 2.50 (t, J = 5.80 Hz, 2 H), 1.89-1.86 (m, 4 H), 1.78-1.75 (m, 1 H), 1.69-
1.64 (m, 2 H), 1.63-1.58 (m, 1 H), 1.57-1.53  (m, 2 H). 13C-NMR (CDCl3, 100 MHz): 171.93, 
170.10, 163.86, 142.79, 141.08, 136.21, 133.78, 128.61, 128.02, 127.29, 125.88, 51.38, 44.39, 
37.98, 32.89, 32.12, 26.47, 25.08, 23.51, 21.36, 19.43.MS (ESI) calculated for C23H26ClN3O3S, 
[M+H]+, m/z 461.00, found for [M+Na]+, m/z 482.20. 
 (R)-1-(2-(4-chlorophenyl)acetyl)-N-(4-(3-oxomorpholino)phenyl)piperidine-2-
carboxamide (81). 1H-NMR (CDCl3, 400 MHz): 7.46 (d, J = 8.80 Hz, 2 H), 7.33 (d, J = 8.56 Hz, 
2 H), 7.26 (d, J = 8.76 Hz, 2 H), 7.19 (d, J = 8.16 Hz, 2 H), 4.30-5.28 (m, 1 H), 4.33 (s, 2 H), 4.02 
(t, J = 3.88 Hz, 2 H), 4.03-3.72 (m, 2 H),  3.79 (s, 2 H), 3.73 (t, J = 4.68 Hz, 2 H), 3.08 (t, J = 13.20 
Hz, 1 H), 2.31-2.27 (m, 1 H), 1.92-1.85 (m, 2 H), 1.82-1.63 (m, 2 H). 13C-NMR (CDCl3, 100 
MHz): 171.92, 169.04, 166.76, 137.15, 133.16, 131.06, 130.02, 129.09, 128.70, 126.13, 120.60, 
68.59, 64.14, 52.83, 49.77, 44.45, 40.22, 25.18, 24.76. MS (ESI) calculated for C24H26ClN3O4, 
[M+H]+, m/z 456.94, found for [M+Na]+, m/z 478.30. 
 (S)-1-(2-(4-chlorophenyl)acetyl)-N-(4-(3-oxomorpholino)phenyl)-1,2,3,6-tetrahydro-
pyridine-2-carboxamide (84). 1H-NMR (CD3OD, 400 MHz): 7.60-7.49 (dd, J = 7.40 Hz, J = 
36.52 Hz, 2 H), 7.33 (d, J = 8.80 Hz, 2 H), 7.32-7.29 (m, 2 H), 7.27 (d, J = 9.32 Hz, 2 H), 5.87-
5.47 (m, 2 H), 4.50-4.27 (m, 1 H), 4.28 (s, 2 H), 4.04 (t, J = 4.40 Hz, 2 H), 3.94-3.84 (m, 2 H), 3.76 
(t, J = 4.40 Hz, 2 H), 2.71-2.55 (m, 2 H).  13C-NMR (CD3OD, 100 MHz): 172.74, 170.42, 168.12, 
137.31, 133.67, 132.33, 130.53, 128.23, 126.00, 124.02, 123.08, 121.98, 120.84, 67.67, 63.68, 
50.89, 49.81, 43.61, 39.61, 26.40. MS (ESI) calculated for C24H24ClN3O4, [M+H]+, m/z 454.93, 
found for [M+H]+, m/z 454.30. 
 (1R, 3S, 4R)-2-(2-(4-chlorophenyl)acetyl)-N-(4-(3-oxomorpholino)phenyl)-2-
azabicyclo [2.2.1]heptane-3-carboxamide (87). 1H-NMR (CDCl3, 400 MHz): 7.52 (d, J = 8.64 
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Hz, 2 H), 7.32 (d, J = 8.32 Hz, 2 H), 7.23 (d, J = 8.36 Hz, 2 H), 7.22 (d, J = 8.20 Hz, 2H), 4.32 (s, 2 
H), 4.26 (s, 2 H), 4.01 (t, J = 4.96 Hz, 2 H), 3.76-3.65 (m, 4 H), 3.11-3.95 (m, 1 H), 2.04-1.99 (m, 
1 H), 1.89-1.74 (m, 3 H), 1.63-1.45 (m, 3 H).  13C-NMR (CD3OD, 100 MHz): 171.24, 170.63, 
169.48, 138.89, 138.48, 135.06, 133.86, 132.02, 129.63, 127.56, 122.03, 69.07, 67.43, 65.09, 
60.21, 51.20, 43.46, 41.58, 36.43, 32.14, 28.55. MS (ESI) calculated for C25H26ClN3O4, [M+H]+, 
m/z 468.95, found for [M+Na]+, m/z 490.27. 
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CHAPTER 6: SIGNIFICANCE OF THE CURRENT WORK 
 
6.1. Synthesis of 1,2,3,4–tetrahydroisoquinoline–3–carboxylic acid (THIQ3CA)—  
Despite the fact that the THIQ3CA scaffold is widely involved in structures of many medicinal 
agents, the reported synthetic options to construct this interesting scaffold are limited. This is 
especially true for electronically activated THIQ3CA derivatives. One of the key reasons is the 
shortage of availability of appropriate precursors and/or the lengthy schemes involved in 
precursor synthesis. The protocol reported in chapter III utilizes commercially available 
benzaldehydes and optimized Horner–Wadsworth–Emmons/Pictet–Spengler reactions and (±)–
Z–α–phosphono–glycine trimethyl ester. The approach is mild, expeditious and high yielding. In 
fact, the approach helped pave the way for the synthesis of a novel library of bicyclic–unicyclic 
and bicyclic–unicyclic–bicyclic methyl–protected poly–
phenolic THIQ3CA derivatives in a straightforward 
manner. A specific advantage of this protocol is that it is 
flexible and is likely to be generally applicable. 
6.2. Implications of Conformational Isomerism—NMR spectroscopic studies 
highlighted an important structural property of N–arylacyl THIQ3CA derivatives that is of 
considerable significance. Two major rotamers –trans and cis –were found to be present in 
solution arising from hindered rotation around the amide bond. From the drug design 
perspective, this observation carries significant implications. Most structure–based drug design 
studies typically utilize only one conformer. The expectation is that rapid inter–conversion 
between the different rotamers (or conformers) will eventually induce dynamic equilibrium in 
favor of the form of that eventually binds to target site.263 This work suggests that such inter–
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conversion may not occur for N–arylacyl THIQ3CA derivatives because of the high rotational 
barrier of ~17 kcal/mol. Thus, both conformers will have to be explicitly studied in structure–
based drug design. 
6.3. Indirect FXa Inhibitors: Antithrombin Activators— Heparins form one of the 
two major classes of anticoagulant drugs in use today. Although heparin–based therapy is 
continuously advancing, the advancements in terms of medicinal chemistry have not led to 
structures beyond the heparin pentasaccharide. Fundamental research is necessary for scaffold 
hopping so as to derive clinically viable candidates. Yet, scaffold hopping is challenging, as 
demonstrated by our earlier work106-110 as well as by recent efforts from the Pinto group,264,265 
both of which indicate relatively weak affinity of the designed molecules. 
Despite this difficulty, our molecular docking and scoring protocol indicates a reasonable 
level of success. The two molecules identified through virtual screening, sodium 2-(2-(2,5-di-O-
sulfonato-phenyl)acetyl)-6,7-di-O-sulfonato-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
tetrasodium  (67A225) and sodium 2-(2-(2,5-di-O-sulfonato-phenyl)acetyl)-5,8-di-O-sulfonato-
1,2,3,4-tetrahydroisoquinoline-3-carboxylate tetrasodium (58A225) showed KD of 81 and 394 
µM, respectively, while their AT acceleration potentials were 53– and 67–fold, respectively. 
These results indicate significant improvements over our second-generation AT activator IAS5. 
This work highlights a critical aspect of allosteric conformational activation of AT. Whereas the 
affinity of the AT activators studied in this work was lower than that studied in our earlier 
work,106,110 the activation potential measured was found to be higher. This shows a segregation 
of affinity and activation potential, as expected on the basis of the theory of two–step allosteric 
activation. Affinity reflects the strength with which an activator binds in the EHBS, whereas 
activation potential is a measure of the stability of the conformational change induced in AT. 
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This work also shows that the two molecules listed above, although not fitting perfectly in the 
EHBS, are able to induce sufficient conformational change in AT to inhibit FXa at a higher rate. 
Because our analysis evaluates the properties of the AT–activator complex, we are able to parse 
affinity and activation parameters, which provides a unique insight into the mechanism of 
allosteric activation. Yet, detailed mechanistic and structural biology studies are necessary to 
ascertain whether the new molecules bind in the EHBS. Overall, the results support the concept 
that targeting the pre–equilibrium pathway may be a viable route to new AT activators. 
An important point that our study affords is the correlation of GOLD and HINT scores 
with affinity measured for the series of sulfated N–arylacyl tetrahydroisoquinoline derivatives. A 
qualitative correlation was evident from this limited study, but upon detailed quantitative 
evaluation, the correlation is not strong. Molecular modeling studies of highly sulfated 
carbohydrates and noncarbohydrates have also been challenging,106-110,220 especially because 
appropriate docking and scoring tools have not been developed for sulfated molecules as they 
have been for traditional hydrophobic small molecules. Sulfated N–arylacyl 
tetrahydroisoquinolines appear to have an added complication. These molecules display 
conformational isomerism, as evident from the NMR studies which raises the possibility of 
complications arising from selectivity of recognition.  
The best molecule in the series studied here, i.e., 
sodium 2-(4-(2,5-di-O-sulfonato-phenyl)butanoyl)-5,8-
di-O-sulfonato-1,2,3,4-tetrahydro isoquinoline- 3-
carboxylate tetrasodium (58A425), is only 3.8–fold less 
efficient at AT activation than the “gold” standard, DEFGH. This is a considerable advance. 
However, this does not imply that the design of a clinically viable nonsaccharide AT activator is 
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within rapid reach. One, the potency of this molecule is inadequate. Two, an AT activation 
higher than the 80–fold achieved thus far may be necessary. This does not imply that 300–fold 
activation, as for the “gold” standard DEFGH, is an absolute necessity for clinical viability. The 
important parameter that will govern clinical relevance is likely to be activation to toxicity ratio, 
which should favor activation by a high margin. In this regard, toxicity studies with liver HepG2 
and lung A549 cells lines show minimal toxicity for these types of highly water–soluble 
molecules at levels as high as 50 mg/L. This implies that activation less than 300–fold may not 
be a major limitation. 
It is expected that molecule 58A425 will serve as an excellent scaffold for further design 
modifications. A specific advantage of the nonsaccharide AT activators is that their synthesis is 
much simpler than the heparin–based activators.266 This implies that a library of diverse 
analogues around this molecule can be prepared without much difficulty to identify more potent 
and efficacious molecules. This work is in progress. 
6.4. Direct FXa Inhibitors—  This work explores the dependence of direct FXa 
inhibition on the flexibility of core scaffold and attempts to optimize the structure of two arms 
AN and AC of a bifunctional cyclic ring system. We 
discovered interesting structural preference for both arms and 
a fine additive relationship that culminated in the design of 
THIQ3CA analog; (R)-2-(2-(4-chlorophenyl)acetyl)-N-(4-(3-
oxomorpholino)phenyl)-1,2,3,4-tetrahydroisoquinoline-3-
carboxamide, which displays direct inhibition with IC50 of 
270 nM (Ki = 135 nM) and more than 279–fold selectivity over related proteases in the 
coagulation and digestive systems. The potency and selectivity profiles of this molecule are 
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comparable to other direct FXa inhibitors designed and reported in the literature. For example, 
rivaroxaban and apixaban have Ki’s in the subnanomolar range,119,125 TAK-442 has Ki of 1.8 
nM,124 LY517717 has Ki of 6.6 nM,118 YM150 possesses Ki of 31 nM,123 and DX-9065a has Ki of 
41 nM.267 Not only that, but also this molecule doubles the PT and aPTTT clotting times at 
concentrations of 17–20 µM, 4–fold less than those of drug candidates in clinical trials.  The 
scaffolds of these inhibitors are significantly different from what has been reported here. 
Synthetically, THIQ3CA–based FXa inhibitors and related derivatives reported here were 
assembled by only three, well-established, and high yielding steps of amidation and 
protection/deprotection reactions which were executed at room temperature avoiding the harsh 
conditions included in the synthesis of other reported FXa inhibitors. 
Our work suggests that the morpholinone ring engineers better inhibition potential than 
any other ring system; that the nitrogen of the carboxamide group at position–3 should be 
optimally unsubstituted; that a (R)–stereochemistry at position-3 is more preferred than its (S)–
enantiomer; and that a 7–atom AN arm containing a para-chloro substituted aromatic ring is 
critical for potent, direct FXa inhibition. It is also worth mentioning that the AN and AC arms 
should be adjacent to each other (1,2-substitution) rather than one carbon away (1,3-
disubstitution). These conclusions may help design more potent molecules based on the 
THIQ3CA scaffold. 
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